ID ARIP4_HUMAN Reviewed; 1467 AA. AC Q9Y4B4; Q8TB57; Q9BV54; DT 15-JAN-2008, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 4. DT 28-JAN-2026, entry version 179. DE RecName: Full=Helicase ARIP4; DE EC=5.6.2.- {ECO:0000269|PubMed:39028815}; DE AltName: Full=Androgen receptor-interacting protein 4; DE AltName: Full=RAD54-like protein 2; GN Name=RAD54L2; Synonyms=ARIP4, KIAA0809; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-1467. RC TISSUE=Brain; RX PubMed=9872452; DOI=10.1093/dnares/5.5.277; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XI. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:277-286(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 97-1467. RC TISSUE=Eye, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1169 AND SER-1172, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1169 AND SER-1172, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1169 AND SER-1172, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1169 AND SER-1172, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1260, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1260, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [12] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-1018, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033; RA Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V., RA Vertegaal A.C.; RT "SUMO-2 orchestrates chromatin modifiers in response to DNA damage."; RL Cell Rep. 10:1778-1791(2015). RN [13] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-115; LYS-127; LYS-272; LYS-665; RP LYS-682; LYS-759; LYS-901; LYS-1014 AND LYS-1018, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [14] RP FUNCTION, INTERACTION WITH DYRK1A, SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=39028815; DOI=10.1126/sciadv.adm9577; RA Ng R.R., Lin Z., Zhang Y., Ti S.C., Javed A., Wong J.W.H., Fang Q., RA Leung J.W.C., Tang A.H.N., Huen M.S.Y.; RT "R-loop resolution by ARIP4 helicase promotes androgen-mediated RT transcription induction."; RL Sci. Adv. 10:eadm9577-eadm9577(2024). CC -!- FUNCTION: Helicase that modulates androgen receptor (AR)-dependent CC transactivation in a promoter-dependent manner (By similarity). May CC stimulate the release of RNA polymerase II, that has paused near the CC transcription start sites of AR-targeted genes and unwind R-loops CC formed at these sites; R-loops result from the hybridization of the CC short RNA strand nascently synthesized by the paused RNA polymerase II CC molecule and the DNA template (PubMed:39028815). May also stimulate CC double-strand break formation by TOP2B, which appears important for CC transcriptional output (PubMed:39028815). Not able to remodel CC mononucleosomes in vitro (By similarity). CC {ECO:0000250|UniProtKB:Q99NG0, ECO:0000269|PubMed:39028815}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; CC Evidence={ECO:0000250|UniProtKB:Q99NG0}; CC -!- ACTIVITY REGULATION: Enzyme activity is enhanced by dsDNA (double- CC stranded DNA) and ssDNA (single-stranded DNA). {ECO:0000250}. CC -!- SUBUNIT: Interacts (via N-terminus) with AR/androgen receptor (By CC similarity). Interacts with DYRK1A (PubMed:39028815). Binds DNA and CC mononucleosomes, but does not seem to form large multiprotein complexes CC (By similarity). {ECO:0000250|UniProtKB:Q99NG0, CC ECO:0000269|PubMed:39028815}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:39028815}. Chromosome CC {ECO:0000269|PubMed:39028815}. Note=Localizes in speckle-like nuclear CC compartments (By similarity). Localizes to promoter proximal regions on CC chromatin (PubMed:39028815). {ECO:0000250|UniProtKB:Q99NG0, CC ECO:0000269|PubMed:39028815}. CC -!- TISSUE SPECIFICITY: Levels elevated in prostatic adenocarcinoma (at CC protein level). {ECO:0000269|PubMed:39028815}. CC -!- DOMAIN: Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs are known to be important CC for the association with nuclear receptors. CC {ECO:0000250|UniProtKB:A5YKK6}. CC -!- PTM: Sumoylated. {ECO:0000250|UniProtKB:Q99NG0}. CC -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAH24298.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AC099050; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC113933; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AB018352; BAA34529.2; -; mRNA. DR EMBL; BC001474; AAH01474.2; -; mRNA. DR EMBL; BC024298; AAH24298.1; ALT_INIT; mRNA. DR CCDS; CCDS33765.2; -. DR RefSeq; NP_001309182.1; NM_001322253.2. DR RefSeq; NP_001309185.1; NM_001322256.2. DR RefSeq; NP_055921.2; NM_015106.4. DR AlphaFoldDB; Q9Y4B4; -. DR SMR; Q9Y4B4; -. DR BioGRID; 116750; 105. DR DIP; DIP-47284N; -. DR FunCoup; Q9Y4B4; 1278. DR MINT; Q9Y4B4; -. DR STRING; 9606.ENSP00000386520; -. DR CarbonylDB; Q9Y4B4; -. DR GlyCosmos; Q9Y4B4; 3 sites, 1 glycan. DR GlyGen; Q9Y4B4; 9 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (8 sites). DR iPTMnet; Q9Y4B4; -. DR PhosphoSitePlus; Q9Y4B4; -. DR BioMuta; RAD54L2; -. DR DMDM; 296439458; -. DR jPOST; Q9Y4B4; -. DR MassIVE; Q9Y4B4; -. DR PaxDb; 9606-ENSP00000386520; -. DR PeptideAtlas; Q9Y4B4; -. DR ProteomicsDB; 86146; -. DR Pumba; Q9Y4B4; -. DR Antibodypedia; 31021; 146 antibodies from 18 providers. DR DNASU; 23132; -. DR Ensembl; ENST00000409535.6; ENSP00000386520.1; ENSG00000164080.15. DR Ensembl; ENST00000684192.1; ENSP00000507587.1; ENSG00000164080.15. DR GeneID; 23132; -. DR KEGG; hsa:23132; -. DR MANE-Select; ENST00000684192.1; ENSP00000507587.1; NM_015106.4; NP_055921.2. DR UCSC; uc011bdt.3; human. DR AGR; HGNC:29123; -. DR ClinPGx; PA143485591; -. DR CTD; 23132; -. DR DisGeNET; 23132; -. DR GeneCards; RAD54L2; -. DR HGNC; HGNC:29123; RAD54L2. DR HPA; ENSG00000164080; Low tissue specificity. DR MIM; 620006; gene. DR OpenTargets; ENSG00000164080; -. DR VEuPathDB; HostDB:ENSG00000164080; -. DR eggNOG; KOG1016; Eukaryota. DR GeneTree; ENSGT00940000155763; -. DR InParanoid; Q9Y4B4; -. DR OMA; SWAVDIM; -. DR OrthoDB; 9900844at2759; -. DR PAN-GO; Q9Y4B4; 1 GO annotation based on evolutionary models. DR PhylomeDB; Q9Y4B4; -. DR PathwayCommons; Q9Y4B4; -. DR SABIO-RK; Q9Y4B4; -. DR SignaLink; Q9Y4B4; -. DR Agora; ENSG00000164080; -. DR BioGRID-ORCS; 23132; 33 hits in 1173 CRISPR screens. DR ChiTaRS; RAD54L2; human. DR GenomeRNAi; 23132; -. DR Pharos; Q9Y4B4; Tbio. DR PRO; PR:Q9Y4B4; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q9Y4B4; protein. DR Bgee; ENSG00000164080; Expressed in secondary oocyte and 172 other cell types or tissues. DR ExpressionAtlas; Q9Y4B4; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0016604; C:nuclear body; IEA:UniProtKB-ARBA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro. DR GO; GO:0140658; F:ATP-dependent chromatin remodeler activity; IBA:GO_Central. DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW. DR GO; GO:0003678; F:DNA helicase activity; IEA:UniProtKB-EC. DR GO; GO:0033677; F:DNA/RNA helicase activity; IDA:UniProtKB. DR GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central. DR GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB. DR GO; GO:0006325; P:chromatin organization; IBA:GO_Central. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:UniProtKB-ARBA. DR GO; GO:0062176; P:R-loop processing; IDA:UniProtKB. DR GO; GO:0006368; P:transcription elongation by RNA polymerase II; IMP:UniProtKB. DR CDD; cd18069; DEXHc_ARIP4; 1. DR CDD; cd18793; SF2_C_SNF; 1. DR FunFam; 3.40.50.10810:FF:000032; Helicase ARIP4; 1. DR FunFam; 3.40.50.300:FF:000377; transcriptional regulator ATRX isoform X1; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 1.20.120.850; SWI2/SNF2 ATPases, N-terminal domain; 1. DR Gene3D; 3.40.50.10810; Tandem AAA-ATPase domain; 1. DR InterPro; IPR044574; ARIP4-like. DR InterPro; IPR044573; ARIP4_DEXHc. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR038718; SNF2-like_sf. DR InterPro; IPR049730; SNF2/RAD54-like_C. DR InterPro; IPR000330; SNF2_N. DR PANTHER; PTHR45797:SF1; HELICASE ARIP4; 1. DR PANTHER; PTHR45797; RAD54-LIKE; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00176; SNF2-rel_dom; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. PE 1: Evidence at protein level; KW ATP-binding; Chromosome; DNA-binding; Helicase; Hydrolase; Isomerase; KW Isopeptide bond; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; Ubl conjugation. FT CHAIN 1..1467 FT /note="Helicase ARIP4" FT /id="PRO_0000315781" FT DOMAIN 292..512 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 728..896 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT REGION 1..150 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 186..234 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 649..673 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1120..1171 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1184..1221 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1247..1284 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1445..1467 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 463..466 FT /note="DEAH box" FT MOTIF 551..555 FT /note="LXXLL motif 1" FT MOTIF 1329..1333 FT /note="LXXLL motif 2" FT COMPBIAS 11..49 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 72..82 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 100..115 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 133..147 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 192..201 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1136..1155 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1452..1467 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 305..312 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOD_RES 1169 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 1172 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231" FT MOD_RES 1260 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT CROSSLNK 115 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 127 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 272 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 665 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 682 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 759 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 901 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 1014 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 1018 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:25772364, FT ECO:0007744|PubMed:28112733" FT VARIANT 1369 FT /note="F -> L (in dbSNP:rs35712917)" FT /id="VAR_038302" FT CONFLICT 123 FT /note="E -> Q (in Ref. 2; BAA34529)" FT /evidence="ECO:0000305" FT CONFLICT 249 FT /note="L -> F (in Ref. 4; AAH24298)" FT /evidence="ECO:0000305" FT CONFLICT 328 FT /note="A -> V (in Ref. 2; BAA34529)" FT /evidence="ECO:0000305" FT CONFLICT 860 FT /note="Y -> F (in Ref. 4; AAH01474)" FT /evidence="ECO:0000305" SQ SEQUENCE 1467 AA; 162769 MW; 9B4144B6BBC4C3B1 CRC64; MSDESASGSD PDLDPDVELE DAEEEEEEEE VAVEECDRDD EEDLLDDPSL EGMCGTEHAQ LGEDGQQPPR CTSTTSSQSE PSEQLRRHQG KNLASEDPKK KRAQKPSHMR RNIRKLLRED QLEPVTKAAQ QEELERRKRL EQQRKDYAAP IPTVPLEFLP EEIALRASDG PQLPPRVLAQ EVICLDSSSG SEDEKSSRDE VIELSSGEED TLHIVDSSES VSEDDEEEEK GGTHVNDVLN QRDALGRVLV NLNHPPEEEN VFLAPQLARA VKPHQIGGIR FLYDNLVESL ERFKTSSGFG CILAHSMGLG KTLQVISFID VLFRHTPAKT VLAIVPVNTL QNWLAEFNMW LPPPEALPAD NKPEEVQPRF FKVHILNDEH KTMASRAKVM ADWVSEGGVL LMGYEMYRLL TLKKSFATGR PKKTKKRSHP VIIDLDEEDR QQEFRREFEK ALCRPGPDVV ICDEGHRIKN CQASTSQALK NIRSRRRVVL TGYPLQNNLI EYWCMVDFVR PDFLGTRQEF SNMFERPILN GQCIDSTPQD VRLMRYRSHV LHSLLEGFVQ RRGHTVLKIH LPAKEENVIL VRLSKIQRDL YTQFMDRFRD CGSSGWLGLN PLKAFCVCCK IWNHPDVLYE ALQKESLANE QDLDVEELGS AGTSARCPPQ GTKGKGEDST LASSMGEATN SKFLQGVGFN PFQERGNNIV TYEWAKDLLT NYQTGVLENS PKMVLLFHLI EESVKLGDKI LVFSQSLSTL ALIEEFLGKR EVPCPPGTEG QGAQKWVRNI SYFRLDGSTP AFERERLINQ FNDPSNLTTW LFLLSTRAGC LGVNLIGANR VVVFDASWNP CHDAQAVCRV YRYGQKKPCY IYRLVADYTL EKKIYDRQIS KQGMSDRVVD DLNPMLNFTR KEVENLLHFV EKEPAPQVSL NVKGIKESVL QLACLKYPHL ITKEPFEHES LLLNRKDHKL TKAEKKAAKK SYEEDKRTSV PYTRPSYAQY YPASDQSLTS IPAFSQRNWQ PTLKGDEKPV ASVRPVQSTP IPMMPRHVPL GGSVSSASST NPSMNFPINY LQRAGVLVQK VVTTTDIVIP GLNSSTDVQA RINAGESIHI IRGTKGTYIR TSDGRIFAVR ATGKPKVPED GRMAASGSQG PSCESTSNGR HSASSPKAPD PEGLARPVSP DSPEIISELQ QYADVAAARE SRQSSPSTNA ALPGPPAQLM DSSAVPGTAL GTEPRLGGHC LNSSLLVTGQ PCGDRHPVLD LRGHKRKLAT PPAAQESSRR RSRKGHLPAP VQPYEHGYPV SGGFAMPPVS LNHNLTTPFT SQAGENSLFM GSTPSYYQLS NLLADARLVF PVTTDPLVPA GPVSSSSTAT SVTASNPSFM LNPSVPGILP SYSLPFSQPL LSEPRMFAPF PSPVLPSNLS RGMSIYPGYM SPHAGYPAGG LLRSQVPPFD SHEVAEVGFS SNDDEDKDDD VIEVTGK // ID AURKA_HUMAN Reviewed; 403 AA. AC O14965; E1P5F9; O60445; O75873; Q9BQD6; Q9UPG5; DT 27-JAN-2003, integrated into UniProtKB/Swiss-Prot. DT 23-FEB-2022, sequence version 3. DT 28-JAN-2026, entry version 254. DE RecName: Full=Aurora kinase A {ECO:0000312|HGNC:HGNC:11393}; DE EC=2.7.11.1 {ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; DE AltName: Full=Aurora 2 {ECO:0000303|PubMed:10851084}; DE AltName: Full=Aurora/IPL1-related kinase 1 {ECO:0000303|PubMed:9153231}; DE Short=ARK-1 {ECO:0000303|PubMed:9153231}; DE Short=Aurora-related kinase 1 {ECO:0000303|PubMed:9514916}; DE AltName: Full=Breast tumor-amplified kinase {ECO:0000303|PubMed:11790771}; DE AltName: Full=Ipl1- and aurora-related kinase 1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase 15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}; DE AltName: Full=Serine/threonine-protein kinase 6 {ECO:0000303|PubMed:9771714}; DE AltName: Full=Serine/threonine-protein kinase Ayk1 {ECO:0000250|UniProtKB:P97477}; DE AltName: Full=Serine/threonine-protein kinase aurora-A {ECO:0000250|UniProtKB:P59241}; GN Name=AURKA {ECO:0000312|HGNC:HGNC:11393}; GN Synonyms=AIK {ECO:0000303|PubMed:9153231}, GN AIRK1 {ECO:0000312|HGNC:HGNC:11393}, ARK1 {ECO:0000312|HGNC:HGNC:11393}, GN AURA {ECO:0000312|HGNC:HGNC:11393}, AYK1 {ECO:0000250|UniProtKB:P97477}, GN BTAK {ECO:0000303|PubMed:9771714}, IAK1 {ECO:0000250|UniProtKB:P97477}, GN STK15 {ECO:0000303|PubMed:15867347, ECO:0000303|PubMed:16011022}, GN STK6 {ECO:0000303|PubMed:9771714}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], INDUCTION, SUBCELLULAR LOCATION, AND VARIANT RP VAL-57. RC TISSUE=Blood; RX PubMed=9153231; DOI=10.1074/jbc.272.21.13766; RA Kimura M., Kotani S., Hattori T., Sumi N., Yoshioka T., Todokoro K., RA Okano Y.; RT "Cell cycle-dependent expression and spindle pole localization of a novel RT human protein kinase, Aik, related to Aurora of Drosophila and yeast RT Ipl1."; RL J. Biol. Chem. 272:13766-13771(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-57. RX PubMed=9514916; DOI=10.1006/bbrc.1998.8250; RA Shindo M., Nakano H., Kuroyanagi H., Shirasawa T., Mihara M., Gilbert D.J., RA Jenkins N.A., Copeland N.G., Yagita H., Okumura K.; RT "cDNA cloning, expression, subcellular localization, and chromosomal RT assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 RT and 2."; RL Biochem. Biophys. Res. Commun. 244:285-292(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ILE-31 AND VAL-57. RC TISSUE=Mammary gland; RX PubMed=9771714; DOI=10.1038/2496; RA Zhou H., Kuang J., Zhong L., Kuo W.-L., Gray J.W., Sahin A., Brinkley B.R., RA Sen S.; RT "Tumour amplified kinase STK15/BTAK induces centrosome amplification, RT aneuploidy and transformation."; RL Nat. Genet. 20:189-193(1998). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang L., Thibodeau S.N.; RT "Mutational analysis of the STK15 gene in human tumors."; RL Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-57. RC TISSUE=Cervix, Colon, Kidney, and Muscle; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INDUCTION, AND SUBCELLULAR LOCATION. RX PubMed=9606188; DOI=10.1093/emboj/17.11.3052; RA Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., RA Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S., RA Novotny M., Slamon D.J., Plowman G.D.; RT "A homologue of Drosophila aurora kinase is oncogenic and amplified in RT human colorectal cancers."; RL EMBO J. 17:3052-3065(1998). RN [9] RP UBIQUITINATION, PROTEASOMAL DEGRADATION, AND MUTAGENESIS OF ARG-205. RX PubMed=10851084; DOI=10.1038/sj.onc.1203609; RA Honda K., Mihara H., Kato Y., Yamaguchi A., Tanaka H., Yasuda H., RA Furukawa K., Urano T.; RT "Degradation of human Aurora2 protein kinase by the anaphase-promoting RT complex-ubiquitin-proteasome pathway."; RL Oncogene 19:2812-2819(2000). RN [10] RP FUNCTION, PHOSPHORYLATION AT THR-288, MUTAGENESIS OF THR-288, RP UBIQUITINATION, AND ACTIVITY REGULATION. RX PubMed=11039908; DOI=10.1038/sj.onc.1203847; RA Walter A.O., Seghezzi W., Korver W., Sheung J., Lees E.; RT "The mitotic serine/threonine kinase Aurora2/AIK is regulated by RT phosphorylation and degradation."; RL Oncogene 19:4906-4916(2000). RN [11] RP FUNCTION, INTERACTION WITH PPP1CA; PPP1CB AND PPP1CC, MUTAGENESIS OF RP PHE-165 AND PHE-346, AND PHOSPHORYLATION. RX PubMed=11551964; DOI=10.1074/jbc.m107540200; RA Katayama H., Zhou H., Li Q., Tatsuka M., Sen S.; RT "Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and RT protein phosphatase 1 through mitotic cell division cycle."; RL J. Biol. Chem. 276:46219-46224(2001). RN [12] RP SUBCELLULAR LOCATION. RX PubMed=12576638; DOI=10.1247/csf.27.457; RA Sugimoto K., Urano T., Zushi H., Inoue K., Tasaka H., Tachibana M., RA Dotsu M.; RT "Molecular dynamics of Aurora-A kinase in living mitotic cells RT simultaneously visualized with histone H3 and nuclear membrane protein RT importinalpha."; RL Cell Struct. Funct. 27:457-467(2002). RN [13] RP FUNCTION, INDUCTION, PHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=12390251; DOI=10.1046/j.1365-2443.2002.00592.x; RA Marumoto T., Hirota T., Morisaki T., Kunitoku N., Zhang D., Ichikawa Y., RA Sasayama T., Kuninaka S., Mimori T., Tamaki N., Kimura M., Okano Y., RA Saya H.; RT "Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian RT cells."; RL Genes Cells 7:1173-1182(2002). RN [14] RP INDUCTION. RX PubMed=11790771; DOI=10.1074/jbc.m108252200; RA Tanaka M., Ueda A., Kanamori H., Ideguchi H., Yang J., Kitajima S., RA Ishigatsubo Y.; RT "Cell-cycle-dependent regulation of human aurora A transcription is RT mediated by periodic repression of E4TF1."; RL J. Biol. Chem. 277:10719-10726(2002). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT THR-288. RX PubMed=13678582; DOI=10.1016/s0092-8674(03)00642-1; RA Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., RA Hatakeyama K., Saya H.; RT "Aurora-A and an interacting activator, the LIM protein Ajuba, are required RT for mitotic commitment in human cells."; RL Cell 114:585-598(2003). RN [16] RP FUNCTION. RX PubMed=14523000; DOI=10.1074/jbc.m306275200; RA Marumoto T., Honda S., Hara T., Nitta M., Hirota T., Kohmura E., Saya H.; RT "Aurora-A kinase maintains the fidelity of early and late mitotic events in RT HeLa cells."; RL J. Biol. Chem. 278:51786-51795(2003). RN [17] RP INTERACTION WITH TACC1. RX PubMed=14603251; DOI=10.1038/sj.onc.1206972; RA Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., RA Prigent C., Seraphin B., Jacquemier J., Birnbaum D.; RT "TACC1-chTOG-Aurora A protein complex in breast cancer."; RL Oncogene 22:8102-8116(2003). RN [18] RP FUNCTION. RX PubMed=15147269; DOI=10.1111/j.1356-9597.2004.00732.x; RA Toji S., Yabuta N., Hosomi T., Nishihara S., Kobayashi T., Suzuki S., RA Tamai K., Nojima H.; RT "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A RT kinase."; RL Genes Cells 9:383-397(2004). RN [19] RP RETRACTED PAPER. RX PubMed=14990569; DOI=10.1074/jbc.m311780200; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RT "BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M RT transition."; RL J. Biol. Chem. 279:19643-19648(2004). RN [20] RP RETRACTION NOTICE OF PUBMED:14990569. RX PubMed=26341884; DOI=10.1074/jbc.a115.311780; RA Ouchi M., Fujiuchi N., Sasai K., Katayama H., Minamishima Y.A., RA Ongusaha P.P., Deng C., Sen S., Lee S.W., Ouchi T.; RL J. Biol. Chem. 290:22311-22311(2015). RN [21] RP FUNCTION. RX PubMed=15128871; DOI=10.1242/jcs.01108; RA Dutertre S., Cazales M., Quaranta M., Froment C., Trabut V., Dozier C., RA Mirey G., Bouche J.P., Theis-Febvre N., Schmitt E., Monsarrat B., RA Prigent C., Ducommun B.; RT "Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the RT G2-M transition."; RL J. Cell Sci. 117:2523-2531(2004). RN [22] RP FUNCTION, MUTAGENESIS OF LYS-162, AND INTERACTION WITH TP53. RX PubMed=14702041; DOI=10.1038/ng1279; RA Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F., RA Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.; RT "Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization RT and inhibition of p53."; RL Nat. Genet. 36:55-62(2004). RN [23] RP INTERACTION WITH CPEB1. RX PubMed=15966895; DOI=10.1111/j.1365-2443.2005.00870.x; RA Sasayama T., Marumoto T., Kunitoku N., Zhang D., Tamaki N., Kohmura E., RA Saya H., Hirota T.; RT "Over-expression of Aurora-A targets cytoplasmic polyadenylation element RT binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1."; RL Genes Cells 10:627-638(2005). RN [24] RP PHOSPHORYLATION AT THR-288 AND SER-342. RX PubMed=16246726; DOI=10.1016/j.molcel.2005.08.035; RA Zhao Z.S., Lim J.P., Ng Y.W., Lim L., Manser E.; RT "The GIT-associated kinase PAK targets to the centrosome and regulates RT Aurora-A."; RL Mol. Cell 20:237-249(2005). RN [25] RP INDUCTION, AND FUNCTION. RX PubMed=15987997; DOI=10.1128/mcb.25.14.5789-5800.2005; RA Yu C.T., Hsu J.M., Lee Y.C., Tsou A.P., Chou C.K., Huang C.Y.; RT "Phosphorylation and stabilization of HURP by Aurora-A: implication of HURP RT as a transforming target of Aurora-A."; RL Mol. Cell. Biol. 25:5789-5800(2005). RN [26] RP INTERACTION WITH BORA. RX PubMed=16890155; DOI=10.1016/j.devcel.2006.06.002; RA Hutterer A., Berdnik D., Wirtz-Peitz F., Zigman M., Schleiffer A., RA Knoblich J.A.; RT "Mitotic activation of the kinase Aurora-A requires its binding partner RT Bora."; RL Dev. Cell 11:147-157(2006). RN [27] RP FUNCTION. RX PubMed=18056443; DOI=10.1158/0008-5472.can-07-2578; RA Sankaran S., Crone D.E., Palazzo R.E., Parvin J.D.; RT "Aurora-A kinase regulates breast cancer associated gene 1 inhibition of RT centrosome-dependent microtubule nucleation."; RL Cancer Res. 67:11186-11194(2007). RN [28] RP FUNCTION, INTERACTION WITH HDAC6, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP ASP-274 AND THR-288. RX PubMed=17604723; DOI=10.1016/j.cell.2007.04.035; RA Pugacheva E.N., Jablonski S.A., Hartman T.R., Henske E.P., Golemis E.A.; RT "HEF1-dependent Aurora A activation induces disassembly of the primary RT cilium."; RL Cell 129:1351-1363(2007). RN [29] RP INTERACTION WITH ARHGEF2. RX PubMed=17488622; DOI=10.1016/j.devcel.2007.03.014; RA Birkenfeld J., Nalbant P., Bohl B.P., Pertz O., Hahn K.M., Bokoch G.M.; RT "GEF-H1 modulates localized RhoA activation during cytokinesis under the RT control of mitotic kinases."; RL Dev. Cell 12:699-712(2007). RN [30] RP SUBCELLULAR LOCATION, INTERACTION WITH PPP2CA, AND PHOSPHORYLATION AT RP SER-51. RX PubMed=17229885; DOI=10.1091/mbc.e06-12-1152; RA Horn V., Thelu J., Garcia A., Albiges-Rizo C., Block M.R., Viallet J.; RT "Functional interaction of Aurora-A and PP2A during mitosis."; RL Mol. Biol. Cell 18:1233-1241(2007). RN [31] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=17726514; DOI=10.1371/journal.pone.0000784; RA North B.J., Verdin E.; RT "Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during RT mitosis."; RL PLoS ONE 2:E784-E784(2007). RN [32] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=17360485; DOI=10.1073/pnas.0608798104; RA Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., RA Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., RA Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., RA Wysong D.R., Zhang M., Bolen J.B., Claiborne C.F.; RT "Antitumor activity of MLN8054, an orally active small-molecule inhibitor RT of Aurora A kinase."; RL Proc. Natl. Acad. Sci. U.S.A. 104:4106-4111(2007). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [34] RP FUNCTION. RX PubMed=18615013; DOI=10.1038/nature07185; RA Macurek L., Lindqvist A., Lim D., Lampson M.A., Klompmaker R., Freire R., RA Clouin C., Taylor S.S., Yaffe M.B., Medema R.H.; RT "Polo-like kinase-1 is activated by aurora A to promote checkpoint RT recovery."; RL Nature 455:119-123(2008). RN [35] RP FUNCTION, AUTOPHOSPHORYLATION, AND INTERACTION WITH PARD3. RX PubMed=19812038; DOI=10.1074/jbc.m109.055897; RA Khazaei M.R., Puschel A.W.; RT "Phosphorylation of the par polarity complex protein Par3 at serine 962 is RT mediated by aurora A and regulates its function in neuronal polarity."; RL J. Biol. Chem. 284:33571-33579(2009). RN [36] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH KIF2A. RX PubMed=19351716; DOI=10.1242/jcs.044321; RA Jang C.Y., Coppinger J.A., Seki A., Yates J.R. III, Fang G.; RT "Plk1 and Aurora A regulate the depolymerase activity and the cellular RT localization of Kif2a."; RL J. Cell Sci. 122:1334-1341(2009). RN [37] RP FUNCTION, INTERACTION WITH TPX2, PHOSPHORYLATION AT THR-287 AND THR-288, RP AND MUTAGENESIS OF THR-287. RX PubMed=19668197; DOI=10.1038/ncb1919; RA Mori D., Yamada M., Mimori-Kiyosue Y., Shirai Y., Suzuki A., Ohno S., RA Saya H., Wynshaw-Boris A., Hirotsune S.; RT "An essential role of the aPKC-Aurora A-NDEL1 pathway in neurite elongation RT by modulation of microtubule dynamics."; RL Nat. Cell Biol. 11:1057-1068(2009). RN [38] RP INTERACTION WITH TPX2, MUTAGENESIS OF GLY-198, AND SUBCELLULAR LOCATION. RX PubMed=19357306; DOI=10.1073/pnas.0900833106; RA Fu J., Bian M., Liu J., Jiang Q., Zhang C.; RT "A single amino acid change converts Aurora-A into Aurora-B-like kinase in RT terms of partner specificity and cellular function."; RL Proc. Natl. Acad. Sci. U.S.A. 106:6939-6944(2009). RN [39] RP FUNCTION, INTERACTION WITH CIMAP3, AND ACTIVATION BY CIMAP3. RX PubMed=20643351; DOI=10.1016/j.devcel.2010.06.005; RA Kinzel D., Boldt K., Davis E.E., Burtscher I., Trumbach D., Diplas B., RA Attie-Bitach T., Wurst W., Katsanis N., Ueffing M., Lickert H.; RT "Pitchfork regulates primary cilia disassembly and left-right asymmetry."; RL Dev. Cell 19:66-77(2010). RN [40] RP IDENTIFICATION IN A COMPLEX WITH AUNIP AND NIN. RX PubMed=20596670; DOI=10.3892/ijo_00000691; RA Lieu A.S., Cheng T.S., Chou C.H., Wu C.H., Hsu C.Y., Huang C.Y., RA Chang L.K., Loh J.K., Chang C.S., Hsu C.M., Howng S.L., Hong Y.R.; RT "Functional characterization of AIBp, a novel Aurora-A binding protein in RT centrosome structure and spindle formation."; RL Int. J. Oncol. 37:429-436(2010). RN [41] RP INTERACTION WITH GADD45A. RX PubMed=20460379; DOI=10.1074/jbc.m109.069344; RA Sanchez R., Pantoja-Uceda D., Prieto J., Diercks T., Marcaida M.J., RA Montoya G., Campos-Olivas R., Blanco F.J.; RT "Solution structure of human growth arrest and DNA damage 45alpha RT (Gadd45alpha) and its interactions with proliferating cell nuclear antigen RT (PCNA) and Aurora A kinase."; RL J. Biol. Chem. 285:22196-22201(2010). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [43] RP SUBCELLULAR LOCATION, AND INTERACTION WITH JTB. RX PubMed=21225229; DOI=10.3892/ijo.2011.900; RA Platica M., Ionescu A., Ivan E., Holland J.F., Mandeli J., Platica O.; RT "PAR, a protein involved in the cell cycle, is functionally related to RT chromosomal passenger proteins."; RL Int. J. Oncol. 38:777-785(2011). RN [44] RP REVIEW ON FUNCTION. RX PubMed=14625535; DOI=10.1038/nrm1245; RA Carmena M., Earnshaw W.C.; RT "The cellular geography of aurora kinases."; RL Nat. Rev. Mol. Cell Biol. 4:842-854(2003). RN [45] RP REVIEW ON FUNCTION. RX PubMed=19774610; DOI=10.1002/em.20533; RA Lukasiewicz K.B., Lingle W.L.; RT "Aurora A, centrosome structure, and the centrosome cycle."; RL Environ. Mol. Mutagen. 50:602-619(2009). RN [46] RP INTERACTION WITH SIRT2, AND SUBCELLULAR LOCATION. RX PubMed=22014574; DOI=10.1016/j.ccr.2011.09.004; RA Kim H.S., Vassilopoulos A., Wang R.H., Lahusen T., Xiao Z., Xu X., Li C., RA Veenstra T.D., Li B., Yu H., Ji J., Wang X.W., Park S.H., Cha Y.I., RA Gius D., Deng C.X.; RT "SIRT2 maintains genome integrity and suppresses tumorigenesis through RT regulating APC/C activity."; RL Cancer Cell 20:487-499(2011). RN [47] RP INTERACTION WITH HNRNPU. RX PubMed=21242313; DOI=10.1242/jcs.063347; RA Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S., RA Fukui K.; RT "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule RT attachment and contributes to the targeting of Aurora-A to mitotic RT spindles."; RL J. Cell Sci. 124:394-404(2011). RN [48] RP INTERACTION WITH KLHL18 AND CUL3, UBIQUITINATION, AND SUBCELLULAR LOCATION. RX PubMed=23213400; DOI=10.1242/bio.2011018; RA Moghe S., Jiang F., Miura Y., Cerny R.L., Tsai M.Y., Furukawa M.; RT "The CUL3-KLHL18 ligase regulates mitotic entry and ubiquitylates Aurora- RT A."; RL Biol. Open 1:82-91(2012). RN [49] RP INTERACTION WITH FRY. RX PubMed=22753416; DOI=10.1074/jbc.m112.378968; RA Ikeda M., Chiba S., Ohashi K., Mizuno K.; RT "Furry protein promotes Aurora A-mediated polo-like kinase 1 activation."; RL J. Biol. Chem. 287:27670-27681(2012). RN [50] RP SUBCELLULAR LOCATION. RX PubMed=25657325; DOI=10.1091/mbc.e14-09-1366; RA Ohta S., Wood L., Toramoto I., Yagyu K., Fukagawa T., Earnshaw W.C.; RT "CENP-32 is required to maintain centrosomal dominance in bipolar spindle RT assembly."; RL Mol. Biol. Cell 26:1225-1237(2015). RN [51] RP INTERACTION WITH HNRNPU. RX PubMed=25986610; DOI=10.1128/mcb.01312-14; RA Douglas P., Ye R., Morrice N., Britton S., Trinkle-Mulcahy L., RA Lees-Miller S.P.; RT "Phosphorylation of SAF-A/hnRNP-U serine 59 by polo-like kinase 1 is RT required for mitosis."; RL Mol. Cell. Biol. 35:2699-2713(2015). RN [52] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=27192185; DOI=10.1080/15384101.2016.1187342; RA Meunier S., Timon K., Vernos I.; RT "Aurora-A regulates MCRS1 function during mitosis."; RL Cell Cycle 15:1779-1786(2016). RN [53] RP FUNCTION. RX PubMed=27335426; DOI=10.1242/jcs.184416; RA Kotak S., Afshar K., Busso C., Goenczy P.; RT "Aurora A kinase regulates proper spindle positioning in C. elegans and in RT human cells."; RL J. Cell Sci. 129:3015-3025(2016). RN [54] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [55] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH RP FOXP1. RX PubMed=28218735; DOI=10.1038/oncsis.2016.80; RA Kamran M., Long Z.J., Xu D., Lv S.S., Liu B., Wang C.L., Xu J., Lam E.W., RA Liu Q.; RT "Aurora kinase A regulates Survivin stability through targeting FBXL7 in RT gastric cancer drug resistance and prognosis."; RL Oncogenesis 6:E298-E298(2017). RN [56] RP SUBCELLULAR LOCATION. RX PubMed=30538148; DOI=10.1261/rna.069773.118; RA Jiao A.L., Perales R., Umbreit N.T., Haswell J.R., Piper M.E., Adams B.D., RA Pellman D., Kennedy S., Slack F.J.; RT "Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing RT factor."; RL RNA 25:352-363(2019). RN [57] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 107-403 IN COMPLEX WITH ADENOSINE, RP AND CATALYTIC ACTIVITY. RX PubMed=12237287; DOI=10.1074/jbc.c200426200; RA Cheetham G.M., Knegtel R.M., Coll J.T., Renwick S.B., Swenson L., Weber P., RA Lippke J.A., Austen D.A.; RT "Crystal structure of aurora-2, an oncogenic serine/threonine kinase."; RL J. Biol. Chem. 277:42419-42422(2002). RN [58] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 125-391 IN COMPLEX WITH ADP. RX PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3; RA Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G., RA Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V., RA Thompson D.A.; RT "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases RT from nanovolume crystallography."; RL Structure 10:1659-1667(2002). RN [59] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 122-403 IN COMPLEX WITH TPX2, RP MUTAGENESIS OF ASP-274, ACTIVE SITE, PHOSPHORYLATION AT THR-287 AND RP THR-288, AND REGION ACTIVATION SEGMENT. RX PubMed=14580337; DOI=10.1016/s1097-2765(03)00392-7; RA Bayliss R., Sardon T., Vernos I., Conti E.; RT "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle."; RL Mol. Cell 12:851-862(2003). RN [60] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 123-401 IN COMPLEXES WITH ADPNP RP AND 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=16337122; DOI=10.1016/j.bmcl.2005.11.053; RA Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., RA Hill G.B., Johnson T., Jung F.H., McMiken H.H., Mortlock A.A., RA Pannifer A.D., Pauptit R.A., Pink J., Roberts N.J., Rowsell S.; RT "SAR and inhibitor complex structure determination of a novel class of RT potent and specific Aurora kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 16:1320-1323(2006). RN [61] RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 100-403 IN COMPLEXES WITH RP SYNTHETIC INHIBITORS, AND FUNCTION. RX PubMed=17125279; DOI=10.1021/jm060897w; RA Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., RA Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., RA Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., RA Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., RA Vianello P.; RT "1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent RT aurora kinase inhibitor with a favorable antitumor kinase inhibition RT profile."; RL J. Med. Chem. 49:7247-7251(2006). RN [62] RP X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 125-391 IN COMPLEX WITH VX-680 AND RP TPX2, PHOSPHORYLATION AT THR-288, IDENTIFICATION BY MASS SPECTROMETRY, AND RP SUBUNIT. RX PubMed=18662907; DOI=10.1110/ps.036590.108; RA Zhao B., Smallwood A., Yang J., Koretke K., Nurse K., Calamari A., RA Kirkpatrick R.B., Lai Z.; RT "Modulation of kinase-inhibitor interactions by auxiliary protein binding: RT crystallography studies on Aurora A interactions with VX-680 and with RT TPX2."; RL Protein Sci. 17:1791-1797(2008). RN [63] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 127-388 IN COMPLEX WITH ADP, RP CHARACTERIZATION OF VARIANTS ARG-155 AND MET-174, AND INTERACTION WITH RP TPX2. RX PubMed=19801554; DOI=10.1074/jbc.m109.032722; RA Bibby R.A., Tang C., Faisal A., Drosopoulos K., Lubbe S., Houlston R., RA Bayliss R., Linardopoulos S.; RT "A cancer-associated aurora A mutant is mislocalized and misregulated due RT to loss of interaction with TPX2."; RL J. Biol. Chem. 284:33177-33184(2009). RN [64] RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 123-401 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19140666; DOI=10.1021/jm801270e; RA Coumar M.S., Leou J.S., Shukla P., Wu J.S., Dixit A.K., Lin W.H., RA Chang C.Y., Lien T.W., Tan U.K., Chen C.H., Hsu J.T., Chao Y.S., Wu S.Y., RA Hsieh H.P.; RT "Structure-based drug design of novel Aurora kinase A inhibitors: RT structural basis for potency and specificity."; RL J. Med. Chem. 52:1050-1062(2009). RN [65] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 125-391 IN COMPLEX WITH SYNTHETIC RP INHIBITOR, AND CATALYTIC ACTIVITY. RX PubMed=19402633; DOI=10.1021/jm9000314; RA Aliagas-Martin I., Burdick D., Corson L., Dotson J., Drummond J., RA Fields C., Huang O.W., Hunsaker T., Kleinheinz T., Krueger E., Liang J., RA Moffat J., Phillips G., Pulk R., Rawson T.E., Ultsch M., Walker L., RA Wiesmann C., Zhang B., Zhu B.Y., Cochran A.G.; RT "A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually RT high selectivity against Aurora B."; RL J. Med. Chem. 52:3300-3307(2009). RN [66] RP X-RAY CRYSTALLOGRAPHY (1.72 ANGSTROMS) OF 122-403 OF MUTANTS ALA-290 AND RP ALA-393 IN COMPLEX WITH ADP, INTERACTION WITH MYCN AND TPX2, MUTAGENESIS OF RP CYS-290; TYR-334; GLN-335 AND CYS-393, AND CATALYTIC ACTIVITY. RX PubMed=27837025; DOI=10.1073/pnas.1610626113; RA Richards M.W., Burgess S.G., Poon E., Carstensen A., Eilers M., Chesler L., RA Bayliss R.; RT "Structural basis of N-Myc binding by Aurora-A and its destabilization by RT kinase inhibitors."; RL Proc. Natl. Acad. Sci. U.S.A. 113:13726-13731(2016). RN [67] RP VARIANTS ILE-31 AND VAL-57, AND CHARACTERIZATION OF VARIANT VAL-57. RX PubMed=15867347; DOI=10.1158/0008-5472.can-04-2149; RA Kimura M.T., Mori T., Conroy J., Nowak N.J., Satomi S., Tamai K., RA Nagase H.; RT "Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) RT coordinately increase esophageal cancer risk."; RL Cancer Res. 65:3548-3554(2005). RN [68] RP VARIANTS ILE-31 AND VAL-57. RX PubMed=16011022; RA Chen L., Ao X., Ren Q., Wang Z.N., Lu C., Xu Y., Jiang L., Luo Y., Xu H.M., RA Zhang X.; RT "Linkage disequilibrium and haplotype analysis of two single nucleotide RT polymorphisms in STK15 in Chinese."; RL Yi Chuan Xue Bao 32:331-336(2005). RN [69] RP VARIANT ILE-31. RX PubMed=16762494; DOI=10.1016/j.canlet.2006.05.002; RA Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., RA Wappenschmidt B., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., RA Burwinkel B.; RT "Aurora kinases A and B and familial breast cancer risk."; RL Cancer Lett. 247:266-272(2007). RN [70] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-31; LEU-50; VAL-57; ARG-155; MET-174 RP AND VAL-373. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [71] RP IDENTIFICATION IN A COMPLEX WITH NEDD9 AND CTTN. RX PubMed=24574519; DOI=10.1158/1541-7786.mcr-13-0654; RA Kozyreva V.K., McLaughlin S.L., Livengood R.H., Calkins R.A., Kelley L.C., RA Rajulapati A., Ice R.J., Smolkin M.B., Weed S.A., Pugacheva E.N.; RT "NEDD9 regulates actin dynamics through cortactin deacetylation in an RT AURKA/HDAC6-dependent manner."; RL Mol. Cancer Res. 12:681-693(2014). RN [72] RP FUNCTION, INTERACTION WITH AAAS, SUBCELLULAR LOCATION, AND PHOSPHORYLATION RP AT THR-288. RX PubMed=26246606; DOI=10.1091/mbc.e15-02-0113; RA Carvalhal S., Ribeiro S.A., Arocena M., Kasciukovic T., Temme A., RA Koehler K., Huebner A., Griffis E.R.; RT "The nucleoporin ALADIN regulates Aurora A localization to ensure robust RT mitotic spindle formation."; RL Mol. Biol. Cell 26:3424-3438(2015). CC -!- FUNCTION: Mitotic serine/threonine kinase that contributes to the CC regulation of cell cycle progression (PubMed:11039908, PubMed:12390251, CC PubMed:17125279, PubMed:17360485, PubMed:18615013, PubMed:26246606). CC Associates with the centrosome and the spindle microtubules during CC mitosis and plays a critical role in various mitotic events including CC the establishment of mitotic spindle, centrosome duplication, CC centrosome separation as well as maturation, chromosomal alignment, CC spindle assembly checkpoint, and cytokinesis (PubMed:14523000, CC PubMed:26246606). Required for normal spindle positioning during CC mitosis and for the localization of NUMA1 and DCTN1 to the cell cortex CC during metaphase (PubMed:27335426). Required for initial activation of CC CDK1 at centrosomes (PubMed:13678582, PubMed:15128871). Phosphorylates CC numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, CC DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, CC p53/TP53 and TPX2 (PubMed:11551964, PubMed:14702041, PubMed:15128871, CC PubMed:15147269, PubMed:15987997, PubMed:17604723, PubMed:18056443, CC PubMed:18615013). Phosphorylates MCRS1 which is required for MCRS1- CC mediated kinetochore fiber assembly and mitotic progression CC (PubMed:27192185). Regulates KIF2A tubulin depolymerase activity CC (PubMed:19351716). Important for microtubule formation and/or CC stabilization (PubMed:18056443). Required for normal axon formation CC (PubMed:19812038). Plays a role in microtubule remodeling during CC neurite extension (PubMed:19668197). Also acts as a key regulatory CC component of the p53/TP53 pathway, and particularly the checkpoint- CC response pathways critical for oncogenic transformation of cells, by CC phosphorylating and destabilizing p53/TP53 (PubMed:14702041). CC Phosphorylates its own inhibitors, the protein phosphatase type 1 (PP1) CC isoforms, to inhibit their activity (PubMed:11551964). Inhibits cilia CC outgrowth (By similarity). Required for cilia disassembly via CC phosphorylation of HDAC6 and subsequent deacetylation of alpha-tubulin CC (PubMed:17604723, PubMed:20643351). Regulates protein levels of the CC anti-apoptosis protein BIRC5 by suppressing the expression of the CC SCF(FBXL7) E3 ubiquitin-protein ligase substrate adapter FBXL7 through CC the phosphorylation of the transcription factor FOXP1 CC (PubMed:28218735). {ECO:0000250|UniProtKB:A0A8I3S724, CC ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14523000, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15128871, ECO:0000269|PubMed:15147269, CC ECO:0000269|PubMed:15987997, ECO:0000269|PubMed:17125279, CC ECO:0000269|PubMed:17360485, ECO:0000269|PubMed:17604723, CC ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:18615013, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19812038, ECO:0000269|PubMed:20643351, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27192185, CC ECO:0000269|PubMed:27335426, ECO:0000269|PubMed:28218735}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27192185, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12237287, ECO:0000269|PubMed:16337122, CC ECO:0000269|PubMed:19140666, ECO:0000269|PubMed:19402633, CC ECO:0000269|PubMed:27837025, ECO:0000269|PubMed:28218735}; CC -!- ACTIVITY REGULATION: Activation of CDK1, appears to be an upstream CC event of AURKA activation. Phosphatase inhibitor-2 (PPP1R2) and TPX2 CC act also as activators. Inactivated by the G2 checkpoint. Inhibited by CC GADD45A and p53/TP53, and through dephosphorylation by protein CC phosphatase type 1 (PP1). MLN8054 is also a potent and selective CC inhibitor. Activated during the early phase of cilia disassembly in the CC presence of CIMAP3. Inhibited by the small molecule inhibitor VX-680 CC (PubMed:28218735). {ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:17360485, CC ECO:0000269|PubMed:28218735}. CC -!- SUBUNIT: Part of a complex composed of NEDD9, AURKA and CTTN; within CC the complex NEDD9 acts as a scaffold protein and is required for CC complex formation (PubMed:24574519). Identified in a complex with AUNIP CC and NIN (PubMed:20596670). Interacts with FBXL7 (By similarity). CC Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the CC protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC CC (PubMed:11551964, PubMed:14580337, PubMed:14603251, PubMed:15966895, CC PubMed:17229885, PubMed:18662907, PubMed:19357306, PubMed:19668197, CC PubMed:19801554, PubMed:21225229, PubMed:27837025). Also interacts with CC its substrates ARHGEF2, BORA, KIF2A, PARD3, and p53/TP53 CC (PubMed:14702041, PubMed:16890155, PubMed:17488622, PubMed:19351716, CC PubMed:19812038). Interaction with BORA promotes phosphorylation of CC PLK1 (By similarity). Interacts with CIMAP3 (PubMed:20643351). CC Interacts with GADD45A, competing with its oligomerization CC (PubMed:20460379). Interacts (via C-terminus) with AUNIP (via C- CC terminus) (PubMed:20596670). Interacts with FRY; this interaction CC facilitates AURKA-mediated PLK1 phosphorylation (PubMed:22753416). CC Interacts with SIRT2 (PubMed:17726514, PubMed:22014574). Interacts with CC MYCN; interaction is phospho-independent and triggers AURKA activation; CC AURKA competes with FBXW7 for binding to unphosphorylated MYCN but not CC for binding to phosphorylated MYCN (PubMed:27837025). Interacts with CC HNRNPU (PubMed:21242313, PubMed:25986610). Interacts with AAAS CC (PubMed:26246606). Interacts with KLHL18 and CUL3 (PubMed:23213400). CC Interacts with FOXP1 (PubMed:28218735). Interacts with HDAC6; AURKA- CC mediated phosphorylation of HDAC6 promotes deacetylation of alpha- CC tubulin (PubMed:17604723). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:11551964, ECO:0000269|PubMed:12237287, CC ECO:0000269|PubMed:12467573, ECO:0000269|PubMed:14580337, CC ECO:0000269|PubMed:14603251, ECO:0000269|PubMed:14702041, CC ECO:0000269|PubMed:15966895, ECO:0000269|PubMed:16890155, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:17488622, CC ECO:0000269|PubMed:17604723, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:18662907, ECO:0000269|PubMed:19140666, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:19402633, ECO:0000269|PubMed:19668197, CC ECO:0000269|PubMed:19801554, ECO:0000269|PubMed:19812038, CC ECO:0000269|PubMed:20460379, ECO:0000269|PubMed:20596670, CC ECO:0000269|PubMed:20643351, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:22753416, ECO:0000269|PubMed:23213400, CC ECO:0000269|PubMed:24574519, ECO:0000269|PubMed:25986610, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:27837025, CC ECO:0000269|PubMed:28218735}. CC -!- INTERACTION: CC O14965; Q9NWT8: AURKAIP1; NbExp=2; IntAct=EBI-448680, EBI-448665; CC O14965; O15392: BIRC5; NbExp=2; IntAct=EBI-448680, EBI-518823; CC O14965; Q6PGQ7: BORA; NbExp=3; IntAct=EBI-448680, EBI-719836; CC O14965; P15056: BRAF; NbExp=5; IntAct=EBI-448680, EBI-365980; CC O14965; P00533: EGFR; NbExp=5; IntAct=EBI-448680, EBI-297353; CC O14965; P06730: EIF4E; NbExp=2; IntAct=EBI-448680, EBI-73440; CC O14965; P61978: HNRNPK; NbExp=2; IntAct=EBI-448680, EBI-304185; CC O14965; Q13123: IK; NbExp=3; IntAct=EBI-448680, EBI-713456; CC O14965; O14920: IKBKB; NbExp=2; IntAct=EBI-448680, EBI-81266; CC O14965; Q9NQS7: INCENP; NbExp=2; IntAct=EBI-448680, EBI-307907; CC O14965; Q9NQS7-1: INCENP; NbExp=2; IntAct=EBI-448680, EBI-15767972; CC O14965; P04198: MYCN; NbExp=12; IntAct=EBI-448680, EBI-878369; CC O14965; P06748: NPM1; NbExp=3; IntAct=EBI-448680, EBI-78579; CC O14965; P53350: PLK1; NbExp=4; IntAct=EBI-448680, EBI-476768; CC O14965; P23468: PTPRD; NbExp=2; IntAct=EBI-448680, EBI-2682990; CC O14965; Q96R06: SPAG5; NbExp=3; IntAct=EBI-448680, EBI-413317; CC O14965; O15350: TP73; NbExp=11; IntAct=EBI-448680, EBI-389606; CC O14965; Q9ULW0: TPX2; NbExp=10; IntAct=EBI-448680, EBI-1037322; CC O14965; Q8VDQ8: Sirt2; Xeno; NbExp=5; IntAct=EBI-448680, EBI-911012; CC -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing CC center, centrosome {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:19357306, CC ECO:0000269|PubMed:21225229, ECO:0000269|PubMed:22014574, CC ECO:0000269|PubMed:23213400, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:30538148, ECO:0000269|PubMed:9153231}. Cytoplasm, CC cytoskeleton, spindle pole {ECO:0000269|PubMed:12576638, CC ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:17726514, CC ECO:0000269|PubMed:19351716, ECO:0000269|PubMed:25657325, CC ECO:0000269|PubMed:26246606, ECO:0000269|PubMed:9153231, CC ECO:0000269|PubMed:9606188}. Cytoplasm, cytoskeleton, microtubule CC organizing center, centrosome, centriole CC {ECO:0000250|UniProtKB:P97477}. Cell projection, neuron projection CC {ECO:0000250|UniProtKB:P97477}. Cell projection, cilium CC {ECO:0000269|PubMed:17604723}. Cytoplasm, cytoskeleton, cilium basal CC body {ECO:0000269|PubMed:17604723}. Basolateral cell membrane CC {ECO:0000250|UniProtKB:F1PNY0}. Note=Detected at the neurite hillock in CC developing neurons (By similarity). Localizes at the centrosome in CC mitotic cells from early prophase until telophase, but also localizes CC to the spindle pole MTs from prophase to anaphase (PubMed:17229885, CC PubMed:21225229, PubMed:9606188). Colocalized with SIRT2 at centrosome CC (PubMed:22014574). Moves to the midbody during both telophase and CC cytokinesis (PubMed:17726514). Associates with both the pericentriolar CC material (PCM) and centrioles (PubMed:22014574). The localization to CC the spindle poles is regulated by AAAS (PubMed:26246606). CC {ECO:0000250|UniProtKB:P97477, ECO:0000269|PubMed:17229885, CC ECO:0000269|PubMed:17726514, ECO:0000269|PubMed:21225229, CC ECO:0000269|PubMed:22014574, ECO:0000269|PubMed:26246606, CC ECO:0000269|PubMed:9606188}. CC -!- TISSUE SPECIFICITY: Highly expressed in testis and weakly in skeletal CC muscle, thymus and spleen. Also highly expressed in colon, ovarian, CC prostate, neuroblastoma, breast and cervical cancer cell lines. CC -!- INDUCTION: Expression is cell-cycle regulated, low in G1/S, accumulates CC during G2/M, and decreases rapidly after. {ECO:0000269|PubMed:11790771, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:15987997, CC ECO:0000269|PubMed:9153231, ECO:0000269|PubMed:9606188}. CC -!- PTM: Activated by phosphorylation at Thr-288; this brings about a CC change in the conformation of the activation segment. Phosphorylation CC at Thr-288 varies during the cell cycle and is highest during M phase. CC Autophosphorylated at Thr-288 upon TPX2 binding. Thr-288 can be CC phosphorylated by several kinases, including PAK and PKA. Protein CC phosphatase type 1 (PP1) binds AURKA and inhibits its activity by CC dephosphorylating Thr-288 during mitosis. Phosphorylation at Ser-342 CC decreases the kinase activity. PPP2CA controls degradation by CC dephosphorylating Ser-51 at the end of mitosis. CC {ECO:0000269|PubMed:11039908, ECO:0000269|PubMed:11551964, CC ECO:0000269|PubMed:12390251, ECO:0000269|PubMed:13678582, CC ECO:0000269|PubMed:14580337, ECO:0000269|PubMed:16246726, CC ECO:0000269|PubMed:17229885, ECO:0000269|PubMed:18662907, CC ECO:0000269|PubMed:19668197}. CC -!- PTM: Ubiquitinated by the E3 ubiquitin-protein ligase complex CC SCF(FBXL7) during mitosis, leading to its degradation by the proteasome CC (By similarity). Ubiquitinated by CHFR, leading to its degradation by CC the proteasome (By similarity). Ubiquitinated by the anaphase-promoting CC complex (APC), leading to its degradation by the proteasome CC (PubMed:10851084, PubMed:11039908). Ubiquitinated by the CUL3-KLHL18 CC ligase leading to its activation at the centrosome which is required CC for initiating mitotic entry (PubMed:23213400). Ubiquitination mediated CC by CUL3-KLHL18 ligase does not lead to its degradation by the CC proteasome (PubMed:23213400). {ECO:0000250|UniProtKB:P97477, CC ECO:0000269|PubMed:10851084, ECO:0000269|PubMed:11039908, CC ECO:0000269|PubMed:23213400}. CC -!- MISCELLANEOUS: Centrosome amplification can occur when the cycles are CC uncoupled, and this amplification is associated with cancer and with an CC increase in the levels of chromosomal instability. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. Aurora subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- CAUTION: Authors initially considered AURKA/STK6 and STK15 as 2 CC different proteins (PubMed:9771714). It is clear that they are the same CC protein. {ECO:0000305|PubMed:9771714}. CC -!- CAUTION: An article that concluded that AURKA-mediated phosphorylation CC of BRCA1 'Ser-308' plays a role in the normal cell cycle G2/M CC transition was withdrawn due to data manipulation of flow cytometry CC data. {ECO:0000305|PubMed:14990569, ECO:0000305|PubMed:26341884}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA23592.1; Type=Frameshift; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/730/AURKA"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D84212; BAA23592.1; ALT_FRAME; mRNA. DR EMBL; AF008551; AAC12708.1; -; mRNA. DR EMBL; AF011467; AAC23448.1; -; Genomic_DNA. DR EMBL; AF011468; AAC63902.1; -; mRNA. DR EMBL; AF195947; AAF29508.1; -; Genomic_DNA. DR EMBL; AF195942; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195943; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195944; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195945; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AF195946; AAF29508.1; JOINED; Genomic_DNA. DR EMBL; AL121914; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471077; EAW75550.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75551.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75552.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75553.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75554.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75555.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75556.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75557.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75558.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75559.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75561.1; -; Genomic_DNA. DR EMBL; CH471077; EAW75562.1; -; Genomic_DNA. DR EMBL; BC001280; AAH01280.1; -; mRNA. DR EMBL; BC002499; AAH02499.1; -; mRNA. DR EMBL; BC006423; AAH06423.1; -; mRNA. DR EMBL; BC027464; AAH27464.1; -; mRNA. DR CCDS; CCDS13451.1; -. DR PIR; JC5974; JC5974. DR RefSeq; NP_001310232.1; NM_001323303.2. DR RefSeq; NP_001310233.1; NM_001323304.2. DR RefSeq; NP_001310234.1; NM_001323305.2. DR RefSeq; NP_001411346.1; NM_001424417.1. DR RefSeq; NP_003591.2; NM_003600.3. DR RefSeq; NP_940835.1; NM_198433.3. DR RefSeq; NP_940836.1; NM_198434.3. DR RefSeq; NP_940837.1; NM_198435.3. DR RefSeq; NP_940838.1; NM_198436.3. DR RefSeq; NP_940839.1; NM_198437.3. DR PDB; 1MQ4; X-ray; 1.90 A; A=125-391. DR PDB; 1MUO; X-ray; 2.90 A; A=107-403. DR PDB; 1OL5; X-ray; 2.50 A; A=122-403. DR PDB; 1OL6; X-ray; 3.00 A; A=122-403. DR PDB; 1OL7; X-ray; 2.75 A; A=122-403. DR PDB; 2BMC; X-ray; 2.60 A; A/B/C/D/E/F=100-403. DR PDB; 2C6D; X-ray; 2.20 A; A=124-398. DR PDB; 2C6E; X-ray; 2.10 A; A/B=123-401. DR PDB; 2DWB; X-ray; 2.50 A; A=122-403. DR PDB; 2J4Z; X-ray; 2.00 A; A/B=100-403. DR PDB; 2J50; X-ray; 3.00 A; A/B=126-403. DR PDB; 2NP8; X-ray; 2.25 A; A=125-391. DR PDB; 2W1C; X-ray; 3.24 A; A=122-389. DR PDB; 2W1D; X-ray; 2.97 A; A=122-389. DR PDB; 2W1E; X-ray; 2.93 A; A=122-389. DR PDB; 2W1F; X-ray; 2.85 A; A=122-389. DR PDB; 2W1G; X-ray; 2.71 A; A=122-389. DR PDB; 2WQE; X-ray; 2.50 A; A=127-388. DR PDB; 2WTV; X-ray; 2.40 A; A/B/C/D=122-403. DR PDB; 2WTW; X-ray; 3.30 A; A=122-403. DR PDB; 2X6D; X-ray; 2.80 A; A=122-403. DR PDB; 2X6E; X-ray; 3.35 A; A=122-403. DR PDB; 2X81; X-ray; 2.91 A; A=126-391. DR PDB; 2XNE; X-ray; 2.80 A; A=122-392. DR PDB; 2XNG; X-ray; 2.60 A; A=122-403. DR PDB; 2XRU; X-ray; 2.90 A; A=126-403. DR PDB; 3COH; X-ray; 2.70 A; A/B=124-391. DR PDB; 3E5A; X-ray; 2.30 A; A=125-391. DR PDB; 3EFW; X-ray; 2.29 A; A/B=125-391. DR PDB; 3FDN; X-ray; 1.90 A; A=123-401. DR PDB; 3H0Y; X-ray; 2.50 A; A=124-391. DR PDB; 3H0Z; X-ray; 2.92 A; A/B/C=124-391. DR PDB; 3H10; X-ray; 2.20 A; A/B/D=124-391. DR PDB; 3HA6; X-ray; 2.36 A; A=125-391. DR PDB; 3K5U; X-ray; 2.35 A; A=123-401. DR PDB; 3LAU; X-ray; 2.10 A; A=125-399. DR PDB; 3M11; X-ray; 2.75 A; A=123-401. DR PDB; 3MYG; X-ray; 2.40 A; A=125-391. DR PDB; 3NRM; X-ray; 3.05 A; A=126-403. DR PDB; 3O50; X-ray; 2.00 A; A/B=125-391. DR PDB; 3O51; X-ray; 3.20 A; A=125-391. DR PDB; 3P9J; X-ray; 2.80 A; A=125-391. DR PDB; 3QBN; X-ray; 3.50 A; A=124-403. DR PDB; 3R21; X-ray; 2.90 A; A=126-391. DR PDB; 3R22; X-ray; 2.90 A; A=126-391. DR PDB; 3UNZ; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UO4; X-ray; 2.45 A; A=123-401. DR PDB; 3UO5; X-ray; 2.70 A; A=123-401. DR PDB; 3UO6; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOD; X-ray; 2.50 A; A=123-401. DR PDB; 3UOH; X-ray; 2.80 A; A/B=123-401. DR PDB; 3UOJ; X-ray; 2.90 A; A/B=123-401. DR PDB; 3UOK; X-ray; 2.95 A; A/B=123-401. DR PDB; 3UOL; X-ray; 2.40 A; A/B=123-401. DR PDB; 3UP2; X-ray; 2.30 A; A=123-401. DR PDB; 3UP7; X-ray; 3.05 A; A=123-401. DR PDB; 3VAP; X-ray; 2.66 A; A=125-391. DR PDB; 3W10; X-ray; 2.70 A; A=126-403. DR PDB; 3W16; X-ray; 2.80 A; A=126-403. DR PDB; 3W18; X-ray; 2.50 A; A/B=126-403. DR PDB; 3W2C; X-ray; 2.45 A; A/C/E/G=128-388. DR PDB; 4B0G; X-ray; 2.50 A; A=122-403. DR PDB; 4BN1; X-ray; 2.50 A; A=122-403. DR PDB; 4BYI; X-ray; 2.60 A; A=122-403. DR PDB; 4BYJ; X-ray; 2.75 A; A=122-403. DR PDB; 4C3P; X-ray; 2.69 A; A/D=122-403. DR PDB; 4C3R; X-ray; 2.79 A; A=122-403. DR PDB; 4CEG; X-ray; 2.10 A; A=122-403. DR PDB; 4DEA; X-ray; 2.45 A; A=123-401. DR PDB; 4DEB; X-ray; 3.05 A; A=123-401. DR PDB; 4DED; X-ray; 3.05 A; A=123-401. DR PDB; 4DEE; X-ray; 2.30 A; A=123-401. DR PDB; 4DHF; X-ray; 2.80 A; A/B=126-391. DR PDB; 4J8M; X-ray; 1.85 A; A=123-401. DR PDB; 4J8N; X-ray; 3.14 A; A/B/C/D=123-401. DR PDB; 4JAI; X-ray; 3.20 A; A=122-396. DR PDB; 4JAJ; X-ray; 2.70 A; A=122-396. DR PDB; 4JBO; X-ray; 2.49 A; A=123-401. DR PDB; 4JBP; X-ray; 2.45 A; A=123-401. DR PDB; 4JBQ; X-ray; 2.30 A; A=123-401. DR PDB; 4O0S; X-ray; 2.50 A; A=122-403. DR PDB; 4O0U; X-ray; 2.60 A; A=122-403. DR PDB; 4O0W; X-ray; 2.60 A; A=122-403. DR PDB; 4PRJ; X-ray; 2.80 A; A=124-391. DR PDB; 4UYN; X-ray; 1.90 A; A=125-399. DR PDB; 4UZD; X-ray; 3.20 A; A/B=125-399. DR PDB; 4UZH; X-ray; 2.00 A; A=125-399. DR PDB; 4ZS0; X-ray; 3.00 A; A=122-403. DR PDB; 4ZTQ; X-ray; 2.80 A; A=122-403. DR PDB; 4ZTR; X-ray; 2.85 A; A=122-403. DR PDB; 4ZTS; X-ray; 2.90 A; A=122-403. DR PDB; 5AAD; X-ray; 3.10 A; A=122-403. DR PDB; 5AAE; X-ray; 3.11 A; A=122-403. DR PDB; 5AAF; X-ray; 2.78 A; A=122-403. DR PDB; 5AAG; X-ray; 2.85 A; A=122-403. DR PDB; 5DN3; X-ray; 2.05 A; A=125-391. DR PDB; 5DNR; X-ray; 1.95 A; A=125-391. DR PDB; 5DOS; X-ray; 2.98 A; A=126-390. DR PDB; 5DPV; X-ray; 2.29 A; A=126-390. DR PDB; 5DR2; X-ray; 2.46 A; A=128-390. DR PDB; 5DR6; X-ray; 2.53 A; A=126-390. DR PDB; 5DR9; X-ray; 2.47 A; A=126-390. DR PDB; 5DRD; X-ray; 2.13 A; A=126-390. DR PDB; 5DT0; X-ray; 2.15 A; A=126-390. DR PDB; 5DT3; X-ray; 2.33 A; A=126-390. DR PDB; 5DT4; X-ray; 2.86 A; A=126-390. DR PDB; 5EW9; X-ray; 2.18 A; A=123-390. DR PDB; 5G15; X-ray; 2.06 A; A=122-403. DR PDB; 5G1X; X-ray; 1.72 A; A=122-403. DR PDB; 5L8J; X-ray; 1.68 A; A=122-403. DR PDB; 5L8K; X-ray; 1.79 A; A=122-403. DR PDB; 5L8L; X-ray; 1.67 A; A=122-403. DR PDB; 5LXM; X-ray; 2.08 A; A=122-403. DR PDB; 5OBJ; X-ray; 2.90 A; A=125-391. DR PDB; 5OBR; X-ray; 2.62 A; A=125-391. DR PDB; 5ODT; X-ray; 2.02 A; A=122-403. DR PDB; 5ONE; X-ray; 2.60 A; A=122-403. DR PDB; 5ORL; X-ray; 1.69 A; A=127-391. DR PDB; 5ORN; X-ray; 2.19 A; A=127-391. DR PDB; 5ORO; X-ray; 2.12 A; A=127-391. DR PDB; 5ORP; X-ray; 2.19 A; A=127-391. DR PDB; 5ORR; X-ray; 2.09 A; A=127-391. DR PDB; 5ORS; X-ray; 1.98 A; A=127-391. DR PDB; 5ORT; X-ray; 2.56 A; A=127-391. DR PDB; 5ORV; X-ray; 1.88 A; A=127-391. DR PDB; 5ORW; X-ray; 2.00 A; A=127-391. DR PDB; 5ORX; X-ray; 1.88 A; A=127-391. DR PDB; 5ORY; X-ray; 1.99 A; A=127-391. DR PDB; 5ORZ; X-ray; 1.92 A; A=127-391. DR PDB; 5OS0; X-ray; 1.74 A; A=127-391. DR PDB; 5OS1; X-ray; 1.90 A; A=127-391. DR PDB; 5OS2; X-ray; 1.92 A; A=127-391. DR PDB; 5OS3; X-ray; 1.81 A; A=127-391. DR PDB; 5OS4; X-ray; 1.88 A; A=127-391. DR PDB; 5OS5; X-ray; 1.74 A; A=125-392. DR PDB; 5OS6; X-ray; 2.20 A; A=127-391. DR PDB; 5OSD; X-ray; 1.99 A; A=125-391. DR PDB; 5OSE; X-ray; 1.90 A; A=127-391. DR PDB; 5OSF; X-ray; 1.89 A; A=127-391. DR PDB; 5ZAN; X-ray; 2.85 A; A=123-403. DR PDB; 6C2R; X-ray; 1.96 A; A=125-391. DR PDB; 6C2T; X-ray; 1.73 A; A=125-391. DR PDB; 6C83; X-ray; 2.55 A; A/B=122-403. DR PDB; 6CPE; X-ray; 2.45 A; A=122-403. DR PDB; 6CPF; X-ray; 2.30 A; A=122-403. DR PDB; 6CPG; X-ray; 2.80 A; A/D=122-403. DR PDB; 6GRA; X-ray; 2.60 A; A=122-403. DR PDB; 6HJJ; X-ray; 2.13 A; A=122-403. DR PDB; 6HJK; X-ray; 2.40 A; A=122-403. DR PDB; 6I2U; X-ray; 2.50 A; A=122-403. DR PDB; 6R49; X-ray; 2.21 A; A=122-403. DR PDB; 6R4A; X-ray; 1.94 A; A=122-403. DR PDB; 6R4B; X-ray; 2.15 A; A=122-403. DR PDB; 6R4C; X-ray; 2.04 A; A=122-403. DR PDB; 6R4D; X-ray; 2.01 A; A=122-403. DR PDB; 6VPG; X-ray; 2.64 A; A=117-389. DR PDB; 6VPH; X-ray; 2.14 A; A=117-389. DR PDB; 6VPI; X-ray; 2.00 A; A=117-389. DR PDB; 6VPJ; X-ray; 2.10 A; A=117-389. DR PDB; 6VPL; X-ray; 1.86 A; A/B=117-389. DR PDB; 6VPM; X-ray; 1.58 A; A/B=117-389. DR PDB; 6XKA; X-ray; 2.65 A; A=117-389. DR PDB; 6Z4Y; X-ray; 2.25 A; A=122-403. DR PDB; 7AYH; X-ray; 2.80 A; A=122-403. DR PDB; 7AYI; X-ray; 2.86 A; A=122-403. DR PDB; 7FIC; X-ray; 2.32 A; A=127-391. DR PDB; 7O2V; X-ray; 3.10 A; A=116-403. DR PDB; 7ZTL; X-ray; 1.90 A; A=122-403. DR PDB; 8C14; X-ray; 1.93 A; A=125-391. DR PDB; 8C15; X-ray; 2.41 A; A=126-388. DR PDB; 8C1D; X-ray; 2.12 A; A=126-388. DR PDB; 8C1E; X-ray; 2.80 A; A=125-391. DR PDB; 8C1F; X-ray; 1.92 A; A=126-388. DR PDB; 8C1G; X-ray; 1.96 A; A=126-388. DR PDB; 8C1H; X-ray; 2.23 A; A=126-388. DR PDB; 8C1I; X-ray; 2.81 A; A=126-388. DR PDB; 8C1K; X-ray; 2.43 A; A=126-390. DR PDB; 8C1M; X-ray; 2.84 A; A=125-391. DR PDB; 8GUW; X-ray; 2.70 A; A/B/C=123-403. DR PDB; 8JF4; X-ray; 2.89 A; A=127-389. DR PDB; 8JG8; X-ray; 2.90 A; A=127-389. DR PDB; 8JMX; X-ray; 2.95 A; A=127-389. DR PDB; 8OF5; X-ray; 1.97 A; A=122-403. DR PDB; 8PR7; X-ray; 2.76 A; A/D=122-403. DR PDB; 8SSO; X-ray; 1.97 A; A/D=122-403. DR PDB; 8SSP; X-ray; 2.60 A; A=122-403. DR PDB; 9BZG; X-ray; 1.80 A; A=122-403. DR PDB; 9BZL; X-ray; 1.81 A; B=122-403. DR PDBsum; 1MQ4; -. DR PDBsum; 1MUO; -. DR PDBsum; 1OL5; -. DR PDBsum; 1OL6; -. DR PDBsum; 1OL7; -. DR PDBsum; 2BMC; -. DR PDBsum; 2C6D; -. DR PDBsum; 2C6E; -. DR PDBsum; 2DWB; -. DR PDBsum; 2J4Z; -. DR PDBsum; 2J50; -. DR PDBsum; 2NP8; -. DR PDBsum; 2W1C; -. DR PDBsum; 2W1D; -. DR PDBsum; 2W1E; -. DR PDBsum; 2W1F; -. DR PDBsum; 2W1G; -. DR PDBsum; 2WQE; -. DR PDBsum; 2WTV; -. DR PDBsum; 2WTW; -. DR PDBsum; 2X6D; -. DR PDBsum; 2X6E; -. DR PDBsum; 2X81; -. DR PDBsum; 2XNE; -. DR PDBsum; 2XNG; -. DR PDBsum; 2XRU; -. DR PDBsum; 3COH; -. DR PDBsum; 3E5A; -. DR PDBsum; 3EFW; -. DR PDBsum; 3FDN; -. DR PDBsum; 3H0Y; -. DR PDBsum; 3H0Z; -. DR PDBsum; 3H10; -. DR PDBsum; 3HA6; -. DR PDBsum; 3K5U; -. DR PDBsum; 3LAU; -. DR PDBsum; 3M11; -. DR PDBsum; 3MYG; -. DR PDBsum; 3NRM; -. DR PDBsum; 3O50; -. DR PDBsum; 3O51; -. DR PDBsum; 3P9J; -. DR PDBsum; 3QBN; -. DR PDBsum; 3R21; -. DR PDBsum; 3R22; -. DR PDBsum; 3UNZ; -. DR PDBsum; 3UO4; -. DR PDBsum; 3UO5; -. DR PDBsum; 3UO6; -. DR PDBsum; 3UOD; -. DR PDBsum; 3UOH; -. DR PDBsum; 3UOJ; -. DR PDBsum; 3UOK; -. DR PDBsum; 3UOL; -. DR PDBsum; 3UP2; -. DR PDBsum; 3UP7; -. DR PDBsum; 3VAP; -. DR PDBsum; 3W10; -. DR PDBsum; 3W16; -. DR PDBsum; 3W18; -. DR PDBsum; 3W2C; -. DR PDBsum; 4B0G; -. DR PDBsum; 4BN1; -. DR PDBsum; 4BYI; -. DR PDBsum; 4BYJ; -. DR PDBsum; 4C3P; -. DR PDBsum; 4C3R; -. DR PDBsum; 4CEG; -. DR PDBsum; 4DEA; -. DR PDBsum; 4DEB; -. DR PDBsum; 4DED; -. DR PDBsum; 4DEE; -. DR PDBsum; 4DHF; -. DR PDBsum; 4J8M; -. DR PDBsum; 4J8N; -. DR PDBsum; 4JAI; -. DR PDBsum; 4JAJ; -. DR PDBsum; 4JBO; -. DR PDBsum; 4JBP; -. DR PDBsum; 4JBQ; -. DR PDBsum; 4O0S; -. DR PDBsum; 4O0U; -. DR PDBsum; 4O0W; -. DR PDBsum; 4PRJ; -. DR PDBsum; 4UYN; -. DR PDBsum; 4UZD; -. DR PDBsum; 4UZH; -. DR PDBsum; 4ZS0; -. DR PDBsum; 4ZTQ; -. DR PDBsum; 4ZTR; -. DR PDBsum; 4ZTS; -. DR PDBsum; 5AAD; -. DR PDBsum; 5AAE; -. DR PDBsum; 5AAF; -. DR PDBsum; 5AAG; -. DR PDBsum; 5DN3; -. DR PDBsum; 5DNR; -. DR PDBsum; 5DOS; -. DR PDBsum; 5DPV; -. DR PDBsum; 5DR2; -. DR PDBsum; 5DR6; -. DR PDBsum; 5DR9; -. DR PDBsum; 5DRD; -. DR PDBsum; 5DT0; -. DR PDBsum; 5DT3; -. DR PDBsum; 5DT4; -. DR PDBsum; 5EW9; -. DR PDBsum; 5G15; -. DR PDBsum; 5G1X; -. DR PDBsum; 5L8J; -. DR PDBsum; 5L8K; -. DR PDBsum; 5L8L; -. DR PDBsum; 5LXM; -. DR PDBsum; 5OBJ; -. DR PDBsum; 5OBR; -. DR PDBsum; 5ODT; -. DR PDBsum; 5ONE; -. DR PDBsum; 5ORL; -. DR PDBsum; 5ORN; -. DR PDBsum; 5ORO; -. DR PDBsum; 5ORP; -. DR PDBsum; 5ORR; -. DR PDBsum; 5ORS; -. DR PDBsum; 5ORT; -. DR PDBsum; 5ORV; -. DR PDBsum; 5ORW; -. DR PDBsum; 5ORX; -. DR PDBsum; 5ORY; -. DR PDBsum; 5ORZ; -. DR PDBsum; 5OS0; -. DR PDBsum; 5OS1; -. DR PDBsum; 5OS2; -. DR PDBsum; 5OS3; -. DR PDBsum; 5OS4; -. DR PDBsum; 5OS5; -. DR PDBsum; 5OS6; -. DR PDBsum; 5OSD; -. DR PDBsum; 5OSE; -. DR PDBsum; 5OSF; -. DR PDBsum; 5ZAN; -. DR PDBsum; 6C2R; -. DR PDBsum; 6C2T; -. DR PDBsum; 6C83; -. DR PDBsum; 6CPE; -. DR PDBsum; 6CPF; -. DR PDBsum; 6CPG; -. DR PDBsum; 6GRA; -. DR PDBsum; 6HJJ; -. DR PDBsum; 6HJK; -. DR PDBsum; 6I2U; -. DR PDBsum; 6R49; -. DR PDBsum; 6R4A; -. DR PDBsum; 6R4B; -. DR PDBsum; 6R4C; -. DR PDBsum; 6R4D; -. DR PDBsum; 6VPG; -. DR PDBsum; 6VPH; -. DR PDBsum; 6VPI; -. DR PDBsum; 6VPJ; -. DR PDBsum; 6VPL; -. DR PDBsum; 6VPM; -. DR PDBsum; 6XKA; -. DR PDBsum; 6Z4Y; -. DR PDBsum; 7AYH; -. DR PDBsum; 7AYI; -. DR PDBsum; 7FIC; -. DR PDBsum; 7O2V; -. DR PDBsum; 7ZTL; -. DR PDBsum; 8C14; -. DR PDBsum; 8C15; -. DR PDBsum; 8C1D; -. DR PDBsum; 8C1E; -. DR PDBsum; 8C1F; -. DR PDBsum; 8C1G; -. DR PDBsum; 8C1H; -. DR PDBsum; 8C1I; -. DR PDBsum; 8C1K; -. DR PDBsum; 8C1M; -. DR PDBsum; 8GUW; -. DR PDBsum; 8JF4; -. DR PDBsum; 8JG8; -. DR PDBsum; 8JMX; -. DR PDBsum; 8OF5; -. DR PDBsum; 8PR7; -. DR PDBsum; 8SSO; -. DR PDBsum; 8SSP; -. DR PDBsum; 9BZG; -. DR PDBsum; 9BZL; -. DR AlphaFoldDB; O14965; -. DR SMR; O14965; -. DR BioGRID; 112666; 697. DR CORUM; O14965; -. DR DIP; DIP-33068N; -. DR ELM; O14965; -. DR FunCoup; O14965; 1695. DR IntAct; O14965; 219. DR MINT; O14965; -. DR STRING; 9606.ENSP00000216911; -. DR BindingDB; O14965; -. DR ChEMBL; CHEMBL4722; -. DR DrugBank; DB07362; 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB07360; 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea. DR DrugBank; DB08065; 2-(1H-pyrazol-3-yl)-1H-benzimidazole. DR DrugBank; DB07186; 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE. DR DrugBank; DB07266; AKI-001. DR DrugBank; DB05220; Alisertib. DR DrugBank; DB17197; AMG-900. DR DrugBank; DB05169; AT9283. DR DrugBank; DB06347; Cenisertib. DR DrugBank; DB05198; CYC116. DR DrugBank; DB11778; Danusertib. DR DrugBank; DB16891; ENMD-981693. DR DrugBank; DB06486; Enzastaurin. DR DrugBank; DB18019; Erbumine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB11694; Ilorasertib. DR DrugBank; DB12556; MK-5108. DR DrugBank; DB13061; MLN8054. DR DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE. DR DrugBank; DB07801; N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide. DR DrugBank; DB07545; N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE. DR DrugBank; DB12072; Orantinib. DR DrugBank; DB13059; PF-03814735. DR DrugBank; DB02482; Phosphonothreonine. DR DrugBank; DB06134; SNS-314. DR DrugCentral; O14965; -. DR GuidetoPHARMACOLOGY; 1936; -. DR GlyGen; O14965; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O14965; -. DR PhosphoSitePlus; O14965; -. DR BioMuta; AURKA; -. DR CPTAC; CPTAC-1341; -. DR CPTAC; CPTAC-3083; -. DR CPTAC; CPTAC-3084; -. DR jPOST; O14965; -. DR MassIVE; O14965; -. DR PaxDb; 9606-ENSP00000216911; -. DR PeptideAtlas; O14965; -. DR ProteomicsDB; 48339; -. DR Pumba; O14965; -. DR ABCD; O14965; 7 sequenced antibodies. DR Antibodypedia; 1129; 1084 antibodies from 47 providers. DR DNASU; 6790; -. DR Ensembl; ENST00000312783.10; ENSP00000321591.6; ENSG00000087586.19. DR Ensembl; ENST00000347343.6; ENSP00000216911.2; ENSG00000087586.19. DR Ensembl; ENST00000371356.6; ENSP00000360407.2; ENSG00000087586.19. DR Ensembl; ENST00000395911.5; ENSP00000379247.1; ENSG00000087586.19. DR Ensembl; ENST00000395913.7; ENSP00000379249.3; ENSG00000087586.19. DR Ensembl; ENST00000395914.5; ENSP00000379250.1; ENSG00000087586.19. DR Ensembl; ENST00000395915.8; ENSP00000379251.3; ENSG00000087586.19. DR GeneID; 6790; -. DR KEGG; hsa:6790; -. DR MANE-Select; ENST00000395915.8; ENSP00000379251.3; NM_198437.3; NP_940839.1. DR UCSC; uc002xxe.1; human. DR AGR; HGNC:11393; -. DR CIViC; 6790; 8 evidence items across 3 molecular profiles. DR ClinPGx; PA36201; -. DR CTD; 6790; -. DR DisGeNET; 6790; -. DR GeneCards; AURKA; -. DR HGNC; HGNC:11393; AURKA. DR HPA; ENSG00000087586; Tissue enhanced (lymphoid tissue, testis). DR MalaCards; AURKA; -. DR MIM; 603072; gene. DR OpenTargets; ENSG00000087586; -. DR VEuPathDB; HostDB:ENSG00000087586; -. DR eggNOG; KOG0580; Eukaryota. DR GeneTree; ENSGT00940000154900; -. DR InParanoid; O14965; -. DR OMA; KIMNLMF; -. DR OrthoDB; 377346at2759; -. DR PAN-GO; O14965; 6 GO annotations based on evolutionary models. DR PhylomeDB; O14965; -. DR BRENDA; 2.7.11.1; 2681. DR PathwayCommons; O14965; -. DR Reactome; R-HSA-174178; APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1. DR Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition. DR Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins. DR Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis. DR Reactome; R-HSA-8854518; AURKA Activation by TPX2. DR Reactome; R-HSA-8854521; Interaction between PHLDA1 and AURKA. DR SignaLink; O14965; -. DR SIGNOR; O14965; -. DR Agora; ENSG00000087586; -. DR BioGRID-ORCS; 6790; 713 hits in 1214 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR ChiTaRS; AURKA; human. DR EvolutionaryTrace; O14965; -. DR GeneWiki; Aurora_A_kinase; -. DR GenomeRNAi; 6790; -. DR Pharos; O14965; Tchem. DR PRO; PR:O14965; -. DR Proteomes; UP000005640; Chromosome 20. DR RNAct; O14965; protein. DR Bgee; ENSG00000087586; Expressed in oocyte and 159 other cell types or tissues. DR ExpressionAtlas; O14965; baseline and differential. DR GO; GO:0043203; C:axon hillock; IEA:Ensembl. DR GO; GO:0016323; C:basolateral plasma membrane; ISS:UniProtKB. DR GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0032133; C:chromosome passenger complex; IBA:GO_Central. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0042585; C:germinal vesicle; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0000776; C:kinetochore; IBA:GO_Central. DR GO; GO:0072687; C:meiotic spindle; IEA:Ensembl. DR GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW. DR GO; GO:0015630; C:microtubule cytoskeleton; IDA:BHF-UCL. DR GO; GO:0030496; C:midbody; TAS:UniProtKB. DR GO; GO:0072686; C:mitotic spindle; IDA:HPA. DR GO; GO:0097431; C:mitotic spindle pole; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:BHF-UCL. DR GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL. DR GO; GO:0014069; C:postsynaptic density; IEA:Ensembl. DR GO; GO:0045120; C:pronucleus; IEA:Ensembl. DR GO; GO:0005819; C:spindle; TAS:UniProtKB. DR GO; GO:0051233; C:spindle midzone; IBA:GO_Central. DR GO; GO:0000922; C:spindle pole; IBA:GO_Central. DR GO; GO:0031616; C:spindle pole centrosome; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0035175; F:histone H3S10 kinase activity; IEA:Ensembl. DR GO; GO:0140677; F:molecular function activator activity; EXP:DisProt. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IMP:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl. DR GO; GO:0009948; P:anterior/posterior axis specification; IEA:Ensembl. DR GO; GO:0006915; P:apoptotic process; IEA:Ensembl. DR GO; GO:0051301; P:cell division; IEA:UniProtKB-KW. DR GO; GO:0051642; P:centrosome localization; IEA:Ensembl. DR GO; GO:0061523; P:cilium disassembly; IMP:UniProtKB. DR GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0097421; P:liver regeneration; IDA:MGI. DR GO; GO:0000278; P:mitotic cell cycle; TAS:ProtInc. DR GO; GO:0007100; P:mitotic centrosome separation; IEA:Ensembl. DR GO; GO:0007052; P:mitotic spindle organization; IBA:GO_Central. DR GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB. DR GO; GO:0032091; P:negative regulation of protein binding; IDA:UniProtKB. DR GO; GO:1990138; P:neuron projection extension; IEA:Ensembl. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0090141; P:positive regulation of mitochondrial fission; IMP:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; ISS:UniProtKB. DR GO; GO:0045840; P:positive regulation of mitotic nuclear division; TAS:UniProtKB. DR GO; GO:1900195; P:positive regulation of oocyte maturation; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0071539; P:protein localization to centrosome; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0046605; P:regulation of centrosome cycle; TAS:UniProtKB. DR GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central. DR GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; TAS:Reactome. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0009611; P:response to wounding; IDA:MGI. DR GO; GO:0007057; P:spindle assembly involved in female meiosis I; IEA:Ensembl. DR GO; GO:0007051; P:spindle organization; IMP:UniProtKB. DR CDD; cd14116; STKc_Aurora-A; 1. DR DisProt; DP03125; -. DR FunFam; 3.30.200.20:FF:000042; Aurora kinase A; 1. DR FunFam; 1.10.510.10:FF:000235; Serine/threonine-protein kinase ark1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR030616; Aur-like. DR InterPro; IPR030611; AURKA. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24350; SERINE/THREONINE-PROTEIN KINASE IAL-RELATED; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Cell cycle; Cell division; Cell membrane; KW Cell projection; Cilium; Cilium biogenesis/degradation; Cytoplasm; KW Cytoskeleton; Isopeptide bond; Kinase; Membrane; Microtubule; Mitosis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Reference proteome; Serine/threonine-protein kinase; KW Transferase; Ubl conjugation. FT CHAIN 1..403 FT /note="Aurora kinase A" FT /id="PRO_0000086692" FT DOMAIN 133..383 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..125 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 280..293 FT /note="Activation segment" FT /evidence="ECO:0000269|PubMed:14580337" FT COMPBIAS 27..83 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 91..101 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 114..125 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 256 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027, FT ECO:0000269|PubMed:14580337" FT BINDING 143 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 162 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 211..213 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 260..261 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT BINDING 274 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27837025, FT ECO:0007744|PDB:5G1X" FT MOD_RES 41 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 51 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17229885" FT MOD_RES 287 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:19668197" FT MOD_RES 288 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:11039908, FT ECO:0000269|PubMed:13678582, ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:16246726, ECO:0000269|PubMed:18662907, FT ECO:0000269|PubMed:19668197, ECO:0000269|PubMed:26246606" FT MOD_RES 342 FT /note="Phosphoserine; by PKA and PAK" FT /evidence="ECO:0000269|PubMed:16246726" FT CROSSLNK 258 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 11 FT /note="G -> R (in dbSNP:rs6069717)" FT /id="VAR_030840" FT VARIANT 31 FT /note="F -> I (in dbSNP:rs2273535)" FT /evidence="ECO:0000269|PubMed:15867347, FT ECO:0000269|PubMed:16011022, ECO:0000269|PubMed:16762494, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9771714" FT /id="VAR_030841" FT VARIANT 50 FT /note="P -> L (in dbSNP:rs34572020)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041127" FT VARIANT 57 FT /note="I -> V (increased kinase activity; dbSNP:rs1047972)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:15867347, ECO:0000269|PubMed:16011022, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9153231, FT ECO:0000269|PubMed:9514916, ECO:0000269|PubMed:9771714" FT /id="VAR_030842" FT VARIANT 104 FT /note="S -> L (in dbSNP:rs2230743)" FT /id="VAR_061745" FT VARIANT 155 FT /note="S -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; reduces interaction with TPX2)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041128" FT VARIANT 174 FT /note="V -> M (in a metastatic melanoma sample; somatic FT mutation; constitutively enhanced kinase activity)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:19801554" FT /id="VAR_041129" FT VARIANT 373 FT /note="M -> V (in dbSNP:rs33923703)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041130" FT MUTAGEN 162 FT /note="K->R: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:14702041" FT MUTAGEN 165 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 198 FT /note="G->N: Reduces interaction with TPX2. Reduces kinase FT activity tenfold. Promotes interaction with the AURKB FT binding partners INCENP and BIRC5 that are normally not FT bound by AURKA." FT /evidence="ECO:0000269|PubMed:19357306" FT MUTAGEN 205 FT /note="R->A: Reduces ubiquitination and proteasomal FT degradation." FT /evidence="ECO:0000269|PubMed:10851084" FT MUTAGEN 274 FT /note="D->N: Abolishes cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:14580337, FT ECO:0000269|PubMed:17604723" FT MUTAGEN 287 FT /note="T->A: No direct effect on catalytic activity." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 287 FT /note="T->E: Enhances interaction with TPX2." FT /evidence="ECO:0000269|PubMed:19668197" FT MUTAGEN 288 FT /note="T->A: Reduces cilia disassembly and kinase FT activity." FT /evidence="ECO:0000269|PubMed:17604723" FT MUTAGEN 288 FT /note="T->D: Mimics phosphorylation state and increases FT kinase activity." FT /evidence="ECO:0000269|PubMed:11039908" FT MUTAGEN 290 FT /note="C->A: Enhances stability; when associated with A- FT 393." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 334 FT /note="Y->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 335 FT /note="Q->A: Reduces binding to MYCN." FT /evidence="ECO:0000269|PubMed:27837025" FT MUTAGEN 346 FT /note="F->A: Decreases the interaction with phosphatase FT type 1 isoforms." FT /evidence="ECO:0000269|PubMed:11551964" FT MUTAGEN 393 FT /note="C->A: Enhances stability; when associated with A- FT 290." FT /evidence="ECO:0000269|PubMed:27837025" FT HELIX 130..132 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 133..141 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 143..152 FT /evidence="ECO:0007829|PDB:6VPM" FT TURN 153..156 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 157..165 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 166..172 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 175..185 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 191..193 FT /evidence="ECO:0007829|PDB:3UO6" FT STRAND 196..201 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 203..210 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 214..217 FT /evidence="ECO:0007829|PDB:2J50" FT HELIX 218..225 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 230..249 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6XKA" FT HELIX 259..261 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 266..268 FT /evidence="ECO:0007829|PDB:3UOL" FT STRAND 270..272 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 275..277 FT /evidence="ECO:0007829|PDB:5ORL" FT STRAND 280..283 FT /evidence="ECO:0007829|PDB:5L8L" FT HELIX 288..291 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 293..295 FT /evidence="ECO:0007829|PDB:5L8J" FT HELIX 298..302 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 304..306 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 307..309 FT /evidence="ECO:0007829|PDB:6C2T" FT HELIX 310..324 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 334..342 FT /evidence="ECO:0007829|PDB:6VPM" FT STRAND 350..352 FT /evidence="ECO:0007829|PDB:8JF4" FT HELIX 354..363 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 368..370 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 374..378 FT /evidence="ECO:0007829|PDB:6VPM" FT HELIX 381..386 FT /evidence="ECO:0007829|PDB:6VPM" SQ SEQUENCE 403 AA; 45823 MW; 7C2E7B438D969187 CRC64; MDRSKENCIS GPVKATAPVG GPKRVLVTQQ FPCQNPLPVN SGQAQRVLCP SNSSQRIPLQ AQKLVSSHKP VQNQKQKQLQ ATSVPHPVSR PLNNTQKSKQ PLPSAPENNP EEELASKQKN EESKKRQWAL EDFEIGRPLG KGKFGNVYLA REKQSKFILA LKVLFKAQLE KAGVEHQLRR EVEIQSHLRH PNILRLYGYF HDATRVYLIL EYAPLGTVYR ELQKLSKFDE QRTATYITEL ANALSYCHSK RVIHRDIKPE NLLLGSAGEL KIADFGWSVH APSSRRTTLC GTLDYLPPEM IEGRMHDEKV DLWSLGVLCY EFLVGKPPFE ANTYQETYKR ISRVEFTFPD FVTEGARDLI SRLLKHNPSQ RPMLREVLEH PWITANSSKP SNCQNKESAS KQS // ID BRD2_HUMAN Reviewed; 801 AA. AC P25440; A2AAU0; B0S7P0; B1AZT1; O00699; O00700; Q15310; Q5STC9; Q63HQ9; AC Q658Y7; Q6P3U2; Q969U4; DT 01-MAY-1992, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2001, sequence version 2. DT 28-JAN-2026, entry version 228. DE RecName: Full=Bromodomain-containing protein 2 {ECO:0000305}; DE AltName: Full=O27.1.1; GN Name=BRD2 {ECO:0000303|PubMed:16227282, ECO:0000312|HGNC:HGNC:1103}; GN Synonyms=KIAA9001 {ECO:0000303|Ref.3}, RING3 {ECO:0000303|PubMed:8781126}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=T-cell; RX PubMed=1352711; DOI=10.3109/10425179209020804; RA Beck S., Hanson I., Kelly A., Pappin D.J.C., Trowsdale J.; RT "A homologue of the Drosophila female sterile homeotic (fsh) gene in the RT class II region of the human MHC."; RL DNA Seq. 2:203-210(1992). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION TO N-TERMINUS. RX PubMed=8781126; DOI=10.1007/bf02602785; RA Thorpe K.L., Abdulla S., Kaufman J., Trowsdale J., Beck S.; RT "Phylogeny and structure of the RING3 gene."; RL Immunogenetics 44:391-396(1996). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Bone marrow; RA Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y., Sato S., RA Nagase T., Seki T., Ishikawa K., Tabata S.; RL Submitted (JUL-1997) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 3 AND 4). RC TISSUE=Bone marrow, and Testis; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PHE-238. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=PNS; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION). RX PubMed=16227282; DOI=10.1128/jvi.79.21.13618-13629.2005; RA Viejo-Borbolla A., Ottinger M., Bruening E., Buerger A., Koenig R., RA Kati E., Sheldon J.A., Schulz T.F.; RT "Brd2/RING3 interacts with a chromatin-binding domain in the Kaposi's RT Sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (LANA- RT 1) that is required for multiple functions of LANA-1."; RL J. Virol. 79:13618-13629(2005). RN [9] RP FUNCTION, INTERACTION WITH ACETYLATED CHROMATIN, AND SUBCELLULAR LOCATION. RX PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018; RA LeRoy G., Rickards B., Flint S.J.; RT "The double bromodomain proteins Brd2 and Brd3 couple histone acetylation RT to transcription."; RL Mol. Cell 30:51-60(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298; SER-301; SER-305 AND RP SER-633, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [11] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; SER-298 AND SER-301, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [13] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE RP ANALYSIS] AT THR-6; SER-298 AND SER-301, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298 AND SER-633, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-298; SER-301 AND SER-305, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [18] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [19] RP FUNCTION. RX PubMed=35410381; DOI=10.1038/s41588-022-01044-9; RA Xie L., Dong P., Qi Y., Hsieh T.S., English B.P., Jung S., Chen X., RA De Marzio M., Casellas R., Chang H.Y., Zhang B., Tjian R., Liu Z.; RT "BRD2 compartmentalizes the accessible genome."; RL Nat. Genet. 54:481-491(2022). RN [20] {ECO:0007744|PDB:2G4A} RP STRUCTURE BY NMR OF 348-455, FUNCTION, SUBUNIT, AND MUTAGENESIS OF VAL-376; RP LEU-381; LEU-383 AND ASN-429. RX PubMed=17848202; DOI=10.1186/1472-6807-7-57; RA Huang H., Zhang J., Shen W., Wang X., Wu J., Wu J., Shi Y.; RT "Solution structure of the second bromodomain of Brd2 and its specific RT interaction with acetylated histone tails."; RL BMC Struct. Biol. 7:57-57(2007). RN [21] RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 73-194, FUNCTION, RP HOMODIMERIZATION, INTERACTION WITH E2F1 AND HISTONE H4, AND MUTAGENESIS OF RP GLN-78; 142-MET-GLN-143; TYR-153; ILE-154; GLU-170; LEU-174; VAL-177 AND RP GLN-182. RX PubMed=17148447; DOI=10.1074/jbc.m605971200; RA Nakamura Y., Umehara T., Nakano K., Jang M.K., Shirouzu M., Morita S., RA Uda-Tochio H., Hamana H., Terada T., Adachi N., Matsumoto T., Tanaka A., RA Horikoshi M., Ozato K., Padmanabhan B., Yokoyama S.; RT "Crystal structure of the human BRD2 bromodomain: insights into RT dimerization and recognition of acetylated histone h4."; RL J. Biol. Chem. 282:4193-4201(2007). RN [22] {ECO:0007744|PDB:2E3K} RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 348-455, FUNCTION, RP HOMODIMERIZATION, DOMAIN, AND MUTAGENESIS OF 111-PRO-ASP-112; RP 112-ASP--ILE-116; TYR-113; ILE-154; 156-ASN--ASP-160; ASN-156; RP 157-LYS--ASP-160; PRO-158 AND ASP-160. RX PubMed=20709061; DOI=10.1016/j.febslet.2010.08.013; RA Umehara T., Nakamura Y., Wakamori M., Ozato K., Yokoyama S., RA Padmanabhan B.; RT "Structural implications for K5/K12-di-acetylated histone H4 recognition by RT the second bromodomain of BRD2."; RL FEBS Lett. 584:3901-3908(2010). RN [23] {ECO:0007744|PDB:1X0J, ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVR, ECO:0007744|PDB:2DVS} RP X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 73-194, FUNCTION, RP HOMODIMERIZATION, AND DOMAIN. RX PubMed=20048151; DOI=10.1074/jbc.m109.062422; RA Umehara T., Nakamura Y., Jang M.K., Nakano K., Tanaka A., Ozato K., RA Padmanabhan B., Yokoyama S.; RT "Structural basis for acetylated histone H4 recognition by the human BRD2 RT bromodomain."; RL J. Biol. Chem. 285:7610-7618(2010). RN [24] RP X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 344-452, FUNCTION, AND ACTIVITY RP REGULATION. RX PubMed=20871596; DOI=10.1038/nature09504; RA Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., RA Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., RA McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., RA Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., RA Bradner J.E.; RT "Selective inhibition of BET bromodomains."; RL Nature 468:1067-1073(2010). RN [25] {ECO:0007744|PDB:5U5S} RP STRUCTURE BY NMR OF 344-455 IN COMPLEX WITH STAT3, FUNCTION, SUBCELLULAR RP LOCATION, AND INTERACTION WITH STAT3. RX PubMed=28262505; DOI=10.1016/j.molcel.2016.12.022; RA Cheung K.L., Zhang F., Jaganathan A., Sharma R., Zhang Q., Konuma T., RA Shen T., Lee J.Y., Ren C., Chen C.H., Lu G., Olson M.R., Zhang W., RA Kaplan M.H., Littman D.R., Walsh M.J., Xiong H., Zeng L., Zhou M.M.; RT "Distinct roles of Brd2 and Brd4 in potentiating the transcriptional RT program for th17 cell differentiation."; RL Mol. Cell 65:1068-1080(2017). RN [26] {ECO:0007744|PDB:6E6J, ECO:0007744|PDB:6ONY} RP X-RAY CRYSTALLOGRAPHY (1.98 ANGSTROMS) OF 73-194 IN COMPLEX WITH ABBV-744 RP INHIBITOR, FUNCTION, AND ACTIVITY REGULATION. RX PubMed=31969702; DOI=10.1038/s41586-020-1930-8; RA Faivre E.J., McDaniel K.F., Albert D.H., Mantena S.R., Plotnik J.P., RA Wilcox D., Zhang L., Bui M.H., Sheppard G.S., Wang L., Sehgal V., Lin X., RA Huang X., Lu X., Uziel T., Hessler P., Lam L.T., Bellin R.J., Mehta G., RA Fidanze S., Pratt J.K., Liu D., Hasvold L.A., Sun C., Panchal S.C., RA Nicolette J.J., Fossey S.L., Park C.H., Longenecker K., Bigelow L., RA Torrent M., Rosenberg S.H., Kati W.M., Shen Y.; RT "Selective inhibition of the BD2 bromodomain of BET proteins in prostate RT cancer."; RL Nature 578:306-310(2020). RN [27] {ECO:0007744|PDB:6SWO, ECO:0007744|PDB:6SWP} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 344-455 IN COMPLEX WITH GSK778 RP AND GSK046, AND ACTIVITY REGULATION. RX PubMed=32193360; DOI=10.1126/science.aaz8455; RA Gilan O., Rioja I., Knezevic K., Bell M.J., Yeung M.M., Harker N.R., RA Lam E.Y.N., Chung C.W., Bamborough P., Petretich M., Urh M., Atkinson S.J., RA Bassil A.K., Roberts E.J., Vassiliadis D., Burr M.L., Preston A.G.S., RA Wellaway C., Werner T., Gray J.R., Michon A.M., Gobbetti T., Kumar V., RA Soden P.E., Haynes A., Vappiani J., Tough D.F., Taylor S., Dawson S.J., RA Bantscheff M., Lindon M., Drewes G., Demont E.H., Daniels D.L., Grandi P., RA Prinjha R.K., Dawson M.A.; RT "Selective targeting of BD1 and BD2 of the BET proteins in cancer and RT immunoinflammation."; RL Science 368:387-394(2020). RN [28] {ECO:0007744|PDB:8SB6} RP X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 86-206 IN COMPLEX WITH RP N6-ACETYL-N6-METHYLLYSINE, FUNCTION, AND MUTAGENESIS OF ASN-156. RX PubMed=37731000; DOI=10.1038/s41586-023-06565-9; RA Lu-Culligan W.J., Connor L.J., Xie Y., Ekundayo B.E., Rose B.T., RA Machyna M., Pintado-Urbanc A.P., Zimmer J.T., Vock I.W., Bhanu N.V., RA King M.C., Garcia B.A., Bleichert F., Simon M.D.; RT "Acetyl-methyllysine marks chromatin at active transcription start sites."; RL Nature 622:173-179(2023). RN [29] RP VARIANTS [LARGE SCALE ANALYSIS] GLU-30; GLY-49; SER-49; PRO-212; PHE-238; RP GLN-260; VAL-474; GLY-558; THR-569; PRO-599 AND LEU-714. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Chromatin reader protein that specifically recognizes and CC binds histone H4 acetylated at 'Lys-5' and 'Lys-12' (H4K5ac and CC H4K12ac, respectively), thereby controlling gene expression and CC remodeling chromatin structures (PubMed:17148447, PubMed:17848202, CC PubMed:18406326, PubMed:20048151, PubMed:20709061, PubMed:20871596). CC Recruits transcription factors and coactivators to target gene sites, CC and activates RNA polymerase II machinery for transcriptional CC elongation (PubMed:28262505). Plays a key role in genome CC compartmentalization via its association with CTCF and cohesin: CC recruited to chromatin by CTCF and promotes formation of topologically CC associating domains (TADs) via its ability to bind acetylated histones, CC contributing to CTCF boundary formation and enhancer insulation CC (PubMed:35410381). Also recognizes and binds acetylated non-histone CC proteins, such as STAT3 (PubMed:28262505). Involved in inflammatory CC response by regulating differentiation of naive CD4(+) T-cells into T- CC helper Th17: recognizes and binds STAT3 acetylated at 'Lys-87', CC promoting STAT3 recruitment to chromatin (PubMed:28262505). In addition CC to acetylated lysines, also recognizes and binds lysine residues on CC histones that are both methylated and acetylated on the same side chain CC to form N6-acetyl-N6-methyllysine (Kacme), an epigenetic mark of active CC chromatin associated with increased transcriptional initiation CC (PubMed:37731000). Specifically binds histone H4 acetyl-methylated at CC 'Lys-5' and 'Lys-12' (H4K5acme and H4K12acme, respectively) CC (PubMed:37731000). {ECO:0000269|PubMed:17148447, CC ECO:0000269|PubMed:17848202, ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:20871596, ECO:0000269|PubMed:28262505, CC ECO:0000269|PubMed:35410381, ECO:0000269|PubMed:37731000}. CC -!- ACTIVITY REGULATION: Inhibited by JQ1, a thieno-triazolo-1,4-diazepine CC derivative, which specifically inhibits members of the BET family CC (BRD2, BRD3 and BRD4) (PubMed:20871596). The first bromo domain is CC inhibited by GSK778 (iBET-BD1), which specifically inhibits the first CC bromo domain of members of the BET family (BRD2, BRD3 and BRD4) CC (PubMed:32193360). The second bromo domain is inhibited by ABBV-744, CC which specifically inhibits the second bromo domain of members of the CC BET family (BRD2, BRD3 and BRD4) (PubMed:31969702). The second bromo CC domain is inhibited by GSK046 (iBET-BD2), which specifically inhibits CC the second bromo domain of members of the BET family (BRD2, BRD3 and CC BRD4) (PubMed:32193360). {ECO:0000269|PubMed:20871596, CC ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SUBUNIT: Homodimer (PubMed:17148447, PubMed:17848202, PubMed:20048151, CC PubMed:20709061). Interacts with E2F1 (PubMed:17148447). Interacts with CC (acetylated) STAT3; promoting STAT3 recruitment to chromatin CC (PubMed:28262505). Interacts with CTCF; promoting BRD2 recruitment to CC chromatin (By similarity). {ECO:0000250|UniProtKB:Q7JJ13, CC ECO:0000269|PubMed:17148447, ECO:0000269|PubMed:17848202, CC ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:28262505}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein CC LANA1. {ECO:0000269|PubMed:16227282}. CC -!- INTERACTION: CC P25440; P62805: H4C9; NbExp=5; IntAct=EBI-2874802, EBI-302023; CC P25440; Q13761: RUNX3; NbExp=8; IntAct=EBI-2874802, EBI-925990; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:25593309}. Chromosome {ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:25593309, ECO:0000269|PubMed:28262505}. CC Note=Detected on chromatin and nucleosomes. CC {ECO:0000269|PubMed:18406326}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=P25440-1; Sequence=Displayed; CC Name=2; CC IsoId=P25440-2; Sequence=VSP_022600; CC Name=3; CC IsoId=P25440-3; Sequence=VSP_055029; CC Name=4; CC IsoId=P25440-4; Sequence=VSP_055028; CC -!- DOMAIN: The first bromo domain specifically recognizes histone H4 CC acetylated at 'Lys-12' (H4K12ac) (PubMed:20048151). It also CC specifically binds histone H4 acetyl-methylated at 'Lys-5' and 'Lys-12' CC (H4K5acme and H4K12acme, respectively) (PubMed:37731000). The second CC bromo domain recognizes and binds histone H4 acetylated at 'Lys-5' and CC 'Lys-12' (H4K5ac and H4K12ac, respectively) (PubMed:20709061). CC {ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, CC ECO:0000269|PubMed:37731000}. CC -!- MISCELLANEOUS: Some specific inhibitors of BRD2 that prevent binding to CC acetylated histone are promising therapeutic molecules for the CC treatment of cancers or inflammatory diseases (PubMed:31969702, CC PubMed:32193360). ABBV-744, a small molecule, has been tested on tumors CC with success: ABBV-744 antiproliferative activity is mainly restricted CC to cell lines of acute myeloid leukaemia and prostate cancer and is CC able to displace BRD4 from chromatin (PubMed:31969702). GSK046 (iBET- CC BD2), which specifically inhibits the second bromo domain, is a CC promising therapeutic small molecule for the treatment of inflammatory CC and autoimmune diseases (PubMed:32193360). CC {ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA68890.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X62083; CAA43996.1; -; mRNA. DR EMBL; M80613; AAA68890.1; ALT_INIT; mRNA. DR EMBL; X96670; CAA65450.1; -; Genomic_DNA. DR EMBL; Z96104; CAC69989.1; -; Genomic_DNA. DR EMBL; D42040; BAA07641.1; -; mRNA. DR EMBL; BX647233; CAH56179.1; -; mRNA. DR EMBL; BX648109; CAH56171.1; -; mRNA. DR EMBL; AL832722; CAH56208.1; -; mRNA. DR EMBL; AL645941; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL662845; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL805913; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX005422; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BX908719; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CR936909; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL935042; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471081; EAX03662.1; -; Genomic_DNA. DR EMBL; CH471081; EAX03663.1; -; Genomic_DNA. DR EMBL; BC063840; AAH63840.1; -; mRNA. DR CCDS; CCDS4762.1; -. [P25440-1] DR CCDS; CCDS56420.1; -. [P25440-2] DR PIR; A56619; A56619. DR RefSeq; NP_001106653.1; NM_001113182.3. [P25440-1] DR RefSeq; NP_001186384.1; NM_001199455.1. [P25440-2] DR RefSeq; NP_001186385.1; NM_001199456.2. [P25440-3] DR RefSeq; NP_001278915.1; NM_001291986.2. [P25440-4] DR RefSeq; NP_005095.1; NM_005104.4. [P25440-1] DR PDB; 1X0J; X-ray; 1.80 A; A/B/C=73-194. DR PDB; 2DVQ; X-ray; 2.04 A; A/B/C=73-194. DR PDB; 2DVR; X-ray; 2.30 A; A/B/C=73-194. DR PDB; 2DVS; X-ray; 2.04 A; A/B/C=73-194. DR PDB; 2DVV; X-ray; 1.80 A; A=348-455. DR PDB; 2E3K; X-ray; 2.30 A; A/B/C/D=348-455. DR PDB; 2G4A; NMR; -; A=348-455. DR PDB; 2YDW; X-ray; 1.90 A; A/B/C=67-200. DR PDB; 2YEK; X-ray; 1.98 A; A/B/C=67-200. DR PDB; 3AQA; X-ray; 2.30 A; A/B/C=73-194. DR PDB; 3ONI; X-ray; 1.61 A; A=344-455. DR PDB; 4A9E; X-ray; 1.91 A; A/B/C=67-200. DR PDB; 4A9F; X-ray; 1.73 A; A/B/C=67-200. DR PDB; 4A9H; X-ray; 2.05 A; A/B/C=67-200. DR PDB; 4A9I; X-ray; 2.25 A; A/B/C=67-200. DR PDB; 4A9J; X-ray; 1.90 A; A/B/C=67-200. DR PDB; 4A9M; X-ray; 2.06 A; A/B/C=67-200. DR PDB; 4A9N; X-ray; 1.85 A; A/B/C=67-200. DR PDB; 4A9O; X-ray; 1.78 A; A/B/C=67-200. DR PDB; 4AKN; X-ray; 1.82 A; A/B/C=67-200. DR PDB; 4ALG; X-ray; 1.60 A; A=67-200. DR PDB; 4ALH; X-ray; 1.78 A; A/B/C=67-200. DR PDB; 4J1P; X-ray; 1.08 A; A=344-455. DR PDB; 4MR5; X-ray; 1.63 A; A=344-455. DR PDB; 4MR6; X-ray; 1.67 A; A=344-455. DR PDB; 4QEU; X-ray; 1.50 A; A=344-455. DR PDB; 4QEV; X-ray; 1.80 A; A=344-455. DR PDB; 4QEW; X-ray; 1.70 A; A=344-455. DR PDB; 4UYF; X-ray; 1.60 A; A/B/C=67-200. DR PDB; 4UYG; X-ray; 2.50 A; A/B/C/D/E/F=338-473. DR PDB; 4UYH; X-ray; 1.73 A; A/B/C=67-200. DR PDB; 5BT5; X-ray; 1.40 A; A=344-455. DR PDB; 5DFB; X-ray; 1.40 A; A=344-455. DR PDB; 5DFC; X-ray; 1.50 A; A=344-455. DR PDB; 5DFD; X-ray; 1.50 A; A=344-455. DR PDB; 5DW1; X-ray; 1.55 A; A/B/C/D=345-455. DR PDB; 5EK9; X-ray; 2.08 A; A/B=344-455. DR PDB; 5HEL; X-ray; 1.45 A; A=71-194. DR PDB; 5HEM; X-ray; 1.65 A; A/B=71-194. DR PDB; 5HEN; X-ray; 1.79 A; A/B/C=71-194. DR PDB; 5HFQ; X-ray; 1.40 A; A=344-455. DR PDB; 5IBN; X-ray; 0.94 A; A=348-455. DR PDB; 5IG6; X-ray; 0.91 A; A=348-454. DR PDB; 5N2L; X-ray; 1.89 A; A/B/C/D=344-455. DR PDB; 5O38; X-ray; 1.20 A; A=344-455. DR PDB; 5O39; X-ray; 1.74 A; A=344-455. DR PDB; 5O3A; X-ray; 2.40 A; A=344-455. DR PDB; 5O3B; X-ray; 1.95 A; A/B/C/D=344-455. DR PDB; 5O3C; X-ray; 1.60 A; A=344-455. DR PDB; 5O3D; X-ray; 1.60 A; A=345-455. DR PDB; 5O3E; X-ray; 1.40 A; A=344-455. DR PDB; 5O3F; X-ray; 1.75 A; A=344-455. DR PDB; 5O3G; X-ray; 1.85 A; A/B=344-455. DR PDB; 5O3H; X-ray; 1.40 A; A=344-455. DR PDB; 5O3I; X-ray; 1.20 A; A=344-455. DR PDB; 5S9O; X-ray; 2.49 A; A/B=73-194. DR PDB; 5U5S; NMR; -; A=344-455. DR PDB; 5U6V; X-ray; 1.77 A; A=347-455. DR PDB; 5UEW; X-ray; 1.83 A; A/B=347-454. DR PDB; 5XHE; X-ray; 1.40 A; A=348-455. DR PDB; 5XHK; X-ray; 1.28 A; A=348-455. DR PDB; 6CUI; NMR; -; A=621-750. DR PDB; 6DB0; X-ray; 1.70 A; A/B/C=67-200. DR PDB; 6DBC; X-ray; 1.05 A; A=348-455. DR PDB; 6DDI; X-ray; 1.50 A; A/B/C=67-200. DR PDB; 6DDJ; X-ray; 1.05 A; A=348-455. DR PDB; 6E6J; X-ray; 2.44 A; A/B/C/D/E/F=348-455. DR PDB; 6FFE; X-ray; 1.76 A; A=344-455. DR PDB; 6FFF; X-ray; 1.67 A; A=344-455. DR PDB; 6FFG; X-ray; 1.59 A; A=344-455. DR PDB; 6I80; X-ray; 1.14 A; A/B=348-455. DR PDB; 6I81; X-ray; 1.74 A; A=348-455. DR PDB; 6JKE; X-ray; 1.50 A; A/B/C=73-194. DR PDB; 6K04; X-ray; 1.25 A; A=344-455. DR PDB; 6K05; X-ray; 1.94 A; A/B/C=73-194. DR PDB; 6MO7; X-ray; 1.85 A; A/B/C=71-194. DR PDB; 6MO8; X-ray; 1.80 A; A/B/C=71-194. DR PDB; 6MO9; X-ray; 1.80 A; A/B/C=71-194. DR PDB; 6MOA; X-ray; 1.27 A; A=346-455. DR PDB; 6ONY; X-ray; 1.98 A; A/B=73-194. DR PDB; 6SWO; X-ray; 1.60 A; AAA=344-455. DR PDB; 6SWP; X-ray; 1.60 A; AAA=344-455. DR PDB; 6TQ1; X-ray; 1.90 A; AAA/BBB/CCC=67-200. DR PDB; 6TQ2; X-ray; 2.26 A; AAA/BBB/CCC=67-200. DR PDB; 6U61; X-ray; 2.29 A; A/B=65-194. DR PDB; 6U71; X-ray; 1.47 A; A=347-455. DR PDB; 6U8H; X-ray; 2.07 A; A=65-194. DR PDB; 6ULQ; X-ray; 2.70 A; A/B/C=65-194. DR PDB; 6ULT; X-ray; 2.80 A; A/B/C/D/E/F/G/H=347-454. DR PDB; 6VIY; X-ray; 1.90 A; A/B=348-455. DR PDB; 6WWB; X-ray; 1.31 A; A=348-455. DR PDB; 6YTM; X-ray; 1.56 A; A/B=345-455. DR PDB; 6Z7F; X-ray; 1.60 A; AAA=344-455. DR PDB; 6Z8P; X-ray; 1.55 A; AAA=344-455. DR PDB; 6ZB0; X-ray; 1.61 A; AAA=344-455. DR PDB; 6ZB1; X-ray; 1.60 A; AAA=344-455. DR PDB; 6ZB2; X-ray; 2.28 A; AAA=344-455. DR PDB; 7DPN; X-ray; 1.80 A; A/B/C=73-194. DR PDB; 7DPO; X-ray; 2.30 A; A=348-455. DR PDB; 7ENV; X-ray; 2.45 A; A/B/C=73-194. DR PDB; 7ENZ; X-ray; 1.70 A; A=348-455. DR PDB; 7EO5; X-ray; 2.00 A; A=348-455. DR PDB; 7JX7; X-ray; 1.75 A; A=347-455. DR PDB; 7L6D; X-ray; 1.55 A; A=344-455. DR PDB; 7L9G; X-ray; 1.36 A; A=344-455. DR PDB; 7L9J; X-ray; 1.85 A; A=344-455. DR PDB; 7L9K; X-ray; 1.95 A; A/B=344-455. DR PDB; 7LAK; X-ray; 1.83 A; A=73-194. DR PDB; 7NPY; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NPZ; X-ray; 1.28 A; AAA=344-455. DR PDB; 7NQ0; X-ray; 1.30 A; AAA=344-455. DR PDB; 7NQ1; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ2; X-ray; 1.74 A; AAA=344-455. DR PDB; 7NQ3; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ5; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQ7; X-ray; 1.70 A; AAA=344-455. DR PDB; 7NQ8; X-ray; 1.60 A; A=344-455. DR PDB; 7NQ9; X-ray; 1.60 A; AAA=344-455. DR PDB; 7NQI; X-ray; 1.60 A; A=344-455. DR PDB; 7NQJ; X-ray; 1.73 A; A=344-455. DR PDB; 7OE4; X-ray; 1.65 A; AAA=344-455. DR PDB; 7OE5; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OE6; X-ray; 1.76 A; AAA=344-455. DR PDB; 7OE8; X-ray; 1.30 A; A=344-455. DR PDB; 7OE9; X-ray; 1.60 A; A=344-455. DR PDB; 7OEP; X-ray; 1.80 A; AAA=344-455. DR PDB; 7OER; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OES; X-ray; 1.60 A; AAA=344-455. DR PDB; 7OET; X-ray; 1.41 A; AAA=344-455. DR PDB; 7OGY; X-ray; 1.60 A; AAA=344-455. DR PDB; 7Q5O; X-ray; 1.52 A; A=346-454. DR PDB; 7USG; X-ray; 1.20 A; A=348-455. DR PDB; 7USH; X-ray; 1.27 A; A=348-455. DR PDB; 7USI; X-ray; 2.50 A; A/B/C/D/E/F=73-183. DR PDB; 7UU0; X-ray; 1.30 A; A=344-455. DR PDB; 7VRH; X-ray; 2.20 A; A/B/C=73-194. DR PDB; 7VRI; X-ray; 1.50 A; A=348-455. DR PDB; 7VRK; X-ray; 2.48 A; A/B/C=73-194. DR PDB; 7VRM; X-ray; 1.10 A; A=348-455. DR PDB; 7VRO; X-ray; 2.35 A; A/B/C=73-194. DR PDB; 7VRQ; X-ray; 1.15 A; A=348-455. DR PDB; 7VRZ; X-ray; 2.05 A; A/B/C=73-194. DR PDB; 7VS0; X-ray; 1.25 A; A=348-455. DR PDB; 7VS1; X-ray; 1.25 A; A=348-455. DR PDB; 7VSF; X-ray; 2.50 A; A/B/C=73-194. DR PDB; 7WLN; X-ray; 2.85 A; A/B/C/D=344-455. DR PDB; 7WMQ; X-ray; 2.37 A; A/B/C/D=344-455. DR PDB; 7WMU; X-ray; 1.73 A; A=344-455. DR PDB; 7WN5; X-ray; 1.70 A; A/B=344-455. DR PDB; 7WNA; X-ray; 2.60 A; A/B/C/D/E/F=344-455. DR PDB; 7WNI; X-ray; 3.12 A; A/B=344-455. DR PDB; 8B5G; X-ray; 1.62 A; AAA=344-455. DR PDB; 8B5H; X-ray; 1.60 A; AAA=344-455. DR PDB; 8B5I; X-ray; 1.60 A; AAA=344-455. DR PDB; 8B5J; X-ray; 1.60 A; AAA=344-455. DR PDB; 8CV7; X-ray; 1.60 A; A/B=347-455. DR PDB; 8DNQ; X-ray; 1.84 A; A/B=65-194. DR PDB; 8PX2; X-ray; 1.62 A; A=344-455. DR PDB; 8PX8; X-ray; 1.60 A; A=344-455. DR PDB; 8SB6; X-ray; 1.80 A; A/B/C=86-206. DR PDB; 8UGU; X-ray; 2.34 A; A/B/C/D=348-455. DR PDB; 8UGV; X-ray; 1.99 A; A/B=348-455. DR PDB; 8WYG; X-ray; 3.13 A; A/B/C/D=344-455. DR PDB; 8Z69; X-ray; 1.77 A; A/B/C/D=344-455. DR PDB; 9FBX; X-ray; 1.60 A; A=344-455. DR PDBsum; 1X0J; -. DR PDBsum; 2DVQ; -. DR PDBsum; 2DVR; -. DR PDBsum; 2DVS; -. DR PDBsum; 2DVV; -. DR PDBsum; 2E3K; -. DR PDBsum; 2G4A; -. DR PDBsum; 2YDW; -. DR PDBsum; 2YEK; -. DR PDBsum; 3AQA; -. DR PDBsum; 3ONI; -. DR PDBsum; 4A9E; -. DR PDBsum; 4A9F; -. DR PDBsum; 4A9H; -. DR PDBsum; 4A9I; -. DR PDBsum; 4A9J; -. DR PDBsum; 4A9M; -. DR PDBsum; 4A9N; -. DR PDBsum; 4A9O; -. DR PDBsum; 4AKN; -. DR PDBsum; 4ALG; -. DR PDBsum; 4ALH; -. DR PDBsum; 4J1P; -. DR PDBsum; 4MR5; -. DR PDBsum; 4MR6; -. DR PDBsum; 4QEU; -. DR PDBsum; 4QEV; -. DR PDBsum; 4QEW; -. DR PDBsum; 4UYF; -. DR PDBsum; 4UYG; -. DR PDBsum; 4UYH; -. DR PDBsum; 5BT5; -. DR PDBsum; 5DFB; -. DR PDBsum; 5DFC; -. DR PDBsum; 5DFD; -. DR PDBsum; 5DW1; -. DR PDBsum; 5EK9; -. DR PDBsum; 5HEL; -. DR PDBsum; 5HEM; -. DR PDBsum; 5HEN; -. DR PDBsum; 5HFQ; -. DR PDBsum; 5IBN; -. DR PDBsum; 5IG6; -. DR PDBsum; 5N2L; -. DR PDBsum; 5O38; -. DR PDBsum; 5O39; -. DR PDBsum; 5O3A; -. DR PDBsum; 5O3B; -. DR PDBsum; 5O3C; -. DR PDBsum; 5O3D; -. DR PDBsum; 5O3E; -. DR PDBsum; 5O3F; -. DR PDBsum; 5O3G; -. DR PDBsum; 5O3H; -. DR PDBsum; 5O3I; -. DR PDBsum; 5S9O; -. DR PDBsum; 5U5S; -. DR PDBsum; 5U6V; -. DR PDBsum; 5UEW; -. DR PDBsum; 5XHE; -. DR PDBsum; 5XHK; -. DR PDBsum; 6CUI; -. DR PDBsum; 6DB0; -. DR PDBsum; 6DBC; -. DR PDBsum; 6DDI; -. DR PDBsum; 6DDJ; -. DR PDBsum; 6E6J; -. DR PDBsum; 6FFE; -. DR PDBsum; 6FFF; -. DR PDBsum; 6FFG; -. DR PDBsum; 6I80; -. DR PDBsum; 6I81; -. DR PDBsum; 6JKE; -. DR PDBsum; 6K04; -. DR PDBsum; 6K05; -. DR PDBsum; 6MO7; -. DR PDBsum; 6MO8; -. DR PDBsum; 6MO9; -. DR PDBsum; 6MOA; -. DR PDBsum; 6ONY; -. DR PDBsum; 6SWO; -. DR PDBsum; 6SWP; -. DR PDBsum; 6TQ1; -. DR PDBsum; 6TQ2; -. DR PDBsum; 6U61; -. DR PDBsum; 6U71; -. DR PDBsum; 6U8H; -. DR PDBsum; 6ULQ; -. DR PDBsum; 6ULT; -. DR PDBsum; 6VIY; -. DR PDBsum; 6WWB; -. DR PDBsum; 6YTM; -. DR PDBsum; 6Z7F; -. DR PDBsum; 6Z8P; -. DR PDBsum; 6ZB0; -. DR PDBsum; 6ZB1; -. DR PDBsum; 6ZB2; -. DR PDBsum; 7DPN; -. DR PDBsum; 7DPO; -. DR PDBsum; 7ENV; -. DR PDBsum; 7ENZ; -. DR PDBsum; 7EO5; -. DR PDBsum; 7JX7; -. DR PDBsum; 7L6D; -. DR PDBsum; 7L9G; -. DR PDBsum; 7L9J; -. DR PDBsum; 7L9K; -. DR PDBsum; 7LAK; -. DR PDBsum; 7NPY; -. DR PDBsum; 7NPZ; -. DR PDBsum; 7NQ0; -. DR PDBsum; 7NQ1; -. DR PDBsum; 7NQ2; -. DR PDBsum; 7NQ3; -. DR PDBsum; 7NQ5; -. DR PDBsum; 7NQ7; -. DR PDBsum; 7NQ8; -. DR PDBsum; 7NQ9; -. DR PDBsum; 7NQI; -. DR PDBsum; 7NQJ; -. DR PDBsum; 7OE4; -. DR PDBsum; 7OE5; -. DR PDBsum; 7OE6; -. DR PDBsum; 7OE8; -. DR PDBsum; 7OE9; -. DR PDBsum; 7OEP; -. DR PDBsum; 7OER; -. DR PDBsum; 7OES; -. DR PDBsum; 7OET; -. DR PDBsum; 7OGY; -. DR PDBsum; 7Q5O; -. DR PDBsum; 7USG; -. DR PDBsum; 7USH; -. DR PDBsum; 7USI; -. DR PDBsum; 7UU0; -. DR PDBsum; 7VRH; -. DR PDBsum; 7VRI; -. DR PDBsum; 7VRK; -. DR PDBsum; 7VRM; -. DR PDBsum; 7VRO; -. DR PDBsum; 7VRQ; -. DR PDBsum; 7VRZ; -. DR PDBsum; 7VS0; -. DR PDBsum; 7VS1; -. DR PDBsum; 7VSF; -. DR PDBsum; 7WLN; -. DR PDBsum; 7WMQ; -. DR PDBsum; 7WMU; -. DR PDBsum; 7WN5; -. DR PDBsum; 7WNA; -. DR PDBsum; 7WNI; -. DR PDBsum; 8B5G; -. DR PDBsum; 8B5H; -. DR PDBsum; 8B5I; -. DR PDBsum; 8B5J; -. DR PDBsum; 8CV7; -. DR PDBsum; 8DNQ; -. DR PDBsum; 8PX2; -. DR PDBsum; 8PX8; -. DR PDBsum; 8SB6; -. DR PDBsum; 8UGU; -. DR PDBsum; 8UGV; -. DR PDBsum; 8WYG; -. DR PDBsum; 8Z69; -. DR PDBsum; 9FBX; -. DR AlphaFoldDB; P25440; -. DR SASBDB; P25440; -. DR SMR; P25440; -. DR BioGRID; 111973; 446. DR DIP; DIP-60835N; -. DR FunCoup; P25440; 3292. DR IntAct; P25440; 79. DR MINT; P25440; -. DR STRING; 9606.ENSP00000378702; -. DR BindingDB; P25440; -. DR ChEMBL; CHEMBL1293289; -. DR DrugBank; DB19199; ABBV-744. DR DrugBank; DB15189; Birabresib. DR GuidetoPHARMACOLOGY; 1944; -. DR GlyCosmos; P25440; 6 sites, 2 glycans. DR GlyGen; P25440; 8 sites, 2 O-linked glycans (8 sites). DR iPTMnet; P25440; -. DR PhosphoSitePlus; P25440; -. DR BioMuta; BRD2; -. DR DMDM; 12230989; -. DR CPTAC; CPTAC-1598; -. DR jPOST; P25440; -. DR MassIVE; P25440; -. DR PaxDb; 9606-ENSP00000378704; -. DR PeptideAtlas; P25440; -. DR ProteomicsDB; 54271; -. [P25440-1] DR ProteomicsDB; 54272; -. [P25440-2] DR ProteomicsDB; 65931; -. DR Pumba; P25440; -. DR ABCD; P25440; 1 sequenced antibody. DR Antibodypedia; 28816; 415 antibodies from 39 providers. DR DNASU; 6046; -. DR Ensembl; ENST00000374825.9; ENSP00000363958.4; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000374831.8; ENSP00000363964.4; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000383108.6; ENSP00000372588.2; ENSG00000234507.9. [P25440-1] DR Ensembl; ENST00000395287.5; ENSP00000378702.1; ENSG00000204256.16. [P25440-2] DR Ensembl; ENST00000399527.5; ENSP00000382443.1; ENSG00000215077.10. [P25440-2] DR Ensembl; ENST00000399528.5; ENSP00000382444.1; ENSG00000215077.10. [P25440-1] DR Ensembl; ENST00000399529.7; ENSP00000382445.3; ENSG00000215077.10. [P25440-1] DR Ensembl; ENST00000414731.6; ENSP00000391246.2; ENSG00000234704.9. DR Ensembl; ENST00000436979.5; ENSP00000405634.1; ENSG00000235307.12. [P25440-3] DR Ensembl; ENST00000438194.6; ENSP00000401791.2; ENSG00000234507.9. [P25440-1] DR Ensembl; ENST00000442863.5; ENSP00000410994.1; ENSG00000234507.9. [P25440-2] DR Ensembl; ENST00000448067.5; ENSP00000412885.1; ENSG00000235307.12. [P25440-2] DR Ensembl; ENST00000449085.4; ENSP00000409145.3; ENSG00000204256.16. [P25440-1] DR Ensembl; ENST00000449118.5; ENSP00000399009.1; ENSG00000234704.9. DR Ensembl; ENST00000549126.4; ENSP00000449380.2; ENSG00000235307.12. [P25440-1] DR Ensembl; ENST00000552587.4; ENSP00000449609.1; ENSG00000235307.12. [P25440-1] DR Ensembl; ENST00000678250.1; ENSP00000502900.1; ENSG00000204256.16. [P25440-1] DR GeneID; 6046; -. DR KEGG; hsa:6046; -. DR MANE-Select; ENST00000374825.9; ENSP00000363958.4; NM_005104.4; NP_005095.1. DR UCSC; uc003ocn.4; human. [P25440-1] DR AGR; HGNC:1103; -. DR ClinPGx; PA25414; -. DR CTD; 6046; -. DR DisGeNET; 6046; -. DR GeneCards; BRD2; -. DR HGNC; HGNC:1103; BRD2. DR HPA; ENSG00000204256; Low tissue specificity. DR MIM; 601540; gene. DR OpenTargets; ENSG00000204256; -. DR VEuPathDB; HostDB:ENSG00000204256; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000153385; -. DR HOGENOM; CLU_001499_0_4_1; -. DR InParanoid; P25440; -. DR OMA; GGMDQHT; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; P25440; 5 GO annotations based on evolutionary models. DR PhylomeDB; P25440; -. DR PathwayCommons; P25440; -. DR Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF. DR SignaLink; P25440; -. DR SIGNOR; P25440; -. DR Agora; ENSG00000204256; -. DR BioGRID-ORCS; 6046; 296 hits in 1214 CRISPR screens. DR ChiTaRS; BRD2; human. DR EvolutionaryTrace; P25440; -. DR GeneWiki; BRD2; -. DR GenomeRNAi; 6046; -. DR Pharos; P25440; Tchem. DR PRO; PR:P25440; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; P25440; protein. DR Bgee; ENSG00000204256; Expressed in ventricular zone and 98 other cell types or tissues. DR ExpressionAtlas; P25440; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0140033; F:acetylation-dependent protein binding; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IBA:GO_Central. DR GO; GO:0140015; F:histone H3K14ac reader activity; IDA:GO_Central. DR GO; GO:0140011; F:histone H4K12ac reader activity; IDA:UniProtKB. DR GO; GO:0140012; F:histone H4K5ac reader activity; IDA:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:FlyBase. DR GO; GO:0140588; P:chromatin looping; IDA:UniProtKB. DR GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central. DR GO; GO:0001843; P:neural tube closure; IEA:Ensembl. DR GO; GO:0006334; P:nucleosome assembly; IMP:UniProtKB. DR GO; GO:2000330; P:positive regulation of T-helper 17 cell lineage commitment; IDA:UniProtKB. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0007283; P:spermatogenesis; TAS:ProtInc. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF240; BROMODOMAIN-CONTAINING PROTEIN 2; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromatin regulator; Chromosome; Host-virus interaction; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Transcription; Transcription regulation. FT CHAIN 1..801 FT /note="Bromodomain-containing protein 2" FT /id="PRO_0000211180" FT DOMAIN 74..180 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 344..453 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 632..714 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 53..73 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 268..349 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 456..647 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 737..801 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 555..559 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 285..298 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 316..332 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 481..514 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 544..566 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 592..612 FT /note="Gly residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 763..795 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 112 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 155 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 156 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT BINDING 156 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 157 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-N(6)-methyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:197459" FT /evidence="ECO:0000269|PubMed:37731000, FT ECO:0007744|PDB:8SB6" FT BINDING 160 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT BINDING 161 FT /ligand="a protein" FT /ligand_id="ChEBI:CHEBI:16541" FT /ligand_part="N(6)-acetyl-L-lysine residue" FT /ligand_part_id="ChEBI:CHEBI:61930" FT /evidence="ECO:0000269|PubMed:20048151, FT ECO:0007744|PDB:2DVQ, ECO:0007744|PDB:2DVS" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:20068231" FT MOD_RES 6 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 37 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 298 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 301 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:24275569" FT MOD_RES 305 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:24275569" FT MOD_RES 633 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..120 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_055028" FT VAR_SEQ 1..47 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:17974005" FT /id="VSP_055029" FT VAR_SEQ 615 FT /note="L -> LQAGVQWRDLGLLQPPLLGFKRFSCLSLPSSQDYRL (in FT isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_022600" FT VARIANT 30 FT /note="G -> E (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041904" FT VARIANT 49 FT /note="A -> G (in dbSNP:rs3918144)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041905" FT VARIANT 49 FT /note="A -> S (in dbSNP:rs55669504)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041906" FT VARIANT 212 FT /note="A -> P (in dbSNP:rs35952031)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041907" FT VARIANT 238 FT /note="L -> F (in dbSNP:rs176250)" FT /evidence="ECO:0000269|PubMed:14574404, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022132" FT VARIANT 260 FT /note="P -> Q (in dbSNP:rs35294809)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041908" FT VARIANT 474 FT /note="A -> V (in dbSNP:rs3918143)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_029300" FT VARIANT 547 FT /note="R -> K (in dbSNP:rs1049369)" FT /id="VAR_029301" FT VARIANT 558 FT /note="R -> G (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041909" FT VARIANT 569 FT /note="A -> T (in dbSNP:rs34530779)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041910" FT VARIANT 599 FT /note="A -> P (in dbSNP:rs55952113)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041911" FT VARIANT 714 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041912" FT MUTAGEN 78 FT /note="Q->A: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 111..112 FT /note="PD->AA: Abolished binding to histone H4 acetylated FT at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 112..116 FT /note="DYHKI->AHYA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 113 FT /note="Y->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 142..143 FT /note="MQ->AA: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 153 FT /note="Y->K: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 154 FT /note="I->A: Partial loss of homodimerization; when FT associated with A-182. Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17148447, FT ECO:0000269|PubMed:20709061" FT MUTAGEN 156..160 FT /note="NKPTD->AKPTA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 156 FT /note="N->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac). Abolished binding to histone H4 acetyl- FT methylated." FT /evidence="ECO:0000269|PubMed:20709061, FT ECO:0000269|PubMed:37731000" FT MUTAGEN 157..160 FT /note="KPTD->APTA: Abolished binding to histone H4 FT acetylated at 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 158 FT /note="P->D: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 160 FT /note="D->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:20709061" FT MUTAGEN 170 FT /note="E->A: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 174 FT /note="L->E: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 177 FT /note="V->E: Loss of homodimerization." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 182 FT /note="Q->A: Partial loss of homodimerization; when FT associated with A-154." FT /evidence="ECO:0000269|PubMed:17148447" FT MUTAGEN 376 FT /note="V->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 381 FT /note="L->A: Reduced binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 383 FT /note="L->A: Reduced binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT MUTAGEN 429 FT /note="N->A: Abolished binding to histone H4 acetylated at FT 'Lys-12' (H4K12ac)." FT /evidence="ECO:0000269|PubMed:17848202" FT CONFLICT 490 FT /note="S -> F (in Ref. 4; CAH56179)" FT /evidence="ECO:0000305" FT HELIX 77..84 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 86..91 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 105..108 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 113..116 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 123..131 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 138..155 FT /evidence="ECO:0007829|PDB:5HEL" FT HELIX 161..177 FT /evidence="ECO:0007829|PDB:5HEL" FT STRAND 186..189 FT /evidence="ECO:0007829|PDB:6ULQ" FT HELIX 348..360 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 363..365 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 366..369 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 370..372 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 378..381 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 386..389 FT /evidence="ECO:0007829|PDB:5IG6" FT HELIX 396..404 FT /evidence="ECO:0007829|PDB:5IG6" FT TURN 406..408 FT /evidence="ECO:0007829|PDB:2G4A" FT HELIX 411..428 FT /evidence="ECO:0007829|PDB:5IG6" FT STRAND 431..433 FT /evidence="ECO:0007829|PDB:7WNI" FT HELIX 434..450 FT /evidence="ECO:0007829|PDB:5IG6" FT STRAND 628..631 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 634..638 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 644..654 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 659..670 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 674..678 FT /evidence="ECO:0007829|PDB:6CUI" FT STRAND 681..683 FT /evidence="ECO:0007829|PDB:6CUI" FT TURN 688..690 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 693..707 FT /evidence="ECO:0007829|PDB:6CUI" FT HELIX 725..743 FT /evidence="ECO:0007829|PDB:6CUI" SQ SEQUENCE 801 AA; 88061 MW; 9A075EEB13507D8E CRC64; MLQNVTPHNK LPGEGNAGLL GLGPEAAAPG KRIRKPSLLY EGFESPTMAS VPALQLTPAN PPPPEVSNPK KPGRVTNQLQ YLHKVVMKAL WKHQFAWPFR QPVDAVKLGL PDYHKIIKQP MDMGTIKRRL ENNYYWAASE CMQDFNTMFT NCYIYNKPTD DIVLMAQTLE KIFLQKVASM PQEEQELVVT IPKNSHKKGA KLAALQGSVT SAHQVPAVSS VSHTALYTPP PEIPTTVLNI PHPSVISSPL LKSLHSAGPP LLAVTAAPPA QPLAKKKGVK RKADTTTPTP TAILAPGSPA SPPGSLEPKA ARLPPMRRES GRPIKPPRKD LPDSQQQHQS SKKGKLSEQL KHCNGILKEL LSKKHAAYAW PFYKPVDASA LGLHDYHDII KHPMDLSTVK RKMENRDYRD AQEFAADVRL MFSNCYKYNP PDHDVVAMAR KLQDVFEFRY AKMPDEPLEP GPLPVSTAMP PGLAKSSSES SSEESSSESS SEEEEEEDEE DEEEEESESS DSEEERAHRL AELQEQLRAV HEQLAALSQG PISKPKRKRE KKEKKKKRKA EKHRGRAGAD EDDKGPRAPR PPQPKKSKKA SGSGGGSAAL GPSGFGPSGG SGTKLPKKAT KTAPPALPTG YDSEEEEESR PMSYDEKRQL SLDINKLPGE KLGRVVHIIQ AREPSLRDSN PEEIEIDFET LKPSTLRELE RYVLSCLRKK PRKPYTIKKP VGKTKEELAL EKKRELEKRL QDVSGQLNST KKPPKKANEK TESSSAQQVA VSRLSASSSS SDSSSSSSSS SSSDTSDSDS G // ID BRD3_HUMAN Reviewed; 726 AA. AC Q15059; B1APD9; Q4G5Y3; Q5T1R7; Q8N5M3; Q92645; DT 11-JAN-2001, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 213. DE RecName: Full=Bromodomain-containing protein 3; DE AltName: Full=RING3-like protein; GN Name=BRD3 {ECO:0000303|PubMed:18406326, ECO:0000312|HGNC:HGNC:1104}; GN Synonyms=KIAA0043 {ECO:0000303|PubMed:7584044}, RING3L; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Bone marrow; RX PubMed=7584044; DOI=10.1093/dnares/1.5.223; RA Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S., Seki N., RA Kawarabayasi Y., Ishikawa K., Tabata S.; RT "Prediction of the coding sequences of unidentified human genes. II. The RT coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of RT cDNA clones from human cell line KG-1."; RL DNA Res. 1:223-229(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=16008511; DOI=10.1089/dna.2005.24.432; RA Ishii H., Mimori K., Mori M., Vecchione A.; RT "Differentially expressed genes in endothelial differentiation."; RL DNA Cell Biol. 24:432-437(2005). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 363-726, AND TISSUE SPECIFICITY. RX PubMed=9373153; DOI=10.1016/s0378-1119(97)00415-0; RA Thorpe K.L., Gorman P., Thomas C., Sheer D., Trowsdale J., Beck S.; RT "Chromosomal localization, gene structure and transcription pattern of the RT ORFX gene, a homologue of the MHC-linked RING3 gene."; RL Gene 200:177-183(1997). RN [7] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ACETYLATED CHROMATIN. RX PubMed=18406326; DOI=10.1016/j.molcel.2008.01.018; RA LeRoy G., Rickards B., Flint S.J.; RT "The double bromodomain proteins Brd2 and Brd3 couple histone acetylation RT to transcription."; RL Mol. Cell 30:51-60(2008). RN [8] RP CHROMOSOMAL TRANSLOCATION WITH NUTM1. RX PubMed=17934517; DOI=10.1038/sj.onc.1210852; RA French C.A., Ramirez C.L., Kolmakova J., Hickman T.T., Cameron M.J., RA Thyne M.E., Kutok J.L., Toretsky J.A., Tadavarthy A.K., Kees U.R., RA Fletcher J.A., Aster J.C.; RT "BRD-NUT oncoproteins: a family of closely related nuclear proteins that RT block epithelial differentiation and maintain the growth of carcinoma RT cells."; RL Oncogene 27:2237-2242(2008). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [12] RP ACTIVITY REGULATION. RX PubMed=20871596; DOI=10.1038/nature09504; RA Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., RA Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., RA McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., RA Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., RA Bradner J.E.; RT "Selective inhibition of BET bromodomains."; RL Nature 468:1067-1073(2010). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-563, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-281, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [17] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [18] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-414, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [19] RP ACTIVITY REGULATION. RX PubMed=31969702; DOI=10.1038/s41586-020-1930-8; RA Faivre E.J., McDaniel K.F., Albert D.H., Mantena S.R., Plotnik J.P., RA Wilcox D., Zhang L., Bui M.H., Sheppard G.S., Wang L., Sehgal V., Lin X., RA Huang X., Lu X., Uziel T., Hessler P., Lam L.T., Bellin R.J., Mehta G., RA Fidanze S., Pratt J.K., Liu D., Hasvold L.A., Sun C., Panchal S.C., RA Nicolette J.J., Fossey S.L., Park C.H., Longenecker K., Bigelow L., RA Torrent M., Rosenberg S.H., Kati W.M., Shen Y.; RT "Selective inhibition of the BD2 bromodomain of BET proteins in prostate RT cancer."; RL Nature 578:306-310(2020). RN [20] RP FUNCTION. RX PubMed=32895492; DOI=10.1038/s41556-020-0572-2; RA Daneshvar K., Ardehali M.B., Klein I.A., Hsieh F.K., Kratkiewicz A.J., RA Mahpour A., Cancelliere S.O.L., Zhou C., Cook B.M., Li W., Pondick J.V., RA Gupta S.K., Moran S.P., Young R.A., Kingston R.E., Mullen A.C.; RT "lncRNA DIGIT and BRD3 protein form phase-separated condensates to regulate RT endoderm differentiation."; RL Nat. Cell Biol. 22:1211-1222(2020). RN [21] RP ACTIVITY REGULATION. RX PubMed=32193360; DOI=10.1126/science.aaz8455; RA Gilan O., Rioja I., Knezevic K., Bell M.J., Yeung M.M., Harker N.R., RA Lam E.Y.N., Chung C.W., Bamborough P., Petretich M., Urh M., Atkinson S.J., RA Bassil A.K., Roberts E.J., Vassiliadis D., Burr M.L., Preston A.G.S., RA Wellaway C., Werner T., Gray J.R., Michon A.M., Gobbetti T., Kumar V., RA Soden P.E., Haynes A., Vappiani J., Tough D.F., Taylor S., Dawson S.J., RA Bantscheff M., Lindon M., Drewes G., Demont E.H., Daniels D.L., Grandi P., RA Prinjha R.K., Dawson M.A.; RT "Selective targeting of BD1 and BD2 of the BET proteins in cancer and RT immunoinflammation."; RL Science 368:387-394(2020). RN [22] RP STRUCTURE BY NMR OF 25-415. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the first and second bromodomain from human RT bromodomain containing protein 3."; RL Submitted (FEB-2009) to the PDB data bank. RN [23] RP X-RAY CRYSTALLOGRAPHY (1.36 ANGSTROMS) OF 24-416, FUNCTION, SUBUNIT, AND RP DOMAIN. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [24] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 307-416 IN COMPLEX WITH RP ACETYLATED HISTONE H3 PEPTIDE, FUNCTION, AND DOMAIN. RX PubMed=27105114; DOI=10.1016/j.molcel.2016.03.028; RA Li Y., Sabari B.R., Panchenko T., Wen H., Zhao D., Guan H., Wan L., RA Huang H., Tang Z., Zhao Y., Roeder R.G., Shi X., Allis C.D., Li H.; RT "Molecular coupling of histone crotonylation and active transcription by RT AF9 YEATS domain."; RL Mol. Cell 62:181-193(2016). RN [25] {ECO:0007744|PDB:6BGG, ECO:0007744|PDB:6BGH} RP STRUCTURE BY NMR OF 557-644 IN COMPLEX WITH CHD4 AND SMARCA4, FUNCTION, RP DOMAIN, AND INTERACTION WITH CHD4; NSD3 AND SMARCA4. RX PubMed=29567837; DOI=10.1074/jbc.ra117.000678; RA Wai D.C.C., Szyszka T.N., Campbell A.E., Kwong C., Wilkinson-White L.E., RA Silva A.P.G., Low J.K.K., Kwan A.H., Gamsjaeger R., Chalmers J.D., RA Patrick W.M., Lu B., Vakoc C.R., Blobel G.A., Mackay J.P.; RT "The BRD3 ET domain recognizes a short peptide motif through a mechanism RT that is conserved across chromatin remodelers and transcriptional RT regulators."; RL J. Biol. Chem. 293:7160-7175(2018). RN [26] {ECO:0007744|PDB:7JMY, ECO:0007744|PDB:7JQ8, ECO:0007744|PDB:7JYN, ECO:0007744|PDB:7JYZ} RP STRUCTURE BY NMR OF 554-640 IN COMPLEX WITH NSD3, INTERACTION WITH NSD3, RP AND INTERACTION WITH INTEGRASE PROTEIN OF MLV VIRUS (MICROBIAL INFECTION). RX PubMed=33592170; DOI=10.1016/j.str.2021.01.010; RA Aiyer S., Swapna G.V.T., Ma L.C., Liu G., Hao J., Chalmers G., Jacobs B.C., RA Montelione G.T., Roth M.J.; RT "A common binding motif in the ET domain of BRD3 forms polymorphic RT structural interfaces with host and viral proteins."; RL Structure 29:886-898(2021). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-36; THR-161; VAL-172; GLN-435; HIS-441 RP AND PRO-447. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Chromatin reader that recognizes and binds acetylated CC histones, thereby controlling gene expression and remodeling chromatin CC structures (PubMed:18406326, PubMed:22464331, PubMed:27105114, CC PubMed:32895492). Recruits transcription factors and coactivators to CC target gene sites, and activates RNA polymerase II machinery for CC transcriptional elongation (PubMed:29567837, PubMed:32895492). In CC vitro, binds acetylated lysine residues on the N-terminus of histone CC H2A, H2B, H3 and H4 (PubMed:18406326). Involved in endoderm CC differentiation via its association with long non-coding RNA (lncRNA) CC DIGIT: BRD3 undergoes liquid-liquid phase separation upon binding to CC lncRNA DIGIT, promoting binding to histone H3 acetylated at 'Lys-18' CC (H3K18ac) to induce endoderm gene expression (PubMed:32895492). Also CC binds non-histones acetylated proteins, such as GATA1 and GATA2: CC regulates transcription by promoting the binding of the transcription CC factor GATA1 to its targets (By similarity). CC {ECO:0000250|UniProtKB:Q8K2F0, ECO:0000269|PubMed:18406326, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:27105114, CC ECO:0000269|PubMed:29567837, ECO:0000269|PubMed:32895492}. CC -!- ACTIVITY REGULATION: Inhibited by JQ1, a thieno-triazolo-1,4-diazepine CC derivative, which specifically inhibits members of the BET family CC (BRD2, BRD3 and BRD4) (PubMed:20871596). The first bromo domain is CC inhibited by GSK778 (iBET-BD1), which specifically inhibits the first CC bromo domain of members of the BET family (BRD2, BRD3 and BRD4) CC (PubMed:32193360). The second bromo domain is inhibited by ABBV-744, CC which specifically inhibits the second bromo domain of members of the CC BET family (BRD2, BRD3 and BRD4) (PubMed:31969702). The second bromo CC domain is inhibited by GSK046 (iBET-BD2), which specifically inhibits CC the second bromo domain of members of the BET family (BRD2, BRD3 and CC BRD4) (PubMed:32193360). {ECO:0000269|PubMed:20871596, CC ECO:0000269|PubMed:31969702, ECO:0000269|PubMed:32193360}. CC -!- SUBUNIT: Interacts (via bromo domain 1) with GATA1 acetylated at 'Lys- CC 312' and 'Lys-315' (By similarity). Interacts (via bromo domain 1) with CC GATA2 acetylated on lysine residues (By similarity). Interacts (via NET CC domain) with CHD4 (via KIKL motif) (PubMed:29567837). Interacts (via CC NET domain) with SMARCA4 (via KIKL motif) (PubMed:29567837). Interacts CC (via NET domain) with NSD3 (via KIKL motif) (PubMed:29567837, CC PubMed:33592170). {ECO:0000250|UniProtKB:Q8K2F0, CC ECO:0000269|PubMed:29567837, ECO:0000269|PubMed:33592170}. CC -!- SUBUNIT: (Microbial infection) Interacts with the Integrase protein of CC Moloney murine leukemia virus (MLV). {ECO:0000269|PubMed:33592170}. CC -!- INTERACTION: CC Q15059; P01106: MYC; NbExp=3; IntAct=EBI-1383460, EBI-447544; CC Q15059-2; O00505: KPNA3; NbExp=3; IntAct=EBI-13468085, EBI-358297; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:25593309}. Chromosome CC {ECO:0000269|PubMed:18406326}. Note=Detected on chromatin. CC {ECO:0000269|PubMed:18406326}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=Q15059-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15059-2; Sequence=VSP_010247, VSP_010248; CC -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9373153}. CC -!- DOMAIN: The Bromo domains specifically recognize and bind acetylated CC histones. {ECO:0000269|PubMed:27105114}. CC -!- DOMAIN: The NET domain recognizes and binds the 'KIKL' motif found in CC chromatin proteins. {ECO:0000269|PubMed:29567837}. CC -!- DISEASE: Note=A chromosomal aberration involving BRD3 is found in a CC rare, aggressive, and lethal carcinoma arising in midline organs of CC young people. Translocation t(15;9)(q14;q34) with NUTM1 which produces CC a BRD3-NUTM1 fusion protein. {ECO:0000269|PubMed:17934517}. CC -!- SIMILARITY: Belongs to the BET family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA05393.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26362; BAA05393.2; ALT_INIT; mRNA. DR EMBL; AY513270; AAS82952.1; -; mRNA. DR EMBL; AL445931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471090; EAW88113.1; -; Genomic_DNA. DR EMBL; CH471090; EAW88114.1; -; Genomic_DNA. DR EMBL; BC032124; AAH32124.1; -; mRNA. DR EMBL; Z81330; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6980.1; -. [Q15059-1] DR RefSeq; NP_031397.1; NM_007371.4. [Q15059-1] DR RefSeq; XP_006717354.1; XM_006717291.4. [Q15059-1] DR RefSeq; XP_011517354.1; XM_011519052.3. [Q15059-1] DR RefSeq; XP_047279859.1; XM_047423903.1. [Q15059-1] DR RefSeq; XP_047279860.1; XM_047423904.1. [Q15059-1] DR RefSeq; XP_054219849.1; XM_054363874.1. [Q15059-1] DR RefSeq; XP_054219850.1; XM_054363875.1. [Q15059-1] DR RefSeq; XP_054219851.1; XM_054363876.1. [Q15059-1] DR RefSeq; XP_054219852.1; XM_054363877.1. [Q15059-1] DR PDB; 2E7N; NMR; -; A=306-415. DR PDB; 2NXB; X-ray; 1.40 A; A/B=24-144. DR PDB; 2OO1; X-ray; 1.70 A; A/B/C/D=307-416. DR PDB; 2YW5; NMR; -; A=25-155. DR PDB; 3S91; X-ray; 2.06 A; A=24-144. DR PDB; 3S92; X-ray; 1.36 A; A=306-416. DR PDB; 5A7C; X-ray; 1.90 A; A/B/C/D=306-416. DR PDB; 5HFR; X-ray; 1.70 A; A/B/C/D=306-416. DR PDB; 5HJC; X-ray; 2.60 A; A=307-416. DR PDB; 6BGG; NMR; -; B=557-644. DR PDB; 6BGH; NMR; -; A=557-643. DR PDB; 6I41; X-ray; 1.90 A; B=245-253. DR PDB; 6I5P; X-ray; 1.81 A; B/D/F/H=245-253. DR PDB; 6I68; X-ray; 1.85 A; B/D/F/H=245-253. DR PDB; 6I7A; X-ray; 2.20 A; B/D/F/H=245-253. DR PDB; 6QJU; X-ray; 1.20 A; A/B=24-144. DR PDB; 6U4A; X-ray; 1.88 A; A/B=25-147. DR PDB; 6ULP; X-ray; 2.80 A; A/B=307-419. DR PDB; 7JMY; NMR; -; A=554-640. DR PDB; 7JQ8; NMR; -; A=554-640. DR PDB; 7JYN; NMR; -; A=554-640. DR PDB; 7JYZ; NMR; -; B=554-640. DR PDB; 7L72; X-ray; 1.50 A; A=306-416. DR PDB; 7L9L; X-ray; 1.55 A; A=306-416. DR PDB; 7LAY; X-ray; 1.45 A; A/B=24-144. DR PDB; 7LAZ; X-ray; 2.30 A; A/B=24-144. DR PDB; 7LB4; X-ray; 2.00 A; A/B=306-416. DR PDB; 7LBT; X-ray; 2.70 A; A/B/C/D=306-416. DR PDB; 7R8R; X-ray; 1.80 A; A=24-144. DR PDB; 7RJK; X-ray; 1.85 A; A/B=24-144. DR PDB; 7RJL; X-ray; 1.50 A; A/B=24-144. DR PDB; 7RJM; X-ray; 2.10 A; A/B=24-144. DR PDB; 7RJN; X-ray; 1.95 A; A/B=24-144. DR PDB; 7S3P; X-ray; 2.89 A; A/B/C/D/E/F/G/H/I/J/K=306-416. DR PDB; 7TO7; X-ray; 1.93 A; A/B/D/E=25-147. DR PDB; 7TO8; X-ray; 1.50 A; A/B=25-147. DR PDB; 7TO9; X-ray; 1.60 A; A/B=25-147. DR PDB; 7TOA; X-ray; 1.41 A; A/B=32-147. DR PDB; 7UG5; X-ray; 1.80 A; A/B/C/D=306-416. DR PDB; 8B5A; X-ray; 1.92 A; A=307-416. DR PDB; 8CV5; X-ray; 1.47 A; A=307-419. DR PDBsum; 2E7N; -. DR PDBsum; 2NXB; -. DR PDBsum; 2OO1; -. DR PDBsum; 2YW5; -. DR PDBsum; 3S91; -. DR PDBsum; 3S92; -. DR PDBsum; 5A7C; -. DR PDBsum; 5HFR; -. DR PDBsum; 5HJC; -. DR PDBsum; 6BGG; -. DR PDBsum; 6BGH; -. DR PDBsum; 6I41; -. DR PDBsum; 6I5P; -. DR PDBsum; 6I68; -. DR PDBsum; 6I7A; -. DR PDBsum; 6QJU; -. DR PDBsum; 6U4A; -. DR PDBsum; 6ULP; -. DR PDBsum; 7JMY; -. DR PDBsum; 7JQ8; -. DR PDBsum; 7JYN; -. DR PDBsum; 7JYZ; -. DR PDBsum; 7L72; -. DR PDBsum; 7L9L; -. DR PDBsum; 7LAY; -. DR PDBsum; 7LAZ; -. DR PDBsum; 7LB4; -. DR PDBsum; 7LBT; -. DR PDBsum; 7R8R; -. DR PDBsum; 7RJK; -. DR PDBsum; 7RJL; -. DR PDBsum; 7RJM; -. DR PDBsum; 7RJN; -. DR PDBsum; 7S3P; -. DR PDBsum; 7TO7; -. DR PDBsum; 7TO8; -. DR PDBsum; 7TO9; -. DR PDBsum; 7TOA; -. DR PDBsum; 7UG5; -. DR PDBsum; 8B5A; -. DR PDBsum; 8CV5; -. DR AlphaFoldDB; Q15059; -. DR SASBDB; Q15059; -. DR SMR; Q15059; -. DR BioGRID; 113715; 504. DR DIP; DIP-39755N; -. DR FunCoup; Q15059; 2558. DR IntAct; Q15059; 36. DR MINT; Q15059; -. DR STRING; 9606.ENSP00000305918; -. DR BindingDB; Q15059; -. DR ChEMBL; CHEMBL1795186; -. DR DrugBank; DB19199; ABBV-744. DR GuidetoPHARMACOLOGY; 2725; -. DR GlyCosmos; Q15059; 5 sites, 1 glycan. DR GlyGen; Q15059; 9 sites, 1 O-linked glycan (6 sites). DR iPTMnet; Q15059; -. DR PhosphoSitePlus; Q15059; -. DR BioMuta; BRD3; -. DR DMDM; 12643726; -. DR jPOST; Q15059; -. DR MassIVE; Q15059; -. DR PaxDb; 9606-ENSP00000305918; -. DR PeptideAtlas; Q15059; -. DR ProteomicsDB; 60414; -. [Q15059-1] DR ProteomicsDB; 60415; -. [Q15059-2] DR Pumba; Q15059; -. DR ABCD; Q15059; 1 sequenced antibody. DR Antibodypedia; 31966; 413 antibodies from 34 providers. DR DNASU; 8019; -. DR Ensembl; ENST00000303407.12; ENSP00000305918.6; ENSG00000169925.18. [Q15059-1] DR Ensembl; ENST00000371834.6; ENSP00000360900.2; ENSG00000169925.18. [Q15059-2] DR GeneID; 8019; -. DR KEGG; hsa:8019; -. DR MANE-Select; ENST00000303407.12; ENSP00000305918.6; NM_007371.4; NP_031397.1. DR UCSC; uc004cew.4; human. [Q15059-1] DR AGR; HGNC:1104; -. DR ClinPGx; PA25415; -. DR CTD; 8019; -. DR DisGeNET; 8019; -. DR GeneCards; BRD3; -. DR HGNC; HGNC:1104; BRD3. DR HPA; ENSG00000169925; Low tissue specificity. DR MalaCards; BRD3; -. DR MIM; 601541; gene. DR OpenTargets; ENSG00000169925; -. DR VEuPathDB; HostDB:ENSG00000169925; -. DR eggNOG; KOG1474; Eukaryota. DR GeneTree; ENSGT00940000153385; -. DR HOGENOM; CLU_001499_0_4_1; -. DR InParanoid; Q15059; -. DR OMA; KMNIPHY; -. DR OrthoDB; 21449at2759; -. DR PAN-GO; Q15059; 5 GO annotations based on evolutionary models. DR PhylomeDB; Q15059; -. DR PathwayCommons; Q15059; -. DR SignaLink; Q15059; -. DR SIGNOR; Q15059; -. DR Agora; ENSG00000169925; -. DR BioGRID-ORCS; 8019; 18 hits in 1176 CRISPR screens. DR CD-CODE; 38EC0B30; Transcriptional condensate. DR ChiTaRS; BRD3; human. DR EvolutionaryTrace; Q15059; -. DR GeneWiki; BRD3; -. DR GenomeRNAi; 8019; -. DR Pharos; Q15059; Tchem. DR PRO; PR:Q15059; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q15059; protein. DR Bgee; ENSG00000169925; Expressed in nipple and 220 other cell types or tissues. DR ExpressionAtlas; Q15059; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:UniProt. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003682; F:chromatin binding; IBA:GO_Central. DR GO; GO:0042393; F:histone binding; IBA:GO_Central. DR GO; GO:0140017; F:histone H3K18cr reader activity; IDA:UniProtKB. DR GO; GO:0140038; F:histone H3K27cr reader activity; IDA:UniProtKB. DR GO; GO:0140019; F:histone H3K9cr reader activity; IDA:UniProtKB. DR GO; GO:0062072; F:histone H3K9me2/3 reader activity; IDA:UniProtKB. DR GO; GO:0140566; F:histone reader activity; IDA:GO_Central. DR GO; GO:0106222; F:lncRNA binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central. DR GO; GO:0035987; P:endodermal cell differentiation; IDA:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProt. DR GO; GO:0071168; P:protein localization to chromatin; IDA:UniProtKB. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR CDD; cd05497; Bromo_Brdt_I_like; 1. DR CDD; cd05498; Bromo_Brdt_II_like; 1. DR DisProt; DP03059; -. DR FunFam; 1.20.920.10:FF:000003; Bromodomain-containing protein 2; 1. DR FunFam; 1.20.1270.220:FF:000001; bromodomain-containing protein 2 isoform X1; 1. DR FunFam; 1.20.920.10:FF:000002; Bromodomain-containing protein 4; 1. DR Gene3D; 1.20.1270.220; -; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR InterPro; IPR043508; Bromo_Brdt_I. DR InterPro; IPR043509; Bromo_Brdt_II. DR InterPro; IPR050935; Bromo_chromatin_reader. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR027353; NET_dom. DR InterPro; IPR038336; NET_sf. DR PANTHER; PTHR22880:SF246; BROMODOMAIN-CONTAINING PROTEIN 3; 1. DR PANTHER; PTHR22880; FALZ-RELATED BROMODOMAIN-CONTAINING PROTEINS; 1. DR Pfam; PF17035; BET; 1. DR Pfam; PF00439; Bromodomain; 2. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. DR PROSITE; PS51525; NET; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; Bromodomain; KW Chromatin regulator; Chromosomal rearrangement; Chromosome; Coiled coil; KW Isopeptide bond; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Transcription; Transcription regulation; KW Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330" FT CHAIN 2..726 FT /note="Bromodomain-containing protein 3" FT /id="PRO_0000211181" FT DOMAIN 34..140 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 306..415 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 562..644 FT /note="NET" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00857" FT REGION 1..35 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 78..80 FT /note="Acetylated histone H3 binding" FT /evidence="ECO:0000269|PubMed:27105114" FT REGION 149..169 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 237..305 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 421..462 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 477..575 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 637..726 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COILED 453..524 FT /evidence="ECO:0000255" FT COILED 645..684 FT /evidence="ECO:0000255" FT COMPBIAS 15..26 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 248..261 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 487..503 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 504..521 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 523..540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 655..673 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 692..726 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT SITE 647..648 FT /note="Breakpoint for translocation to form BDR3-NUTM1 FT fusion protein" FT /evidence="ECO:0000269|PubMed:17934517" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:19413330" FT MOD_RES 263 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 281 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 563 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT CROSSLNK 414 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 549..556 FT /note="QLKKGGKQ -> DHFLTCGV (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_010247" FT VAR_SEQ 557..726 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_010248" FT VARIANT 36 FT /note="T -> N (in a renal clear cell carcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041913" FT VARIANT 161 FT /note="A -> T (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041914" FT VARIANT 172 FT /note="A -> V (in dbSNP:rs34609592)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041915" FT VARIANT 435 FT /note="K -> Q (in dbSNP:rs36093130)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041916" FT VARIANT 441 FT /note="R -> H (in dbSNP:rs56017928)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041917" FT VARIANT 447 FT /note="S -> P (in dbSNP:rs55754444)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041918" FT STRAND 29..31 FT /evidence="ECO:0007829|PDB:2YW5" FT HELIX 37..44 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 46..52 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 57..59 FT /evidence="ECO:0007829|PDB:6QJU" FT TURN 65..69 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 73..76 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 83..91 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 98..115 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 121..137 FT /evidence="ECO:0007829|PDB:6QJU" FT HELIX 310..323 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 328..331 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 332..334 FT /evidence="ECO:0007829|PDB:3S92" FT TURN 340..344 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 348..351 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 358..366 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 373..390 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 396..413 FT /evidence="ECO:0007829|PDB:3S92" FT HELIX 558..561 FT /evidence="ECO:0007829|PDB:6BGH" FT HELIX 567..569 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 574..585 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 589..602 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 604..608 FT /evidence="ECO:0007829|PDB:6BGG" FT STRAND 611..613 FT /evidence="ECO:0007829|PDB:6BGH" FT STRAND 615..617 FT /evidence="ECO:0007829|PDB:6BGG" FT TURN 618..620 FT /evidence="ECO:0007829|PDB:6BGG" FT HELIX 623..636 FT /evidence="ECO:0007829|PDB:6BGG" FT TURN 640..642 FT /evidence="ECO:0007829|PDB:6BGG" SQ SEQUENCE 726 AA; 79542 MW; 64F526FC3C1033AA CRC64; MSTATTVAPA GIPATPGPVN PPPPEVSNPS KPGRKTNQLQ YMQNVVVKTL WKHQFAWPFY QPVDAIKLNL PDYHKIIKNP MDMGTIKKRL ENNYYWSASE CMQDFNTMFT NCYIYNKPTD DIVLMAQALE KIFLQKVAQM PQEEVELLPP APKGKGRKPA AGAQSAGTQQ VAAVSSVSPA TPFQSVPPTV SQTPVIAATP VPTITANVTS VPVPPAAAPP PPATPIVPVV PPTPPVVKKK GVKRKADTTT PTTSAITASR SESPPPLSDP KQAKVVARRE SGGRPIKPPK KDLEDGEVPQ HAGKKGKLSE HLRYCDSILR EMLSKKHAAY AWPFYKPVDA EALELHDYHD IIKHPMDLST VKRKMDGREY PDAQGFAADV RLMFSNCYKY NPPDHEVVAM ARKLQDVFEM RFAKMPDEPV EAPALPAPAA PMVSKGAESS RSSEESSSDS GSSDSEEERA TRLAELQEQL KAVHEQLAAL SQAPVNKPKK KKEKKEKEKK KKDKEKEKEK HKVKAEEEKK AKVAPPAKQA QQKKAPAKKA NSTTTAGRQL KKGGKQASAS YDSEEEEEGL PMSYDEKRQL SLDINRLPGE KLGRVVHIIQ SREPSLRDSN PDEIEIDFET LKPTTLRELE RYVKSCLQKK QRKPFSASGK KQAAKSKEEL AQEKKKELEK RLQDVSGQLS SSKKPARKEK PGSAPSGGPS RLSSSSSSES GSSSSSGSSS DSSDSE // ID CDK12_HUMAN Reviewed; 1490 AA. AC Q9NYV4; A7E2B2; B4DYX4; B9EIQ6; O94978; DT 01-DEC-2000, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 2. DT 28-JAN-2026, entry version 215. DE RecName: Full=Cyclin-dependent kinase 12; DE EC=2.7.11.22; DE EC=2.7.11.23 {ECO:0000305|PubMed:20952539}; DE AltName: Full=Cdc2-related kinase, arginine/serine-rich; DE Short=CrkRS; DE AltName: Full=Cell division cycle 2-related protein kinase 7; DE Short=CDC2-related protein kinase 7; DE AltName: Full=Cell division protein kinase 12; DE Short=hCDK12; GN Name=CDK12; Synonyms=CRK7, CRKRS, KIAA0904; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND FUNCTION. RX PubMed=11683387; DOI=10.1242/jcs.114.14.2591; RA Ko T.K., Kelly E., Pines J.; RT "CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with RT SC35 speckles."; RL J. Cell Sci. 114:2591-2603(2001). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=10048485; DOI=10.1093/dnares/5.6.355; RA Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XII. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 5:355-364(1998). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Testis; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-681 AND SER-685, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-57; TYR-73; SER-400; SER-423; RP THR-514; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [11] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-249; SER-301; SER-303; RP SER-318; SER-323; SER-325; SER-332; SER-333; SER-334; SER-345; SER-383; RP SER-385; SER-400; SER-681; SER-685 AND THR-692, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [13] RP FUNCTION. RX PubMed=19651820; DOI=10.1093/carcin/bgp187; RA Iorns E., Martens-de Kemp S.R., Lord C.J., Ashworth A.; RT "CRK7 modifies the MAPK pathway and influences the response to endocrine RT therapy."; RL Carcinogenesis 30:1696-1701(2009). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-420; SER-423; SER-681; RP SER-685; THR-692 AND SER-1053, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [15] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-383; SER-385; RP SER-681; SER-685 AND THR-1244, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [16] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=20952539; DOI=10.1101/gad.1968210; RA Bartkowiak B., Liu P., Phatnani H.P., Fuda N.J., Cooper J.J., Price D.H., RA Adelman K., Lis J.T., Greenleaf A.L.; RT "CDK12 is a transcription elongation-associated CTD kinase, the metazoan RT ortholog of yeast Ctk1."; RL Genes Dev. 24:2303-2316(2010). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-385; RP SER-400; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [19] RP CHROMOSOMAL REARRANGEMENT WITH ERBB2, AND POSSIBLE INVOLVEMENT IN GASTRIC RP CANCER. RX PubMed=21097718; DOI=10.1158/0008-5472.can-10-1749; RA Zang Z.J., Ong C.K., Cutcutache I., Yu W., Zhang S.L., Huang D., Ler L.D., RA Dykema K., Gan A., Tao J., Lim S., Liu Y., Futreal P.A., Grabsch H., RA Furge K.A., Goh L.K., Rozen S., Teh B.T., Tan P.; RT "Genetic and structural variation in the gastric cancer kinome revealed RT through targeted deep sequencing."; RL Cancer Res. 71:29-39(2011). RN [20] RP FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION. RX PubMed=22012619; DOI=10.1101/gad.16962311; RA Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P., RA Luo Z., Cimermancic P., Ule J., Peterlin B.M.; RT "The Cyclin K/Cdk12 complex maintains genomic stability via regulation of RT expression of DNA damage response genes."; RL Genes Dev. 25:2158-2172(2011). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-274; RP SER-276; SER-301; SER-303; SER-310; SER-312; SER-332; SER-333; SER-334; RP SER-338; SER-423; SER-681; SER-685; THR-893 AND SER-1083, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-236; SER-249; SER-265; RP SER-274; SER-276; SER-318; SER-323; SER-325; SER-332; SER-333; SER-334; RP SER-341; SER-343; SER-345; SER-423; THR-514; SER-614; SER-681; THR-692; RP SER-889; THR-893; SER-1053 AND SER-1083, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-423; SER-681 AND SER-685, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [24] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-263; LYS-509 AND LYS-655, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [25] RP INTERACTION WITH HHV-1 TRANSCRIPTIONAL REGULATOR ICP22 (MICROBIAL RP INFECTION). RX PubMed=34696162; DOI=10.3390/vaccines9101054; RA Isa N.F., Bensaude O., Aziz N.C., Murphy S.; RT "HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II- RT Mediated Transcription Elongation."; RL Vaccines (Basel) 9:0-0(2021). RN [26] RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 714-1063 IN COMPLEX WITH THE ATP RP ANALOG ADP; TRANSITION STATE ANALOG AND CCNK, FUNCTION, CATALYTIC ACTIVITY, RP SUBUNIT, INTERACTION WITH CCNK, PHOSPHORYLATION AT THR-893, IDENTIFICATION RP BY MASS SPECTROMETRY, MUTAGENESIS OF ASP-877, AND ACTIVITY REGULATION. RX PubMed=24662513; DOI=10.1038/ncomms4505; RA Boesken C.A., Farnung L., Hintermair C., Merzel Schachter M., RA Vogel-Bachmayr K., Blazek D., Anand K., Fisher R.P., Eick D., Geyer M.; RT "The structure and substrate specificity of human Cdk12/Cyclin K."; RL Nat. Commun. 5:3505-3505(2014). RN [27] RP VARIANTS [LARGE SCALE ANALYSIS] ALA-530; HIS-912; GLN-1189 AND LEU-1275. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Cyclin-dependent kinase that phosphorylates the C-terminal CC domain (CTD) of the large subunit of RNA polymerase II (POLR2A), CC thereby acting as a key regulator of transcription elongation. CC Regulates the expression of genes involved in DNA repair and is CC required for the maintenance of genomic stability. Preferentially CC phosphorylates 'Ser-5' in CTD repeats that are already phosphorylated CC at 'Ser-7', but can also phosphorylate 'Ser-2'. Required for RNA CC splicing, possibly by phosphorylating SRSF1/SF2. Involved in regulation CC of MAP kinase activity, possibly leading to affect the response to CC estrogen inhibitors. {ECO:0000269|PubMed:11683387, CC ECO:0000269|PubMed:19651820, ECO:0000269|PubMed:20952539, CC ECO:0000269|PubMed:22012619, ECO:0000269|PubMed:24662513}. CC -!- CATALYTIC ACTIVITY: CC Reaction=[DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed CC RNA polymerase] + ADP + H(+); Xref=Rhea:RHEA:10216, Rhea:RHEA- CC COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.23; CC Evidence={ECO:0000305|PubMed:20952539}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC -!- ACTIVITY REGULATION: Inhibited by the ATP analog flavopiridol, CC purvalanol A, purvalanol B, staurosporine and CR8. CC {ECO:0000269|PubMed:24662513}. CC -!- SUBUNIT: Interacts with CCNL1 and CCNL2 (By similarity). Interacts with CC CCNK. {ECO:0000250, ECO:0000269|PubMed:22012619, CC ECO:0000269|PubMed:24662513}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 1 CC (HHV-1) transcriptional regulator ICP22. {ECO:0000269|PubMed:34696162}. CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11683387}. Nucleus CC speckle {ECO:0000269|PubMed:11683387}. Note=Colocalized with nuclear CC speckles throughout interphase. {ECO:0000269|PubMed:11683387}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q9NYV4-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9NYV4-2; Sequence=VSP_030284; CC Name=3; CC IsoId=Q9NYV4-3; Sequence=VSP_040908, VSP_040909, VSP_040910; CC -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:11683387}. CC -!- PTM: Phosphorylation at Thr-893 increases kinase activity. CC {ECO:0000269|PubMed:24662513}. CC -!- DISEASE: Note=Chromosomal aberrations involving CDK12 may be a cause CC gastric cancer. Deletions within 17q12 region producing fusion CC transcripts with ERBB2, leading to CDK12-ERBB2 fusion leading to CC trunctated CDK12 protein not in-frame with ERBB2. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA74927.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF227198; AAF36401.1; -; mRNA. DR EMBL; AB020711; BAA74927.2; ALT_INIT; mRNA. DR EMBL; AK302645; BAG63886.1; -; mRNA. DR EMBL; AC009283; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471152; EAW60577.1; -; Genomic_DNA. DR EMBL; BC140854; AAI40855.1; -; mRNA. DR EMBL; BC150265; AAI50266.1; -; mRNA. DR CCDS; CCDS11337.1; -. [Q9NYV4-1] DR CCDS; CCDS45666.1; -. [Q9NYV4-2] DR RefSeq; NP_055898.1; NM_015083.4. [Q9NYV4-2] DR RefSeq; NP_057591.2; NM_016507.4. [Q9NYV4-1] DR PDB; 4CXA; X-ray; 3.15 A; A/C=715-1052. DR PDB; 4NST; X-ray; 2.20 A; A/C=714-1063. DR PDB; 4UN0; X-ray; 3.15 A; C/D=715-1038. DR PDB; 5ACB; X-ray; 2.70 A; C/D=715-1052. DR PDB; 6B3E; X-ray; 3.06 A; A/C=717-1036. DR PDB; 6CKX; X-ray; 2.80 A; A/C=714-1063. DR PDB; 6TD3; X-ray; 3.46 A; B/E/H=712-1051. DR PDB; 7NXK; X-ray; 3.00 A; A/C=714-1063. DR PDB; 8BU1; X-ray; 2.98 A; B/E/H=712-1051. DR PDB; 8BU2; X-ray; 3.13 A; B/E/H=712-1051. DR PDB; 8BU3; X-ray; 3.42 A; B/E/H=712-1051. DR PDB; 8BU4; X-ray; 3.09 A; B/E/H=712-1051. DR PDB; 8BU5; X-ray; 3.13 A; B/E/H=712-1051. DR PDB; 8BU6; X-ray; 3.45 A; B/E/H=712-1051. DR PDB; 8BU7; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8BU9; X-ray; 3.51 A; B/E/H=712-1051. DR PDB; 8BUA; X-ray; 3.19 A; B/E/H=712-1051. DR PDB; 8BUB; X-ray; 3.42 A; B/E/H=712-1051. DR PDB; 8BUC; X-ray; 3.85 A; B/E/H=712-1051. DR PDB; 8BUD; X-ray; 3.20 A; B/E/H=712-1051. DR PDB; 8BUE; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8BUF; X-ray; 3.30 A; B/E/H=712-1051. DR PDB; 8BUG; X-ray; 3.53 A; B/E/H=712-1051. DR PDB; 8BUH; X-ray; 3.79 A; B/E/H=712-1051. DR PDB; 8BUI; X-ray; 3.50 A; B/E/H=712-1051. DR PDB; 8BUJ; X-ray; 3.62 A; B/E/H=712-1051. DR PDB; 8BUK; X-ray; 3.41 A; B/E/H=712-1051. DR PDB; 8BUL; X-ray; 3.40 A; B/E/H=712-1052. DR PDB; 8BUM; X-ray; 3.36 A; B/E/H=712-1051. DR PDB; 8BUN; X-ray; 3.08 A; B/E/H=712-1051. DR PDB; 8BUO; X-ray; 3.58 A; B/E/H=712-1051. DR PDB; 8BUP; X-ray; 3.41 A; B/E/H=712-1051. DR PDB; 8BUQ; X-ray; 3.20 A; B/E/H=712-1051. DR PDB; 8BUR; X-ray; 3.64 A; B/E/H=712-1051. DR PDB; 8BUS; X-ray; 3.26 A; B/E/H=712-1051. DR PDB; 8BUT; X-ray; 3.25 A; B/E/H=712-1051. DR PDB; 8P81; X-ray; 2.68 A; A=714-1063. DR PDB; 9FMR; X-ray; 3.90 A; B/E/H=714-1063. DR PDB; 9JK1; X-ray; 2.72 A; A/B=715-1052. DR PDBsum; 4CXA; -. DR PDBsum; 4NST; -. DR PDBsum; 4UN0; -. DR PDBsum; 5ACB; -. DR PDBsum; 6B3E; -. DR PDBsum; 6CKX; -. DR PDBsum; 6TD3; -. DR PDBsum; 7NXK; -. DR PDBsum; 8BU1; -. DR PDBsum; 8BU2; -. DR PDBsum; 8BU3; -. DR PDBsum; 8BU4; -. DR PDBsum; 8BU5; -. DR PDBsum; 8BU6; -. DR PDBsum; 8BU7; -. DR PDBsum; 8BU9; -. DR PDBsum; 8BUA; -. DR PDBsum; 8BUB; -. DR PDBsum; 8BUC; -. DR PDBsum; 8BUD; -. DR PDBsum; 8BUE; -. DR PDBsum; 8BUF; -. DR PDBsum; 8BUG; -. DR PDBsum; 8BUH; -. DR PDBsum; 8BUI; -. DR PDBsum; 8BUJ; -. DR PDBsum; 8BUK; -. DR PDBsum; 8BUL; -. DR PDBsum; 8BUM; -. DR PDBsum; 8BUN; -. DR PDBsum; 8BUO; -. DR PDBsum; 8BUP; -. DR PDBsum; 8BUQ; -. DR PDBsum; 8BUR; -. DR PDBsum; 8BUS; -. DR PDBsum; 8BUT; -. DR PDBsum; 8P81; -. DR PDBsum; 9FMR; -. DR PDBsum; 9JK1; -. DR AlphaFoldDB; Q9NYV4; -. DR SMR; Q9NYV4; -. DR BioGRID; 119715; 286. DR ComplexPortal; CPX-241; Cyclin K-CDK12 complex. DR CORUM; Q9NYV4; -. DR DIP; DIP-39768N; -. DR FunCoup; Q9NYV4; 3170. DR IntAct; Q9NYV4; 109. DR MINT; Q9NYV4; -. DR STRING; 9606.ENSP00000398880; -. DR BindingDB; Q9NYV4; -. DR ChEMBL; CHEMBL3559692; -. DR DrugCentral; Q9NYV4; -. DR GuidetoPHARMACOLOGY; 1965; -. DR CarbonylDB; Q9NYV4; -. DR GlyConnect; 2877; 1 O-GlcNAc glycan (2 sites). DR GlyCosmos; Q9NYV4; 6 sites, 1 glycan. DR GlyGen; Q9NYV4; 18 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (17 sites). DR iPTMnet; Q9NYV4; -. DR PhosphoSitePlus; Q9NYV4; -. DR SwissPalm; Q9NYV4; -. DR BioMuta; CDK12; -. DR DMDM; 308153421; -. DR CPTAC; non-CPTAC-2958; -. DR CPTAC; non-CPTAC-2959; -. DR jPOST; Q9NYV4; -. DR MassIVE; Q9NYV4; -. DR PaxDb; 9606-ENSP00000398880; -. DR PeptideAtlas; Q9NYV4; -. DR ProteomicsDB; 83279; -. [Q9NYV4-1] DR ProteomicsDB; 83280; -. [Q9NYV4-2] DR ProteomicsDB; 83281; -. [Q9NYV4-3] DR Pumba; Q9NYV4; -. DR Antibodypedia; 2096; 236 antibodies from 32 providers. DR CPTC; Q9NYV4; 2 antibodies. DR DNASU; 51755; -. DR Ensembl; ENST00000430627.6; ENSP00000407720.2; ENSG00000167258.17. [Q9NYV4-2] DR Ensembl; ENST00000447079.6; ENSP00000398880.4; ENSG00000167258.17. [Q9NYV4-1] DR GeneID; 51755; -. DR KEGG; hsa:51755; -. DR MANE-Select; ENST00000447079.6; ENSP00000398880.4; NM_016507.4; NP_057591.2. DR UCSC; uc002hrw.6; human. [Q9NYV4-1] DR AGR; HGNC:24224; -. DR CIViC; 51755; 4 evidence items across 2 molecular profiles. DR ClinPGx; PA165431656; -. DR CTD; 51755; -. DR DisGeNET; 51755; -. DR GeneCards; CDK12; -. DR HGNC; HGNC:24224; CDK12. DR HPA; ENSG00000167258; Low tissue specificity. DR MalaCards; CDK12; -. DR MIM; 615514; gene. DR OpenTargets; ENSG00000167258; -. DR VEuPathDB; HostDB:ENSG00000167258; -. DR eggNOG; KOG0600; Eukaryota. DR GeneTree; ENSGT00940000157595; -. DR InParanoid; Q9NYV4; -. DR OMA; HWGAPAQ; -. DR OrthoDB; 28397at2759; -. DR PAN-GO; Q9NYV4; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q9NYV4; -. DR BRENDA; 2.7.11.22; 2681. DR BRENDA; 2.7.11.23; 2681. DR PathwayCommons; Q9NYV4; -. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR SignaLink; Q9NYV4; -. DR SIGNOR; Q9NYV4; -. DR Agora; ENSG00000167258; -. DR BioGRID-ORCS; 51755; 350 hits in 1217 CRISPR screens. DR ChiTaRS; CDK12; human. DR EvolutionaryTrace; Q9NYV4; -. DR GeneWiki; CRKRS; -. DR GenomeRNAi; 51755; -. DR Pharos; Q9NYV4; Tchem. DR PRO; PR:Q9NYV4; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; Q9NYV4; protein. DR Bgee; ENSG00000167258; Expressed in buccal mucosa cell and 175 other cell types or tissues. DR ExpressionAtlas; Q9NYV4; baseline and differential. DR GO; GO:0002944; C:cyclin K-CDK12 complex; IPI:MGI. DR GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IBA:GO_Central. DR GO; GO:0019908; C:nuclear cyclin-dependent protein kinase holoenzyme complex; ISS:UniProtKB. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0030332; F:cyclin binding; IPI:MGI. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IDA:HGNC-UCL. DR GO; GO:0019901; F:protein kinase binding; IEA:Ensembl. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:GO_Central. DR GO; GO:0071391; P:cellular response to estrogen stimulus; IMP:HGNC-UCL. DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW. DR GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IMP:HGNC-UCL. DR GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:HGNC-UCL. DR GO; GO:2000737; P:negative regulation of stem cell differentiation; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:UniProtKB. DR GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0043405; P:regulation of MAP kinase activity; IMP:UniProtKB. DR GO; GO:0008380; P:RNA splicing; ISS:UniProtKB. DR GO; GO:0006366; P:transcription by RNA polymerase II; IDA:GO_Central. DR CDD; cd07864; STKc_CDK12; 1. DR DisProt; DP03248; -. DR FunFam; 1.10.510.10:FF:000102; cyclin-dependent kinase 12 isoform X1; 1. DR FunFam; 3.30.200.20:FF:000074; cyclin-dependent kinase 12 isoform X2; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF126; CYCLIN-DEPENDENT KINASE 12; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Chromosomal rearrangement; KW Host-virus interaction; Isopeptide bond; Kinase; mRNA processing; KW mRNA splicing; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..1490 FT /note="Cyclin-dependent kinase 12" FT /id="PRO_0000085715" FT DOMAIN 727..1020 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..703 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1047..1098 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1161..1189 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1220..1348 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1441..1460 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1466..1490 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1..13 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 34..49 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 72..84 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 87..106 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 107..119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 120..134 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 142..162 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 184..195 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 196..205 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 226..235 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 250..276 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 287..305 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 313..350 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..381 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 428..458 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 466..478 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 479..525 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 526..570 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 577..593 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 601..616 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..666 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1071..1083 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1161..1171 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1268..1281 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1473..1490 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 859 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 733..741 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 756 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 814..819 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT BINDING 1040 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT MOD_RES 57 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 73 FT /note="Phosphotyrosine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 236 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 249 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 265 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 274 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 276 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 301 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 303 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692" FT MOD_RES 310 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 312 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 318 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 323 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 325 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 332 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 333 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 334 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 338 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692" FT MOD_RES 341 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 343 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 345 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 383 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 385 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231" FT MOD_RES 400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231" FT MOD_RES 420 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 423 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 514 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:23186163" FT MOD_RES 614 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 644 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q3MJK5" FT MOD_RES 681 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 685 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:24275569" FT MOD_RES 692 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 889 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 893 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:24662513, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1053 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1083 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163" FT MOD_RES 1244 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 1246 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q14AX6" FT CROSSLNK 263 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 509 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 655 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 349 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040908" FT VAR_SEQ 1205..1274 FT /note="DMQNILAVLLSQLMKTQEPAGSLEENNSDKNSGPQGPRRTPTMPQEEAAACP FT PHILPPEKRPPEPPGPPP -> ILWYMQRPNCKTMGSWGQEPLGPAAQEQAFTGGAQLS FT LLLMENSIGGLQESHQEGEEGEEFLTNPETSVS (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040909" FT VAR_SEQ 1254..1262 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:10048485, FT ECO:0000303|PubMed:15489334" FT /id="VSP_030284" FT VAR_SEQ 1275..1490 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_040910" FT VARIANT 530 FT /note="P -> A (in dbSNP:rs56121596)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041968" FT VARIANT 912 FT /note="R -> H (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041969" FT VARIANT 1189 FT /note="L -> Q (in dbSNP:rs56362165)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041970" FT VARIANT 1275 FT /note="P -> L (in dbSNP:rs34070318)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041971" FT MUTAGEN 877 FT /note="D->N: Abolishes kinase activity." FT /evidence="ECO:0000269|PubMed:24662513" FT CONFLICT 133 FT /note="S -> G (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 268 FT /note="S -> G (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 639 FT /note="D -> G (in Ref. 1; AAF36401)" FT /evidence="ECO:0000305" FT CONFLICT 737 FT /note="T -> I (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 745 FT /note="K -> R (in Ref. 1; AAF36401)" FT /evidence="ECO:0000305" FT CONFLICT 822 FT /note="G -> V (in Ref. 4; BAG63886)" FT /evidence="ECO:0000305" FT CONFLICT 1195 FT /note="T -> M (in Ref. 1; AAF36401, 2; BAA74927 and 6; FT AAI50266)" FT /evidence="ECO:0000305" FT STRAND 715..717 FT /evidence="ECO:0007829|PDB:8BU5" FT TURN 719..721 FT /evidence="ECO:0007829|PDB:8P81" FT HELIX 724..726 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 727..735 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 737..746 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 747..749 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 752..758 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 762..767 FT /evidence="ECO:0007829|PDB:8P81" FT HELIX 769..778 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 789..794 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 802..804 FT /evidence="ECO:0007829|PDB:8P81" FT STRAND 809..814 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 817..819 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 820..826 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 833..852 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 855..857 FT /evidence="ECO:0007829|PDB:8BUP" FT HELIX 862..864 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 865..867 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 869..871 FT /evidence="ECO:0007829|PDB:8BUB" FT STRAND 873..875 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 878..880 FT /evidence="ECO:0007829|PDB:8BU7" FT STRAND 881..883 FT /evidence="ECO:0007829|PDB:8BUI" FT STRAND 886..888 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 899..901 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 904..907 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 916..931 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 941..952 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 957..959 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 961..965 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 967..971 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 982..985 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 986..988 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 991..1000 FT /evidence="ECO:0007829|PDB:4NST" FT TURN 1005..1007 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1011..1014 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1018..1021 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1025..1027 FT /evidence="ECO:0007829|PDB:4NST" FT STRAND 1035..1037 FT /evidence="ECO:0007829|PDB:4NST" FT HELIX 1041..1045 FT /evidence="ECO:0007829|PDB:4NST" SQ SEQUENCE 1490 AA; 164155 MW; D6B04B998ECDE58E CRC64; MPNSERHGGK KDGSGGASGT LQPSSGGGSS NSRERHRLVS KHKRHKSKHS KDMGLVTPEA ASLGTVIKPL VEYDDISSDS DTFSDDMAFK LDRRENDERR GSDRSDRLHK HRHHQHRRSR DLLKAKQTEK EKSQEVSSKS GSMKDRISGS SKRSNEETDD YGKAQVAKSS SKESRSSKLH KEKTRKEREL KSGHKDRSKS HRKRETPKSY KTVDSPKRRS RSPHRKWSDS SKQDDSPSGA SYGQDYDLSP SRSHTSSNYD SYKKSPGSTS RRQSVSPPYK EPSAYQSSTR SPSPYSRRQR SVSPYSRRRS SSYERSGSYS GRSPSPYGRR RSSSPFLSKR SLSRSPLPSR KSMKSRSRSP AYSRHSSSHS KKKRSSSRSR HSSISPVRLP LNSSLGAELS RKKKERAAAA AAAKMDGKES KGSPVFLPRK ENSSVEAKDS GLESKKLPRS VKLEKSAPDT ELVNVTHLNT EVKNSSDTGK VKLDENSEKH LVKDLKAQGT RDSKPIALKE EIVTPKETET SEKETPPPLP TIASPPPPLP TTTPPPQTPP LPPLPPIPAL PQQPPLPPSQ PAFSQVPASS TSTLPPSTHS KTSAVSSQAN SQPPVQVSVK TQVSVTAAIP HLKTSTLPPL PLPPLLPGDD DMDSPKETLP SKPVKKEKEQ RTRHLLTDLP LPPELPGGDL SPPDSPEPKA ITPPQQPYKK RPKICCPRYG ERRQTESDWG KRCVDKFDII GIIGEGTYGQ VYKAKDKDTG ELVALKKVRL DNEKEGFPIT AIREIKILRQ LIHRSVVNMK EIVTDKQDAL DFKKDKGAFY LVFEYMDHDL MGLLESGLVH FSEDHIKSFM KQLMEGLEYC HKKNFLHRDI KCSNILLNNS GQIKLADFGL ARLYNSEESR PYTNKVITLW YRPPELLLGE ERYTPAIDVW SCGCILGELF TKKPIFQANL ELAQLELISR LCGSPCPAVW PDVIKLPYFN TMKPKKQYRR RLREEFSFIP SAALDLLDHM LTLDPSKRCT AEQTLQSDFL KDVELSKMAP PDLPHWQDCH ELWSKKRRRQ RQSGVVVEEP PPSKTSRKET TSGTSTEPVK NSSPAPPQPA PGKVESGAGD AIGLADITQQ LNQSELAVLL NLLQSQTDLS IPQMAQLLNI HSNPEMQQQL EALNQSISAL TEATSQQQDS ETMAPEESLK EAPSAPVILP SAEQTTLEAS STPADMQNIL AVLLSQLMKT QEPAGSLEEN NSDKNSGPQG PRRTPTMPQE EAAACPPHIL PPEKRPPEPP GPPPPPPPPP LVEGDLSSAP QELNPAVTAA LLQLLSQPEA EPPGHLPHEH QALRPMEYST RPRPNRTYGN TDGPETGFSA IDTDERNSGP ALTESLVQTL VKNRTFSGSL SHLGESSSYQ GTGSVQFPGD QDLRFARVPL ALHPVVGQPF LKAEGSSNSV VHAETKLQNY GELGPGTTGA SSSGAGLHWG GPTQSSAYGK LYRGPTRVPP RGGRGRGVPY // ID CDK8_HUMAN Reviewed; 464 AA. AC P49336; Q5VUF3; Q6ISB5; DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1996, sequence version 1. DT 28-JAN-2026, entry version 214. DE RecName: Full=Cyclin-dependent kinase 8; DE EC=2.7.11.22; DE EC=2.7.11.23; DE AltName: Full=Cell division protein kinase 8; DE AltName: Full=Mediator complex subunit CDK8; DE AltName: Full=Mediator of RNA polymerase II transcription subunit CDK8; DE AltName: Full=Protein kinase K35; GN Name=CDK8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Testis; RX PubMed=7568034; DOI=10.1073/pnas.92.19.8871; RA Tassan J.-P., Jaquenoud M., Leopold P., Schultz S.J., Nigg E.A.; RT "Identification of human cyclin-dependent kinase 8, a putative protein RT kinase partner for cyclin C."; RL Proc. Natl. Acad. Sci. U.S.A. 92:8871-8875(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR RP COMPLEX. RX PubMed=9734358; DOI=10.1016/s1097-2765(00)80131-8; RA Sun X., Zhang Y., Cho H., Rickert P., Lees E., Lane W.S., Reinberg D.; RT "NAT, a human complex containing Srb polypeptides that functions as a RT negative regulator of activated transcription."; RL Mol. Cell 2:213-222(1998). RN [6] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE SMCC RP COMPLEX. RX PubMed=10024883; DOI=10.1016/s1097-2765(00)80178-1; RA Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E., RA Qin J., Roeder R.G.; RT "A novel human SRB/MED-containing cofactor complex, SMCC, involved in RT transcription regulation."; RL Mol. Cell 3:97-108(1999). RN [7] RP ERRATUM OF PUBMED:10024883. RA Gu W., Malik S., Ito M., Yuan C.-X., Fondell J.D., Zhang X., Martinez E., RA Qin J., Roeder R.G.; RL Mol. Cell 3:541-541(1999). RN [8] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-173. RX PubMed=10993082; DOI=10.1038/35024111; RA Akoulitchev S., Chuikov S., Reinberg D.; RT "TFIIH is negatively regulated by cdk8-containing mediator complexes."; RL Nature 407:102-106(2000). RN [9] RP FUNCTION, AND INTERACTION WITH MAML1. RX PubMed=15546612; DOI=10.1016/j.molcel.2004.10.014; RA Fryer C.J., White J.B., Jones K.A.; RT "Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and RT coordinate activation with turnover."; RL Mol. Cell 16:509-520(2004). RN [10] RP IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN THE MEDIATOR RP COMPLEX. RX PubMed=15175163; DOI=10.1016/j.molcel.2004.05.006; RA Sato S., Tomomori-Sato C., Parmely T.J., Florens L., Zybailov B., RA Swanson S.K., Banks C.A.S., Jin J., Cai Y., Washburn M.P., Conaway J.W., RA Conaway R.C.; RT "A set of consensus mammalian mediator subunits identified by RT multidimensional protein identification technology."; RL Mol. Cell 14:685-691(2004). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE MEDIATOR RP COMPLEX, AND ASSOCIATION OF THE MEDIATOR COMPLEX WITH RNA POLYMERASE II. RX PubMed=15989967; DOI=10.1016/j.molcel.2005.05.015; RA Zhang X., Krutchinsky A., Fukuda A., Chen W., Yamamura S., Chait B.T., RA Roeder R.G.; RT "MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation RT enriched in RNA polymerase II and is required for ER-mediated RT transcription."; RL Mol. Cell 19:89-100(2005). RN [12] RP INTERACTION WITH CTNNB1; GLI3; MED1; MED6; MED12 AND MED23. RX PubMed=17000779; DOI=10.1128/mcb.00443-06; RA Zhou H., Kim S., Ishii S., Boyer T.G.; RT "Mediator modulates Gli3-dependent Sonic hedgehog signaling."; RL Mol. Cell. Biol. 26:8667-8682(2006). RN [13] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [14] RP INVOLVEMENT IN IDDHBA, VARIANTS IDDHBA LEU-27; GLY-29; SER-30; LEU-62; RP LEU-97; GLN-178; GLY-193 AND MET-223, CHARACTERIZATION OF VARIANTS IDDHBA RP LEU-27; GLY-29; SER-30; LEU-62; GLN-178; GLY-193 AND MET-223, FUNCTION, AND RP MUTAGENESIS OF ASP-173. RX PubMed=30905399; DOI=10.1016/j.ajhg.2019.02.006; RG Deciphering Developmental Disorders Study; RA Calpena E., Hervieu A., Kaserer T., Swagemakers S.M.A., Goos J.A.C., RA Popoola O., Ortiz-Ruiz M.J., Barbaro-Dieber T., Bownass L., Brilstra E.H., RA Brimble E., Foulds N., Grebe T.A., Harder A.V.E., Lees M.M., Monaghan K.G., RA Newbury-Ecob R.A., Ong K.R., Osio D., Reynoso Santos F.J., RA Ruzhnikov M.R.Z., Telegrafi A., van Binsbergen E., van Dooren M.F., RA van der Spek P.J., Blagg J., Twigg S.R.F., Mathijssen I.M.J., Clarke P.A., RA Wilkie A.O.M.; RT "De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of RT the Mediator Complex, Cause a Syndromic Developmental Disorder."; RL Am. J. Hum. Genet. 104:709-720(2019). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-403 IN COMPLEX WITH CCNC AND RP INHIBITOR. RX PubMed=21806996; DOI=10.1016/j.jmb.2011.07.020; RA Schneider E.V., Bottcher J., Blaesse M., Neumann L., Huber R., Maskos K.; RT "The structure of CDK8/CycC implicates specificity in the CDK/cyclin family RT and reveals interaction with a deep pocket binder."; RL J. Mol. Biol. 412:251-266(2011). RN [16] RP VARIANTS [LARGE SCALE ANALYSIS] ASN-189 AND CYS-424. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Component of the Mediator complex, a coactivator involved in CC regulated gene transcription of nearly all RNA polymerase II-dependent CC genes. Mediator functions as a bridge to convey information from gene- CC specific regulatory proteins to the basal RNA polymerase II CC transcription machinery. Mediator is recruited to promoters by direct CC interactions with regulatory proteins and serves as a scaffold for the CC assembly of a functional pre-initiation complex with RNA polymerase II CC and the general transcription factors. Phosphorylates the CTD (C- CC terminal domain) of the large subunit of RNA polymerase II (RNAp II), CC which may inhibit the formation of a transcription initiation complex. CC Phosphorylates CCNH leading to down-regulation of the TFIIH complex and CC transcriptional repression. Recruited through interaction with MAML1 to CC hyperphosphorylate the intracellular domain of NOTCH, leading to its CC degradation. {ECO:0000269|PubMed:10993082, ECO:0000269|PubMed:15546612, CC ECO:0000269|PubMed:30905399}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- CATALYTIC ACTIVITY: CC Reaction=[DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed CC RNA polymerase] + ADP + H(+); Xref=Rhea:RHEA:10216, Rhea:RHEA- CC COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546, CC ChEBI:CHEBI:456216; EC=2.7.11.23; CC Evidence={ECO:0000269|PubMed:10993082}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250}; CC -!- SUBUNIT: Component of the Mediator complex, which is composed of MED1, CC MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, CC MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, CC MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CC CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct CC module termed the CDK8 module. Mediator containing the CDK8 module is CC less active than Mediator lacking this module in supporting CC transcriptional activation. Individual preparations of the Mediator CC complex lacking one or more distinct subunits have been variously CC termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. The cylin/CDK pair formed CC by CCNC/CDK8 also associates with the large subunit of RNA polymerase CC II. Interacts with CTNNB1, GLI3 and MAML1. CC {ECO:0000269|PubMed:10024883, ECO:0000269|PubMed:15175163, CC ECO:0000269|PubMed:15546612, ECO:0000269|PubMed:15989967, CC ECO:0000269|PubMed:17000779, ECO:0000269|PubMed:21806996, CC ECO:0000269|PubMed:9734358}. CC -!- INTERACTION: CC P49336; P24863: CCNC; NbExp=41; IntAct=EBI-394377, EBI-395261; CC P49336; Q01094: E2F1; NbExp=3; IntAct=EBI-394377, EBI-448924; CC P49336-2; P02489: CRYAA; NbExp=3; IntAct=EBI-11039720, EBI-6875961; CC P49336-2; Q14204: DYNC1H1; NbExp=3; IntAct=EBI-11039720, EBI-356015; CC P49336-2; Q92876: KLK6; NbExp=3; IntAct=EBI-11039720, EBI-2432309; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; CC IsoId=P49336-1; Sequence=Displayed; CC Name=2; CC IsoId=P49336-2; Sequence=VSP_029970; CC -!- DISEASE: Intellectual developmental disorder with hypotonia and CC behavioral abnormalities (IDDHBA) [MIM:618748]: An autosomal dominant CC neurodevelopmental disorder with onset in infancy. IDDHBA is CC characterized by hypotonia, global developmental delay, learning CC disability, and behavioral abnormalities, such as autistic features and CC attention deficit-hyperactivity disorder. Additional variable features CC may include non-specific facial dysmorphism, congenital heart defects, CC ocular anomalies, and poor feeding. {ECO:0000269|PubMed:30905399}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X85753; CAA59754.1; -; mRNA. DR EMBL; AL159159; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590108; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471075; EAX08386.1; -; Genomic_DNA. DR EMBL; CH471075; EAX08387.1; -; Genomic_DNA. DR EMBL; BC069634; AAH69634.1; -; mRNA. DR EMBL; BC104492; AAI04493.1; -; mRNA. DR EMBL; BC105950; AAI05951.1; -; mRNA. DR EMBL; BC107601; AAI07602.1; -; mRNA. DR CCDS; CCDS9317.1; -. [P49336-1] DR PIR; I37227; I37227. DR RefSeq; NP_001251.1; NM_001260.3. [P49336-1] DR RefSeq; NP_001305297.1; NM_001318368.2. [P49336-2] DR PDB; 3RGF; X-ray; 2.20 A; A=1-403. DR PDB; 4CRL; X-ray; 2.40 A; A=1-403. DR PDB; 4F6S; X-ray; 2.60 A; A=1-403. DR PDB; 4F6U; X-ray; 2.10 A; A=1-403. DR PDB; 4F6W; X-ray; 2.39 A; A=1-403. DR PDB; 4F70; X-ray; 3.00 A; A=1-403. DR PDB; 4F7J; X-ray; 2.60 A; A=1-403. DR PDB; 4F7L; X-ray; 2.90 A; A=1-403. DR PDB; 4F7N; X-ray; 2.65 A; A=1-403. DR PDB; 4F7S; X-ray; 2.20 A; A=1-403. DR PDB; 4G6L; X-ray; 2.70 A; A=1-403. DR PDB; 5BNJ; X-ray; 2.64 A; A=1-403. DR PDB; 5CEI; X-ray; 2.24 A; A=1-403. DR PDB; 5FGK; X-ray; 2.36 A; A=1-362. DR PDB; 5HBE; X-ray; 2.38 A; A=1-362. DR PDB; 5HBH; X-ray; 2.50 A; A=1-362. DR PDB; 5HBJ; X-ray; 3.00 A; A=1-362. DR PDB; 5HNB; X-ray; 2.35 A; A=1-362. DR PDB; 5HVY; X-ray; 2.39 A; A=1-403. DR PDB; 5I5Z; X-ray; 2.60 A; A=1-362. DR PDB; 5ICP; X-ray; 2.18 A; A=1-362. DR PDB; 5IDN; X-ray; 2.26 A; A=1-364. DR PDB; 5IDP; X-ray; 2.65 A; A=1-364. DR PDB; 5XQX; X-ray; 2.30 A; A=1-371. DR PDB; 5XS2; X-ray; 2.04 A; A=1-371. DR PDB; 6QTG; X-ray; 2.70 A; A=1-403. DR PDB; 6QTJ; X-ray; 2.48 A; A=1-403. DR PDB; 6R3S; X-ray; 2.19 A; A=1-403. DR PDB; 6T41; X-ray; 2.45 A; A=1-404. DR PDB; 6TPA; X-ray; 2.80 A; A=1-403. DR PDB; 6Y0A; X-ray; 2.19 A; A=1-403. DR PDB; 8TQ2; EM; 3.80 A; A=1-464. DR PDB; 8TQC; EM; 3.80 A; A=1-464. DR PDB; 8TQW; EM; 8.20 A; a=1-464. DR PDB; 9H8C; X-ray; 2.57 A; A=1-403. DR PDB; 9H8S; X-ray; 2.16 A; A=1-403. DR PDBsum; 3RGF; -. DR PDBsum; 4CRL; -. DR PDBsum; 4F6S; -. DR PDBsum; 4F6U; -. DR PDBsum; 4F6W; -. DR PDBsum; 4F70; -. DR PDBsum; 4F7J; -. DR PDBsum; 4F7L; -. DR PDBsum; 4F7N; -. DR PDBsum; 4F7S; -. DR PDBsum; 4G6L; -. DR PDBsum; 5BNJ; -. DR PDBsum; 5CEI; -. DR PDBsum; 5FGK; -. DR PDBsum; 5HBE; -. DR PDBsum; 5HBH; -. DR PDBsum; 5HBJ; -. DR PDBsum; 5HNB; -. DR PDBsum; 5HVY; -. DR PDBsum; 5I5Z; -. DR PDBsum; 5ICP; -. DR PDBsum; 5IDN; -. DR PDBsum; 5IDP; -. DR PDBsum; 5XQX; -. DR PDBsum; 5XS2; -. DR PDBsum; 6QTG; -. DR PDBsum; 6QTJ; -. DR PDBsum; 6R3S; -. DR PDBsum; 6T41; -. DR PDBsum; 6TPA; -. DR PDBsum; 6Y0A; -. DR PDBsum; 8TQ2; -. DR PDBsum; 8TQC; -. DR PDBsum; 8TQW; -. DR PDBsum; 9H8C; -. DR PDBsum; 9H8S; -. DR AlphaFoldDB; P49336; -. DR EMDB; EMD-41499; -. DR EMDB; EMD-41502; -. DR EMDB; EMD-41565; -. DR SMR; P49336; -. DR BioGRID; 107458; 229. DR ComplexPortal; CPX-1969; Cyclin C-CDK8 complex. DR ComplexPortal; CPX-3232; CKM complex variant 1. DR CORUM; P49336; -. DR DIP; DIP-32595N; -. DR FunCoup; P49336; 3225. DR IntAct; P49336; 203. DR MINT; P49336; -. DR STRING; 9606.ENSP00000370938; -. DR BindingDB; P49336; -. DR ChEMBL; CHEMBL5719; -. DR DrugBank; DB03496; Alvocidib. DR DrugBank; DB18107; SEL120-34A free base. DR DrugCentral; P49336; -. DR GuidetoPHARMACOLOGY; 1980; -. DR GlyCosmos; P49336; 3 sites, 1 glycan. DR GlyGen; P49336; 10 sites, 1 O-linked glycan (10 sites). DR iPTMnet; P49336; -. DR PhosphoSitePlus; P49336; -. DR BioMuta; CDK8; -. DR DMDM; 1345718; -. DR CPTAC; CPTAC-3153; -. DR CPTAC; CPTAC-3154; -. DR jPOST; P49336; -. DR MassIVE; P49336; -. DR PaxDb; 9606-ENSP00000370938; -. DR PeptideAtlas; P49336; -. DR ProteomicsDB; 55991; -. [P49336-1] DR ProteomicsDB; 55992; -. [P49336-2] DR Pumba; P49336; -. DR Antibodypedia; 7248; 457 antibodies from 38 providers. DR DNASU; 1024; -. DR Ensembl; ENST00000381527.8; ENSP00000370938.3; ENSG00000132964.14. [P49336-1] DR GeneID; 1024; -. DR KEGG; hsa:1024; -. DR MANE-Select; ENST00000381527.8; ENSP00000370938.3; NM_001260.3; NP_001251.1. DR UCSC; uc001uqr.2; human. [P49336-1] DR AGR; HGNC:1779; -. DR ClinPGx; PA26315; -. DR CTD; 1024; -. DR DisGeNET; 1024; -. DR GeneCards; CDK8; -. DR HGNC; HGNC:1779; CDK8. DR HPA; ENSG00000132964; Low tissue specificity. DR MalaCards; CDK8; -. DR MIM; 603184; gene. DR MIM; 618748; phenotype. DR OpenTargets; ENSG00000132964; -. DR Orphanet; 528084; Non-specific syndromic intellectual disability. DR VEuPathDB; HostDB:ENSG00000132964; -. DR eggNOG; KOG0666; Eukaryota. DR GeneTree; ENSGT00940000157104; -. DR HOGENOM; CLU_000288_181_6_1; -. DR InParanoid; P49336; -. DR OMA; YFKNGGP; -. DR OrthoDB; 6284126at2759; -. DR PAN-GO; P49336; 5 GO annotations based on evolutionary models. DR PhylomeDB; P49336; -. DR BRENDA; 2.7.11.22; 2681. DR BRENDA; 2.7.11.23; 2681. DR PathwayCommons; P49336; -. DR Reactome; R-HSA-1989781; PPARA activates gene expression. DR Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription. DR Reactome; R-HSA-212436; Generic Transcription Pathway. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants. DR Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants. DR Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation. DR Reactome; R-HSA-9833110; RSV-host interactions. DR Reactome; R-HSA-9841922; MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis. DR SignaLink; P49336; -. DR SIGNOR; P49336; -. DR Agora; ENSG00000132964; -. DR BioGRID-ORCS; 1024; 47 hits in 1097 CRISPR screens. DR ChiTaRS; CDK8; human. DR EvolutionaryTrace; P49336; -. DR GeneWiki; Cyclin-dependent_kinase_8; -. DR GenomeRNAi; 1024; -. DR Pharos; P49336; Tchem. DR PRO; PR:P49336; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; P49336; protein. DR Bgee; ENSG00000132964; Expressed in adrenal tissue and 208 other cell types or tissues. DR ExpressionAtlas; P49336; baseline and differential. DR GO; GO:1990508; C:CKM complex; IPI:ComplexPortal. DR GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:ComplexPortal. DR GO; GO:0016592; C:mediator complex; IDA:MGI. DR GO; GO:0005730; C:nucleolus; IDA:MGI. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:MGI. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0004672; F:protein kinase activity; IMP:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IEA:UniProtKB-EC. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ComplexPortal. DR CDD; cd07868; STKc_CDK8; 1. DR FunFam; 1.10.510.10:FF:000088; cyclin-dependent kinase 8 isoform X1; 1. DR FunFam; 3.30.200.20:FF:000122; cyclin-dependent kinase 8 isoform X1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR050108; CDK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24056; CELL DIVISION PROTEIN KINASE; 1. DR PANTHER; PTHR24056:SF243; CYCLIN-DEPENDENT KINASE 8; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Activator; Alternative splicing; ATP-binding; KW Autism spectrum disorder; Disease variant; Intellectual disability; Kinase; KW Nucleotide-binding; Nucleus; Proteomics identification; Reference proteome; KW Repressor; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase. FT CHAIN 1..464 FT /note="Cyclin-dependent kinase 8" FT /id="PRO_0000085797" FT DOMAIN 21..335 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..15 FT /note="Interaction with CCNC" FT REGION 361..464 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 373..391 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 409..426 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..464 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 151 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 27..35 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 52 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VAR_SEQ 370 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029970" FT VARIANT 27 FT /note="V -> L (in IDDHBA; decreased protein kinase FT activity)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083786" FT VARIANT 29 FT /note="R -> G (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593218885)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083787" FT VARIANT 30 FT /note="G -> S (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593218890)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083788" FT VARIANT 62 FT /note="S -> L (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1565977796)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083789" FT VARIANT 97 FT /note="F -> L (in IDDHBA; uncertain significance)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083790" FT VARIANT 178 FT /note="R -> Q (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1418353379)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083791" FT VARIANT 189 FT /note="D -> N (in a lung neuroendocrine carcinoma sample; FT somatic mutation; dbSNP:rs2138050298)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041980" FT VARIANT 193 FT /note="V -> G (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1875421510)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083792" FT VARIANT 223 FT /note="I -> M (in IDDHBA; decreased protein kinase FT activity; dbSNP:rs1593310364)" FT /evidence="ECO:0000269|PubMed:30905399" FT /id="VAR_083793" FT VARIANT 424 FT /note="R -> C (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs2138079506)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041981" FT MUTAGEN 173 FT /note="D->A: Abrogates kinase activity and TFIIH-dependent FT transcriptional repression." FT /evidence="ECO:0000269|PubMed:10993082, FT ECO:0000269|PubMed:30905399" FT HELIX 3..12 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 16..19 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 26..30 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 33..44 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 49..58 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 61..72 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 83..87 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 88..91 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 92..98 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 101..103 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 104..115 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 116..118 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 125..144 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 164..167 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 169..171 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 174..178 FT /evidence="ECO:0007829|PDB:6TPA" FT HELIX 179..181 FT /evidence="ECO:0007829|PDB:5ICP" FT STRAND 186..188 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 202..205 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 213..229 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 249..259 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 264..266 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 268..272 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 276..282 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 285..288 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 293..299 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 307..315 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 320..322 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 326..330 FT /evidence="ECO:0007829|PDB:5XS2" FT HELIX 333..335 FT /evidence="ECO:0007829|PDB:5XS2" FT STRAND 337..339 FT /evidence="ECO:0007829|PDB:5XS2" FT TURN 345..348 FT /evidence="ECO:0007829|PDB:5XS2" SQ SEQUENCE 464 AA; 53284 MW; 00CBAB6CE354605F CRC64; MDYDFKVKLS SERERVEDLF EYEGCKVGRG TYGHVYKAKR KDGKDDKDYA LKQIEGTGIS MSACREIALL RELKHPNVIS LQKVFLSHAD RKVWLLFDYA EHDLWHIIKF HRASKANKKP VQLPRGMVKS LLYQILDGIH YLHANWVLHR DLKPANILVM GEGPERGRVK IADMGFARLF NSPLKPLADL DPVVVTFWYR APELLLGARH YTKAIDIWAI GCIFAELLTS EPIFHCRQED IKTSNPYHHD QLDRIFNVMG FPADKDWEDI KKMPEHSTLM KDFRRNTYTN CSLIKYMEKH KVKPDSKAFH LLQKLLTMDP IKRITSEQAM QDPYFLEDPL PTSDVFAGCQ IPYPKREFLT EEEPDDKGDK KNQQQQQGNN HTNGTGHPGN QDSSHTQGPP LKKVRVVPPT TTSGGLIMTS DYQRSNPHAA YPNPGPSTSQ PQSSMGYSAT SQQPPQYSHQ THRY // ID DPOD1_HUMAN Reviewed; 1107 AA. AC P28340; Q8NER3; Q96H98; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 19-JUL-2004, sequence version 2. DT 28-JAN-2026, entry version 232. DE RecName: Full=DNA polymerase delta catalytic subunit {ECO:0000305}; DE EC=2.7.7.7 {ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433}; DE AltName: Full=3'-5' exodeoxyribonuclease {ECO:0000305}; DE EC=3.1.11.- {ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433}; DE AltName: Full=DNA polymerase subunit delta p125; GN Name=POLD1 {ECO:0000312|HGNC:HGNC:9175}; Synonyms=POLD; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TRP-30. RC TISSUE=Hepatoma; RX PubMed=1722322; DOI=10.1073/pnas.88.24.11197; RA Chung D.W., Zhang J., Tan C.-K., Davie E.W., So A.G., Downey K.M.; RT "Primary structure of the catalytic subunit of human DNA polymerase delta RT and chromosomal location of the gene."; RL Proc. Natl. Acad. Sci. U.S.A. 88:11197-11201(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], VARIANTS HIS-119 AND ASN-173, AND INDUCTION BY RP SERUM. RC TISSUE=Cervix carcinoma; RX PubMed=1542570; DOI=10.1093/nar/20.4.735; RA Yang C.-L., Chang L.-S., Zhang P., Hao H., Zhu L., Toomey N.L., RA Lee M.Y.W.T.; RT "Molecular cloning of the cDNA for the catalytic subunit of human DNA RT polymerase delta."; RL Nucleic Acids Res. 20:735-745(1992). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-19; TRP-30; HIS-119; RP ASN-173; HIS-177; HIS-849 AND GLN-1086. RG NIEHS SNPs program; RL Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-119. RC TISSUE=Lymph; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP INTERACTION WITH POLD2 AND PCNA. RX PubMed=11328591; DOI=10.1093/oxfordjournals.jbchem.a002909; RA Shikata K., Ohta S., Yamada K., Obuse C., Yoshikawa H., Tsurimoto T.; RT "The human homologue of fission Yeast cdc27, p66, is a component of active RT human DNA polymerase delta."; RL J. Biochem. 129:699-708(2001). RN [6] RP INTERACTION WITH POLD3, AND SUBCELLULAR LOCATION. RX PubMed=11595739; DOI=10.1074/jbc.m106990200; RA Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S., RA Christensen J., Hughes P.; RT "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA RT replication through a conserved p21(Cip1)-like PCNA-binding motif present RT in the third subunit of human DNA polymerase delta."; RL J. Biol. Chem. 276:49258-49266(2001). RN [7] RP INTERACTION WITH PCNA AND POLD4, AND CHARACTERIZATION OF POL-DELTA2 AND RP POL-DELTA4 COMPLEXES. RX PubMed=12403614; DOI=10.1021/bi0262707; RA Xie B., Mazloum N., Liu L., Rahmeh A., Li H., Lee M.Y.; RT "Reconstitution and characterization of the human DNA polymerase delta RT four-subunit holoenzyme."; RL Biochemistry 41:13133-13142(2002). RN [8] RP INTERACTION WITH POLD2 AND POLDIP2, AND STIMULATION BY PCNA. RX PubMed=12522211; DOI=10.1074/jbc.m208694200; RA Liu L., Rodriguez-Belmonte E.M., Mazloum N., Xie B., Lee M.Y.W.T.; RT "Identification of a novel protein, PDIP38, that interacts with the p50 RT subunit of DNA polymerase delta and proliferating cell nuclear antigen."; RL J. Biol. Chem. 278:10041-10047(2003). RN [9] RP INTERACTION WITH WRNIP1. RX PubMed=15670210; DOI=10.1111/j.1365-2443.2004.00812.x; RA Tsurimoto T., Shinozaki A., Yano M., Seki M., Enomoto T.; RT "Human Werner helicase interacting protein 1 (WRNIP1) functions as a novel RT modulator for DNA polymerase delta."; RL Genes Cells 10:13-22(2005). RN [10] RP FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH POLD2; POLD4 AND PCNA. RX PubMed=16510448; DOI=10.1074/jbc.m600322200; RA Li H., Xie B., Zhou Y., Rahmeh A., Trusa S., Zhang S., Gao Y., Lee E.Y., RA Lee M.Y.; RT "Functional roles of p12, the fourth subunit of human DNA polymerase RT delta."; RL J. Biol. Chem. 281:14748-14755(2006). RN [11] RP IDENTIFICATION IN POL-DELTA COMPLEX. RX PubMed=17317665; DOI=10.1074/jbc.m610356200; RA Zhang S., Zhou Y., Trusa S., Meng X., Lee E.Y., Lee M.Y.; RT "A novel DNA damage response: rapid degradation of the p12 subunit of dna RT polymerase delta."; RL J. Biol. Chem. 282:15330-15340(2007). RN [12] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ASP-402, CHARACTERIZATION OF RP POL-DELTA3 AND POL-DELTA4, AND ACTIVITY REGULATION. RX PubMed=19074196; DOI=10.1093/nar/gkn1000; RA Meng X., Zhou Y., Zhang S., Lee E.Y., Frick D.N., Lee M.Y.; RT "DNA damage alters DNA polymerase delta to a form that exhibits increased RT discrimination against modified template bases and mismatched primers."; RL Nucleic Acids Res. 37:647-657(2009). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, CHARACTERIZATION OF POL-DELTA3 AND RP POL-DELTA4, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-402. RX PubMed=20334433; DOI=10.1021/bi100042b; RA Meng X., Zhou Y., Lee E.Y., Lee M.Y., Frick D.N.; RT "The p12 subunit of human polymerase delta modulates the rate and fidelity RT of DNA synthesis."; RL Biochemistry 49:3545-3554(2010). RN [15] RP FUNCTION IN NUCLEOTIDE EXCISION REPAIR, AND SUBCELLULAR LOCATION. RX PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009; RA Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K., RA Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G., Mullenders L.H., RA Yamashita S., Fousteri M.I., Lehmann A.R.; RT "Three DNA polymerases, recruited by different mechanisms, carry out NER RT repair synthesis in human cells."; RL Mol. Cell 37:714-727(2010). RN [16] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [17] RP SUBCELLULAR LOCATION, IDENTIFICATION IN POLD COMPLEX, AND DEVELOPMENTAL RP STAGE. RX PubMed=22801543; DOI=10.4161/cc.21280; RA Chea J., Zhang S., Zhao H., Zhang Z., Lee E.Y., Darzynkiewicz Z., Lee M.Y.; RT "Spatiotemporal recruitment of human DNA polymerase delta to sites of UV RT damage."; RL Cell Cycle 11:2885-2895(2012). RN [18] RP INTERACTION WITH CIAO1. RX PubMed=23891004; DOI=10.1016/j.cmet.2013.06.015; RA Stehling O., Mascarenhas J., Vashisht A.A., Sheftel A.D., Niggemeyer B., RA Roesser R., Pierik A.J., Wohlschlegel J.A., Lill R.; RT "Human CIA2A-FAM96A and CIA2B-FAM96B integrate iron homeostasis and RT maturation of different subsets of cytosolic-nuclear iron-sulfur RT proteins."; RL Cell Metab. 18:187-198(2013). RN [19] RP ERRATUM OF PUBMED:23891004. RX PubMed=29320706; DOI=10.1016/j.cmet.2017.12.009; RA Stehling O., Mascarenhas J., Vashisht A.A., Sheftel A.D., Niggemeyer B., RA Roesser R., Pierik A.J., Wohlschlegel J.A., Lill R.; RT "Human CIA2A-FAM96A and CIA2B-FAM96B Integrate Iron Homeostasis and RT Maturation of Different Subsets of Cytosolic-Nuclear Iron-Sulfur RT Proteins."; RL Cell Metab. 27:263-263(2018). RN [20] RP FUNCTION IN OKAZAKI FRAGMENT PROCESSING. RX PubMed=24035200; DOI=10.1016/j.dnarep.2013.08.008; RA Lin S.H., Wang X., Zhang S., Zhang Z., Lee E.Y., Lee M.Y.; RT "Dynamics of enzymatic interactions during short flap human Okazaki RT fragment processing by two forms of human DNA polymerase delta."; RL DNA Repair 12:922-935(2013). RN [21] RP POL-DELTA3 COMPLEX EXPRESSION DURING CELL CYCLE. RX PubMed=23913683; DOI=10.1074/jbc.m113.490466; RA Zhang S., Zhao H., Darzynkiewicz Z., Zhou P., Zhang Z., Lee E.Y., Lee M.Y.; RT "A novel function of CRL4(Cdt2): regulation of the subunit structure of DNA RT polymerase delta in response to DNA damage and during the S phase."; RL J. Biol. Chem. 288:29550-29561(2013). RN [22] RP FUNCTION, AND INTERACTION WITH PCNA. RX PubMed=24022480; DOI=10.1074/jbc.c113.505586; RA Terai K., Shibata E., Abbas T., Dutta A.; RT "Degradation of p12 subunit by CRL4Cdt2 E3 ligase inhibits fork progression RT after DNA damage."; RL J. Biol. Chem. 288:30509-30514(2013). RN [23] RP TISSUE SPECIFICITY, AND VARIANT MDPL SER-605 DEL. RX PubMed=23770608; DOI=10.1038/ng.2670; RA Weedon M.N., Ellard S., Prindle M.J., Caswell R., Allen H.L., Oram R., RA Godbole K., Yajnik C.S., Sbraccia P., Novelli G., Turnpenny P., McCann E., RA Goh K.J., Wang Y., Fulford J., McCulloch L.J., Savage D.B., O'Rahilly S., RA Kos K., Loeb L.A., Semple R.K., Hattersley A.T.; RT "An in-frame deletion at the polymerase active site of POLD1 causes a RT multisystem disorder with lipodystrophy."; RL Nat. Genet. 45:947-950(2013). RN [24] RP FUNCTION, AND INTERACTION WITH POLDIP2. RX PubMed=24191025; DOI=10.1073/pnas.1308760110; RA Maga G., Crespan E., Markkanen E., Imhof R., Furrer A., Villani G., RA Huebscher U., van Loon B.; RT "DNA polymerase delta-interacting protein 2 is a processivity factor for RT DNA polymerase lambda during 8-oxo-7,8-dihydroguanine bypass."; RL Proc. Natl. Acad. Sci. U.S.A. 110:18850-18855(2013). RN [25] RP METHYLATION [LARGE SCALE ANALYSIS] AT ARG-19, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Colon carcinoma; RX PubMed=24129315; DOI=10.1074/mcp.o113.027870; RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M., RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V., RA Bedford M.T., Comb M.J.; RT "Immunoaffinity enrichment and mass spectrometry analysis of protein RT methylation."; RL Mol. Cell. Proteomics 13:372-387(2014). RN [26] RP INTERACTION WITH PCNA. RX PubMed=24939902; DOI=10.1093/nar/gku533; RA Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A., RA Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A., RA Prosperi E.; RT "CBP and p300 acetylate PCNA to link its degradation with nucleotide RT excision repair synthesis."; RL Nucleic Acids Res. 42:8433-8448(2014). RN [27] RP FUNCTION IN BIR. RX PubMed=24310611; DOI=10.1126/science.1243211; RA Costantino L., Sotiriou S.K., Rantala J.K., Magin S., Mladenov E., RA Helleday T., Haber J.E., Iliakis G., Kallioniemi O.P., Halazonetis T.D.; RT "Break-induced replication repair of damaged forks induces genomic RT duplications in human cells."; RL Science 343:88-91(2014). RN [28] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-574, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [29] RP VARIANTS ASP-145; HIS-461; ASN-478; LEU-787; HIS-808 AND THR-864, AND RP INVOLVEMENT IN CRCS10. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [30] RP VARIANT CRCS10 PRO-474. RX PubMed=24501277; DOI=10.1093/hmg/ddu058; RA Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A., RA Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C., Juarez M., RA Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A., Juan M.J., RA Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R., Lazaro C., RA Capella G., Pineda M., Soto J.L., Blanco I.; RT "New insights into POLE and POLD1 germline mutations in familial colorectal RT cancer and polyposis."; RL Hum. Mol. Genet. 23:3506-3512(2014). RN [31] RP INVOLVEMENT IN IMD120, VARIANTS IMD120 HIS-684; TRP-939 AND TRP-1074, RP CHARACTERIZATION OF VARIANTS IMD120 HIS-684; TRP-939 AND TRP-1074, RP FUNCTION, INTERACTION WITH POLD2 AND POLD3, AND MUTAGENESIS OF ASP-602 AND RP ASP-757. RX PubMed=31449058; DOI=10.1172/jci128903; RA Conde C.D., Petronczki O.Y., Baris S., Willmann K.L., Girardi E., RA Salzer E., Weitzer S., Ardy R.C., Krolo A., Ijspeert H., Kiykim A., RA Karakoc-Aydiner E., Foerster-Waldl E., Kager L., Pickl W.F., RA Superti-Furga G., Martinez J., Loizou J.I., Ozen A., van der Burg M., RA Boztug K.; RT "Polymerase delta deficiency causes syndromic immunodeficiency with RT replicative stress."; RL J. Clin. Invest. 129:4194-4206(2019). RN [32] RP INVOLVEMENT IN IMD120, VARIANT IMD120 CYS-1060, CHARACTERIZATION OF VARIANT RP IMD120 CYS-1060, AND INTERACTION WITH POLD2 AND RFC1. RX PubMed=31629014; DOI=10.1016/j.jaci.2019.10.004; RA Cui Y., Keles S., Charbonnier L.M., Jule A.M., Henderson L., Celik S.C., RA Reisli I., Shen C., Xie W.J., Schmitz-Abe K., Wu H., Chatila T.A.; RT "Combined immunodeficiency caused by a loss-of-function mutation in DNA RT polymerase delta 1."; RL J. Allergy Clin. Immunol. 145:391-401.e8(2020). CC -!- FUNCTION: As the catalytic component of the trimeric (Pol-delta3 CC complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 CC complex), plays a crucial role in high fidelity genome replication, CC including in lagging strand synthesis, and repair (PubMed:16510448, CC PubMed:19074196, PubMed:20334433, PubMed:24022480, PubMed:24035200, CC PubMed:31449058). Exhibits both DNA polymerase and 3'- to 5'- CC exonuclease activities (PubMed:16510448, PubMed:19074196, CC PubMed:20334433, PubMed:24022480, PubMed:24035200). Requires the CC presence of accessory proteins POLD2, POLD3 and POLD4 for full CC activity. Depending upon the absence (Pol-delta3) or the presence of CC POLD4 (Pol-delta4), displays differences in catalytic activity. Most CC notably, expresses higher proofreading activity in the context of Pol- CC delta3 compared with that of Pol-delta4 (PubMed:19074196, CC PubMed:20334433). Although both Pol-delta3 and Pol-delta4 process CC Okazaki fragments in vitro, Pol-delta3 may be better suited to fulfill CC this task, exhibiting near-absence of strand displacement activity CC compared to Pol-delta4 and stalling on encounter with the 5'-blocking CC oligonucleotides. Pol-delta3 idling process may avoid the formation of CC a gap, while maintaining a nick that can be readily ligated CC (PubMed:24035200). Along with DNA polymerase kappa, DNA polymerase CC delta carries out approximately half of nucleotide excision repair CC (NER) synthesis following UV irradiation (PubMed:20227374). Under CC conditions of DNA replication stress, in the presence of POLD3 and CC POLD4, may catalyze the repair of broken replication forks through CC break-induced replication (BIR) (PubMed:24310611). Involved in the CC translesion synthesis (TLS) of templates carrying O6-methylguanine, CC 8oxoG or abasic sites (PubMed:19074196, PubMed:24191025). CC {ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:20334433, CC ECO:0000269|PubMed:24022480, ECO:0000269|PubMed:24035200, CC ECO:0000269|PubMed:24191025, ECO:0000269|PubMed:24310611, CC ECO:0000269|PubMed:31449058}. CC -!- CATALYTIC ACTIVITY: CC Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + CC diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA- CC COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112; CC EC=2.7.7.7; Evidence={ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20334433}; CC -!- COFACTOR: CC Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883; Evidence={ECO:0000250}; CC Note=Binds 1 [4Fe-4S] cluster. {ECO:0000250}; CC -!- ACTIVITY REGULATION: Regulated by alteration of quaternary structure. CC Exhibits burst rates of DNA synthesis are about 5 times faster in the CC presence of POLD4 (Pol-delta4 complex) than in its absence (Pol-delta3 CC complex), while the affinity of the enzyme for its DNA and dNTP CC substrates appears unchanged. The Pol-delta3 complex is more likely to CC proofread DNA synthesis because it cleaves single-stranded DNA twice as CC fast and transfers mismatched DNA from the polymerase to the CC exonuclease sites 9 times faster compared to the Pol-delta3 complex. CC Pol-delta3 also extends mismatched primers 3 times more slowly in the CC absence of POLD4. The conversion of Pol-delta4 into Pol-delta3 is CC induced by genotoxic stress or by replication stress leading POLD4 CC degradation (PubMed:19074196, PubMed:20334433). Stimulated in the CC presence of PCNA (PubMed:11328591, PubMed:12403614, PubMed:12522211, CC PubMed:16510448, PubMed:24022480, PubMed:24939902). This stimulation is CC further increased in the presence of KCTD13/PDIP1, most probably via CC direct interaction between KCTD13 and POLD2 (By similarity). CC {ECO:0000250|UniProtKB:P28339, ECO:0000269|PubMed:11328591, CC ECO:0000269|PubMed:12403614, ECO:0000269|PubMed:12522211, CC ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196, CC ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:24022480, CC ECO:0000269|PubMed:24939902}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC Note=kcat is 87 sec(-1) for DNA synthesis by Pol-delta4 and 19 sec(- CC 1) for Pol-delta3. kcat for exonuclease activity determined using a CC 26mer/40mer duplex DNA gives a value of 0.003 sec(-1) for Pol-delta4 CC and 0.026 sec(-1) for Pol-delta3. When using a 26mer/40mer with a T:G CC mismatch at the primer terminus, the switching rates from the CC polymerase to the exonuclease site for Pol-delta4 and Pol-delta3 are CC increased 20- and 10-fold, respectively, but the rate constant for CC Pol-delta3 is still 5-fold faster than that for Pol-delta4.; CC -!- SUBUNIT: Component of the tetrameric DNA polymerase delta complex (Pol- CC delta4), which consists of POLD1/p125, POLD2/p50, POLD3/p66/p68 and CC POLD4/p12, with POLD1 bearing both DNA polymerase and 3' to 5' CC proofreading exonuclease activities (PubMed:11595739, PubMed:12522211, CC PubMed:17317665, PubMed:22801543, PubMed:31449058, PubMed:31629014). CC Within Pol-delta4, directly interacts with POLD2 and POLD4 CC (PubMed:11328591, PubMed:12403614, PubMed:16510448). Following CC genotoxic stress by DNA-damaging agents, such as ultraviolet light and CC methyl methanesulfonate, or by replication stress induced by treatment CC with hydroxyurea or aphidicolin, Pol-delta4 is converted into a CC trimeric form of the complex (Pol-delta3) by POLD4 degradation. Pol- CC delta3 is the major form at S phase replication sites and DNA damage CC sites (PubMed:17317665, PubMed:22801543). POLD1 displays different CC catalytic properties depending upon the complex it is found in CC (PubMed:17317665). It exhibits higher proofreading activity and CC fidelity than Pol-delta4, making it particularly well suited to respond CC to DNA damage (PubMed:19074196, PubMed:20334433). Directly interacts CC with PCNA, as do POLD3 and POLD4; this interaction stimulates Pol- CC delta4 polymerase activity (PubMed:11328591, PubMed:12403614, CC PubMed:12522211, PubMed:16510448, PubMed:24022480, PubMed:24939902). As CC POLD2 and POLD4, directly interacts with WRNIP1; this interaction CC stimulates DNA polymerase delta-mediated DNA synthesis, independently CC of the presence of PCNA. This stimulation may be due predominantly to CC an increase of initiation frequency and also to increased processivity CC (PubMed:15670210). Also observed as a dimeric complex with POLD2 (Pol- CC delta2 complex). Pol-delta2 is relatively insensitive to the PCNA CC stimulation (2-5-fold) compared to Pol-delta4 that is stimulated by CC over 50-fold (PubMed:12403614). The DNA polymerase delta complex CC interacts with POLDIP2; this interaction is probably mediated through CC direct binding to POLD2 (PubMed:12522211). Interacts with CIAO1 CC (PubMed:23891004). Interacts with POLDIP2 (PubMed:24191025). Interacts CC with RFC1 (PubMed:31629014). {ECO:0000269|PubMed:11328591, CC ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:12403614, CC ECO:0000269|PubMed:12522211, ECO:0000269|PubMed:15670210, CC ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:17317665, CC ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20334433, CC ECO:0000269|PubMed:22801543, ECO:0000269|PubMed:23891004, CC ECO:0000269|PubMed:24022480, ECO:0000269|PubMed:24191025, CC ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:31449058, CC ECO:0000269|PubMed:31629014}. CC -!- INTERACTION: CC P28340; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-716569, EBI-10173507; CC P28340; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-716569, EBI-3867333; CC P28340; Q53G59: KLHL12; NbExp=3; IntAct=EBI-716569, EBI-740929; CC P28340; Q14847-2: LASP1; NbExp=3; IntAct=EBI-716569, EBI-9088686; CC P28340; P12004: PCNA; NbExp=3; IntAct=EBI-716569, EBI-358311; CC P28340; P49005: POLD2; NbExp=16; IntAct=EBI-716569, EBI-372354; CC P28340; Q9HCU8: POLD4; NbExp=14; IntAct=EBI-716569, EBI-864968; CC P28340; Q13485: SMAD4; NbExp=7; IntAct=EBI-716569, EBI-347263; CC P28340; Q9NYB0: TERF2IP; NbExp=2; IntAct=EBI-716569, EBI-750109; CC P28340; Q96S55: WRNIP1; NbExp=2; IntAct=EBI-716569, EBI-2513471; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11595739, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:22801543}. CC Note=Colocalizes with PCNA and POLD3 at S phase replication sites CC (PubMed:11595739). After UV irradiation, recruited to DNA damage sites CC within 2 hours, independently of the cell cycle phase, nor on PCNA CC ubiquitination. This recruitment requires POLD3, PCNA and RFC1- CC replication factor C complex (PubMed:20227374, PubMed:22801543). CC {ECO:0000269|PubMed:11595739, ECO:0000269|PubMed:20227374, CC ECO:0000269|PubMed:22801543}. CC -!- TISSUE SPECIFICITY: Widely expressed, with high levels of expression in CC heart and lung. {ECO:0000269|PubMed:23770608}. CC -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent, with highest CC levels in G2/M phase and lowest in G1. {ECO:0000269|PubMed:22801543}. CC -!- INDUCTION: Up-regulated by serum stimulation. CC {ECO:0000269|PubMed:1542570}. CC -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for the CC formation of polymerase complexes. {ECO:0000250}. CC -!- DISEASE: Colorectal cancer 10 (CRCS10) [MIM:612591]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24501277}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Mandibular hypoplasia, deafness, progeroid features, and CC lipodystrophy syndrome (MDPL) [MIM:615381]: An autosomal dominant CC systemic disorder characterized by prominent loss of subcutaneous fat, CC metabolic abnormalities including insulin resistance and diabetes CC mellitus, sclerodermatous skin, and a facial appearance characterized CC by mandibular hypoplasia. Sensorineural deafness occurs late in the CC first or second decades of life. {ECO:0000269|PubMed:23770608}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Immunodeficiency 120 (IMD120) [MIM:620836]: An autosomal CC recessive immunologic disorder manifesting in early childhood with CC recurrent upper and lower respiratory tract infections, lymphopenia, CC and hypogammaglobulinemia. Affected individuals may also develop CC persistent viral infections, particularly of the herpes family. CC Additional variable features include hearing loss, speech delay, short CC stature, and mildly impaired intellectual development. CC {ECO:0000269|PubMed:31449058, ECO:0000269|PubMed:31629014}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the DNA polymerase type-B family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M80397; AAA58439.1; -; mRNA. DR EMBL; M81735; AAA35768.1; -; mRNA. DR EMBL; AY129569; AAM76971.1; -; Genomic_DNA. DR EMBL; BC008800; AAH08800.1; -; mRNA. DR CCDS; CCDS12795.1; -. DR PIR; A41618; A41618. DR RefSeq; NP_001243778.1; NM_001256849.1. DR RefSeq; NP_001425141.1; NM_001438212.1. DR RefSeq; NP_001425142.1; NM_001438213.1. DR RefSeq; NP_002682.2; NM_002691.4. DR RefSeq; XP_011525340.1; XM_011527038.2. DR RefSeq; XP_047294903.1; XM_047438947.1. DR RefSeq; XP_054177208.1; XM_054321233.1. DR RefSeq; XP_054177209.1; XM_054321234.1. DR PDB; 6S1M; EM; 4.27 A; A=1-1107. DR PDB; 6S1N; EM; 4.86 A; A=1-1107. DR PDB; 6S1O; EM; 8.10 A; A=1-1107. DR PDB; 6TNY; EM; 3.08 A; A=1-1107. DR PDB; 6TNZ; EM; 4.05 A; A=1-1107. DR PDB; 9EKB; EM; 3.65 A; A=1-1107. DR PDBsum; 6S1M; -. DR PDBsum; 6S1N; -. DR PDBsum; 6S1O; -. DR PDBsum; 6TNY; -. DR PDBsum; 6TNZ; -. DR PDBsum; 9EKB; -. DR AlphaFoldDB; P28340; -. DR EMDB; EMD-10080; -. DR EMDB; EMD-10081; -. DR EMDB; EMD-10082; -. DR EMDB; EMD-10539; -. DR EMDB; EMD-10540; -. DR EMDB; EMD-48117; -. DR SMR; P28340; -. DR BioGRID; 111420; 365. DR ComplexPortal; CPX-2097; DNA polymerase delta complex. DR CORUM; P28340; -. DR FunCoup; P28340; 2398. DR IntAct; P28340; 125. DR MINT; P28340; -. DR STRING; 9606.ENSP00000472445; -. DR BindingDB; P28340; -. DR ChEMBL; CHEMBL2735; -. DR DrugBank; DB12151; Brincidofovir. DR DrugCentral; P28340; -. DR GlyGen; P28340; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P28340; -. DR PhosphoSitePlus; P28340; -. DR BioMuta; POLD1; -. DR DMDM; 50403732; -. DR jPOST; P28340; -. DR MassIVE; P28340; -. DR PaxDb; 9606-ENSP00000406046; -. DR PeptideAtlas; P28340; -. DR ProteomicsDB; 54478; -. DR Pumba; P28340; -. DR Antibodypedia; 3821; 357 antibodies from 38 providers. DR CPTC; P28340; 1 antibody. DR DNASU; 5424; -. DR Ensembl; ENST00000440232.7; ENSP00000406046.1; ENSG00000062822.17. DR Ensembl; ENST00000593887.2; ENSP00000472607.2; ENSG00000062822.17. DR Ensembl; ENST00000599857.7; ENSP00000473052.1; ENSG00000062822.17. DR Ensembl; ENST00000601098.6; ENSP00000472600.2; ENSG00000062822.17. DR Ensembl; ENST00000687454.1; ENSP00000510052.1; ENSG00000062822.17. DR GeneID; 5424; -. DR KEGG; hsa:5424; -. DR MANE-Select; ENST00000440232.7; ENSP00000406046.1; NM_002691.4; NP_002682.2. DR UCSC; uc002psb.6; human. DR AGR; HGNC:9175; -. DR CIViC; 5424; 3 evidence items across 3 molecular profiles. DR ClinPGx; PA33496; -. DR CTD; 5424; -. DR DisGeNET; 5424; -. DR GeneCards; POLD1; -. DR HGNC; HGNC:9175; POLD1. DR HPA; ENSG00000062822; Low tissue specificity. DR MalaCards; POLD1; -. DR MIM; 174761; gene. DR MIM; 612591; phenotype. DR MIM; 615381; phenotype. DR MIM; 620836; phenotype. DR OpenTargets; ENSG00000062822; -. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 363649; Mandibular hypoplasia-deafness-progeroid features-lipodystrophy syndrome. DR Orphanet; 447877; Polymerase proofreading-related polyposis. DR VEuPathDB; HostDB:ENSG00000062822; -. DR eggNOG; KOG0969; Eukaryota. DR GeneTree; ENSGT00560000077365; -. DR HOGENOM; CLU_000203_2_0_1; -. DR InParanoid; P28340; -. DR OrthoDB; 2414538at2759; -. DR PAN-GO; P28340; 7 GO annotations based on evolutionary models. DR PhylomeDB; P28340; -. DR BRENDA; 2.7.7.7; 2681. DR PathwayCommons; P28340; -. DR Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex. DR Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair. DR Reactome; R-HSA-5656169; Termination of translesion DNA synthesis. DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER. DR Reactome; R-HSA-5696400; Dual Incision in GG-NER. DR Reactome; R-HSA-6782135; Dual incision in TC-NER. DR Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER. DR Reactome; R-HSA-69091; Polymerase switching. DR Reactome; R-HSA-69166; Removal of the Flap Intermediate. DR Reactome; R-HSA-69183; Processive synthesis on the lagging strand. DR SignaLink; P28340; -. DR SIGNOR; P28340; -. DR Agora; ENSG00000062822; -. DR BioGRID-ORCS; 5424; 795 hits in 1163 CRISPR screens. DR ChiTaRS; POLD1; human. DR GeneWiki; POLD1; -. DR GenomeRNAi; 5424; -. DR Pharos; P28340; Tclin. DR PRO; PR:P28340; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; P28340; protein. DR Bgee; ENSG00000062822; Expressed in mucosa of transverse colon and 96 other cell types or tissues. DR ExpressionAtlas; P28340; baseline and differential. DR GO; GO:0016235; C:aggresome; IDA:HPA. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043625; C:delta DNA polymerase complex; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0000109; C:nucleotide-excision repair complex; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0008296; F:3'-5'-DNA exonuclease activity; IBA:GO_Central. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB. DR GO; GO:0019899; F:enzyme binding; IEA:Ensembl. DR GO; GO:0000166; F:nucleotide binding; IEA:InterPro. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB. DR GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB. DR GO; GO:0071897; P:DNA biosynthetic process; IDA:UniProtKB. DR GO; GO:0006281; P:DNA repair; TAS:ProtInc. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006261; P:DNA-templated DNA replication; IDA:ComplexPortal. DR GO; GO:0070987; P:error-free translesion synthesis; IDA:UniProtKB. DR GO; GO:0055089; P:fatty acid homeostasis; IMP:UniProtKB. DR GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB. DR GO; GO:0009411; P:response to UV; TAS:ProtInc. DR CDD; cd05777; DNA_polB_delta_exo; 1. DR CDD; cd05533; POLBc_delta; 1. DR FunFam; 1.10.132.60:FF:000001; DNA polymerase; 1. DR FunFam; 1.10.287.690:FF:000001; DNA polymerase; 1. DR FunFam; 3.30.342.10:FF:000003; DNA polymerase; 1. DR FunFam; 3.30.420.10:FF:000351; DNA polymerase; 1. DR Gene3D; 1.10.132.60; DNA polymerase family B, C-terminal domain; 1. DR Gene3D; 3.30.342.10; DNA Polymerase, chain B, domain 1; 1. DR Gene3D; 1.10.287.690; Helix hairpin bin; 1. DR Gene3D; 3.90.1600.10; Palm domain of DNA polymerase; 1. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR InterPro; IPR006172; DNA-dir_DNA_pol_B. DR InterPro; IPR017964; DNA-dir_DNA_pol_B_CS. DR InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc. DR InterPro; IPR006134; DNA-dir_DNA_pol_B_multi_dom. DR InterPro; IPR043502; DNA/RNA_pol_sf. DR InterPro; IPR042087; DNA_pol_B_thumb. DR InterPro; IPR023211; DNA_pol_palm_dom_sf. DR InterPro; IPR050240; DNA_pol_type-B. DR InterPro; IPR056435; DPOD/Z_N. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR025687; Znf-C4pol. DR NCBIfam; TIGR00592; pol2; 1. DR PANTHER; PTHR10322; DNA POLYMERASE CATALYTIC SUBUNIT; 1. DR PANTHER; PTHR10322:SF23; DNA POLYMERASE DELTA CATALYTIC SUBUNIT; 1. DR Pfam; PF00136; DNA_pol_B; 1. DR Pfam; PF03104; DNA_pol_B_exo1; 1. DR Pfam; PF24055; POL3_N; 1. DR Pfam; PF14260; zf-C4pol; 1. DR PRINTS; PR00106; DNAPOLB. DR SMART; SM00486; POLBc; 1. DR SUPFAM; SSF56672; DNA/RNA polymerases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR PROSITE; PS00116; DNA_POLYMERASE_B; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Disease variant; DNA damage; DNA excision; KW DNA repair; DNA replication; DNA-binding; DNA-directed DNA polymerase; KW Exonuclease; Hydrolase; Iron; Iron-sulfur; Isopeptide bond; Metal-binding; KW Methylation; Nuclease; Nucleotidyltransferase; Nucleus; KW Proteomics identification; Reference proteome; Transferase; KW Ubl conjugation; Zinc; Zinc-finger. FT CHAIN 1..1107 FT /note="DNA polymerase delta catalytic subunit" FT /id="PRO_0000046442" FT ZN_FING 1012..1029 FT /note="CysA-type" FT REGION 1..34 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 4..19 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT MOTIF 1058..1076 FT /note="CysB motif" FT BINDING 1012 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1015 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1026 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1029 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250" FT BINDING 1058 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1061 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1071 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT BINDING 1076 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250" FT MOD_RES 19 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0007744|PubMed:24129315" FT CROSSLNK 574 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 5 FT /note="R -> W (in dbSNP:rs9282830)" FT /id="VAR_048878" FT VARIANT 19 FT /note="R -> H (in dbSNP:rs3218773)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019340" FT VARIANT 21 FT /note="G -> C (in dbSNP:rs9282831)" FT /id="VAR_048879" FT VARIANT 30 FT /note="R -> W (in dbSNP:rs3218772)" FT /evidence="ECO:0000269|PubMed:1722322, ECO:0000269|Ref.3" FT /id="VAR_016146" FT VARIANT 119 FT /note="R -> H (in dbSNP:rs1726801)" FT /evidence="ECO:0000269|PubMed:1542570, FT ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3" FT /id="VAR_019341" FT VARIANT 145 FT /note="A -> D (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069333" FT VARIANT 173 FT /note="S -> N (in dbSNP:rs1726803)" FT /evidence="ECO:0000269|PubMed:1542570, ECO:0000269|Ref.3" FT /id="VAR_019342" FT VARIANT 177 FT /note="R -> H (in dbSNP:rs3218750)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019343" FT VARIANT 347 FT /note="P -> L (in dbSNP:rs2230243)" FT /id="VAR_048880" FT VARIANT 461 FT /note="Q -> H (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069334" FT VARIANT 474 FT /note="L -> P (in CRCS10; dbSNP:rs587777627)" FT /evidence="ECO:0000269|PubMed:24501277" FT /id="VAR_071966" FT VARIANT 478 FT /note="S -> N (risk factor for CRCS10; dbSNP:rs397514632)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069335" FT VARIANT 605 FT /note="Missing (in MDPL; the mutant enzyme lacks DNA FT polymerase ability; has decreased exonuclease activity; can FT bind DNA but is unable to interact with and incorporate FT dNTPs)" FT /evidence="ECO:0000269|PubMed:23770608" FT /id="VAR_070231" FT VARIANT 684 FT /note="Q -> H (in IMD120; uncertain significance; does not FT affect interaction with POLD2 and POLD3; does not affect FT protein stability when tested in a heterologous system; FT strongly decreased polymerase activity, when tested in FT transfected HEK293 cells in association with W-939)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089633" FT VARIANT 787 FT /note="P -> L (found in a colorectal sample; somatic FT mutation; dbSNP:rs199783227)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069336" FT VARIANT 808 FT /note="R -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs771700024)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069337" FT VARIANT 849 FT /note="R -> H (in dbSNP:rs3218775)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019344" FT VARIANT 864 FT /note="A -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs765437818)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069338" FT VARIANT 939 FT /note="S -> W (in IMD120; uncertain significance; does not FT affect interaction with POLD2 and POLD3; strongly decreased FT polymerase activity, when tested in transfected HEK293 FT cells in association with H-684)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089634" FT VARIANT 1060 FT /note="R -> C (in IMD120; likely pathogenic; strongly FT reduced interaction with POLD2 and RFC1; leads to lower T FT cell proliferation following cell activation)" FT /evidence="ECO:0000269|PubMed:31629014" FT /id="VAR_089635" FT VARIANT 1074 FT /note="R -> W (in IMD120; uncertain significance; decreased FT polymerase activity, when tested in transfected HEK293 FT cells; does not affect protein stability when tested in a FT heterologous system; does not affect interaction with POLD2 FT and POLD3)" FT /evidence="ECO:0000269|PubMed:31449058" FT /id="VAR_089636" FT VARIANT 1086 FT /note="R -> Q (in dbSNP:rs3219457)" FT /evidence="ECO:0000269|Ref.3" FT /id="VAR_019345" FT MUTAGEN 402 FT /note="D->A: Loss of exonuclease activity. No effect on DNA FT polymerase activity." FT /evidence="ECO:0000269|PubMed:19074196, FT ECO:0000269|PubMed:20334433" FT MUTAGEN 602 FT /note="D->A: Loss of polymerase activity; when associated FT with A-757." FT /evidence="ECO:0000269|PubMed:31449058" FT MUTAGEN 757 FT /note="D->A: Loss of polymerase activity; when associated FT with A-602." FT /evidence="ECO:0000269|PubMed:31449058" FT CONFLICT 472 FT /note="Y -> H (in Ref. 1; AAA58439)" FT /evidence="ECO:0000305" FT CONFLICT 776 FT /note="R -> G (in Ref. 2; AAA35768)" FT /evidence="ECO:0000305" FT TURN 89..91 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 94..105 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 123..134 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 136..142 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 147..151 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 154..157 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 161..168 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 174..176 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 177..179 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 180..183 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 192..195 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 197..200 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 207..213 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 217..219 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 220..227 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 228..230 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 234..238 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 250..258 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 265..268 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 285..291 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 296..298 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 302..305 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 311..319 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 329..331 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 334..343 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 346..348 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 350..358 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 366..370 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 374..388 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 391..397 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 398..401 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 402..412 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 416..419 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 431..438 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 439..441 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 442..449 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 455..458 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 459..466 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 474..481 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 494..498 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 502..525 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 528..539 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 545..547 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 552..563 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 564..567 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 592..594 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 598..605 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 606..613 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 624..629 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 634..636 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 637..639 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 649..651 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 656..674 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 680..704 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 707..710 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 714..738 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 741..744 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 750..762 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 768..782 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 784..786 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 792..805 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 808..819 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 824..829 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 830..832 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 834..836 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 838..852 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 857..872 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 878..881 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 883..886 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 890..894 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 899..905 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 920..927 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 937..940 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 942..948 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 954..959 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 960..962 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 963..970 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 977..989 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1002..1004 FT /evidence="ECO:0007829|PDB:6TNY" FT TURN 1013..1015 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 1020..1022 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1034..1055 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1057..1062 FT /evidence="ECO:0007829|PDB:6TNY" FT STRAND 1065..1067 FT /evidence="ECO:0007829|PDB:6TNY" FT HELIX 1078..1095 FT /evidence="ECO:0007829|PDB:6TNY" SQ SEQUENCE 1107 AA; 123631 MW; 9D04D34AB4AEE810 CRC64; MDGKRRPGPG PGVPPKRARG GLWDDDDAPR PSQFEEDLAL MEEMEAEHRL QEQEEEELQS VLEGVADGQV PPSAIDPRWL RPTPPALDPQ TEPLIFQQLE IDHYVGPAQP VPGGPPPSRG SVPVLRAFGV TDEGFSVCCH IHGFAPYFYT PAPPGFGPEH MGDLQRELNL AISRDSRGGR ELTGPAVLAV ELCSRESMFG YHGHGPSPFL RITVALPRLV APARRLLEQG IRVAGLGTPS FAPYEANVDF EIRFMVDTDI VGCNWLELPA GKYALRLKEK ATQCQLEADV LWSDVVSHPP EGPWQRIAPL RVLSFDIECA GRKGIFPEPE RDPVIQICSL GLRWGEPEPF LRLALTLRPC APILGAKVQS YEKEEDLLQA WSTFIRIMDP DVITGYNIQN FDLPYLISRA QTLKVQTFPF LGRVAGLCSN IRDSSFQSKQ TGRRDTKVVS MVGRVQMDML QVLLREYKLR SYTLNAVSFH FLGEQKEDVQ HSIITDLQNG NDQTRRRLAV YCLKDAYLPL RLLERLMVLV NAVEMARVTG VPLSYLLSRG QQVKVVSQLL RQAMHEGLLM PVVKSEGGED YTGATVIEPL KGYYDVPIAT LDFSSLYPSI MMAHNLCYTT LLRPGTAQKL GLTEDQFIRT PTGDEFVKTS VRKGLLPQIL ENLLSARKRA KAELAKETDP LRRQVLDGRQ LALKVSANSV YGFTGAQVGK LPCLEISQSV TGFGRQMIEK TKQLVESKYT VENGYSTSAK VVYGDTDSVM CRFGVSSVAE AMALGREAAD WVSGHFPSPI RLEFEKVYFP YLLISKKRYA GLLFSSRPDA HDRMDCKGLE AVRRDNCPLV ANLVTASLRR LLIDRDPEGA VAHAQDVISD LLCNRIDISQ LVITKELTRA ASDYAGKQAH VELAERMRKR DPGSAPSLGD RVPYVIISAA KGVAAYMKSE DPLFVLEHSL PIDTQYYLEQ QLAKPLLRIF EPILGEGRAE AVLLRGDHTR CKTVLTGKVG GLLAFAKRRN CCIGCRTVLS HQGAVCEFCQ PRESELYQKE VSHLNALEER FSRLWTQCQR CQGSLHEDVI CTSRDCPIFY MRKKVRKDLE DQEQLLRRFG PPGPEAW // ID DPOE1_HUMAN Reviewed; 2286 AA. AC Q07864; Q13533; Q86VH9; DT 01-OCT-1994, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 5. DT 28-JAN-2026, entry version 229. DE RecName: Full=DNA polymerase epsilon catalytic subunit A; DE EC=2.7.7.7 {ECO:0000250|UniProtKB:P21951}; DE AltName: Full=3'-5' exodeoxyribonuclease {ECO:0000305}; DE EC=3.1.11.- {ECO:0000250|UniProtKB:P21951}; DE AltName: Full=DNA polymerase II subunit A; GN Name=POLE {ECO:0000312|HGNC:HGNC:9177}; Synonyms=POLE1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 48-51; 876-886 AND RP 1338-1344. RC TISSUE=T-cell; RX PubMed=8486689; DOI=10.1016/s0021-9258(18)82195-0; RA Kesti T., Frantti H., Syvaeoja J.E.; RT "Molecular cloning of the cDNA for the catalytic subunit of human DNA RT polymerase epsilon."; RL J. Biol. Chem. 268:10238-10245(1993). RN [2] RP SEQUENCE REVISION. RA Syvaeoja J.E.; RL Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [MRNA]. RA Asahara H., Goldsmith J.S., Lee E., Linn S.; RL Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 22-2286. RG NIEHS SNPs program; RL Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP FUNCTION, AND IDENTIFICATION IN EPSILON DNA POLYMERASE COMPLEX. RC TISSUE=Cervix carcinoma; RX PubMed=10801849; DOI=10.1074/jbc.m002548200; RA Li Y., Pursell Z.F., Linn S.; RT "Identification and cloning of two histone fold motif-containing subunits RT of HeLa DNA polymerase epsilon."; RL J. Biol. Chem. 275:23247-23252(2000). RN [6] RP INTERACTION WITH TOPBP1. RX PubMed=11395493; DOI=10.1074/jbc.m102245200; RA Maekiniemi M., Hillukkala T., Tuusa J., Reini K., Vaara M., Huang D., RA Pospiech H., Majuri I., Westerling T., Maekelae T.P., Syvaeoja J.E.; RT "BRCT domain-containing protein TopBP1 functions in DNA replication and RT damage response."; RL J. Biol. Chem. 276:30399-30406(2001). RN [7] RP INTERACTION WITH RAD17. RX PubMed=14500819; DOI=10.1093/nar/gkg765; RA Post S.M., Tomkinson A.E., Lee E.Y.-H.P.; RT "The human checkpoint Rad protein Rad17 is chromatin-associated throughout RT the cell cycle, localizes to DNA replication sites, and interacts with DNA RT polymerase epsilon."; RL Nucleic Acids Res. 31:5568-5575(2003). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1940, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [9] RP FUNCTION. RX PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009; RA Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K., RA Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G., Mullenders L.H., RA Yamashita S., Fousteri M.I., Lehmann A.R.; RT "Three DNA polymerases, recruited by different mechanisms, carry out NER RT repair synthesis in human cells."; RL Mol. Cell 37:714-727(2010). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1184, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP INVOLVEMENT IN FILS. RX PubMed=23230001; DOI=10.1084/jem.20121303; RA Pachlopnik Schmid J., Lemoine R., Nehme N., Cormier-Daire V., Revy P., RA Debeurme F., Debre M., Nitschke P., Bole-Feysot C., Legeai-Mallet L., RA Lim A., de Villartay J.P., Picard C., Durandy A., Fischer A., RA de Saint Basile G.; RT "Polymerase epsilon1 mutation in a human syndrome with facial dysmorphism, RT immunodeficiency, livedo, and short stature (FILS syndrome)."; RL J. Exp. Med. 209:2323-2330(2012). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1297 AND SER-1317, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [14] {ECO:0007744|PDB:7PFO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS) IN COMPLEX WITH RP REPLISOME. RX PubMed=34694004; DOI=10.15252/embj.2021108819; RA Jones M.L., Baris Y., Taylor M.R.G., Yeeles J.T.P.; RT "Structure of a human replisome shows the organisation and interactions of RT a DNA replication machine."; RL EMBO J. 40:e108819-e108819(2021). RN [15] {ECO:0007744|PDB:7PLO} RP STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS) IN COMPLEX WITH RP REPLISOME. RX PubMed=34700328; DOI=10.1038/s41586-021-04145-3; RA Jenkyn-Bedford M., Jones M.L., Baris Y., Labib K.P.M., Cannone G., RA Yeeles J.T.P., Deegan T.D.; RT "A conserved mechanism for regulating replisome disassembly in RT eukaryotes."; RL Nature 600:743-747(2021). RN [16] RP VARIANTS CRCS12 LEU-411 AND VAL-424, AND VARIANTS THR-189; HIS-231; RP HIS-286; SER-367; ARG-436; PHE-459; TRP-762; ASN-777; ASN-1008; VAL-1255; RP MET-1368; SER-1421; ASN-1752; ASN-2013; THR-2056 AND VAL-2213. RX PubMed=23263490; DOI=10.1038/ng.2503; RG CORGI Consortium; RG WGS500 Consortium; RA Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M., Broderick P., RA Kemp Z., Spain S.L., Guarino Almeida E., Salguero I., Sherborne A., RA Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K., Dobbins S., Barclay E., RA Gorman M., Martin L., Kovac M.B., Humphray S., Lucassen A., Holmes C.C., RA Bentley D., Donnelly P., Taylor J., Petridis C., Roylance R., Sawyer E.J., RA Kerr D.J., Clark S., Grimes J., Kearsey S.E., Thomas H.J., McVean G., RA Houlston R.S., Tomlinson I.; RT "Germline mutations affecting the proofreading domains of POLE and POLD1 RT predispose to colorectal adenomas and carcinomas."; RL Nat. Genet. 45:136-144(2013). RN [17] RP VARIANT CRCS12 VAL-424. RX PubMed=24501277; DOI=10.1093/hmg/ddu058; RA Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A., RA Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C., Juarez M., RA Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A., Juan M.J., RA Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R., Lazaro C., RA Capella G., Pineda M., Soto J.L., Blanco I.; RT "New insights into POLE and POLD1 germline mutations in familial colorectal RT cancer and polyposis."; RL Hum. Mol. Genet. 23:3506-3512(2014). RN [18] RP VARIANT CRCS12 PHE-458. RX PubMed=25860647; DOI=10.1007/s10689-015-9803-2; RA Hansen M.F., Johansen J., Bjoernevoll I., Sylvander A.E., Steinsbekk K.S., RA Saetrom P., Sandvik A.K., Drabloes F., Sjursen W.; RT "A novel POLE mutation associated with cancers of colon, pancreas, ovaries RT and small intestine."; RL Fam. Cancer 14:437-448(2015). RN [19] RP FUNCTION, AND VARIANT CRCS12 LEU-411. RX PubMed=27573199; DOI=10.1007/s10689-016-9925-1; RA Wimmer K., Beilken A., Nustede R., Ripperger T., Lamottke B., Ure B., RA Steinmann D., Reineke-Plaass T., Lehmann U., Zschocke J., Valle L., RA Fauth C., Kratz C.P.; RT "A novel germline POLE mutation causes an early onset cancer prone syndrome RT mimicking constitutional mismatch repair deficiency."; RL Fam. Cancer 16:67-71(2017). RN [20] RP VARIANTS ARG-286; CYS-1382 AND THR-1925. RX PubMed=27612425; DOI=10.18632/oncotarget.11862; RA Ahn S.M., Ansari A.A., Kim J., Kim D., Chun S.M., Kim J., Kim T.W., RA Park I., Yu C.S., Jang S.J.; RT "The somatic POLE P286R mutation defines a unique subclass of colorectal RT cancer featuring hypermutation, representing a potential genomic biomarker RT for immunotherapy."; RL Oncotarget 7:68638-68649(2016). RN [21] RP VARIANTS IMAGEI 683-TYR--HIS-2286 DEL; PRO-1007 AND 1980-TRP--HIS-2286 DEL, RP AND INVOLVEMENT IN IMAGEI. RX PubMed=30503519; DOI=10.1016/j.ajhg.2018.10.024; RG SGP Consortium; RA Logan C.V., Murray J.E., Parry D.A., Robertson A., Bellelli R., RA Tarnauskaite Z., Challis R., Cleal L., Borel V., Fluteau A., RA Santoyo-Lopez J., Aitman T., Barroso I., Basel D., Bicknell L.S., Goel H., RA Hu H., Huff C., Hutchison M., Joyce C., Knox R., Lacroix A.E., Langlois S., RA McCandless S., McCarrier J., Metcalfe K.A., Morrissey R., Murphy N., RA Netchine I., O'Connell S.M., Olney A.H., Paria N., Rosenfeld J.A., RA Sherlock M., Syverson E., White P.C., Wise C., Yu Y., Zacharin M., RA Banerjee I., Reijns M., Bober M.B., Semple R.K., Boulton S.J., Rios J.J., RA Jackson A.P.; RT "DNA polymerase epsilon deficiency causes IMAGe syndrome with variable RT immunodeficiency."; RL Am. J. Hum. Genet. 103:1038-1044(2018). CC -!- FUNCTION: Catalytic component of the DNA polymerase epsilon complex CC (PubMed:10801849). Participates in chromosomal DNA replication (By CC similarity). Required during synthesis of the leading DNA strands at CC the replication fork, binds at/or near replication origins and moves CC along DNA with the replication fork (By similarity). Has 3'-5' CC proofreading exonuclease activity that corrects errors arising during CC DNA replication (By similarity). Involved in DNA synthesis during DNA CC repair (PubMed:20227374, PubMed:27573199). Along with DNA polymerase CC POLD1 and DNA polymerase POLK, has a role in excision repair (NER) CC synthesis following UV irradiation (PubMed:20227374). CC {ECO:0000250|UniProtKB:P21951, ECO:0000269|PubMed:10801849, CC ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:27573199}. CC -!- CATALYTIC ACTIVITY: CC Reaction=DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + CC diphosphate; Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339, Rhea:RHEA- CC COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560, ChEBI:CHEBI:173112; CC EC=2.7.7.7; Evidence={ECO:0000250|UniProtKB:P21951}; CC -!- SUBUNIT: Component of the DNA polymerase epsilon complex consisting of CC four subunits: the catalytic subunit POLE and the accessory subunits CC POLE2, POLE3 and POLE4. Interacts with RAD17 and TOPBP1. CC {ECO:0000269|PubMed:10801849, ECO:0000269|PubMed:11395493, CC ECO:0000269|PubMed:14500819}. CC -!- INTERACTION: CC Q07864; O95870: ABHD16A; NbExp=3; IntAct=EBI-348526, EBI-348517; CC Q07864; P15056: BRAF; NbExp=6; IntAct=EBI-348526, EBI-365980; CC Q07864; P01106: MYC; NbExp=2; IntAct=EBI-348526, EBI-447544; CC Q07864; P56282: POLE2; NbExp=12; IntAct=EBI-348526, EBI-713847; CC -!- SUBCELLULAR LOCATION: Nucleus. CC -!- DOMAIN: The DNA polymerase activity domain resides in the N-terminal CC half of the protein, while the C-terminus is necessary for maintenance CC of the complex. {ECO:0000250|UniProtKB:P21951}. CC -!- DOMAIN: The CysA-type zinc finger is required for PCNA-binding. CC {ECO:0000250|UniProtKB:P15436}. CC -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for the CC formation of polymerase complexes. {ECO:0000250|UniProtKB:P15436}. CC -!- DISEASE: Colorectal cancer 12 (CRCS12) [MIM:615083]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. CRCS12 is characterized by a high-penetrance CC predisposition to the development of colorectal adenomas and CC carcinomas, with a variable tendency to develop multiple and large CC tumors. Onset is usually before age 40 years. The histologic features CC of the tumors are unremarkable. {ECO:0000269|PubMed:23263490, CC ECO:0000269|PubMed:24501277, ECO:0000269|PubMed:25860647, CC ECO:0000269|PubMed:27573199}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Facial dysmorphism, immunodeficiency, livedo, and short CC stature (FILS) [MIM:615139]: A syndrome characterized by mild facial CC dysmorphism, mainly malar hypoplasia, livedo on the skin since birth, CC and immunodeficiency resulting in recurrent infections. Growth CC impairment is observed during early childhood and results in variable CC short stature in adulthood. {ECO:0000269|PubMed:23230001}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intrauterine growth retardation, metaphyseal dysplasia, CC adrenal hypoplasia congenita, genital anomalies, and immunodeficiency CC (IMAGEI) [MIM:618336]: An autosomal recessive disorder characterized by CC intrauterine growth retardation, postnatal growth failure, metaphyseal CC dysplasia, adrenal hypoplasia congenita, growth hormone deficiency, CC genital anomalies, and immunodeficiency resulting in increased CC infections. {ECO:0000269|PubMed:30503519}. Note=The disease is caused CC by variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA polymerase type-B family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA15448.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=AAA15448.1; Type=Miscellaneous discrepancy; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; S60080; AAA15448.1; ALT_SEQ; mRNA. DR EMBL; L09561; AAC19148.1; -; mRNA. DR EMBL; U49356; AAA90924.1; -; mRNA. DR EMBL; AY273166; AAP12650.1; -; Genomic_DNA. DR CCDS; CCDS9278.1; -. DR PIR; G02434; G02434. DR RefSeq; NP_006222.2; NM_006231.4. DR PDB; 5VBN; X-ray; 2.35 A; B/F=2142-2286. DR PDB; 7PFO; EM; 3.20 A; B=1-2286. DR PDB; 7PLO; EM; 2.80 A; B=1-2286. DR PDB; 9B8S; EM; 5.01 A; A=1-2286. DR PDB; 9B8T; EM; 2.95 A; A=1-2286. DR PDB; 9F6D; EM; 3.60 A; A=1-1200. DR PDB; 9F6E; EM; 3.74 A; A=1-1200. DR PDB; 9F6F; EM; 3.75 A; A=1-1200. DR PDB; 9F6I; EM; 3.30 A; A=1-1200. DR PDB; 9F6J; EM; 3.90 A; A=1-1200. DR PDB; 9F6K; EM; 4.20 A; A=1-1200. DR PDB; 9F6L; EM; 3.90 A; A=1-1200. DR PDB; 9NE6; EM; 3.11 A; A=1-1200. DR PDB; 9NE7; EM; 3.53 A; A=1-1200. DR PDB; 9NE8; EM; 3.60 A; A=1-1200. DR PDB; 9NE9; EM; 3.88 A; A=27-1198. DR PDB; 9NEA; EM; 3.81 A; A=1-2286. DR PDBsum; 5VBN; -. DR PDBsum; 7PFO; -. DR PDBsum; 7PLO; -. DR PDBsum; 9B8S; -. DR PDBsum; 9B8T; -. DR PDBsum; 9F6D; -. DR PDBsum; 9F6E; -. DR PDBsum; 9F6F; -. DR PDBsum; 9F6I; -. DR PDBsum; 9F6J; -. DR PDBsum; 9F6K; -. DR PDBsum; 9F6L; -. DR PDBsum; 9NE6; -. DR PDBsum; 9NE7; -. DR PDBsum; 9NE8; -. DR PDBsum; 9NE9; -. DR PDBsum; 9NEA; -. DR AlphaFoldDB; Q07864; -. DR EMDB; EMD-13375; -. DR EMDB; EMD-13494; -. DR EMDB; EMD-44357; -. DR EMDB; EMD-49299; -. DR EMDB; EMD-49300; -. DR EMDB; EMD-49301; -. DR EMDB; EMD-49302; -. DR EMDB; EMD-49303; -. DR EMDB; EMD-50222; -. DR EMDB; EMD-50223; -. DR EMDB; EMD-50224; -. DR EMDB; EMD-50225; -. DR EMDB; EMD-50226; -. DR EMDB; EMD-50227; -. DR EMDB; EMD-50228; -. DR SMR; Q07864; -. DR BioGRID; 111422; 164. DR ComplexPortal; CPX-2108; DNA polymerase epsilon complex. DR CORUM; Q07864; -. DR DIP; DIP-24243N; -. DR FunCoup; Q07864; 2368. DR IntAct; Q07864; 78. DR MINT; Q07864; -. DR STRING; 9606.ENSP00000322570; -. DR ChEMBL; CHEMBL2363042; -. DR DrugBank; DB00242; Cladribine. DR DrugCentral; Q07864; -. DR GlyGen; Q07864; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q07864; -. DR MetOSite; Q07864; -. DR PhosphoSitePlus; Q07864; -. DR SwissPalm; Q07864; -. DR BioMuta; POLE; -. DR DMDM; 116241339; -. DR jPOST; Q07864; -. DR MassIVE; Q07864; -. DR PaxDb; 9606-ENSP00000322570; -. DR PeptideAtlas; Q07864; -. DR ProteomicsDB; 58543; -. DR Pumba; Q07864; -. DR Antibodypedia; 32096; 184 antibodies from 23 providers. DR CPTC; Q07864; 1 antibody. DR DNASU; 5426; -. DR Ensembl; ENST00000320574.10; ENSP00000322570.5; ENSG00000177084.20. DR GeneID; 5426; -. DR KEGG; hsa:5426; -. DR MANE-Select; ENST00000320574.10; ENSP00000322570.5; NM_006231.4; NP_006222.2. DR UCSC; uc001uks.3; human. DR AGR; HGNC:9177; -. DR CIViC; 5426; 13 evidence items across 8 molecular profiles. DR ClinPGx; PA277; -. DR CTD; 5426; -. DR DisGeNET; 5426; -. DR GeneCards; POLE; -. DR HGNC; HGNC:9177; POLE. DR HPA; ENSG00000177084; Low tissue specificity. DR MalaCards; POLE; -. DR MIM; 174762; gene. DR MIM; 615083; phenotype. DR MIM; 615139; phenotype. DR MIM; 618336; phenotype. DR OpenTargets; ENSG00000177084; -. DR Orphanet; 352712; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome. DR Orphanet; 440437; Familial colorectal cancer Type X. DR Orphanet; 85173; IMAGe syndrome. DR Orphanet; 447877; Polymerase proofreading-related polyposis. DR VEuPathDB; HostDB:ENSG00000177084; -. DR eggNOG; KOG1798; Eukaryota. DR GeneTree; ENSGT00390000010194; -. DR HOGENOM; CLU_000556_0_0_1; -. DR InParanoid; Q07864; -. DR OMA; MLDQCRY; -. DR OrthoDB; 10060449at2759; -. DR PAN-GO; Q07864; 9 GO annotations based on evolutionary models. DR PhylomeDB; Q07864; -. DR BRENDA; 2.7.7.7; 2681. DR PathwayCommons; Q07864; -. DR Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex. DR Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair. DR Reactome; R-HSA-5656169; Termination of translesion DNA synthesis. DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER. DR Reactome; R-HSA-5696400; Dual Incision in GG-NER. DR Reactome; R-HSA-6782135; Dual incision in TC-NER. DR Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER. DR Reactome; R-HSA-68952; DNA replication initiation. DR Reactome; R-HSA-68962; Activation of the pre-replicative complex. DR SignaLink; Q07864; -. DR SIGNOR; Q07864; -. DR Agora; ENSG00000177084; -. DR BioGRID-ORCS; 5426; 795 hits in 1174 CRISPR screens. DR ChiTaRS; POLE; human. DR GeneWiki; POLE_(enzyme); -. DR GenomeRNAi; 5426; -. DR Pharos; Q07864; Tclin. DR PRO; PR:Q07864; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q07864; protein. DR Bgee; ENSG00000177084; Expressed in right hemisphere of cerebellum and 149 other cell types or tissues. DR ExpressionAtlas; Q07864; baseline and differential. DR GO; GO:0008622; C:epsilon DNA polymerase complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB. DR GO; GO:0000166; F:nucleotide binding; IEA:InterPro. DR GO; GO:0008310; F:single-stranded DNA 3'-5' DNA exonuclease activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IMP:UniProtKB. DR GO; GO:0006261; P:DNA-templated DNA replication; IDA:ComplexPortal. DR GO; GO:0048568; P:embryonic organ development; IEA:Ensembl. DR GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0006272; P:leading strand elongation; IBA:GO_Central. DR GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central. DR GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB. DR CDD; cd05779; DNA_polB_epsilon_exo; 1. DR CDD; cd05535; POLBc_epsilon; 1. DR FunFam; 1.10.132.60:FF:000002; DNA polymerase epsilon catalytic subunit; 1. DR FunFam; 3.30.420.10:FF:000010; DNA polymerase epsilon catalytic subunit; 1. DR FunFam; 3.90.1600.10:FF:000006; DNA polymerase epsilon catalytic subunit; 1. DR Gene3D; 1.10.132.60; DNA polymerase family B, C-terminal domain; 1. DR Gene3D; 3.30.342.10; DNA Polymerase, chain B, domain 1; 1. DR Gene3D; 3.90.1600.10; Palm domain of DNA polymerase; 1. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR InterPro; IPR006172; DNA-dir_DNA_pol_B. DR InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc. DR InterPro; IPR043502; DNA/RNA_pol_sf. DR InterPro; IPR042087; DNA_pol_B_thumb. DR InterPro; IPR013697; DNA_pol_e_suA_C. DR InterPro; IPR023211; DNA_pol_palm_dom_sf. DR InterPro; IPR029703; POL2. DR InterPro; IPR055191; POL2_thumb. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR054475; Znf-DPOE. DR PANTHER; PTHR10670; DNA POLYMERASE EPSILON CATALYTIC SUBUNIT A; 1. DR PANTHER; PTHR10670:SF0; DNA POLYMERASE EPSILON CATALYTIC SUBUNIT A; 1. DR Pfam; PF03104; DNA_pol_B_exo1; 1. DR Pfam; PF08490; DUF1744; 1. DR Pfam; PF22634; POL2_thumb; 1. DR Pfam; PF22912; zf-DPOE; 1. DR Pfam; PF23250; zf_DPOE_2; 1. DR SMART; SM01159; DUF1744; 1. DR SMART; SM00486; POLBc; 1. DR SUPFAM; SSF56672; DNA/RNA polymerases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. PE 1: Evidence at protein level; KW 3D-structure; 4Fe-4S; Direct protein sequencing; Disease variant; KW DNA damage; DNA repair; DNA replication; DNA-binding; KW DNA-directed DNA polymerase; Hydrolase; Iron; Iron-sulfur; Metal-binding; KW Nucleotidyltransferase; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Transferase; Zinc; Zinc-finger. FT CHAIN 1..2286 FT /note="DNA polymerase epsilon catalytic subunit A" FT /id="PRO_0000046455" FT ZN_FING 2158..2190 FT /note="CysA-type" FT /evidence="ECO:0000250|UniProtKB:P15436" FT REGION 1..30 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1939..1969 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 2221..2238 FT /note="CysB motif" FT /evidence="ECO:0000250|UniProtKB:P15436" FT COMPBIAS 9..24 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1946..1969 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 2158 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2161 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2187 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2190 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2221 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2224 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2236 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT BINDING 2238 FT /ligand="[4Fe-4S] cluster" FT /ligand_id="ChEBI:CHEBI:49883" FT /evidence="ECO:0000250|UniProtKB:P15436" FT MOD_RES 1184 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1297 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1317 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1940 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17525332" FT VARIANT 31 FT /note="A -> S (in dbSNP:rs34047482)" FT /id="VAR_061138" FT VARIANT 99 FT /note="P -> L (in dbSNP:rs5744739)" FT /id="VAR_028429" FT VARIANT 189 FT /note="A -> T (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069339" FT VARIANT 231 FT /note="R -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs1060500835)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069340" FT VARIANT 252 FT /note="A -> V (in dbSNP:rs5744751)" FT /id="VAR_020276" FT VARIANT 260 FT /note="R -> Q (in dbSNP:rs5744752)" FT /id="VAR_028430" FT VARIANT 286 FT /note="P -> H (found in a colorectal sample; somatic FT mutation; dbSNP:rs1057519943)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069341" FT VARIANT 286 FT /note="P -> R (found in a colorectal sample; somatic FT mutation; dbSNP:rs1057519943)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_077349" FT VARIANT 336 FT /note="N -> S (in dbSNP:rs5744760)" FT /id="VAR_020277" FT VARIANT 367 FT /note="F -> S (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069342" FT VARIANT 411 FT /note="V -> L (in CRCS12; uncertain significance; FT dbSNP:rs1057519945)" FT /evidence="ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:27573199" FT /id="VAR_069343" FT VARIANT 424 FT /note="L -> V (in CRCS12; dbSNP:rs483352909)" FT /evidence="ECO:0000269|PubMed:23263490, FT ECO:0000269|PubMed:24501277" FT /id="VAR_069344" FT VARIANT 436 FT /note="P -> R (found in a colorectal sample; somatic FT mutation; dbSNP:rs864622766)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069345" FT VARIANT 458 FT /note="Y -> F (in CRCS12; uncertain significance; FT dbSNP:rs2135996937)" FT /evidence="ECO:0000269|PubMed:25860647" FT /id="VAR_077350" FT VARIANT 459 FT /note="S -> F (found in a colorectal sample; somatic FT mutation; dbSNP:rs765702675)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069346" FT VARIANT 683..2286 FT /note="Missing (in IMAGEI)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081996" FT VARIANT 695 FT /note="F -> I (in dbSNP:rs5744799)" FT /id="VAR_020278" FT VARIANT 762 FT /note="R -> W (found in a colorectal sample; somatic FT mutation; dbSNP:rs1064794759)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069347" FT VARIANT 777 FT /note="K -> N (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069348" FT VARIANT 1007 FT /note="A -> P (in IMAGEI; uncertain significance; FT dbSNP:rs747692201)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081997" FT VARIANT 1008 FT /note="K -> N (found in a colorectal sample; somatic FT mutation; dbSNP:rs2138689242)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069349" FT VARIANT 1255 FT /note="L -> V (found in a colorectal sample; somatic FT mutation; dbSNP:rs745838504)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069350" FT VARIANT 1368 FT /note="V -> M (found in a colorectal sample; somatic FT mutation; dbSNP:rs770558983)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069351" FT VARIANT 1382 FT /note="R -> C (found in a colorectal sample; somatic FT mutation; dbSNP:rs5744904)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_028431" FT VARIANT 1395 FT /note="Y -> C (in dbSNP:rs5744933)" FT /id="VAR_020279" FT VARIANT 1396 FT /note="N -> S (in dbSNP:rs5744934)" FT /id="VAR_020280" FT VARIANT 1399 FT /note="E -> Q (in dbSNP:rs5744935)" FT /id="VAR_020281" FT VARIANT 1421 FT /note="P -> S (in dbSNP:rs2138558999)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069352" FT VARIANT 1577 FT /note="E -> A (in dbSNP:rs5744948)" FT /id="VAR_028432" FT VARIANT 1712 FT /note="A -> V (in dbSNP:rs5744950)" FT /id="VAR_028433" FT VARIANT 1752 FT /note="D -> N (found in a colorectal sample; somatic FT mutation; dbSNP:rs1335665224)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069353" FT VARIANT 1857 FT /note="K -> R (in dbSNP:rs5744971)" FT /id="VAR_028434" FT VARIANT 1925 FT /note="I -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs2138485353)" FT /evidence="ECO:0000269|PubMed:27612425" FT /id="VAR_077351" FT VARIANT 1935 FT /note="C -> Y (in dbSNP:rs5744991)" FT /id="VAR_028435" FT VARIANT 1980..2286 FT /note="Missing (in IMAGEI)" FT /evidence="ECO:0000269|PubMed:30503519" FT /id="VAR_081998" FT VARIANT 2013 FT /note="D -> N" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069354" FT VARIANT 2040 FT /note="A -> V (in dbSNP:rs5745021)" FT /id="VAR_020282" FT VARIANT 2056 FT /note="A -> T (found in a colorectal sample; somatic FT mutation; dbSNP:rs58916399)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069355" FT VARIANT 2140 FT /note="E -> K (in dbSNP:rs5745066)" FT /id="VAR_048881" FT VARIANT 2159 FT /note="R -> C (in dbSNP:rs5745067)" FT /id="VAR_048882" FT VARIANT 2165 FT /note="R -> H (in dbSNP:rs5745068)" FT /id="VAR_020283" FT VARIANT 2213 FT /note="A -> V (found in a colorectal sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:23263490" FT /id="VAR_069356" FT CONFLICT 2237 FT /note="S -> T (in Ref. 1; AAA15448/AAC19148)" FT /evidence="ECO:0000305" FT HELIX 25..47 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 57..65 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 68..72 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 78..87 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 93..99 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 103..111 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 114..121 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 125..127 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 128..137 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 142..145 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 150..159 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 160..179 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 213..217 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 218..223 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 228..235 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 243..248 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 251..253 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 256..260 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 271..273 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 275..278 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 288..290 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 293..302 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 304..308 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 313..315 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 333..335 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 340..354 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 357..363 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 364..367 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 368..379 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 383..387 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 400..402 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 404..406 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 408..414 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 419..421 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 424..430 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 443..447 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 452..473 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 475..482 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 485..487 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 489..494 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 497..511 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 529..531 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 533..539 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 550..556 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 558..561 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 564..583 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 584..586 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 590..592 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 593..595 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 596..599 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 600..609 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 610..612 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 615..618 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 620..629 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 630..638 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 642..644 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 668..675 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 680..692 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 712..730 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 731..734 FT /evidence="ECO:0007829|PDB:9F6I" FT STRAND 736..743 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 745..747 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 753..782 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 783..785 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 791..817 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 818..820 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 821..823 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 829..850 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 851..853 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 854..859 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 861..869 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 876..881 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 886..890 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 892..904 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 911..915 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 916..919 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 921..923 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 931..942 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 956..959 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 965..979 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 980..988 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 991..994 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 995..998 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 999..1018 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1021..1024 FT /evidence="ECO:0007829|PDB:9F6I" FT HELIX 1026..1030 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1035..1038 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1044..1046 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1052..1064 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1066..1068 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1070..1072 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1075..1081 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1090..1092 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1093..1095 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1096..1098 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1099..1101 FT /evidence="ECO:0007829|PDB:9B8T" FT TURN 1104..1106 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1107..1113 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1124..1127 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1130..1144 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1146..1151 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1159..1161 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1165..1175 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1176..1178 FT /evidence="ECO:0007829|PDB:9B8T" FT HELIX 1183..1186 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 1189..1192 FT /evidence="ECO:0007829|PDB:9B8T" FT STRAND 2152..2157 FT /evidence="ECO:0007829|PDB:5VBN" FT TURN 2159..2161 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2164..2168 FT /evidence="ECO:0007829|PDB:5VBN" FT TURN 2169..2171 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2188..2190 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2196..2216 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2219..2224 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2230..2232 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2237..2239 FT /evidence="ECO:0007829|PDB:5VBN" FT STRAND 2241..2246 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2248..2265 FT /evidence="ECO:0007829|PDB:5VBN" FT HELIX 2268..2279 FT /evidence="ECO:0007829|PDB:5VBN" SQ SEQUENCE 2286 AA; 261518 MW; A213AE1EA8437DEC CRC64; MSLRSGGRRR ADPGADGEAS RDDGATSSVS ALKRLERSQW TDKMDLRFGF ERLKEPGEKT GWLINMHPTE ILDEDKRLGS AVDYYFIQDD GSRFKVALPY KPYFYIATRK GCEREVSSFL SKKFQGKIAK VETVPKEDLD LPNHLVGLKR NYIRLSFHTV EDLVKVRKEI SPAVKKNREQ DHASDAYTAL LSSVLQRGGV ITDEEETSKK IADQLDNIVD MREYDVPYHI RLSIDLKIHV AHWYNVRYRG NAFPVEITRR DDLVERPDPV VLAFDIETTK LPLKFPDAET DQIMMISYMI DGQGYLITNR EIVSEDIEDF EFTPKPEYEG PFCVFNEPDE AHLIQRWFEH VQETKPTIMV TYNGDFFDWP FVEARAAVHG LSMQQEIGFQ KDSQGEYKAP QCIHMDCLRW VKRDSYLPVG SHNLKAAAKA KLGYDPVELD PEDMCRMATE QPQTLATYSV SDAVATYYLY MKYVHPFIFA LCTIIPMEPD EVLRKGSGTL CEALLMVQAF HANIIFPNKQ EQEFNKLTDD GHVLDSETYV GGHVEALESG VFRSDIPCRF RMNPAAFDFL LQRVEKTLRH ALEEEEKVPV EQVTNFEEVC DEIKSKLASL KDVPSRIECP LIYHLDVGAM YPNIILTNRL QPSAMVDEAT CAACDFNKPG ANCQRKMAWQ WRGEFMPASR SEYHRIQHQL ESEKFPPLFP EGPARAFHEL SREEQAKYEK RRLADYCRKA YKKIHITKVE ERLTTICQRE NSFYVDTVRA FRDRRYEFKG LHKVWKKKLS AAVEVGDAAE VKRCKNMEVL YDSLQLAHKC ILNSFYGYVM RKGARWYSME MAGIVCFTGA NIITQARELI EQIGRPLELD TDGIWCVLPN SFPENFVFKT TNVKKPKVTI SYPGAMLNIM VKEGFTNDQY QELAEPSSLT YVTRSENSIF FEVDGPYLAM ILPASKEEGK KLKKRYAVFN EDGSLAELKG FEVKRRGELQ LIKIFQSSVF EAFLKGSTLE EVYGSVAKVA DYWLDVLYSK AANMPDSELF ELISENRSMS RKLEDYGEQK STSISTAKRL AEFLGDQMVK DAGLSCRYII SRKPEGSPVT ERAIPLAIFQ AEPTVRKHFL RKWLKSSSLQ DFDIRAILDW DYYIERLGSA IQKIITIPAA LQQVKNPVPR VKHPDWLHKK LLEKNDVYKQ KKISELFTLE GRRQVTMAEA SEDSPRPSAP DMEDFGLVKL PHPAAPVTVK RKRVLWESQE ESQDLTPTVP WQEILGQPPA LGTSQEEWLV WLRFHKKKWQ LQARQRLARR KRQRLESAEG VLRPGAIRDG PATGLGSFLR RTARSILDLP WQIVQISETS QAGLFRLWAL VGSDLHCIRL SIPRVFYVNQ RVAKAEEGAS YRKVNRVLPR SNMVYNLYEY SVPEDMYQEH INEINAELSA PDIEGVYETQ VPLLFRALVH LGCVCVVNKQ LVRHLSGWEA ETFALEHLEM RSLAQFSYLE PGSIRHIYLY HHAQAHKALF GIFIPSQRRA SVFVLDTVRS NQMPSLGALY SAEHGLLLEK VGPELLPPPK HTFEVRAETD LKTICRAIQR FLLAYKEERR GPTLIAVQSS WELKRLASEI PVLEEFPLVP ICVADKINYG VLDWQRHGAR RMIRHYLNLD TCLSQAFEMS RYFHIPIGNL PEDISTFGSD LFFARHLQRH NHLLWLSPTA RPDLGGKEAD DNCLVMEFDD QATVEINSSG CYSTVCVELD LQNLAVNTIL QSHHVNDMEG ADSMGISFDV IQQASLEDMI TGGQAASAPA SYDETALCSN TFRILKSMVV GWVKEITQYH NIYADNQVMH FYRWLRSPSS LLHDPALHRT LHNMMKKLFL QLIAEFKRLG SSVIYANFNR IILCTKKRRV EDAIAYVEYI TSSIHSKETF HSLTISFSRC WEFLLWMDPS NYGGIKGKVS SRIHCGLQDS QKAGGAEDEQ ENEDDEEERD GEEEEEAEES NVEDLLENNW NILQFLPQAA SCQNYFLMIV SAYIVAVYHC MKDGLRRSAP GSTPVRRRGA SQLSQEAEGA VGALPGMITF SQDYVANELT QSFFTITQKI QKKVTGSRNS TELSEMFPVL PGSHLLLNNP ALEFIKYVCK VLSLDTNITN QVNKLNRDLL RLVDVGEFSE EAQFRDPCRS YVLPEVICRS CNFCRDLDLC KDSSFSEDGA VLPQWLCSNC QAPYDSSAIE MTLVEVLQKK LMAFTLQDLV CLKCRGVKET SMPVYCSCAG DFALTIHTQV FMEQIGIFRN IAQHYGMSYL LETLEWLLQK NPQLGH // ID ISG15_HUMAN Reviewed; 165 AA. AC P05161; Q5SVA4; Q7Z2G2; Q96GF0; DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 5. DT 28-JAN-2026, entry version 246. DE RecName: Full=Ubiquitin-like protein ISG15; DE AltName: Full=Interferon-induced 15 kDa protein; DE AltName: Full=Interferon-induced 17 kDa protein; DE Short=IP17; DE AltName: Full=Ubiquitin cross-reactive protein; DE Short=hUCRP; DE Flags: Precursor; GN Name=ISG15 {ECO:0000312|HGNC:HGNC:4053}; Synonyms=G1P2, UCRP; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=3087979; DOI=10.1016/s0021-9258(19)84453-8; RA Blomstrom D.C., Fahey D., Kutny R., Korant B.D., Knight E. Jr.; RT "Molecular characterization of the interferon-induced 15-kDa protein. RT Molecular cloning and nucleotide and amino acid sequence."; RL J. Biol. Chem. 261:8811-8816(1986). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=3476954; DOI=10.1073/pnas.84.18.6394; RA Reich N., Evans B., Levy D., Fahey D., Knight E. Jr., Darnell J.E. Jr.; RT "Interferon-induced transcription of a gene encoding a 15-kDa protein RT depends on an upstream enhancer element."; RL Proc. Natl. Acad. Sci. U.S.A. 84:6394-6398(1987). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND PROTEOLYTIC PROCESSING. RX PubMed=3350799; DOI=10.1016/s0021-9258(18)68812-x; RA Knight E. Jr., Fahey D., Cordova B., Hillman M. Jr., Kutny R., Reich N., RA Blomstrom D.C.; RT "A 15-kDa interferon-induced protein is derived by COOH-terminal processing RT of a 17-kDa precursor."; RL J. Biol. Chem. 263:4520-4522(1988). RN [4] RP ERRATUM OF PUBMED:3350799. RA Knight E. Jr., Fahey D., Cordova B., Hillman M. Jr., Kutny R., Reich N., RA Blomstrom D.C.; RL J. Biol. Chem. 263:10040-10040(1988). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-83. RC TISSUE=Testis; RA Kamitani T., Fukuda-Kamitani T.; RT "Conjugation by ubiquitin-like proteins."; RL Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-83. RA Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., RA Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., RA Phelan M., Farmer A.; RT "Cloning of human full-length CDSs in BD Creator(TM) system donor vector."; RL Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-83. RC TISSUE=Colon; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP PROTEIN SEQUENCE OF 2-38 AND 151-165, AND PROTEOLYTIC PROCESSING. RX PubMed=2477469; DOI=10.1089/jir.1989.9.493; RA Feltham N., Hillman M. Jr., Cordova B., Fahey D., Larsen B., RA Blomstrom D.C., Knight E. Jr.; RT "A 15-kD interferon-induced protein and its 17-kD precursor: expression in RT Escherichia coli, purification, and characterization."; RL J. Interferon Res. 9:493-507(1989). RN [11] RP SIMILARITY TO UBIQUITIN. RX PubMed=2440890; DOI=10.1016/s0021-9258(18)60961-5; RA Haas A.L., Ahrens P., Bright P.M., Ankel H.; RT "Interferon induces a 15-kilodalton protein exhibiting marked homology to RT ubiquitin."; RL J. Biol. Chem. 262:11315-11323(1987). RN [12] RP FUNCTION. RX PubMed=1373138; DOI=10.1016/s0021-9258(18)42585-9; RA Loeb K.R., Haas A.L.; RT "The interferon-inducible 15-kDa ubiquitin homolog conjugates to RT intracellular proteins."; RL J. Biol. Chem. 267:7806-7813(1992). RN [13] RP FUNCTION. RX PubMed=7526157; DOI=10.1128/mcb.14.12.8408-8419.1994; RA Loeb K.R., Haas A.L.; RT "Conjugates of ubiquitin cross-reactive protein distribute in a RT cytoskeletal pattern."; RL Mol. Cell. Biol. 14:8408-8419(1994). RN [14] RP FUNCTION. RX PubMed=8550581; DOI=10.1074/jbc.271.1.324; RA Narasimhan J., Potter J.L., Haas A.L.; RT "Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct RT from that of ubiquitin."; RL J. Biol. Chem. 271:324-330(1996). RN [15] RP FUNCTION. RX PubMed=2005397; RA Knight E. Jr., Cordova B.; RT "IFN-induced 15-kDa protein is released from human lymphocytes and RT monocytes."; RL J. Immunol. 146:2280-2284(1991). RN [16] RP TISSUE SPECIFICITY. RX PubMed=7490683; DOI=10.1002/path.1711770210; RA Lowe J., McDermott H., Loeb K., Landon M., Haas A.L., Mayer R.J.; RT "Immunohistochemical localization of ubiquitin cross-reactive protein in RT human tissues."; RL J. Pathol. 177:163-169(1995). RN [17] RP INTERACTION WITH UBE1L AND INFLUENZA B NS1. RX PubMed=11157743; DOI=10.1093/emboj/20.3.362; RA Yuan W., Krug R.M.; RT "Influenza B virus NS1 protein inhibits conjugation of the interferon RT (IFN)-induced ubiquitin-like ISG15 protein."; RL EMBO J. 20:362-371(2001). RN [18] RP CHARACTERIZATION. RX PubMed=11788588; DOI=10.1074/jbc.m109078200; RA Malakhov M.P., Malakhova O.A., Kim K.I., Ritchie K.J., Zhang D.-E.; RT "UBP43 (USP18) specifically removes ISG15 from conjugated proteins."; RL J. Biol. Chem. 277:9976-9981(2002). RN [19] RP INTERACTION WITH UBE2E2. RX PubMed=15131269; DOI=10.1073/pnas.0402528101; RA Zhao C., Beaudenon S.L., Kelley M.L., Waddell M.B., Yuan W., Schulman B.A., RA Huibregtse J.M., Krug R.M.; RT "The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN- RT alpha/beta-induced ubiquitin-like protein."; RL Proc. Natl. Acad. Sci. U.S.A. 101:7578-7582(2004). RN [20] RP FUNCTION IN UBE2N ISGYLATION. RX PubMed=16112642; DOI=10.1016/j.bbrc.2005.08.034; RA Takeuchi T., Yokosawa H.; RT "ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating RT activity."; RL Biochem. Biophys. Res. Commun. 336:9-13(2005). RN [21] RP FUNCTION IN UBE2E1 AND UBE2L6 ISGYLATION. RX PubMed=16428300; DOI=10.1093/jb/mvi172; RA Takeuchi T., Iwahara S., Saeki Y., Sasajima H., Yokosawa H.; RT "Link between the ubiquitin conjugation system and the ISG15 conjugation RT system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme."; RL J. Biochem. 138:711-719(2005). RN [22] RP FUNCTION IN IFIT1; RIGI AND MX1 ISGYLATION. RX PubMed=16009940; DOI=10.1073/pnas.0504754102; RA Zhao C., Denison C., Huibregtse J.M., Gygi S.P., Krug R.M.; RT "Human ISG15 conjugation targets both IFN-induced and constitutively RT expressed proteins functioning in diverse cellular pathways."; RL Proc. Natl. Acad. Sci. U.S.A. 102:10200-10205(2005). RN [23] RP FUNCTION IN PPM1B ISGYLATION. RX PubMed=16872604; DOI=10.1016/j.febslet.2006.07.032; RA Takeuchi T., Kobayashi T., Tamura S., Yokosawa H.; RT "Negative regulation of protein phosphatase 2Cbeta by ISG15 conjugation."; RL FEBS Lett. 580:4521-4526(2006). RN [24] RP FUNCTION IN HIV-1 RESTRICTION. RX PubMed=16434471; DOI=10.1073/pnas.0510518103; RA Okumura A., Lu G., Pitha-Rowe I., Pitha P.M.; RT "Innate antiviral response targets HIV-1 release by the induction of RT ubiquitin-like protein ISG15."; RL Proc. Natl. Acad. Sci. U.S.A. 103:1440-1445(2006). RN [25] RP DOMAINS UBIQUITIN-LIKE 1 AND 2. RX PubMed=18356159; DOI=10.1074/jbc.m800162200; RA Chang Y.G., Yan X.Z., Xie Y.Y., Gao X.C., Song A.X., Zhang D.E., Hu H.Y.; RT "Different roles for two ubiquitin-like domains of ISG15 in protein RT modification."; RL J. Biol. Chem. 283:13370-13377(2008). RN [26] RP S-NITROSYLATION AT CYS-78. RX PubMed=18606809; DOI=10.1074/jbc.m803795200; RA Okumura F., Lenschow D.J., Zhang D.E.; RT "Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization RT of ISG15 and contributes to effective ISGylation."; RL J. Biol. Chem. 283:24484-24488(2008). RN [27] RP FUNCTION IN EBOLA VIRUS RESTRICTION, AND INTERACTION WITH NEDD4. RX PubMed=18305167; DOI=10.1073/pnas.0710629105; RA Okumura A., Pitha P.M., Harty R.N.; RT "ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by RT blocking Nedd4 ligase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 105:3974-3979(2008). RN [28] RP FUNCTION IN FLNB ISGYLATION. RX PubMed=19270716; DOI=10.1038/embor.2009.23; RA Jeon Y.J., Choi J.S., Lee J.Y., Yu K.R., Kim S.M., Ka S.H., Oh K.H., RA Kim K.I., Zhang D.E., Bang O.S., Chung C.H.; RT "ISG15 modification of filamin B negatively regulates the type I RT interferon-induced JNK signalling pathway."; RL EMBO Rep. 10:374-380(2009). RN [29] RP REVIEW. RX PubMed=19680460; DOI=10.1159/000226245; RA Harty R.N., Pitha P.M., Okumura A.; RT "Antiviral activity of innate immune protein ISG15."; RL J. Innate Immun. 1:397-404(2009). RN [30] RP FUNCTION IN INFLUENZA A VIRUS RESTRICTION. RX PubMed=19357168; DOI=10.1128/jvi.01667-08; RA Hsiang T.Y., Zhao C., Krug R.M.; RT "Interferon-induced ISG15 conjugation inhibits influenza A virus gene RT expression and replication in human cells."; RL J. Virol. 83:5971-5977(2009). RN [31] RP REVIEW. RX PubMed=20153823; DOI=10.1016/j.bbadis.2010.02.006; RA Jeon Y.J., Yoo H.M., Chung C.H.; RT "ISG15 and immune diseases."; RL Biochim. Biophys. Acta 1802:485-496(2010). RN [32] RP REVIEW. RX PubMed=20946978; DOI=10.1016/j.cell.2010.09.033; RA Skaug B., Chen Z.J.; RT "Emerging role of ISG15 in antiviral immunity."; RL Cell 143:187-190(2010). RN [33] RP FUNCTION. RX PubMed=20639253; DOI=10.1136/gut.2009.195545; RA Broering R., Zhang X., Kottilil S., Trippler M., Jiang M., Lu M., RA Gerken G., Schlaak J.F.; RT "The interferon stimulated gene 15 functions as a proviral factor for the RT hepatitis C virus and as a regulator of the IFN response."; RL Gut 59:1111-1119(2010). RN [34] RP FUNCTION IN IRF3 ISGYLATION. RX PubMed=20308324; DOI=10.1128/mcb.01466-09; RA Shi H.X., Yang K., Liu X., Liu X.Y., Wei B., Shan Y.F., Zhu L.H., Wang C.; RT "Positive regulation of interferon regulatory factor 3 activation by Herc5 RT via ISG15 modification."; RL Mol. Cell. Biol. 30:2424-2436(2010). RN [35] RP FUNCTION IN INFLUENZA A VIRUS NS1 ISGYLATION. RX PubMed=20133869; DOI=10.1073/pnas.0909144107; RA Zhao C., Hsiang T.Y., Kuo R.L., Krug R.M.; RT "ISG15 conjugation system targets the viral NS1 protein in influenza A RT virus-infected cells."; RL Proc. Natl. Acad. Sci. U.S.A. 107:2253-2258(2010). RN [36] RP REVIEW. RX PubMed=21994614; DOI=10.3390/v2102154; RA Lenschow D.J.; RT "Antiviral properties of ISG15."; RL Viruses 2:2154-2168(2010). RN [37] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [38] RP REVIEW. RX PubMed=21190487; DOI=10.1089/jir.2010.0110; RA Zhang D., Zhang D.E.; RT "Interferon-stimulated gene 15 and the protein ISGylation system."; RL J. Interferon Cytokine Res. 31:119-130(2011). RN [39] RP FUNCTION IN CHMP5; CHMP2A; CHMP4B AND CHMP6 ISGYLATION. RX PubMed=21543490; DOI=10.1128/jvi.02610-10; RA Kuang Z., Seo E.J., Leis J.; RT "Mechanism of inhibition of retrovirus release from cells by interferon- RT induced gene ISG15."; RL J. Virol. 85:7153-7161(2011). RN [40] RP INTERACTION WITH CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS RNA-DIRECTED RNA RP POLYMERASE L (MICROBIAL INFECTION). RX PubMed=21266548; DOI=10.1073/pnas.1015287108; RA Akutsu M., Ye Y., Virdee S., Chin J.W., Komander D.; RT "Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian RT tumor domains."; RL Proc. Natl. Acad. Sci. U.S.A. 108:2228-2233(2011). RN [41] RP INTERACTION WITH CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS RNA-DIRECTED RNA RP POLYMERASE L (MICROBIAL INFECTION). RX PubMed=21245344; DOI=10.1073/pnas.1013388108; RA James T.W., Frias-Staheli N., Bacik J.P., Levingston Macleod J.M., RA Khajehpour M., Garcia-Sastre A., Mark B.L.; RT "Structural basis for the removal of ubiquitin and interferon-stimulated RT gene 15 by a viral ovarian tumor domain-containing protease."; RL Proc. Natl. Acad. Sci. U.S.A. 108:2222-2227(2011). RN [42] RP REVIEW. RX PubMed=22666250; DOI=10.1155/2012/532723; RA Seo E.J., Leis J.; RT "Budding of enveloped viruses: interferon-induced ISG15-antivirus RT mechanisms targeting the release process."; RL Adv. Virol. 2012:532723-532723(2012). RN [43] RP REVIEW. RX PubMed=22906767; DOI=10.1016/j.cytogfr.2012.07.003; RA Sgorbissa A., Brancolini C.; RT "IFNs, ISGylation and cancer: Cui prodest?"; RL Cytokine Growth Factor Rev. 23:307-314(2012). RN [44] RP FUNCTION IN UBE2N AND UBA7 ISGYLATION, AND DISULFIDE BOND. RX PubMed=22693631; DOI=10.1371/journal.pone.0038294; RA Bade V.N., Nickels J., Keusekotten K., Praefcke G.J.; RT "Covalent protein modification with ISG15 via a conserved cysteine in the RT hinge region."; RL PLoS ONE 7:E38294-E38294(2012). RN [45] RP FUNCTION, INDUCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND RP INVOLVEMENT IN IMD38. RX PubMed=22859821; DOI=10.1126/science.1224026; RA Bogunovic D., Byun M., Durfee L.A., Abhyankar A., Sanal O., Mansouri D., RA Salem S., Radovanovic I., Grant A.V., Adimi P., Mansouri N., Okada S., RA Bryant V.L., Kong X.F., Kreins A., Velez M.M., Boisson B., Khalilzadeh S., RA Ozcelik U., Darazam I.A., Schoggins J.W., Rice C.M., Al-Muhsen S., Behr M., RA Vogt G., Puel A., Bustamante J., Gros P., Huibregtse J.M., Abel L., RA Boisson-Dupuis S., Casanova J.L.; RT "Mycobacterial disease and impaired IFN-gamma immunity in humans with RT inherited ISG15 deficiency."; RL Science 337:1684-1688(2012). RN [46] RP REVIEW. RX PubMed=22964713; DOI=10.1038/cr.2012.133; RA Fan J.B., Zhang D.E.; RT "ISG15 regulates IFN-? immunity in human mycobacterial disease."; RL Cell Res. 23:173-175(2013). RN [47] RP REVIEW. RX PubMed=23579383; DOI=10.1038/emm.2013.36; RA Bogunovic D., Boisson-Dupuis S., Casanova J.L.; RT "ISG15: leading a double life as a secreted molecule."; RL Exp. Mol. Med. 45:E18-E18(2013). RN [48] RP FUNCTION IN EIF2AK2 ISGYLATION. RX PubMed=23229543; DOI=10.1074/jbc.m112.401851; RA Okumura F., Okumura A.J., Uematsu K., Hatakeyama S., Zhang D.E., Kamura T.; RT "Activation of double-stranded RNA-activated protein kinase (PKR) by RT interferon-stimulated gene 15 (ISG15) modification down-regulates protein RT translation."; RL J. Biol. Chem. 288:2839-2847(2013). RN [49] RP REVIEW. RX PubMed=23414970; DOI=10.1016/j.tim.2013.01.005; RA Zhao C., Collins M.N., Hsiang T.Y., Krug R.M.; RT "Interferon-induced ISG15 pathway: an ongoing virus-host battle."; RL Trends Microbiol. 21:181-186(2013). RN [50] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [51] RP INTERACTION WITH VACCINIA VIRUS PROTEIN E3. RX PubMed=24257616; DOI=10.1128/jvi.03293-13; RA Eduardo-Correia B., Martinez-Romero C., Garcia-Sastre A., Guerra S.; RT "ISG15 is counteracted by vaccinia virus E3 protein and controls the RT proinflammatory response against viral infection."; RL J. Virol. 88:2312-2318(2014). RN [52] RP FUNCTION, AND INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL26 RP (MICROBIAL INFECTION). RX PubMed=27564865; DOI=10.1371/journal.ppat.1005850; RA Kim Y.J., Kim E.T., Kim Y.E., Lee M.K., Kwon K.M., Kim K.I., Stamminger T., RA Ahn J.H.; RT "Consecutive Inhibition of ISG15 Expression and ISGylation by RT Cytomegalovirus Regulators."; RL PLoS Pathog. 12:e1005850-e1005850(2016). RN [53] RP FUNCTION, AND MUTAGENESIS OF ARG-44; SER-83; TYR-96; ARG-99; THR-101; RP GLN-102 AND THR-103. RX PubMed=29100055; DOI=10.1016/j.molcel.2017.10.003; RA Swaim C.D., Scott A.F., Canadeo L.A., Huibregtse J.M.; RT "Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin RT receptor."; RL Mol. Cell 68:581-590(2017). RN [54] RP FUNCTION. RX PubMed=33727702; DOI=10.1038/s41564-021-00884-1; RA Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M., RA Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.; RT "ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS- RT CoV-2 papain-like protease to evade host innate immunity."; RL Nat. Microbiol. 6:467-478(2021). RN [55] RP INTERACTION WITH PARP12, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=39465252; DOI=10.1038/s41413-024-00363-3; RA Deng Z., Long D., Li C., Liu H., Li W., Zhong Y., Mo X., Li R., Yang Z., RA Kang Y., Mao G.; RT "IRF1-mediated upregulation of PARP12 promotes cartilage degradation by RT inhibiting PINK1/Parkin dependent mitophagy through ISG15 attenuating RT ubiquitylation and SUMOylation of MFN1/2."; RL Bone Res. 12:63-63(2024). RN [56] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-155 OF MUTANT SER-78. RX PubMed=15917233; DOI=10.1074/jbc.m502814200; RA Narasimhan J., Wang M., Fu Z., Klein J.M., Haas A.L., Kim J.J.; RT "Crystal structure of the interferon-induced ubiquitin-like protein RT ISG15."; RL J. Biol. Chem. 280:27356-27365(2005). RN [57] RP STRUCTURE BY NMR OF 79-157. RG Northeast structural genomics consortium (NESG); RT "Solution NMR structure of the C-terminal domain of the interferon alpha- RT inducible ISG15 protein from Homo sapiens."; RL Submitted (FEB-2009) to the PDB data bank. CC -!- FUNCTION: Ubiquitin-like protein which plays a key role in the innate CC immune response to viral infection either via its conjugation to a CC target protein (ISGylation) or via its action as a free or unconjugated CC protein (PubMed:27564865, PubMed:39465252). ISGylation involves a CC cascade of enzymatic reactions involving E1, E2, and E3 enzymes which CC catalyze the conjugation of ISG15 to a lysine residue in the target CC protein (PubMed:33727702). Its target proteins include IFIT1, MX1/MxA, CC PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Isgylation of the CC viral sensor IFIH1/MDA5 promotes IFIH1/MDA5 oligomerization and CC triggers activation of innate immunity against a range of viruses, CC including coronaviruses, flaviviruses and picornaviruses CC (PubMed:33727702). Can also isgylate: EIF2AK2/PKR which results in its CC activation, RIGI which inhibits its function in antiviral signaling CC response, EIF4E2 which enhances its cap structure-binding activity and CC translation-inhibition activity, UBE2N and UBE2E1 which negatively CC regulates their activity, IRF3 which inhibits its ubiquitination and CC degradation and FLNB which prevents its ability to interact with the CC upstream activators of the JNK cascade thereby inhibiting IFNA-induced CC JNK signaling. Exhibits antiviral activity towards both DNA and RNA CC viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 CC and ebola virus via disruption of viral budding. Inhibits the CC ubiquitination of HIV-1 Gag and host TSG101 and disrupts their CC interaction, thereby preventing assembly and release of virions from CC infected cells. Inhibits Ebola virus budding mediated by the VP40 CC protein by disrupting ubiquitin ligase activity of NEDD4 and its CC ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein CC which causes a loss of function of the protein and the inhibition of CC virus replication. The secreted form of ISG15 can: induce natural CC killer cell proliferation, act as a chemotactic factor for neutrophils CC and act as a IFN-gamma-inducing cytokine playing an essential role in CC antimycobacterial immunity. The secreted form acts through the integrin CC ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine CC kinases including LYN, HCK and FGR which leads to secretion of IFNG and CC IL10; the interaction is mediated by ITGAL (PubMed:29100055). CC {ECO:0000269|PubMed:1373138, ECO:0000269|PubMed:16009940, CC ECO:0000269|PubMed:16112642, ECO:0000269|PubMed:16428300, CC ECO:0000269|PubMed:16434471, ECO:0000269|PubMed:16872604, CC ECO:0000269|PubMed:18305167, ECO:0000269|PubMed:19270716, CC ECO:0000269|PubMed:19357168, ECO:0000269|PubMed:2005397, CC ECO:0000269|PubMed:20133869, ECO:0000269|PubMed:20308324, CC ECO:0000269|PubMed:20639253, ECO:0000269|PubMed:21543490, CC ECO:0000269|PubMed:22693631, ECO:0000269|PubMed:22859821, CC ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:27564865, CC ECO:0000269|PubMed:29100055, ECO:0000269|PubMed:33727702, CC ECO:0000269|PubMed:39465252, ECO:0000269|PubMed:7526157, CC ECO:0000269|PubMed:8550581}. CC -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:2440890). Interacts with, CC and is conjugated to its targets by UBE1L (E1 enzyme) and UBE2E2 (E2 CC enzyme) (PubMed:11157743, PubMed:15131269). Interacts with NEDD4 CC (PubMed:18305167). Interacts with PARP12; this interaction inhibits CC PINK1/Parkin-dependent mitophagy (PubMed:39465252). CC {ECO:0000269|PubMed:11157743, ECO:0000269|PubMed:15131269, CC ECO:0000269|PubMed:18305167, ECO:0000269|PubMed:2440890, CC ECO:0000269|PubMed:39465252}. CC -!- SUBUNIT: (Microbial infection) Interacts with vaccinia virus protein CC E3. {ECO:0000269|PubMed:24257616}. CC -!- SUBUNIT: (Microbial infection) Interaction with influenza B NS1 protein CC inhibits its conjugation. {ECO:0000269|PubMed:11157743}. CC -!- SUBUNIT: (Microbial infection) Interacts (via C-terminus) with Crimean- CC Congo hemorrhagic fever virus (CCHFV) RNA-directed RNA polymerase L CC (via N-terminus); the deISGylase activity of the viral protein CC interferes with antiviral signaling pathways mediated by NF-kappaB and CC IRF signalings. {ECO:0000269|PubMed:21266548}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC protein UL26; this interaction inhibits global protein ISGylation. CC {ECO:0000269|PubMed:27564865}. CC -!- INTERACTION: CC P05161; O75369: FLNB; NbExp=4; IntAct=EBI-746466, EBI-352089; CC P05161; Q9BYX4: IFIH1; NbExp=7; IntAct=EBI-746466, EBI-6115771; CC P05161; P05000: IFNW1; NbExp=2; IntAct=EBI-746466, EBI-4394437; CC P05161; Q14653: IRF3; NbExp=2; IntAct=EBI-746466, EBI-2650369; CC P05161; O75688: PPM1B; NbExp=2; IntAct=EBI-746466, EBI-1047039; CC P05161; O60260-5: PRKN; NbExp=3; IntAct=EBI-746466, EBI-21251460; CC P05161; P41226: UBA7; NbExp=12; IntAct=EBI-746466, EBI-751921; CC P05161; Q9UMW8: USP18; NbExp=9; IntAct=EBI-746466, EBI-356206; CC P05161; PRO_0000338257 [P0C6U8]: 1a; Xeno; NbExp=5; IntAct=EBI-746466, EBI-25635190; CC P05161; Q6TQR6: L; Xeno; NbExp=5; IntAct=EBI-746466, EBI-4403908; CC P05161; P03495: NS; Xeno; NbExp=4; IntAct=EBI-746466, EBI-2548993; CC P05161; P03502: NS; Xeno; NbExp=4; IntAct=EBI-746466, EBI-15938710; CC P05161; K0BWD0: orf1ab; Xeno; NbExp=4; IntAct=EBI-746466, EBI-25565992; CC P05161; PRO_0000422441 [K9N7C7]: rep; Xeno; NbExp=4; IntAct=EBI-746466, EBI-25592237; CC P05161; PRO_0000037311 [P0C6X7]: rep; Xeno; NbExp=2; IntAct=EBI-746466, EBI-25474079; CC P05161; PRO_0000449621 [P0DTD1]: rep; Xeno; NbExp=13; IntAct=EBI-746466, EBI-25492388; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22859821, CC ECO:0000269|PubMed:39465252}. Secreted {ECO:0000269|PubMed:22859821}. CC Note=Exists in three distinct states: free within the cell, released CC into the extracellular space, or conjugated to target proteins. CC -!- TISSUE SPECIFICITY: Detected in lymphoid cells, striated and smooth CC muscle, several epithelia and neurons. Expressed in neutrophils, CC monocytes and lymphocytes. Enhanced expression seen in pancreatic CC adenocarcinoma, endometrial cancer, and bladder cancer, as compared to CC non-cancerous tissue. In bladder cancer, the increase in expression CC exhibits a striking positive correlation with more advanced stages of CC the disease. {ECO:0000269|PubMed:22859821, ECO:0000269|PubMed:7490683}. CC -!- INDUCTION: Strongly induced upon exposure to type I interferons, CC viruses, LPS, and other stresses, including certain genotoxic stresses. CC {ECO:0000269|PubMed:22859821}. CC -!- DOMAIN: Both the Ubiquitin-like 1 and Ubiquitin-like 2 domains are CC required for its efficient conjugation to cellular proteins. The two CC domains play different roles in the ISGylation pathway: Ubiquitin-like CC 2 domain is necessary for the first two steps allowing the linking of CC ISG15 to the E1 and E2 enzymes while Ubiquitin-like 1 domain is CC essential for the final, E3-mediated transfer of ISG15, from the E2 to CC the Lys of the target protein (PubMed:18356159). CC {ECO:0000269|PubMed:18356159}. CC -!- PTM: S-nitrosylation decreases its dimerization, thereby increasing the CC availability as well as the solubility of monomeric ISG15 for its CC conjugation to cellular proteins. {ECO:0000269|PubMed:18606809}. CC -!- PTM: Induced as an inactive, precursor protein that is cleaved by CC specific proteases to expose the C-terminal diglycine (LRLRGG) motif. CC This motif is essential not only for its conjugation to substrates but CC also for its recognition by the relevant processing proteases. CC {ECO:0000269|PubMed:2477469, ECO:0000269|PubMed:3350799}. CC -!- DISEASE: Immunodeficiency 38, with basal ganglia calcification (IMD38) CC [MIM:616126]: A primary immunodeficiency predisposing individuals to CC severe clinical disease upon infection with weakly virulent CC mycobacteria, including Mycobacterium bovis Bacille Calmette-Guerin CC (BCG) vaccines. Patients are also susceptible to Salmonella and CC Mycobacterium tuberculosis infections. Affected individuals have CC intracranial calcification. {ECO:0000269|PubMed:22859821}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=On guard - Issue 240 of CC October 2021; CC URL="https://www.proteinspotlight.org/back_issues/234/"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; M13755; AAA36038.1; -; mRNA. DR EMBL; M21786; AAA36128.1; -; Genomic_DNA. DR EMBL; AY168648; AAN86983.1; -; mRNA. DR EMBL; BT007297; AAP35961.1; -; mRNA. DR EMBL; AL645608; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471183; EAW56295.1; -; Genomic_DNA. DR EMBL; BC009507; AAH09507.1; -; mRNA. DR CCDS; CCDS6.1; -. DR PIR; A28304; A28138. DR RefSeq; NP_005092.1; NM_005101.4. DR PDB; 1Z2M; X-ray; 2.50 A; A=1-155. DR PDB; 2HJ8; NMR; -; A=79-157. DR PDB; 3PHX; X-ray; 1.60 A; B=79-156. DR PDB; 3PSE; X-ray; 2.30 A; B=1-156. DR PDB; 3R66; X-ray; 2.30 A; C/D=1-157. DR PDB; 3RT3; X-ray; 2.01 A; B=1-158. DR PDB; 3SDL; X-ray; 2.29 A; C/D=1-157. DR PDB; 5TL6; X-ray; 2.62 A; A/C=80-157. DR PDB; 5W8T; X-ray; 2.76 A; B/D=80-156. DR PDB; 5W8U; X-ray; 2.41 A; B/D=80-156. DR PDB; 6BI8; X-ray; 3.00 A; C/D=1-156. DR PDB; 6FFA; X-ray; 1.50 A; B=79-155. DR PDB; 6XA9; X-ray; 2.90 A; B/D/F=79-157. DR PDB; 7RBS; X-ray; 2.98 A; B/D/F/H/J=2-157. DR PDB; 7S6P; X-ray; 2.15 A; A/B/C/D/E/F=2-157. DR PDB; 8OIF; EM; 3.50 A; I=1-157. DR PDB; 8SE9; EM; 3.20 A; B/D=1-157. DR PDB; 8SEA; EM; 3.40 A; B/D=1-157. DR PDB; 8SEB; EM; 3.24 A; B=1-157. DR PDB; 8SV8; EM; 3.38 A; B/D=1-157. DR PDBsum; 1Z2M; -. DR PDBsum; 2HJ8; -. DR PDBsum; 3PHX; -. DR PDBsum; 3PSE; -. DR PDBsum; 3R66; -. DR PDBsum; 3RT3; -. DR PDBsum; 3SDL; -. DR PDBsum; 5TL6; -. DR PDBsum; 5W8T; -. DR PDBsum; 5W8U; -. DR PDBsum; 6BI8; -. DR PDBsum; 6FFA; -. DR PDBsum; 6XA9; -. DR PDBsum; 7RBS; -. DR PDBsum; 7S6P; -. DR PDBsum; 8OIF; -. DR PDBsum; 8SE9; -. DR PDBsum; 8SEA; -. DR PDBsum; 8SEB; -. DR PDBsum; 8SV8; -. DR AlphaFoldDB; P05161; -. DR BMRB; P05161; -. DR EMDB; EMD-16891; -. DR EMDB; EMD-18589; -. DR EMDB; EMD-40407; -. DR EMDB; EMD-40408; -. DR EMDB; EMD-40409; -. DR EMDB; EMD-40782; -. DR SMR; P05161; -. DR BioGRID; 114995; 492. DR DIP; DIP-29814N; -. DR FunCoup; P05161; 780. DR IntAct; P05161; 75. DR MINT; P05161; -. DR STRING; 9606.ENSP00000496832; -. DR GlyGen; P05161; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P05161; -. DR PhosphoSitePlus; P05161; -. DR BioMuta; ISG15; -. DR DMDM; 52001470; -. DR jPOST; P05161; -. DR MassIVE; P05161; -. DR PaxDb; 9606-ENSP00000368699; -. DR PeptideAtlas; P05161; -. DR ProteomicsDB; 51809; -. DR Pumba; P05161; -. DR TopDownProteomics; P05161; -. DR Antibodypedia; 809; 567 antibodies from 40 providers. DR DNASU; 9636; -. DR Ensembl; ENST00000649529.1; ENSP00000496832.1; ENSG00000187608.11. DR GeneID; 9636; -. DR KEGG; hsa:9636; -. DR MANE-Select; ENST00000649529.1; ENSP00000496832.1; NM_005101.4; NP_005092.1. DR UCSC; uc001acj.5; human. DR AGR; HGNC:4053; -. DR ClinPGx; PA28465; -. DR CTD; 9636; -. DR DisGeNET; 9636; -. DR GeneCards; ISG15; -. DR HGNC; HGNC:4053; ISG15. DR HPA; ENSG00000187608; Tissue enhanced (salivary). DR MalaCards; ISG15; -. DR MIM; 147571; gene. DR MIM; 616126; phenotype. DR OpenTargets; ENSG00000187608; -. DR Orphanet; 319563; Mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency. DR VEuPathDB; HostDB:ENSG00000187608; -. DR eggNOG; KOG0001; Eukaryota. DR GeneTree; ENSGT00940000162007; -. DR InParanoid; P05161; -. DR OMA; CTVYMNL; -. DR OrthoDB; 1885901at2759; -. DR PAN-GO; P05161; 8 GO annotations based on evolutionary models. DR PhylomeDB; P05161; -. DR PathwayCommons; P05161; -. DR Reactome; R-HSA-1169408; ISG15 antiviral mechanism. DR Reactome; R-HSA-168276; NS1 Mediated Effects on Host Pathways. DR Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta. DR Reactome; R-HSA-5656169; Termination of translesion DNA synthesis. DR Reactome; R-HSA-909733; Interferon alpha/beta signaling. DR Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-9833110; RSV-host interactions. DR Reactome; R-HSA-9833482; PKR-mediated signaling. DR Reactome; R-HSA-9909505; Modulation of host responses by IFN-stimulated genes. DR SignaLink; P05161; -. DR Agora; ENSG00000187608; -. DR BioGRID-ORCS; 9636; 26 hits in 1168 CRISPR screens. DR ChiTaRS; ISG15; human. DR EvolutionaryTrace; P05161; -. DR GeneWiki; ISG15; -. DR GenomeRNAi; 9636; -. DR Pharos; P05161; Tbio. DR PRO; PR:P05161; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P05161; protein. DR Bgee; ENSG00000187608; Expressed in decidua and 206 other cell types or tissues. DR ExpressionAtlas; P05161; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005576; C:extracellular region; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005178; F:integrin binding; IPI:UniProtKB. DR GO; GO:0031386; F:protein tag activity; IDA:UniProt. DR GO; GO:0031625; F:ubiquitin protein ligase binding; IBA:GO_Central. DR GO; GO:0042742; P:defense response to bacterium; IMP:UniProtKB. DR GO; GO:0051607; P:defense response to virus; IDA:UniProtKB. DR GO; GO:0045087; P:innate immune response; IDA:UniProt. DR GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB. DR GO; GO:0032020; P:ISG15-protein conjugation; IDA:UniProtKB. DR GO; GO:0019941; P:modification-dependent protein catabolic process; IBA:GO_Central. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0060339; P:negative regulation of type I interferon-mediated signaling pathway; IMP:ARUK-UCL. DR GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB. DR GO; GO:0030501; P:positive regulation of bone mineralization; ISS:UniProtKB. DR GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IEA:Ensembl. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:UniProtKB. DR GO; GO:0032733; P:positive regulation of interleukin-10 production; IDA:UniProtKB. DR GO; GO:0032461; P:positive regulation of protein oligomerization; IDA:UniProtKB. DR GO; GO:0032729; P:positive regulation of type II interferon production; IDA:UniProtKB. DR GO; GO:0070585; P:protein localization to mitochondrion; IDA:UniProtKB. DR GO; GO:0032649; P:regulation of type II interferon production; IMP:UniProtKB. DR GO; GO:0034340; P:response to type I interferon; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IDA:UniProtKB. DR CDD; cd01792; Ubl1_ISG15; 1. DR CDD; cd01810; Ubl2_ISG15; 1. DR FunFam; 3.10.20.90:FF:000240; ISG15 ubiquitin-like modifier; 1. DR FunFam; 3.10.20.90:FF:000264; ISG15 ubiquitin-like modifier; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR InterPro; IPR015496; Ubiquilin. DR InterPro; IPR000626; Ubiquitin-like_dom. DR InterPro; IPR029071; Ubiquitin-like_domsf. DR InterPro; IPR019956; Ubiquitin_dom. DR PANTHER; PTHR10677; UBIQUILIN; 1. DR PANTHER; PTHR10677:SF16; UBIQUILIN-1; 1. DR Pfam; PF00240; ubiquitin; 2. DR PRINTS; PR00348; UBIQUITIN. DR SMART; SM00213; UBQ; 2. DR SUPFAM; SSF54236; Ubiquitin-like; 2. DR PROSITE; PS50053; UBIQUITIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Antiviral defense; Cytoplasm; Direct protein sequencing; KW Disulfide bond; Host-virus interaction; Immunity; Innate immunity; KW Isopeptide bond; Proteomics identification; Reference proteome; Repeat; KW S-nitrosylation; Secreted; Ubl conjugation pathway. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:2477469" FT CHAIN 2..157 FT /note="Ubiquitin-like protein ISG15" FT /id="PRO_0000035986" FT PROPEP 158..165 FT /note="Removed in mature form" FT /id="PRO_0000035987" FT DOMAIN 2..78 FT /note="Ubiquitin-like 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT DOMAIN 79..157 FT /note="Ubiquitin-like 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT REGION 153..157 FT /note="Involved in the ligation of specific target FT proteins" FT /evidence="ECO:0000250" FT MOTIF 152..157 FT /note="LRLRGG" FT SITE 153 FT /note="Interacts with activating enzyme" FT /evidence="ECO:0000250" FT MOD_RES 78 FT /note="S-nitrosocysteine; alternate" FT /evidence="ECO:0000269|PubMed:18606809" FT DISULFID 78 FT /note="Interchain (with C-87 in UBE2N); alternate" FT /evidence="ECO:0000269|PubMed:22693631" FT CROSSLNK 157 FT /note="Glycyl lysine isopeptide (Gly-Lys) (interchain with FT K-? in acceptor proteins)" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214" FT VARIANT 83 FT /note="S -> N (in dbSNP:rs1921)" FT /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.5, FT ECO:0000269|Ref.6" FT /id="VAR_016181" FT MUTAGEN 44 FT /note="R->A: Does not affect ISG15 signaling, interaction FT with ITGAL or activation of SRC family tyrosine kinases." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 83 FT /note="S->A: Does not affect ISG15 signaling, interaction FT with ITGAL or activation of SRC family tyrosine kinases." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 96 FT /note="Y->L: Reduces ISG15 signaling. Strongly reduces FT ISG15 signaling and abolishes interaction with ITGAL and FT activation of SRC family tyrosine kinases; when associated FT with D-102." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 99 FT /note="R->A: Strongly reduces ISG15 signaling and abolishes FT interaction with ITGAL." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 101 FT /note="T->A: Strongly reduces ISG15 signaling and abolishes FT interaction with ITGAL and activation of SRC family FT tyrosine kinases." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 102 FT /note="Q->D: Reduces ISG15 signaling. Strongly reduces FT ISG15 signaling and abolishes interaction with ITGAL and FT activation of SRC family tyrosine kinases; when associated FT with L-96." FT /evidence="ECO:0000269|PubMed:29100055" FT MUTAGEN 103 FT /note="T->A: Strongly reduces ISG15 signaling and abolishes FT interaction with ITGAL." FT /evidence="ECO:0000269|PubMed:29100055" FT CONFLICT 35 FT /note="K -> N (in Ref. 2; AAA36128)" FT /evidence="ECO:0000305" FT STRAND 4..9 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 10..12 FT /evidence="ECO:0007829|PDB:6BI8" FT STRAND 14..18 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 20..22 FT /evidence="ECO:0007829|PDB:6BI8" FT HELIX 25..36 FT /evidence="ECO:0007829|PDB:3RT3" FT HELIX 40..42 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 43..48 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 56..58 FT /evidence="ECO:0007829|PDB:7S6P" FT HELIX 60..63 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 66..68 FT /evidence="ECO:0007829|PDB:6BI8" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:3RT3" FT STRAND 82..87 FT /evidence="ECO:0007829|PDB:6FFA" FT TURN 89..91 FT /evidence="ECO:0007829|PDB:8SV8" FT STRAND 93..98 FT /evidence="ECO:0007829|PDB:6FFA" FT STRAND 100..103 FT /evidence="ECO:0007829|PDB:8SEA" FT HELIX 104..115 FT /evidence="ECO:0007829|PDB:6FFA" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:6FFA" FT STRAND 122..126 FT /evidence="ECO:0007829|PDB:6FFA" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:5TL6" FT STRAND 133..136 FT /evidence="ECO:0007829|PDB:8SEA" FT HELIX 137..140 FT /evidence="ECO:0007829|PDB:6FFA" FT STRAND 147..152 FT /evidence="ECO:0007829|PDB:6FFA" SQ SEQUENCE 165 AA; 17888 MW; B6858A15AB0FFFDE CRC64; MGWDLTVKML AGNEFQVSLS SSMSVSELKA QITQKIGVHA FQQRLAVHPS GVALQDRVPL ASQGLGPGST VLLVVDKCDE PLSILVRNNK GRSSTYEVRL TQTVAHLKQQ VSGLEGVQDD LFWLTFEGKP LEDQLPLGEY GLKPLSTVFM NLRLRGGGTE PGGRS // ID MK09_HUMAN Reviewed; 424 AA. AC P45984; A8K0S3; B5BU66; B5M0B4; D3DWQ8; D3DWQ9; Q15708; Q15710; Q15711; AC Q8N5C5; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 24-JAN-2006, sequence version 2. DT 28-JAN-2026, entry version 240. DE RecName: Full=Mitogen-activated protein kinase 9; DE Short=MAP kinase 9; DE Short=MAPK 9; DE EC=2.7.11.24 {ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; DE AltName: Full=JNK-55; DE AltName: Full=Stress-activated protein kinase 1a; DE Short=SAPK1a; DE AltName: Full=Stress-activated protein kinase JNK2; DE AltName: Full=c-Jun N-terminal kinase 2; GN Name=MAPK9; Synonyms=JNK2, PRKM9, SAPK1A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=7969172; DOI=10.1128/mcb.14.12.8376-8384.1994; RA Sluss H.K., Barrett T., Derijard B., Davis R.J.; RT "Signal transduction by tumor necrosis factor mediated by JNK protein RT kinases."; RL Mol. Cell. Biol. 14:8376-8384(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=8001819; DOI=10.1101/gad.8.24.2996; RA Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., RA Davis R., Karin M.; RT "JNK2 contains a specificity-determining region responsible for efficient RT c-Jun binding and phosphorylation."; RL Genes Dev. 8:2996-3007(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND CATALYTIC ACTIVITY. RC TISSUE=Brain; RX PubMed=8654373; DOI=10.1002/j.1460-2075.1996.tb00636.x; RA Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., RA Davis R.J.; RT "Selective interaction of JNK protein kinase isoforms with transcription RT factors."; RL EMBO J. 15:2760-2770(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND CATALYTIC ACTIVITY. RX PubMed=21110917; DOI=10.5483/bmbrep.2010.43.11.738; RA Wang P., Xiong Y., Ma C., Shi T., Ma D.; RT "Molecular cloning and characterization of novel human JNK2 (MAPK9) RT transcript variants that show different stimulation activities on AP-1."; RL BMB Rep. 43:738-743(2010). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-2). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-268. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-2). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP INTERACTION WITH ATF7, AND FUNCTION. RX PubMed=10376527; DOI=10.1038/sj.onc.1202723; RA De Graeve F., Bahr A., Sabapathy K.T., Hauss C., Wagner E.F., Kedinger C., RA Chatton B.; RT "Role of the ATFa/JNK2 complex in Jun activation."; RL Oncogene 18:3491-3500(1999). RN [13] RP PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND MAP2K7, RP CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=11062067; DOI=10.1042/bj3520145; RA Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P.; RT "Synergistic activation of stress-activated protein kinase 1/c-Jun N- RT terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase RT kinase 4 (MKK4) and MKK7."; RL Biochem. J. 352:145-154(2000). RN [14] RP INTERACTION WITH SPAG9. RX PubMed=15693750; DOI=10.1042/bj20041577; RA Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C., RA Okumura K., Hasegawa A., Koyama K., Suri A.; RT "Characterization of a novel human sperm-associated antigen 9 (SPAG9) RT having structural homology with c-Jun N-terminal kinase-interacting RT protein."; RL Biochem. J. 389:73-82(2005). RN [15] RP FUNCTION IN PHOSPHORYLATION OF RRN3, AND CATALYTIC ACTIVITY. RX PubMed=15805466; DOI=10.1101/gad.333205; RA Mayer C., Bierhoff H., Grummt I.; RT "The nucleolus as a stress sensor: JNK2 inactivates the transcription RT factor TIF-IA and down-regulates rRNA synthesis."; RL Genes Dev. 19:933-941(2005). RN [16] RP INTERACTION WITH NFATC4, AND CATALYTIC ACTIVITY. RX PubMed=17875713; DOI=10.1158/0008-5472.can-06-4788; RA Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y., RA Bode A.M., Dong Z.; RT "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 RT induced cell transformation."; RL Cancer Res. 67:8725-8735(2007). RN [17] RP INTERACTION WITH BCL10, AND CATALYTIC ACTIVITY. RX PubMed=17189706; DOI=10.1016/j.immuni.2006.11.008; RA Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., Lin X.; RT "The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in RT the T cell receptor-signaling pathway."; RL Immunity 26:55-66(2007). RN [18] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND CATALYTIC ACTIVITY. RX PubMed=17525747; DOI=10.1038/sj.onc.1210526; RA Oleinik N.V., Krupenko N.I., Krupenko S.A.; RT "Cooperation between JNK1 and JNK2 in activation of p53 apoptotic RT pathway."; RL Oncogene 26:7222-7230(2007). RN [19] RP REVIEW ON FUNCTION. RX PubMed=19290929; DOI=10.1111/j.1600-065x.2008.00749.x; RA Blonska M., Lin X.; RT "CARMA1-mediated NF-kappaB and JNK activation in lymphocytes."; RL Immunol. Rev. 228:199-211(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNB1. RX PubMed=19675674; DOI=10.1371/journal.pone.0006640; RA Hu D., Bi X., Fang W., Han A., Yang W.; RT "GSK3beta is involved in JNK2-mediated beta-catenin inhibition."; RL PLoS ONE 4:E6640-E6640(2009). RN [22] RP FUNCTION. RX PubMed=20595622; DOI=10.1152/ajpgi.00265.2010; RA Samak G., Suzuki T., Bhargava A., Rao R.K.; RT "c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction RT disruption in the intestinal epithelium."; RL Am. J. Physiol. 299:G572-G584(2010). RN [23] RP FUNCTION IN PHOSPHORYLATION OF YAP1, AND CATALYTIC ACTIVITY. RX PubMed=21364637; DOI=10.1038/cddis.2010.7; RA Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A., Basu S.; RT "JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis."; RL Cell Death Dis. 1:E29-E29(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22441692; DOI=10.1038/embor.2012.37; RA Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D., RA Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T., Honma K., RA Fukada Y.; RT "JNK regulates the photic response of the mammalian circadian clock."; RL EMBO Rep. 13:455-461(2012). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=34048572; DOI=10.1093/nar/gkab415; RA Yu F., Wei J., Cui X., Yu C., Ni W., Bungert J., Wu L., He C., Qian Z.; RT "Post-translational modification of RNA m6A demethylase ALKBH5 regulates RT ROS-induced DNA damage response."; RL Nucleic Acids Res. 49:5779-5797(2021). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 7-362. RX PubMed=18801372; DOI=10.1016/j.jmb.2008.08.086; RA Shaw D., Wang S.M., Villasenor A.G., Tsing S., Walter D., Browner M.F., RA Barnett J., Kuglstatter A.; RT "The crystal structure of JNK2 reveals conformational flexibility in the RT MAP kinase insert and indicates its involvement in the regulation of RT catalytic activity."; RL J. Mol. Biol. 383:885-893(2008). RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] MET-13; ASN-56; THR-246 AND ILE-366. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [29] RP INTERACTION WITH MAPKBP1. RX PubMed=28089251; DOI=10.1016/j.ajhg.2016.12.011; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RT "Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent RT nephronophthisis."; RL Am. J. Hum. Genet. 100:323-333(2017). RN [30] RP ERRATUM OF PUBMED:28089251. RX PubMed=28157543; DOI=10.1016/j.ajhg.2017.01.025; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RL Am. J. Hum. Genet. 100:372-372(2017). CC -!- FUNCTION: Serine/threonine-protein kinase involved in various processes CC such as cell proliferation, differentiation, migration, transformation CC and programmed cell death (PubMed:10376527, PubMed:15805466, CC PubMed:17525747, PubMed:19675674, PubMed:20595622, PubMed:21364637, CC PubMed:22441692, PubMed:34048572). Extracellular stimuli such as pro- CC inflammatory cytokines or physical stress stimulate the stress- CC activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling CC pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and CC MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2 (PubMed:10376527, CC PubMed:15805466, PubMed:17525747, PubMed:19675674, PubMed:20595622, CC PubMed:21364637, PubMed:22441692, PubMed:34048572). In turn, MAPK9/JNK2 CC phosphorylates a number of transcription factors, primarily components CC of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional CC activity (PubMed:10376527). In response to oxidative or ribotoxic CC stresses, inhibits rRNA synthesis by phosphorylating and inactivating CC the RNA polymerase 1-specific transcription initiation factor RRN3 CC (PubMed:15805466). Promotes stressed cell apoptosis by phosphorylating CC key regulatory factors including TP53 and YAP1 (PubMed:17525747, CC PubMed:21364637). In T-cells, MAPK8 and MAPK9 are required for CC polarized differentiation of T-helper cells into Th1 cells CC (PubMed:19290929). Upon T-cell receptor (TCR) stimulation, is activated CC by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels CC (PubMed:19290929). Plays an important role in the osmotic stress- CC induced epithelial tight-junctions disruption (PubMed:20595622). When CC activated, promotes beta-catenin/CTNNB1 degradation and inhibits the CC canonical Wnt signaling pathway (PubMed:19675674). Also participates in CC neurite growth in spiral ganglion neurons (By similarity). CC Phosphorylates the CLOCK-BMAL1 heterodimer and plays a role in the CC regulation of the circadian clock (PubMed:22441692). Phosphorylates CC POU5F1, which results in the inhibition of POU5F1's transcriptional CC activity and enhances its proteasomal degradation (By similarity). CC Phosphorylates ALKBH5 in response to reactive oxygen species (ROS), CC promoting ALKBH5 sumoylation and inactivation (PubMed:34048572). CC {ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:20595622, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000303|PubMed:19290929}. CC -!- FUNCTION: MAPK9 isoforms display different binding patterns: alpha-1 CC and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind CC to ATF2. However, there is no correlation between binding and CC phosphorylation, which is achieved at about the same efficiency by all CC isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only CC weakly to it. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000269|PubMed:7969172, CC ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, CC ECO:0000269|PubMed:8654373}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:11062067}; CC -!- ACTIVITY REGULATION: Activated by threonine and tyrosine CC phosphorylation by either of two dual specificity kinases, MAP2K4 and CC MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while MAP2K7 CC phosphorylates Tyr-183 preferentially. Inhibited by dual specificity CC phosphatases, such as DUSP1. {ECO:0000269|PubMed:11062067}. CC -!- SUBUNIT: Interacts with MECOM (By similarity). Interacts with DCLK2 (By CC similarity). Binds to at least four scaffolding proteins, MAPK8IP1/JIP- CC 1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These CC proteins also bind other components of the JNK signaling pathway (By CC similarity). Interacts with NFATC4 (PubMed:17875713). Interacts with CC ATF7; the interaction does not phosphorylate ATF7 but acts as a docking CC site for ATF7-associated partners such as JUN (PubMed:10376527). CC Interacts with BCL10 (PubMed:17189706). Interacts with CTNNB1 and GSK3B CC (PubMed:19675674). Interacts with MAPKBP1 (PubMed:28089251). Interacts CC with POU5F1; phosphorylates POU5F1 at 'Ser-355'. Found in a complex CC with SH3RF1, RAC2, MAP3K7/TAK1, MAP2K7/MKK7, MAPK8IP1/JIP1 and CC MAPK8/JNK1 (By similarity). {ECO:0000250|UniProtKB:P49186, CC ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17875713, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:28089251}. CC -!- INTERACTION: CC P45984; P49407: ARRB1; NbExp=9; IntAct=EBI-713568, EBI-743313; CC P45984; P32121: ARRB2; NbExp=9; IntAct=EBI-713568, EBI-714559; CC P45984; P15336: ATF2; NbExp=9; IntAct=EBI-713568, EBI-1170906; CC P45984; P0C671: BNIP5; NbExp=4; IntAct=EBI-713568, EBI-12806802; CC P45984; O95561: C1orf105; NbExp=5; IntAct=EBI-713568, EBI-10191951; CC P45984; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-713568, EBI-946029; CC P45984; Q8N7E2: CBLL2; NbExp=3; IntAct=EBI-713568, EBI-12196065; CC P45984; Q13042: CDC16; NbExp=3; IntAct=EBI-713568, EBI-994830; CC P45984; Q9C0F1: CEP44; NbExp=9; IntAct=EBI-713568, EBI-744115; CC P45984; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-713568, EBI-10171858; CC P45984; O43602-2: DCX; NbExp=3; IntAct=EBI-713568, EBI-14148644; CC P45984; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-713568, EBI-2340258; CC P45984; Q9Y6W6: DUSP10; NbExp=5; IntAct=EBI-713568, EBI-3443946; CC P45984; Q9BY84: DUSP16; NbExp=8; IntAct=EBI-713568, EBI-3443956; CC P45984; Q13115: DUSP4; NbExp=4; IntAct=EBI-713568, EBI-6591081; CC P45984; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-713568, EBI-2349927; CC P45984; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-713568, EBI-744099; CC P45984; P14136: GFAP; NbExp=3; IntAct=EBI-713568, EBI-744302; CC P45984; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-713568, EBI-11163335; CC P45984; O15499: GSC2; NbExp=3; IntAct=EBI-713568, EBI-19954058; CC P45984; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-713568, EBI-8638439; CC P45984; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-713568, EBI-712105; CC P45984; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-713568, EBI-11959635; CC P45984; O00505: KPNA3; NbExp=3; IntAct=EBI-713568, EBI-358297; CC P45984; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-2686809; CC P45984; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-11985629; CC P45984; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-713568, EBI-12039345; CC P45984; Q8TBB1: LNX1; NbExp=7; IntAct=EBI-713568, EBI-739832; CC P45984; Q8N448: LNX2; NbExp=3; IntAct=EBI-713568, EBI-2340947; CC P45984; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-713568, EBI-1216080; CC P45984; P45985: MAP2K4; NbExp=3; IntAct=EBI-713568, EBI-447868; CC P45984; P45983: MAPK8; NbExp=5; IntAct=EBI-713568, EBI-286483; CC P45984; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-713568, EBI-348259; CC P45984; Q86YW9: MED12L; NbExp=3; IntAct=EBI-713568, EBI-3957138; CC P45984; P50221: MEOX1; NbExp=7; IntAct=EBI-713568, EBI-2864512; CC P45984; Q5VWP3-2: MLIP; NbExp=5; IntAct=EBI-713568, EBI-12320785; CC P45984; Q5HYW2: NHSL2; NbExp=5; IntAct=EBI-713568, EBI-2859639; CC P45984; Q02548: PAX5; NbExp=3; IntAct=EBI-713568, EBI-296331; CC P45984; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-713568, EBI-10302990; CC P45984; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-713568, EBI-79165; CC P45984; P78424: POU6F2; NbExp=3; IntAct=EBI-713568, EBI-12029004; CC P45984; P37231: PPARG; NbExp=3; IntAct=EBI-713568, EBI-781384; CC P45984; Q96S79: RASL10B; NbExp=4; IntAct=EBI-713568, EBI-3919507; CC P45984; Q2I0M5: RSPO4; NbExp=3; IntAct=EBI-713568, EBI-12821217; CC P45984; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-713568, EBI-3957636; CC P45984; O00560: SDCBP; NbExp=3; IntAct=EBI-713568, EBI-727004; CC P45984; Q15427: SF3B4; NbExp=7; IntAct=EBI-713568, EBI-348469; CC P45984; P34896: SHMT1; NbExp=7; IntAct=EBI-713568, EBI-715117; CC P45984; A2RU48: SMCO3; NbExp=6; IntAct=EBI-713568, EBI-10173195; CC P45984; P40763: STAT3; NbExp=2; IntAct=EBI-713568, EBI-518675; CC P45984; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-713568, EBI-3923210; CC P45984; Q8IYF3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-742397; CC P45984; Q8IYF3-3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-11523345; CC P45984; O43379: WDR62; NbExp=6; IntAct=EBI-713568, EBI-714790; CC P45984; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-713568, EBI-14104088; CC P45984; P52744: ZNF138; NbExp=3; IntAct=EBI-713568, EBI-10746567; CC P45984; Q9BR84: ZNF559; NbExp=3; IntAct=EBI-713568, EBI-746605; CC P45984; O43257: ZNHIT1; NbExp=3; IntAct=EBI-713568, EBI-347522; CC P45984-1; P40763: STAT3; NbExp=3; IntAct=EBI-713586, EBI-518675; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19675674}. Nucleus CC {ECO:0000269|PubMed:19675674}. Note=Colocalizes with POU5F1 in the CC nucleus. {ECO:0000250|UniProtKB:Q9WTU6}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=Alpha-2; CC IsoId=P45984-1; Sequence=Displayed; CC Name=Alpha-1; CC IsoId=P45984-2; Sequence=VSP_004835; CC Name=Beta-1; CC IsoId=P45984-3; Sequence=VSP_004834, VSP_004835; CC Name=Beta-2; CC IsoId=P45984-4; Sequence=VSP_004834; CC Name=5; CC IsoId=P45984-5; Sequence=VSP_041908, VSP_041909; CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4, CC which activates the enzyme. Autophosphorylated in vitro. CC {ECO:0000269|PubMed:11062067}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/426/JNK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L31951; AAA56831.1; -; mRNA. DR EMBL; U09759; AAA74740.1; -; mRNA. DR EMBL; U34821; AAC50606.1; -; mRNA. DR EMBL; U35002; AAC50608.1; -; mRNA. DR EMBL; U35003; AAC50609.1; -; mRNA. DR EMBL; EU927388; ACH57450.1; -; mRNA. DR EMBL; CR536580; CAG38817.1; -; mRNA. DR EMBL; AK289638; BAF82327.1; -; mRNA. DR EMBL; DQ066599; AAY46156.1; -; Genomic_DNA. DR EMBL; AB451302; BAG70116.1; -; mRNA. DR EMBL; AB451355; BAG70169.1; -; mRNA. DR EMBL; AC008610; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104115; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471165; EAW53759.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53757.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53758.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53762.1; -; Genomic_DNA. DR EMBL; BC032539; AAH32539.1; -; mRNA. DR CCDS; CCDS43409.1; -. [P45984-2] DR CCDS; CCDS43410.1; -. [P45984-3] DR CCDS; CCDS4453.1; -. [P45984-1] DR CCDS; CCDS4454.1; -. [P45984-4] DR CCDS; CCDS47356.1; -. [P45984-5] DR PIR; A55480; A55480. DR PIR; S71102; S71102. DR RefSeq; NP_001128516.1; NM_001135044.2. [P45984-5] DR RefSeq; NP_001295173.1; NM_001308244.1. DR RefSeq; NP_001351536.1; NM_001364607.2. [P45984-2] DR RefSeq; NP_001351537.1; NM_001364608.2. [P45984-1] DR RefSeq; NP_001351538.1; NM_001364609.2. [P45984-4] DR RefSeq; NP_001351539.1; NM_001364610.2. [P45984-5] DR RefSeq; NP_002743.3; NM_002752.4. [P45984-1] DR RefSeq; NP_620707.1; NM_139068.3. [P45984-2] DR RefSeq; NP_620708.1; NM_139069.3. [P45984-3] DR RefSeq; NP_620709.1; NM_139070.3. [P45984-4] DR PDB; 3E7O; X-ray; 2.14 A; A/B=7-362. DR PDB; 3NPC; X-ray; 2.35 A; A/B=1-364. DR PDB; 7CML; X-ray; 2.15 A; A/B=1-364. DR PDB; 7N8T; X-ray; 1.69 A; A=10-364. DR PDB; 8ELC; X-ray; 2.07 A; A=1-424. DR PDBsum; 3E7O; -. DR PDBsum; 3NPC; -. DR PDBsum; 7CML; -. DR PDBsum; 7N8T; -. DR PDBsum; 8ELC; -. DR AlphaFoldDB; P45984; -. DR SMR; P45984; -. DR BioGRID; 111587; 180. DR DIP; DIP-270N; -. DR ELM; P45984; -. DR FunCoup; P45984; 5816. DR IntAct; P45984; 118. DR MINT; P45984; -. DR STRING; 9606.ENSP00000394560; -. DR BindingDB; P45984; -. DR ChEMBL; CHEMBL4179; -. DR DrugBank; DB12432; CC-401. DR DrugBank; DB05660; D-JNKI-1. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15624; Halicin. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB07020; N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide. DR DrugBank; DB16995; NP-51. DR DrugBank; DB01782; Pyrazolanthrone. DR DrugBank; DB11798; Tanzisertib. DR DrugCentral; P45984; -. DR GuidetoPHARMACOLOGY; 1497; -. DR GlyConnect; 1515; 1 N-Linked glycan (1 site). DR GlyCosmos; P45984; 1 site, 1 glycan. DR GlyGen; P45984; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P45984; -. DR MetOSite; P45984; -. DR PhosphoSitePlus; P45984; -. DR BioMuta; MAPK9; -. DR DMDM; 85700366; -. DR REPRODUCTION-2DPAGE; P45984; -. DR CPTAC; CPTAC-3146; -. DR CPTAC; CPTAC-893; -. DR CPTAC; CPTAC-894; -. DR jPOST; P45984; -. DR MassIVE; P45984; -. DR PaxDb; 9606-ENSP00000394560; -. DR PeptideAtlas; P45984; -. DR ProteomicsDB; 55698; -. [P45984-1] DR ProteomicsDB; 55699; -. [P45984-2] DR ProteomicsDB; 55700; -. [P45984-3] DR ProteomicsDB; 55701; -. [P45984-4] DR ProteomicsDB; 55702; -. [P45984-5] DR Pumba; P45984; -. DR Antibodypedia; 4557; 913 antibodies from 47 providers. DR DNASU; 5601; -. DR Ensembl; ENST00000343111.10; ENSP00000345524.6; ENSG00000050748.19. [P45984-3] DR Ensembl; ENST00000393360.7; ENSP00000377028.3; ENSG00000050748.19. [P45984-2] DR Ensembl; ENST00000425491.6; ENSP00000397422.2; ENSG00000050748.19. [P45984-5] DR Ensembl; ENST00000452135.7; ENSP00000394560.2; ENSG00000050748.19. [P45984-1] DR Ensembl; ENST00000455781.5; ENSP00000389338.1; ENSG00000050748.19. [P45984-4] DR GeneID; 5601; -. DR KEGG; hsa:5601; -. DR MANE-Select; ENST00000452135.7; ENSP00000394560.2; NM_002752.5; NP_002743.3. DR UCSC; uc003mls.5; human. [P45984-1] DR AGR; HGNC:6886; -. DR ClinPGx; PA30630; -. DR CTD; 5601; -. DR DisGeNET; 5601; -. DR GeneCards; MAPK9; -. DR HGNC; HGNC:6886; MAPK9. DR HPA; ENSG00000050748; Low tissue specificity. DR MIM; 602896; gene. DR OpenTargets; ENSG00000050748; -. DR VEuPathDB; HostDB:ENSG00000050748; -. DR eggNOG; KOG0665; Eukaryota. DR GeneTree; ENSGT00940000158327; -. DR HOGENOM; CLU_000288_181_1_1; -. DR InParanoid; P45984; -. DR OMA; GCRNILR; -. DR OrthoDB; 192887at2759; -. DR PAN-GO; P45984; 4 GO annotations based on evolutionary models. DR PhylomeDB; P45984; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; P45984; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR SignaLink; P45984; -. DR SIGNOR; P45984; -. DR Agora; ENSG00000050748; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5601; 8 hits in 1191 CRISPR screens. DR ChiTaRS; MAPK9; human. DR EvolutionaryTrace; P45984; -. DR GeneWiki; Mitogen-activated_protein_kinase_9; -. DR GenomeRNAi; 5601; -. DR Pharos; P45984; Tchem. DR PRO; PR:P45984; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P45984; protein. DR Bgee; ENSG00000050748; Expressed in middle temporal gyrus and 214 other cell types or tissues. DR ExpressionAtlas; P45984; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0090594; P:inflammatory response to wounding; IDA:UniProt. DR GO; GO:0007254; P:JNK cascade; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IDA:UniProt. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL. DR GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl. DR GO; GO:0061833; P:protein localization to tricellular tight junction; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR CDD; cd07850; STKc_JNK; 1. DR FunFam; 1.10.510.10:FF:000009; Mitogen-activated protein kinase; 1. DR FunFam; 3.30.200.20:FF:000210; Mitogen-activated protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR008351; MAPK_JNK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01772; JNKMAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Biological rhythms; KW Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..424 FT /note="Mitogen-activated protein kinase 9" FT /id="PRO_0000186273" FT DOMAIN 26..321 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 368..424 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 183..185 FT /note="TXY" FT COMPBIAS 388..417 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 151 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 32..40 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 55 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 183 FT /note="Phosphothreonine; by MAP2K7" FT /evidence="ECO:0000269|PubMed:11062067" FT MOD_RES 185 FT /note="Phosphotyrosine; by MAP2K4" FT /evidence="ECO:0000269|PubMed:11062067" FT VAR_SEQ 216..230 FT /note="GELVKGCVIFQGTDH -> AEMVLHKVLFPGRDY (in isoform Beta- FT 1 and isoform Beta-2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_004834" FT VAR_SEQ 230..242 FT /note="HIDQWNKVIEQLG -> RILPRDLGPAMLS (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041908" FT VAR_SEQ 243..424 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041909" FT VAR_SEQ 378..424 FT /note="DAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR -> A FT QMQQ (in isoform Alpha-1 and isoform Beta-1)" FT /evidence="ECO:0000305" FT /id="VSP_004835" FT VARIANT 13 FT /note="V -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1762231480)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042260" FT VARIANT 56 FT /note="K -> N (in a head & Neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042261" FT VARIANT 246 FT /note="A -> T (in dbSNP:rs35421153)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042262" FT VARIANT 268 FT /note="G -> A (in dbSNP:rs35693958)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_025175" FT VARIANT 366 FT /note="R -> I (in dbSNP:rs55736180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042263" FT CONFLICT 51 FT /note="N -> S (in Ref. 1; AAA56831 and 3; AAC50606/ FT AAC50608/AAC50609)" FT /evidence="ECO:0000305" FT CONFLICT 377 FT /note="S -> P (in Ref. 2; AAA74740)" FT /evidence="ECO:0000305" FT TURN 6..8 FT /evidence="ECO:0007829|PDB:7CML" FT STRAND 11..23 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 38..45 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 46..49 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 50..59 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 60..62 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 64..79 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 88..92 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 125..144 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:3NPC" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 189..191 FT /evidence="ECO:0007829|PDB:7CML" FT HELIX 194..197 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 206..220 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 230..241 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 246..250 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 254..262 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 271..274 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 285..301 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 306..308 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 312..316 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 319..322 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 327..330 FT /evidence="ECO:0007829|PDB:8ELC" FT STRAND 342..344 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 349..361 FT /evidence="ECO:0007829|PDB:7N8T" SQ SEQUENCE 424 AA; 48139 MW; 9C15DA79981290AF CRC64; MSDSKCDSQF YSVQVADSTF TVLKRYQQLK PIGSGAQGIV CAAFDTVLGI NVAVKKLSRP FQNQTHAKRA YRELVLLKCV NHKNIISLLN VFTPQKTLEE FQDVYLVMEL MDANLCQVIH MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTACTNF MMTPYVVTRY YRAPEVILGM GYKENVDIWS VGCIMGELVK GCVIFQGTDH IDQWNKVIEQ LGTPSAEFMK KLQPTVRNYV ENRPKYPGIK FEELFPDWIF PSESERDKIK TSQARDLLSK MLVIDPDKRI SVDEALRHPY ITVWYDPAEA EAPPPQIYDA QLEEREHAIE EWKELIYKEV MDWEERSKNG VVKDQPSDAA VSSNATPSQS SSINDISSMS TEQTLASDTD SSLDASTGPL EGCR // ID MLH1_HUMAN Reviewed; 756 AA. AC P40692; B4DI13; B4DQ11; E9PCU2; DT 01-FEB-1995, integrated into UniProtKB/Swiss-Prot. DT 01-FEB-1995, sequence version 1. DT 28-JAN-2026, entry version 252. DE RecName: Full=DNA mismatch repair protein Mlh1; DE AltName: Full=MutL protein homolog 1; GN Name=MLH1; Synonyms=COCA2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8145827; DOI=10.1038/368258a0; RA Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., RA Lescoe M.K., Kane M.F., Earibino C., Lipford J., Lindblom A., RA Tannergaard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjoeld M., RA Fishel R., Kolodner R.D., Liskay R.M.; RT "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated RT with hereditary non-polyposis colon cancer."; RL Nature 368:258-261(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Gall bladder; RX PubMed=8128251; DOI=10.1126/science.8128251; RA Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., RA Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., RA Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., RA Peltomaeki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., RA Vogelstein B.; RT "Mutation of a mutL homolog in hereditary colon cancer."; RL Science 263:1625-1629(1994). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=7812952; RA Kolodner R.D., Hall N.R., Lipford J.R., Kane M.F., Morrison P., Finan P.J., RA Burn J., Chapman P., Earabino C., Merchant E., Bishop D.T.; RT "Structure of the human MLH1 locus and analysis of a large hereditary RT nonpolyposis colorectal carcinoma kindred for mlh1 mutations."; RL Cancer Res. 55:242-248(1995). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYNCH2 LEU-542; PRO-574; RP VAL-582 AND THR-618. RX PubMed=7757073; DOI=10.1093/hmg/4.2.237; RA Han H.-J., Maruyama M., Baba S., Park J.-G., Nakamura Y.; RT "Genomic structure of human mismatch repair gene, hMLH1, and its mutation RT analysis in patients with hereditary non-polyposis colorectal cancer RT (HNPCC)."; RL Hum. Mol. Genet. 4:237-242(1995). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-32; MET-213 AND RP VAL-219. RG NIEHS SNPs program; RL Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3). RC TISSUE=Brain, Corpus callosum, Kidney, and Substantia nigra; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [10] RP IDENTIFICATION OF MLH1 AS MEMBER OF BASC. RX PubMed=10783165; RA Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.; RT "BASC, a super complex of BRCA1-associated proteins involved in the RT recognition and repair of aberrant DNA structures."; RL Genes Dev. 14:927-939(2000). RN [11] RP INTERACTION WITH MBD4. RX PubMed=10097147; DOI=10.1073/pnas.96.7.3969; RA Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., RA Matsumoto Y., Golemis E.A., Genuardi M., Neri G.; RT "MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA RT mismatch repair protein MLH1."; RL Proc. Natl. Acad. Sci. U.S.A. 96:3969-3974(1999). RN [12] RP INTERACTION WITH EXO1 AND PMS2, CHARACTERIZATION OF VARIANTS LYNCH2 RP PRO-574; LYS-616 DEL; LEU-659 AND THR-681, AND CHARACTERIZATION OF VARIANT RP MMRCS1 LYS-616 DEL. RX PubMed=11427529; DOI=10.1074/jbc.m102670200; RA Schmutte C., Sadoff M.M., Shim K.-S., Acharya S., Fishel R.; RT "The interaction of DNA mismatch repair proteins with human exonuclease RT I."; RL J. Biol. Chem. 276:33011-33018(2001). RN [13] RP INTERACTION WITH EXO1, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF RP VARIANT MET-117. RX PubMed=11429708; DOI=10.1038/sj.onc.1204467; RA Jaeger A.C., Rasmussen M., Bisgaard H.C., Singh K.K., Nielsen F.C., RA Rasmussen L.J.; RT "HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence RT assembly of hMutLalpha and hMLH1-hEXO1 complexes."; RL Oncogene 20:3590-3595(2001). RN [14] RP INTERACTION WITH EXO1. RX PubMed=12414623; RA Sun X., Zheng L., Shen B.; RT "Functional alterations of human exonuclease 1 mutants identified in RT atypical hereditary nonpolyposis colorectal cancer syndrome."; RL Cancer Res. 62:6026-6030(2002). RN [15] RP INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=14676842; DOI=10.1038/sj.onc.1207265; RA Nielsen F.C., Jaeger A.C., Luetzen A., Bundgaard J.R., Rasmussen L.J.; RT "Characterization of human exonuclease 1 in complex with mismatch repair RT proteins, subcellular localization and association with PCNA."; RL Oncogene 23:1457-1468(2004). RN [16] RP INVOLVEMENT IN MRTES. RX PubMed=8751876; RA Bapat B., Xia L., Madlensky L., Mitri A., Tonin P., Narod S.A., RA Gallinger S.; RT "The genetic basis of Muir-Torre syndrome includes the hMLH1 locus."; RL Am. J. Hum. Genet. 59:736-739(1996). RN [17] RP FUNCTION. RX PubMed=16873062; DOI=10.1016/j.cell.2006.05.039; RA Kadyrov F.A., Dzantiev L., Constantin N., Modrich P.; RT "Endonucleolytic function of MutLalpha in human mismatch repair."; RL Cell 126:297-308(2006). RN [18] RP FUNCTION. RX PubMed=18206974; DOI=10.1016/j.molcel.2007.10.030; RA Sacho E.J., Kadyrov F.A., Modrich P., Kunkel T.A., Erie D.A.; RT "Direct visualization of asymmetric adenine nucleotide-induced RT conformational changes in MutL alpha."; RL Mol. Cell 29:112-121(2008). RN [19] RP REVIEW. RX PubMed=16188885; DOI=10.1074/jbc.m509701200; RA Constantin N., Dzantiev L., Kadyrov F.A., Modrich P.; RT "Human mismatch repair: reconstitution of a nick-directed bidirectional RT reaction."; RL J. Biol. Chem. 280:39752-39761(2005). RN [20] RP REVIEW. RX PubMed=16873053; DOI=10.1016/j.cell.2006.07.003; RA Jiricny J.; RT "MutLalpha: at the cutting edge of mismatch repair."; RL Cell 126:239-241(2006). RN [21] RP REVIEW. RX PubMed=18157157; DOI=10.1038/cr.2007.115; RA Li G.M.; RT "Mechanisms and functions of DNA mismatch repair."; RL Cell Res. 18:85-98(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [24] RP INTERACTION WITH MTMR15. RX PubMed=20603073; DOI=10.1016/j.molcel.2010.06.023; RA Smogorzewska A., Desetty R., Saito T.T., Schlabach M., Lach F.P., RA Sowa M.E., Clark A.B., Kunkel T.A., Harper J.W., Colaiacovo M.P., RA Elledge S.J.; RT "A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease RT necessary for DNA interstrand crosslink repair."; RL Mol. Cell 39:36-47(2010). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [27] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22223895; DOI=10.1074/mcp.m111.015131; RA Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T., RA Giglione C.; RT "Comparative large-scale characterisation of plant vs. mammal proteins RT reveals similar and idiosyncratic N-alpha acetylation features."; RL Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-477, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP IDENTIFICATION IN THE MMR COMPLEX, INTERACTION WITH MCM9 AND MCM8, AND RP SUBCELLULAR LOCATION. RX PubMed=26300262; DOI=10.1016/j.molcel.2015.07.010; RA Traver S., Coulombe P., Peiffer I., Hutchins J.R., Kitzmann M., RA Latreille D., Mechali M.; RT "MCM9 Is Required for Mammalian DNA Mismatch Repair."; RL Mol. Cell 59:831-839(2015). RN [31] RP SUBCELLULAR LOCATION, ACETYLATION AT LYS-33; LYS-241; LYS-361 AND LYS-377, RP DEACETYLATION BY HDAC6, AND MUTAGENESIS OF LYS-33; LYS-241; LYS-361 AND RP LYS-377. RX PubMed=30770470; DOI=10.1074/jbc.ra118.006374; RA Zhang M., Hu C., Moses N., Haakenson J., Xiang S., Quan D., Fang B., RA Yang Z., Bai W., Bepler G., Li G.M., Zhang X.M.; RT "HDAC6 regulates DNA damage response via deacetylating MLH1."; RL J. Biol. Chem. 294:5813-5826(2019). RN [32] RP FUNCTION, UBIQUITINATION BY UBR4, DEUBIQUITINATION BY USP5, INTERACTION RP WITH PSM2, AND CHARACTERIZATION OF VARIANT LEU-574 AND ALA-589. RX PubMed=39032648; DOI=10.1016/j.jbc.2024.107592; RA Mao C., Li S., Che J., Liu D., Mao X., Rao H.; RT "The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the RT stability of DNA mismatch repair protein MLH1."; RL J. Biol. Chem. 300:107592-107592(2024). RN [33] RP X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 486-751. RA Dombrovsky L., Dong A., Wernimont A., Loppnau P., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Min J., Wu H.; RT "Crystal structure of MutL protein homolog 1 isoform 1."; RL Submitted (MAR-2011) to the PDB data bank. RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 3-196 IN COMPLEX WITH ADP AND RP MAGNESIUM IONS. RX PubMed=26249686; DOI=10.1107/s2053230x15010183; RA Wu H., Zeng H., Lam R., Tempel W., Kerr I.D., Min J.; RT "Structure of the human MLH1 N-terminus: implications for predisposition to RT Lynch syndrome."; RL Acta Crystallogr. F 71:981-985(2015). RN [35] {ECO:0007744|PDB:5U5P} RP X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 467-476, NUCLEAR LOCALIZATION RP SIGNAL, AND MUTAGENESIS OF LYS-471 AND ARG-472. RX PubMed=29175432; DOI=10.1016/j.biochi.2017.11.013; RA de Barros A.C., Takeda A.A.S., Dreyer T.R., Velazquez-Campoy A., Kobe B., RA Fontes M.R.M.; RT "DNA mismatch repair proteins MLH1 and PMS2 can be imported to the nucleus RT by a classical nuclear import pathway."; RL Biochimie 146:87-96(2018). RN [36] RP CHARACTERIZATION OF VARIANTS LYNCH2 CYS-31; LYS-37; HIS-38; LYS-38; PHE-44; RP ARG-67; PRO-109; PRO-111; MET-117; CYS-265; SER-265; GLN-443; PRO-550; RP GLY-578; PHE-582; ASP-589; ALA-618; CYS-646; LEU-648; LEU-654 AND PRO-659, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP AND FUNCTION. RX PubMed=20020535; DOI=10.1002/humu.21180; RA Drost M., Zonneveld J.B., van Dijk L., Morreau H., Tops C.M., Vasen H.F., RA Wijnen J.T., de Wind N.; RT "A cell-free assay for the functional analysis of variants of the mismatch RT repair protein MLH1."; RL Hum. Mutat. 31:247-253(2010). RN [37] RP CHARACTERIZATION OF VARIANTS LYNCH2 LEU-28; SER-29; 45-THR--ILE-47 DELINS RP CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; RP ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; GLN-443; ALA-460; PRO-550; RP 578-GLU--GLU-632 DEL; ASP-589; VAL-612 DEL; LYS-616 DEL; ALA-618; THR-618; RP 633-GLU--GLU-663 DEL; CYS-646; LEU-648; SER-648; LEU-654; GLN-659; PRO-659; RP THR-681 AND TRP-687, CHARACTERIZATION OF VARIANTS GLY-93; MET-213; VAL-219 RP AND MET-716, SUBCELLULAR LOCATION, AND FUNCTION. RX PubMed=21120944; DOI=10.1002/humu.21409; RA Kansikas M., Kariola R., Nystroem M.; RT "Verification of the three-step model in assessing the pathogenicity of RT mismatch repair gene variants."; RL Hum. Mutat. 32:107-115(2011). RN [38] RP VARIANT LYNCH2 ARG-35. RX PubMed=8521398; RA Tannergaard P., Lipford J.R., Kolodner R., Froedin J.E., Nordenskjoeld M., RA Lindblom A.; RT "Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis RT colon cancer families."; RL Cancer Res. 55:6092-6096(1995). RN [39] RP VARIANT MMRCS1 LYS-616 DEL. RX PubMed=7661930; DOI=10.1056/nejm199503303321302; RA Hamilton S.R., Liu B., Parsons R.E., Papadopoulos N., Jen J., Powell S.M., RA Krush A.J., Berk T., Cohen Z., Tetu B., Burger P.C., Wood P.A., Taqi F., RA Booker S.V., Petersen G.M., Offerhaus G.J.A., Tersmette A.C., RA Giardiello F.M., Vogelstein B., Kinzler K.W.; RT "The molecular basis of Turcot's syndrome."; RL N. Engl. J. Med. 332:839-847(1995). RN [40] RP VARIANT LYNCH2 LYS-616 DEL. RX PubMed=8571956; RA Wijnen J., Khan P.M., Vasen H., Menko F., van der Klift H., RA van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., RA Meijers-Heijboer E.J., Lindhout D., Griffioen G., Cats A., Kleibeuker J., RA Varesco L., Bertario L., Bisgaard M.-L., Mohr J., Kolodner R.D., Fodde R.; RT "Majority of hMLH1 mutations responsible for hereditary nonpolyposis RT colorectal cancer cluster at the exonic region 15-16."; RL Am. J. Hum. Genet. 58:300-307(1996). RN [41] RP VARIANTS LYNCH2 MET-117 AND LEU-226. RX PubMed=8566964; DOI=10.1007/bf02265276; RA Maliaka Y.K., Chudina A.P., Belev N.F., Alday P., Bochkov N.P., RA Buerstedde J.-M.; RT "CpG dinucleotides in the hMSH2 and hMLH1 genes are hotspots for HNPCC RT mutations."; RL Hum. Genet. 97:251-255(1996). RN [42] RP VARIANTS LYNCH2 LYS-616 DEL AND THR-618, AND VARIANT CRC THR-492. RX PubMed=8872463; DOI=10.1093/hmg/5.9.1245; RA Moslein G., Tester D.J., Lindor N.M., Honchel R., Cunningham J.M., RA French A.J., Halling K.C., Schwab M., Goretzki P., Thibodeau S.N.; RT "Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in RT patients with sporadic, familial and hereditary colorectal cancer."; RL Hum. Mol. Genet. 5:1245-1252(1996). RN [43] RP VARIANTS LYNCH2 CYS-217; LEU-542; PRO-549 AND PRO-574. RX PubMed=8797773; DOI=10.1093/jnci/88.18.1317; RA Han H.-J., Yuan Y., Ku J.-L., Oh J.-H., Won Y.-J., Kang K.J., Kim K.Y., RA Kim S., Kim C.Y., Kim J.-P., Oh N.-G., Lee K.H., Choe K.J., Nakamura Y., RA Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in Korean hereditary RT nonpolyposis colorectal cancer."; RL J. Natl. Cancer Inst. 88:1317-1319(1996). RN [44] RP VARIANTS LEU-ASN-HIS-37 INS AND ASP-384. RX PubMed=8609062; DOI=10.1111/j.1349-7006.1996.tb03151.x; RA Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., RA Nakamura Y.; RT "Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic RT endometrial carcinomas with microsatellite instability."; RL Jpn. J. Cancer Res. 87:141-145(1996). RN [45] RP VARIANT LYNCH2 ALA-506. RX PubMed=8574961; DOI=10.1038/nm0296-169; RA Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., RA Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaeki P., RA de la Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W.; RT "Analysis of mismatch repair genes in hereditary non-polyposis colorectal RT cancer patients."; RL Nat. Med. 2:169-174(1996). RN [46] RP VARIANTS LYNCH2 LYS-62; SER-64; LYS-616 DEL; ALA-618 AND PRO-659, RP CHARACTERIZATION OF VARIANT LYNCH2 LYS-62, AND FUNCTION. RX PubMed=9311737; DOI=10.1086/514847; RA Wijnen J., Khan P.M., Vasen H., van der Klift H., Mulder A., RA van Leeuwen-Cornelisse I., Bakker B., Losekoot M., Moeller P., Fodde R.; RT "Hereditary nonpolyposis colorectal cancer families not complying with the RT Amsterdam criteria show extremely low frequency of mismatch-repair-gene RT mutations."; RL Am. J. Hum. Genet. 61:329-335(1997). RN [47] RP VARIANT LYNCH2 LYS-616 DEL, AND VARIANT HIS-265. RX PubMed=8993976; RX DOI=10.1002/(sici)1098-2264(199701)18:1<8::aid-gcc2>3.0.co;2-7; RA Viel A., Genuardi M., Capozzi E., Leonardi F., Bellacosa A., RA Paravatou-Petsotas M., Pomponi M.G., Fornasarig M., Percesepe A., RA Roncucci L., Tamassia M.G., Benatti P., Ponz de Leon M., Valenti A., RA Covino M., Anti M., Foletto M., Boiocchi M., Neri G.; RT "Characterization of MSH2 and MLH1 mutations in Italian families with RT hereditary nonpolyposis colorectal cancer."; RL Genes Chromosomes Cancer 18:8-18(1997). RN [48] RP VARIANTS CRC GLU-54 AND VAL-244, AND VARIANTS VAL-219; GLN-325 AND ASN-406. RX PubMed=9087566; RX DOI=10.1002/(sici)1098-2264(199704)18:4<269::aid-gcc4>3.3.co;2-9; RA Wu Y., Nystroem-Lahti M., Osinga J., Looman M.W.G., Peltomaeki P., RA Aaltonen L.A., de la Chapelle A., Hofstra R.M.W., Buys C.H.C.M.; RT "MSH2 and MLH1 mutations in sporadic replication error-positive colorectal RT carcinoma as assessed by two-dimensional DNA electrophoresis."; RL Genes Chromosomes Cancer 18:269-278(1997). RN [49] RP VARIANTS LYNCH2 PRO-128 AND ASP-244, AND VARIANT VAL-219. RX PubMed=9218993; RX DOI=10.1002/(sici)1098-2264(199707)19:3<135::aid-gcc1>3.3.co;2-x; RA Pensotti V., Radice P., Presciuttini S., Calistri D., Gazzoli I., RA Grimalt Perez A.P., Mondini P., Buonsanti G., Sala P., Rossetti C., RA Ranzani G.N., Bertario L., Pierotti M.A.; RT "Mean age of tumor onset in hereditary nonpolyposis colorectal cancer RT (HNPCC) families correlates with the presence of mutations in DNA mismatch RT repair genes."; RL Genes Chromosomes Cancer 19:135-142(1997). RN [50] RP VARIANT LYNCH2 626-PHE-SER-627 DELINS SER-THR. RX PubMed=9048925; DOI=10.1007/s004390050343; RA Beck N.E., Tomlinson I.P.M., Homfray T., Frayling I., Hodgson S.V., RA Harocopos C.J., Bodmer W.F.; RT "Use of SSCP analysis to identify germline mutations in HNPCC families RT fulfilling the Amsterdam criteria."; RL Hum. Genet. 99:219-224(1997). RN [51] RP VARIANT LYNCH2 PRO-329. RX PubMed=9272156; DOI=10.1007/s004390050517; RA Wang Y., Friedl W., Lamberti C., Ruelfs C., Kruse R., Propping P.; RT "Hereditary nonpolyposis colorectal cancer: causative role of a germline RT missense mutation in the hMLH1 gene confirmed by the independent occurrence RT of the same somatic mutation in tumour tissue."; RL Hum. Genet. 100:362-364(1997). RN [52] RP VARIANT LYNCH2 ARG-67, AND VARIANT VAL-219. RX PubMed=9067757; RX DOI=10.1002/(sici)1098-1004(1997)9:2<164::aid-humu9>3.0.co;2-9; RA Sasaki S., Tokino T., Miyatsu T., Muto T., Nakamura Y.; RT "Mutational analysis of the hMLH1 gene using an automated two-dimensional RT DNA typing system."; RL Hum. Mutat. 9:164-171(1997). RN [53] RP REVIEW ON VARIANTS. RX PubMed=9259192; RX DOI=10.1002/(sici)1098-1004(1997)10:2<89::aid-humu1>3.0.co;2-h; RA Papadopoulos N., Lindblom A.; RT "Molecular basis of HNPCC: mutations of MMR genes."; RL Hum. Mutat. 10:89-99(1997). RN [54] RP VARIANT LYNCH2 LEU-28. RX PubMed=9298827; RX DOI=10.1002/(sici)1098-1004(1997)10:3<241::aid-humu12>3.0.co;2-#; RA Wehner M., Buschhausen L., Lamberti C., Kruse R., Caspari R., Propping P., RA Friedl W.; RT "Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline RT mutations in hMSH2 or hMLH1 genes."; RL Hum. Mutat. 10:241-244(1997). RN [55] RP VARIANTS LYNCH2 GLY-182; THR-295 AND THR-551. RX PubMed=9399661; RX DOI=10.1002/(sici)1097-0215(19971210)73:6<831::aid-ijc11>3.0.co;2-7; RA Wang Q., Desseigne F., Lasset C., Saurin J.-C., Navarro C., Yagci T., RA Keser I., Bagci H., Luleci G., Gelen T., Chayvialle J.-A., Puisieux A., RA Ozturk M.; RT "Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families."; RL Int. J. Cancer 73:831-836(1997). RN [56] RP VARIANT CRC TYR-77, AND VARIANT VAL-219. RX PubMed=9032648; DOI=10.1136/jmg.34.1.39; RA Tomlinson I.P.M., Beck N.E., Homfray T., Harocopos C.J., Bodmer W.F.; RT "Germline HNPCC gene variants have little influence on the risk for RT sporadic colorectal cancer."; RL J. Med. Genet. 34:39-42(1997). RN [57] RP VARIANTS LYNCH2 PHE-44 AND THR-441. RX PubMed=9326924; DOI=10.1038/ng1097-135; RA Hackman P., Tannergaerd P., Osei-Mensa S., Chen J., Kane M.F., RA Kolodner R.D., Lambert B., Hellgren D., Lindblom A.; RT "A human compound heterozygote for two MLH1 missense mutations."; RL Nat. Genet. 17:135-136(1997). RN [58] RP VARIANTS LYNCH2, AND VARIANTS. RX PubMed=9718327; DOI=10.1086/301996; RA Farrington S.M., Lin-Goerke J., Ling J., Wang Y., Burczak J.D., RA Robbins D.J., Dunlop M.G.; RT "Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and RT controls."; RL Am. J. Hum. Genet. 63:749-759(1998). RN [59] RP VARIANT CRC GLY-268. RX PubMed=9611074; DOI=10.1111/j.1399-0004.1998.tb02660.x; RA Liu T., Wahlberg S., Rubio C., Holmberg E., Groenberg H., Lindblom A.; RT "DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in RT 34 Swedish families with colorectal cancer."; RL Clin. Genet. 53:131-135(1998). RN [60] RP VARIANT LYNCH2 CYS-217. RX PubMed=9559627; DOI=10.1007/bf02235756; RA Yuan Y., Han H.-J., Zheng S., Park J.-G.; RT "Germline mutations of hMLH1 and hMSH2 genes in patients with suspected RT hereditary nonpolyposis colorectal cancer and sporadic early-onset RT colorectal cancer."; RL Dis. Colon Rectum 41:434-440(1998). RN [61] RP VARIANT ASP-384, AND ASSOCIATION WITH HNPCC. RX PubMed=9526167; DOI=10.1159/000022786; RA Wang Y., Friedl W., Lamberti C., Noethen M.M., Kruse R., Propping P.; RT "A novel missense mutation in the DNA mismatch repair gene hMLH1 present RT among East Asians but not among Europeans."; RL Hum. Hered. 48:87-91(1998). RN [62] RP VARIANT LYNCH2 LYS-69. RX PubMed=10627141; RX DOI=10.1002/(sici)1098-1004(1998)12:1<73::aid-humu20>3.0.co;2-f; RA Herfarth K.K.-F., Ogunbiyi O.A., Moley J.F., Kodner I.J., Wells S.A. Jr., RA Goodfellow P.J.; RT "Four new mutations in the DNA mismatch repair gene MLH1 in colorectal RT cancers with microsatellite instability."; RL Hum. Mutat. 12:73-73(1998). RN [63] RP VARIANTS LYNCH2 ARG-77 AND PRO-193. RX PubMed=10660333; RA Panariello L., Scarano M.I., de Rosa M., Capasso L., Renda A., Riegler G., RA Rossi G.B., Salvatore F., Izzo P.; RT "hMLH1 mutations in hereditary nonpolyposis colorectal cancer kindreds."; RL Hum. Mutat. 12:216-217(1998). RN [64] RP VARIANT GLY-93. RX PubMed=10671064; RX DOI=10.1002/(sici)1098-1004(1998)12:6<433::aid-humu13>3.0.co;2-j; RA Quaresima B., Grandinetti C., Baudi F., Tassone P., Barbieri V., RA Conforti S., Avvedimento E.V., Costanzo F., Venuta S.; RT "Hereditary nonpolyposis colorectal cancer: identification of novel RT germline mutations in two kindreds not fulfilling the Amsterdam criteria."; RL Hum. Mutat. 12:433-433(1998). RN [65] RP VARIANTS LYNCH2 ARG-67; ILE-262 DEL; THR-551 AND PHE-565, AND VARIANTS RP VAL-219 AND MET-716. RX PubMed=9833759; RX DOI=10.1002/(sici)1097-0215(19981209)78:6<680::aid-ijc3>3.0.co;2-u; RA Hutter P., Couturier A., Membrez V., Joris F., Sappino A.-P., RA Chappuis P.O.; RT "Excess of hMLH1 germline mutations in Swiss families with hereditary non- RT polyposis colorectal cancer."; RL Int. J. Cancer 78:680-684(1998). RN [66] RP VARIANTS LYNCH2 ARG-67; ARG-117 AND GLU-485, AND VARIANT VAL-219. RX PubMed=10375096; RX DOI=10.1002/(sici)1097-0142(19990615)85:12<2512::aid-cncr4>3.0.co;2-g; RA Heinimann K., Scott R.J., Buerstedde J.-M., Weber W., Siebold K., RA Attenhofer M., Mueller H., Dobbie Z.; RT "Influence of selection criteria on mutation detection in patients with RT hereditary nonpolyposis colorectal cancer."; RL Cancer 85:2512-2518(1999). RN [67] RP VARIANT LYNCH2 TRP-67. RX PubMed=9927034; RA Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., RA Ruano E., Puisieux A.; RT "Neurofibromatosis and early onset of cancers in hMLH1-deficient RT children."; RL Cancer Res. 59:294-297(1999). RN [68] RP VARIANTS HIS-265; ALA-326; PRO-385; ASN-406; THR-618 AND MET-716. RX PubMed=10573010; DOI=10.1038/sj.ejhg.5200363; RA Genuardi M., Carrara S., Anti M., Ponz de Leon M., Viel A.; RT "Assessment of pathogenicity criteria for constitutional missense mutations RT of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2."; RL Eur. J. Hum. Genet. 7:778-782(1999). RN [69] RP VARIANTS LYNCH2 LEU-28; GLU-84 AND PRO-329. RX PubMed=10323887; DOI=10.1136/gut.44.6.839; RA Lamberti C., Kruse R., Ruelfs C., Caspari R., Wang Y., Jungck M., RA Mathiak M., Malayeri H.R.H., Friedl W., Sauerbruch T., Propping P.; RT "Microsatellite instability, a useful diagnostic tool to select patients at RT high risk for hereditary non-polyposis colorectal cancer: a study in RT different groups of patients with colorectal cancer."; RL Gut 44:839-843(1999). RN [70] RP VARIANTS LYNCH2 TRP-67; MET-117; GLY-182 AND LYS-616 DEL, AND VARIANT HNPCC RP TRP-755. RX PubMed=10480359; DOI=10.1007/s004399900064; RA Wang Q., Lasset C., Desseigne F., Saurin J.-C., Maugard C., Navarro C., RA Ruano E., Descos L., Trillet-Lenoir V., Bosset J.-F., Puisieux A.; RT "Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 RT genes in 75 French kindreds with nonpolyposis colorectal cancer."; RL Hum. Genet. 105:79-85(1999). RN [71] RP VARIANT CRC GLY-578, AND VARIANT LYNCH2 ALA-618. RX PubMed=10598809; DOI=10.1007/s004390051127; RA Liu T., Tannergaerd P., Hackman P., Rubio C., Kressner U., Lindmark G., RA Hellgren D., Lambert B., Lindblom A.; RT "Missense mutations in hMLH1 associated with colorectal cancer."; RL Hum. Genet. 105:437-441(1999). RN [72] RP VARIANT LYNCH2 PHE-25, AND VARIANT TYR-718. RX PubMed=10386556; DOI=10.1001/jama.281.24.2316; RA Weber T.K., Chin H.-M., Rodriguez-Bigas M., Keitz B., Gilligan R., RA O'Malley L., Urf E., Diba N., Pazik J., Petrelli N.J.; RT "Novel hMLH1 and hMSH2 germline mutations in African Americans with RT colorectal cancer."; RL JAMA 281:2316-2320(1999). RN [73] RP VARIANT LYNCH2 TYR-264. RX PubMed=10413423; DOI=10.1093/jnci/91.14.1221; RA Chan T.L., Yuen S.T., Chung L.P., Ho J.W.C., Kwan K.Y.M., Chan A.S.Y., RA Ho J.C.Y., Leung S.Y., Wyllie A.H.; RT "Frequent microsatellite instability and mismatch repair gene mutations in RT young Chinese patients with colorectal cancer."; RL J. Natl. Cancer Inst. 91:1221-1226(1999). RN [74] RP VARIANTS LYNCH2 VAL-111 AND PRO-588, AND VARIANTS VAL-219 AND ASP-384. RX PubMed=10777691; DOI=10.1006/bbrc.2000.2547; RA Nomura S., Sugano K., Kashiwabara H., Taniguchi T., Fukayama N., Fujita S., RA Akasu T., Moriya Y., Ohhigashi S., Kakizoe T., Sekiya T.; RT "Enhanced detection of deleterious and other germline mutations of hMSH2 RT and hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds."; RL Biochem. Biophys. Res. Commun. 271:120-129(2000). RN [75] RP VARIANTS LYNCH2 HIS-607; ALA-618 AND LEU-659, AND VARIANT MET-213. RX PubMed=10713887; DOI=10.1038/sj.ejhg.5200393; RA Fidalgo P., Almeida M.R., West S., Gaspar C., Maia L., Wijnen J., RA Albuquerque C., Curtis A., Cravo M., Fodde R., Leitao C.N., Burn J.; RT "Detection of mutations in mismatch repair genes in Portuguese families RT with hereditary non-polyposis colorectal cancer (HNPCC) by a multi-method RT approach."; RL Eur. J. Hum. Genet. 8:49-53(2000). RN [76] RP VARIANT CRC ARG-260, AND VARIANT LYNCH2 VAL-304. RX PubMed=10882759; DOI=10.1136/jmg.37.7.e7; RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RT "Mutational germline analysis of hMSH2 and hMLH1 genes in early onset RT colorectal cancer patients."; RL J. Med. Genet. 37:E7-E7(2000). RN [77] RP ERRATUM OF PUBMED:10882759. RA Montera M., Resta N., Simone C., Guanti G., Marchese C., Civitelli S., RA Mancini A., Pozzi S., De Salvo L., Bruzzone D., Donadini A., Romio L., RA Mareni C.; RL J. Med. Genet. 40:472-472(2003). RN [78] RP VARIANTS GASTRIC CANCER ARG-106; GLN-109 AND LYS-635, VARIANTS LYNCH2 RP GLY-234; ILE-321; HIS-485 AND ALA-631, AND VARIANT CRC ILE-472. RX PubMed=12132870; RA Kim J.C., Kim H.C., Roh S.A., Koo K.H., Lee D.H., Yu C.S., Lee J.H., RA Kim T.W., Lee H.I., Beck N.E., Bodmer W.F.; RT "hMLH1 and hMSH2 mutations in families with familial clustering of gastric RT cancer and hereditary non-polyposis colorectal cancer."; RL Cancer Detect. Prev. 25:503-510(2001). RN [79] RP VARIANT HIS-607. RX PubMed=11369138; DOI=10.1016/s0304-3835(01)00448-7; RA Stone J.G., Coleman G., Gusterson B., Marossy A., Lakhani S.R., Ward A., RA Nash A., McKinna A., A'Hern R., Stratton M.R., Houlston R.S.; RT "Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in RT situ of the breast."; RL Cancer Lett. 167:171-174(2001). RN [80] RP INVOLVEMENT IN TUMORIGENESIS. RX PubMed=11389087; RA Vilkki S., Tsao J.-L., Loukola A., Poyhonen M., Vierimaa O., Herva R., RA Aaltonen L.A., Shibata D.; RT "Extensive somatic microsatellite mutations in normal human tissue."; RL Cancer Res. 61:4541-4544(2001). RN [81] RP VARIANTS LYNCH2 VAL-80; PRO-329; ARG-603; ALA-618; LEU-648; PRO-662 AND RP ARG-689. RX PubMed=11726306; RA Mueller-Koch Y., Kopp R., Lohse P., Baretton G., Stoetzer A., Aust D., RA Daum J., Kerker B., Gross M., Dietmeier W., Holinski-Feder E.; RT "Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a RT cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) RT patients: mutations or polymorphisms?"; RL Eur. J. Med. Res. 6:473-482(2001). RN [82] RP CHARACTERIZATION OF VARIANTS. RX PubMed=11555625; DOI=10.1093/hmg/10.18.1889; RA Ellison A.R., Lofing J., Bitter G.A.; RT "Functional analysis of human MLH1 and MSH2 missense variants and hybrid RT human-yeast MLH1 proteins in Saccharomyces cerevisiae."; RL Hum. Mol. Genet. 10:1889-1900(2001). RN [83] RP VARIANT LYNCH2 ARG-751. RX PubMed=11139242; DOI=10.1002/1098-1004(2001)17:1<52::aid-humu6>3.0.co;2-e; RA Jakubowska A., Gorski B., Kurzawski G., Debniak T., Hadaczek P., RA Cybulski C., Kladny J., Oszurek O., Scott R.J., Lubinski J.; RT "Optimization of experimental conditions for RNA-based sequencing of MLH1 RT and MSH2 genes."; RL Hum. Mutat. 17:52-60(2001). RN [84] RP VARIANTS LYNCH2 HIS-622 AND TRP-687. RX PubMed=11748856; DOI=10.1002/humu.1240; RA Godino J., de La Hoya M., Diaz-Rubio E., Benito M., Caldes T.; RT "Eight novel germline MLH1 and MSH2 mutations in hereditary non-polyposis RT colorectal cancer families from Spain."; RL Hum. Mutat. 18:549-549(2001). RN [85] RP VARIANTS LYNCH2 SER-338; ARG-603; THR-618 AND TYR-718. RX PubMed=12095971; DOI=10.1007/bf02573891; RA Rossi B.M., Lopes A., Oliveira Ferreira F., Nakagawa W.T., RA Napoli Ferreira C.C., Casali Da Rocha J.C., Simpson C.C., Simpson A.J.G.; RT "hMLH1 and hMSH2 gene mutation in Brazilian families with suspected RT hereditary nonpolyposis colorectal cancer."; RL Ann. Surg. Oncol. 9:555-561(2002). RN [86] RP VARIANTS LYNCH2 ASN-35; HIS-38; MET-117 AND ALA-618. RX PubMed=12373605; DOI=10.1038/sj.bjc.6600565; RA Gille J.J.P., Hogervorst F.B.L., Pals G., Wijnen J.T., van Schooten R.J., RA Dommering C.J., Meijer G.A., Craanen M.E., Nederlof P.M., de Jong D., RA McElgunn C.J., Schouten J.P., Menko F.H.; RT "Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected RT by a novel mutation detection approach."; RL Br. J. Cancer 87:892-897(2002). RN [87] RP VARIANTS VAL-219 AND VAL-655. RX PubMed=12115348; DOI=10.1002/cncr.10606; RA Baldinu P., Cossu A., Manca A., Satta M.P., Pisano M., Casula M., RA Dessole S., Pintus A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis of candidate genes in RT unselected Sardinian patients with endometrial carcinoma."; RL Cancer 94:3157-3168(2002). RN [88] RP CHARACTERIZATION OF VARIANTS LYNCH2 MET-117; GLY-185; CYS-217; ASP-244 AND RP ALA-326, AND CHARACTERIZATION OF VARIANTS VAL-219 AND HIS-265. RX PubMed=11781295; DOI=10.1053/gast.2002.30296; RA Trojan J., Zeuzem S., Randolph A., Hemmerle C., Brieger A., Raedle J., RA Plotz G., Jiricny J., Marra G.; RT "Functional analysis of hMLH1 variants and HNPCC-related mutations using a RT human expression system."; RL Gastroenterology 122:211-219(2002). RN [89] RP VARIANTS LYNCH2 CYS-385; HIS-607; THR-618 AND SER-648, AND VARIANT MET-213. RX PubMed=11839723; DOI=10.1136/gut.50.3.405; RA Cravo M., Afonso A.J., Lage P., Albuquerque C., Maia L., Lacerda C., RA Fidalgo P., Chaves P., Cruz C., Nobre-Leitao C.; RT "Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 RT mismatch repair genes: implications for genetic testing."; RL Gut 50:405-412(2002). RN [90] RP CHARACTERIZATION OF VARIANTS LYNCH2 ARG-77; ARG-107 AND PRO-659, AND RP CHARACTERIZATION OF VARIANT GLY-93. RX PubMed=11793442; DOI=10.1002/gcc.1225.abs; RA Nystroem-Lahti M., Perrera C., Raeschle M., Panyushkina-Seiler E., RA Marra G., Curci A., Quaresima B., Costanzo F., D'Urso M., Venuta S., RA Jiricny J.; RT "Functional analysis of MLH1 mutations linked to hereditary nonpolyposis RT colon cancer."; RL Genes Chromosomes Cancer 33:160-167(2002). RN [91] RP VARIANT LYNCH2 PRO-662, AND VARIANT VAL-219. RX PubMed=11754112; DOI=10.1002/humu.9004; RA Krueger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kraemer H., RA Hinterseher I., Bier A., Kreuz F.R., Theissig F., Saeger H.D., RA Schackert H.K.; RT "Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis RT colorectal cancer."; RL Hum. Mutat. 19:82-82(2002). RN [92] RP VARIANTS LYNCH2 MET-117 AND PRO-247, AND VARIANTS VAL-219; ALA-618 AND RP MET-716. RX PubMed=12200596; DOI=10.1007/s00432-002-0361-2; RA Ward R., Meldrum C., Williams R., Mokany E., Scott R., Turner J., RA Hawkins N., Burgess B., Groombridge C., Spigelman A.; RT "Impact of microsatellite testing and mismatch repair protein expression on RT the clinical interpretation of genetic testing in hereditary non-polyposis RT colorectal cancer."; RL J. Cancer Res. Clin. Oncol. 128:403-411(2002). RN [93] RP VARIANT LYNCH2 CYS-646, AND VARIANT ALA-618. RX PubMed=11870161; DOI=10.1200/jco.2002.20.5.1203; RA Scartozzi M., Bianchi F., Rosati S., Galizia E., Antolini A., Loretelli C., RA Piga A., Bearzi I., Cellerino R., Porfiri E.; RT "Mutations of hMLH1 and hMSH2 in patients with suspected hereditary RT nonpolyposis colorectal cancer: correlation with microsatellite instability RT and abnormalities of mismatch repair protein expression."; RL J. Clin. Oncol. 20:1203-1208(2002). RN [94] RP VARIANTS LYNCH2 PHE-19; LEU-28; MET-117; PRO-292; THR-681 AND TRP-687, AND RP VARIANT VAL-219. RX PubMed=12362047; DOI=10.1136/jmg.39.10.e65; RA Kurzawski G., Suchy J., Kladny J., Safranow K., Jakubowska A., Elsakov P., RA Kucinskas V., Gardovski J., Irmejs A., Sibul H., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Clark J., Gozdz S., RA Niepsuj S., Slomski R., Plawski A., Lacka-Wojciechowska A., Rozmiarek A., RA Fiszer-Maliszewska L., Bebenek M., Sorokin D., Stawicka M., Godlewski D., RA Richter P., Brozek I., Wysocka B., Jawien A., Banaszkiewicz Z., RA Kowalczyk J., Czudowska D., Goretzki P.E., Moeslein G., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland RT and the Baltic States."; RL J. Med. Genet. 39:E65-E65(2002). RN [95] RP VARIANTS LYNCH2 SER-29; ARG-67; LEU-185 AND ASP-244. RX PubMed=12658575; DOI=10.1086/373963; RA Wagner A., Barrows A., Wijnen J.T., van der Klift H., Franken P.F., RA Verkuijlen P., Nakagawa H., Geugien M., Jaghmohan-Changur S., Breukel C., RA Meijers-Heijboer H., Morreau H., van Puijenbroek M., Burn J., Coronel S., RA Kinarski Y., Okimoto R., Watson P., Lynch J.F., de la Chapelle A., RA Lynch H.T., Fodde R.; RT "Molecular analysis of hereditary nonpolyposis colorectal cancer in the RT United States: high mutation detection rate among clinically selected RT families and characterization of an American founder genomic deletion of RT the MSH2 gene."; RL Am. J. Hum. Genet. 72:1088-1100(2003). RN [96] RP VARIANTS CRC 325-ARG--GLN-327 DEL; ARG-618 AND PRO-749. RX PubMed=14504054; DOI=10.1093/annonc/mdg402; RA Colombino M., Cossu A., Arba A., Manca A., Curci A., Avallone A., RA Comella G., Botti G., Scintu F., Amoruso M., D'Abbicco D., d'Agnessa M.R., RA Spanu A., Tanda F., Palmieri G.; RT "Microsatellite instability and mutation analysis among southern Italian RT patients with colorectal carcinoma: detection of different alterations RT accounting for MLH1 and MSH2 inactivation in familial cases."; RL Ann. Oncol. 14:1530-1536(2003). RN [97] RP VARIANT LYNCH2 PRO-586. RX PubMed=12655562; DOI=10.1002/humu.9121; RA Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., RA Kreuz F.R., Theissig F., Aust D.E., Saeger H.D., Schackert H.K.; RT "Identification of six novel MSH2 and MLH1 germline mutations in HNPCC."; RL Hum. Mutat. 21:445-446(2003). RN [98] RP VARIANT CRC GLY-601. RX PubMed=12655564; DOI=10.1002/humu.9123; RA Chen-Shtoyerman R., Theodor L., Harmati E., Friedman E., Dacka S., RA Kopelman Y., Sternberg A., Zarivach R., Bar-Meir S., Fireman Z.; RT "Genetic analysis of familial colorectal cancer in Israeli Arabs."; RL Hum. Mutat. 21:446-447(2003). RN [99] RP VARIANTS LYNCH2 CYS-18; ASP-101; LYS-182; CYS-379; ARG-559 AND LYS-616 DEL. RX PubMed=14635101; DOI=10.1002/humu.10291; RA Taylor C.F., Charlton R.S., Burn J., Sheridan E., Taylor G.R.; RT "Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non- RT polyposis colorectal cancer: identification of novel and recurrent RT deletions by MLPA."; RL Hum. Mutat. 22:428-433(2003). RN [100] RP VARIANT LYNCH2 SER-648. RX PubMed=15139004; DOI=10.1002/gcc.20040; RA Raevaara T.E., Gerdes A.-M., Loennqvist K.E., Tybjaerg-Hansen A., RA Abdel-Rahman W.M., Kariola R., Peltomaeki P., Nystroem-Lahti M.; RT "HNPCC mutation MLH1 P648S makes the functional protein unstable, and RT homozygosity predisposes to mild neurofibromatosis type 1."; RL Genes Chromosomes Cancer 40:261-265(2004). RN [101] RP VARIANTS LYNCH2 CYS-217; GLY-282; LEU-542; PRO-542; PRO-549; PRO-574; RP PRO-636; SER-640 AND MET-724. RX PubMed=15365995; DOI=10.1002/humu.9277; RA Shin Y.-K., Heo S.-C., Shin J.-H., Hong S.-H., Ku J.-L., Yoo B.-C., RA Kim I.-J., Park J.-G.; RT "Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non- RT polyposis colorectal cancer families."; RL Hum. Mutat. 24:351-351(2004). RN [102] RP ERRATUM OF PUBMED:15365995. RA Shin Y.K., Heo S.C., Shin J.H., Hong S.H., Ku J.L., Yoo B.C., Kim I.J., RA Park J.G.; RL Hum. Mutat. 25:224-224(2005). RN [103] RP VARIANTS LYNCH2 GLY-41 AND ASN-VAL-PHE-HIS-ILE-719 INS. RX PubMed=15365996; DOI=10.1002/humu.9278; RA Krueger S., Bier A., Plaschke J., Hoehl R., Aust D.E., Kreuz F.R., RA Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., Schackert H.K.; RT "Ten novel MSH2 and MLH1 germline mutations in families with HNPCC."; RL Hum. Mutat. 24:351-352(2004). RN [104] RP VARIANTS LYNCH2 VAL-21; ARG-67; ASN-68 AND LYS-616 DEL. RX PubMed=14961575; DOI=10.1002/ijc.11718; RA Cederquist K., Emanuelsson M., Goeransson I., Holinski-Feder E., RA Mueller-Koch Y., Golovleva I., Groenberg H.; RT "Mutation analysis of the MLH1, MSH2 and MSH6 genes in patients with double RT primary cancers of the colorectum and the endometrium: a population-based RT study in northern Sweden."; RL Int. J. Cancer 109:370-376(2004). RN [105] RP ERRATUM OF PUBMED:14961575. RA Cederquist K., Emanuelsson M., Goransson I., Holinski-Feder E., RA Muller-Koch Y., Golovleva I., Gronberg H.; RL Int. J. Cancer 115:1011-1011(2005). RN [106] RP INVOLVEMENT IN LYNCH2 BY EPIGENETIC INHERITANCE. RX PubMed=15064764; DOI=10.1038/ng1342; RA Suter C.M., Martin D.I.K., Ward R.L.; RT "Germline epimutation of MLH1 in individuals with multiple cancers."; RL Nat. Genet. 36:497-501(2004). RN [107] RP VARIANT HIS-132. RX PubMed=15184898; DOI=10.1038/ng1374; RA Lipkin S.M., Rozek L.S., Rennert G., Yang W., Chen P.-C., Hacia J., RA Hunt N., Shin B., Fodor S., Kokoris M., Greenson J.K., Fearon E., Lynch H., RA Collins F., Gruber S.B.; RT "The MLH1 D132H variant is associated with susceptibility to sporadic RT colorectal cancer."; RL Nat. Genet. 36:694-699(2004). RN [108] RP VARIANTS LYNCH2 LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; RP GLU-71 DEL; ARG-77; VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; RP PRO-329; ILE-330 DEL; PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; LEU-648; RP SER-648; LEU-654 AND PRO-659, VARIANTS SER-29; GLY-93; GLN-443; ALA-618; RP CYS-646; GLN-659; THR-681 AND MET-716, CHARACTERIZATION OF VARIANTS LYNCH2 RP LEU-28; 45-THR--PHE-47 DELINS CYS-PHE; GLU-63; ARG-67; GLU-71 DEL; ARG-77; RP VAL-80; GLU-84; ARG-107; ARG-155; GLY-185; PRO-247; PRO-329; ILE-330 DEL; RP PRO-550; ASP-589; VAL-612 DEL; LYS-616 DEL; THR-618; LEU-648; SER-648; RP LEU-654 AND PRO-659, AND CHARACTERIZATION OF VARIANTS SER-29; GLY-93; RP MET-213; VAL-219; GLN-443; ALA-618; CYS-646; GLN-659; THR-681 AND MET-716. RX PubMed=16083711; DOI=10.1016/j.gastro.2005.06.005; RA Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., RA Loennqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., RA Gerdes A.-M., Peltomaeki P., Kohonen-Corish M., Mangold E., Macrae F., RA Greenblatt M., de la Chapelle A., Nystroem M.; RT "Functional significance and clinical phenotype of nontruncating mismatch RT repair variants of MLH1."; RL Gastroenterology 129:537-549(2005). RN [109] RP VARIANTS LYNCH2 LEU-28; LYS-35; ARG-67; VAL-111; MET-117; PRO-292; THR-441; RP LYS-618 DEL; PRO-623; ILE-657 DEL; THR-681; TRP-687 AND ARG-751. RX PubMed=16451135; DOI=10.1111/j.1399-0004.2006.00550.x; RA Kurzawski G., Suchy J., Lener M., Klujszo-Grabowska E., Kladny J., RA Safranow K., Jakubowska K., Jakubowska A., Huzarski T., Byrski T., RA Debniak T., Cybulski C., Gronwald J., Oszurek O., Oszutowska D., RA Kowalska E., Gozdz S., Niepsuj S., Slomski R., Plawski A., RA Lacka-Wojciechowska A., Rozmiarek A., Fiszer-Maliszewska L., Bebenek M., RA Sorokin D., Sasiadek M.M., Stembalska A., Grzebieniak Z., Kilar E., RA Stawicka M., Godlewski D., Richter P., Brozek I., Wysocka B., Limon J., RA Jawien A., Banaszkiewicz Z., Janiszewska H., Kowalczyk J., Czudowska D., RA Scott R.J., Lubinski J.; RT "Germline MSH2 and MLH1 mutational spectrum including large rearrangements RT in HNPCC families from Poland (update study)."; RL Clin. Genet. 69:40-47(2006). RN [110] RP VARIANT MMRCS1 ASN-35. RX PubMed=17440981; DOI=10.1002/cncr.22697; RG Rotterdam initiative on gastrointestinal hereditary tumors; RA Poley J.-W., Wagner A., Hoogmans M.M.C.P., Menko F.H., Tops C., Kros J.M., RA Reddingius R.E., Meijers-Heijboer H., Kuipers E.J., Dinjens W.N.M.; RT "Biallelic germline mutations of mismatch-repair genes: a possible cause RT for multiple pediatric malignancies."; RL Cancer 109:2349-2356(2007). RN [111] RP VARIANTS LYNCH2 LYS-102 AND GLN-474. RX PubMed=17510385; DOI=10.1158/0008-5472.can-06-3509; RA Takahashi M., Shimodaira H., Andreutti-Zaugg C., Iggo R., Kolodner R.D., RA Ishioka C.; RT "Functional analysis of human MLH1 variants using yeast and in vitro RT mismatch repair assays."; RL Cancer Res. 67:4595-4604(2007). RN [112] RP INVOLVEMENT IN LYNCH2 BY GERMLINE EPIMUTATION. RX PubMed=17301300; DOI=10.1056/nejmoa064522; RA Hitchins M.P., Wong J.J.L., Suthers G., Suter C.M., Martin D.I.K., RA Hawkins N.J., Ward R.L.; RT "Inheritance of a cancer-associated MLH1 germ-line epimutation."; RL N. Engl. J. Med. 356:697-705(2007). RN [113] RP VARIANTS CRC GLU-67 AND THR-681, AND VARIANTS ALA-22; GLY-93; SER-309; RP ASN-406; HIS-607; ALA-618; ARG-689; MET-716; TYR-718 AND ARG-751. RX PubMed=18033691; DOI=10.1002/humu.20635; RA Barnetson R.A., Cartwright N., van Vliet A., Haq N., Drew K., RA Farrington S., Williams N., Warner J., Campbell H., Porteous M.E., RA Dunlop M.G.; RT "Classification of ambiguous mutations in DNA mismatch repair genes RT identified in a population-based study of colorectal cancer."; RL Hum. Mutat. 29:367-374(2008). RN [114] RP VARIANTS LYNCH2 HIS-41; SER-101; ILE-330 DEL; PRO-619 AND ARG-689, AND RP VARIANTS ARG-67; ARG-77; SER-98; ASP-101; LYS-116; MET-117; ASN-126; RP MET-213; SER-215; SER-216; PHE-260; CYS-265; HIS-265; ASP-320; ALA-326; RP ILE-330 DEL; TRP-474; GLN-474; ASP-539; PRO-549; THR-551; ARG-585; ARG-603; RP HIS-607; SER-640; LEU-640; VAL-655; SER-656; ARG-666 AND THR-681. RX PubMed=18561205; DOI=10.1002/humu.20796; RA Tournier I., Vezain M., Martins A., Charbonnier F., Baert-Desurmont S., RA Olschwang S., Wang Q., Buisine M.P., Soret J., Tazi J., Frebourg T., RA Tosi M.; RT "A large fraction of unclassified variants of the mismatch repair genes RT MLH1 and MSH2 is associated with splicing defects."; RL Hum. Mutat. 29:1412-1424(2008). RN [115] RP VARIANTS LYNCH2 CYS-233 DEL AND TRP-389, CHARACTERIZATION OF VARIANTS RP LYNCH2 LEU-28; LYS-37; HIS-38; LYS-38; PHE-44; ARG-67; PRO-109; PRO-111; RP MET-117; CYS-233 DEL; CYS-265; TRP-389; GLN-443; PRO-550; GLY-578; PHE-582; RP ASP-589; ALA-618; CYS-646; LEU-648; LEU-654; PRO-659 AND VAL-716 DEL, RP CHARACTERIZATION OF VARIANTS GLY-93; VAL-219; SER-403; ASN-406 AND MET-716, RP INTERACTION WITH PMS2, INTERACTION WITH EXO1, AND SUBCELLULAR LOCATION. RX PubMed=22753075; DOI=10.1002/humu.22153; RA Andersen S.D., Liberti S.E., Luetzen A., Drost M., Bernstein I., RA Nilbert M., Dominguez M., Nystroem M., Hansen T.V., Christoffersen J.W., RA Jaeger A.C., de Wind N., Nielsen F.C., Toerring P.M., Rasmussen L.J.; RT "Functional characterization of MLH1 missense variants identified in Lynch RT syndrome patients."; RL Hum. Mutat. 33:1647-1655(2012). RN [116] RP VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND HIS-725, AND RP CHARACTERIZATION OF VARIANTS ARG-116; LEU-213; LEU-264; THR-423 AND RP HIS-725. RX PubMed=28494185; DOI=10.1080/15384047.2017.1326439; RA Arora S., Huwe P.J., Sikder R., Shah M., Browne A.J., Lesh R., Nicolas E., RA Deshpande S., Hall M.J., Dunbrack R.L. Jr., Golemis E.A.; RT "Functional analysis of rare variants in mismatch repair proteins augments RT results from computation-based predictive methods."; RL Cancer Biol. Ther. 18:519-533(2017). CC -!- FUNCTION: Heterodimerizes with PMS2 to form MutL alpha, a component of CC the post-replicative DNA mismatch repair system (MMR). DNA repair is CC initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to CC a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. CC Assembly of the MutL-MutS-heteroduplex ternary complex in presence of CC RFC and PCNA is sufficient to activate endonuclease activity of PMS2. CC It introduces single-strand breaks near the mismatch and thus generates CC new entry points for the exonuclease EXO1 to degrade the strand CC containing the mismatch. DNA methylation would prevent cleavage and CC therefore assure that only the newly mutated DNA strand is going to be CC corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp CC loader subunits of DNA polymerase III, suggesting that it may play a CC role to recruit the DNA polymerase III to the site of the MMR. Also CC implicated in DNA damage signaling, a process which induces cell cycle CC arrest and can lead to apoptosis in case of major DNA damages. CC Heterodimerizes with MLH3 to form MutL gamma which plays a role in CC meiosis. {ECO:0000269|PubMed:16873062, ECO:0000269|PubMed:18206974, CC ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:39032648, ECO:0000269|PubMed:9311737}. CC -!- SUBUNIT: Component of the DNA mismatch repair (MMR) complex composed at CC least of MSH2, MSH3, MSH6, PMS1 and MLH1 (PubMed:26300262). Heterodimer CC of MLH1 and PMS2 (MutL alpha), MLH1 and PMS1 (MutL beta) or MLH1 and CC MLH3 (MutL gamma). Forms a ternary complex with MutS alpha (MSH2-MSH6) CC or MutS beta (MSH2-MSH3). Part of the BRCA1-associated genome CC surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, CC ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex CC (PubMed:10783165). This association could be a dynamic process changing CC throughout the cell cycle and within subnuclear domains CC (PubMed:10097147). Interacts with MCM9; the interaction recruits MLH1 CC to chromatin (PubMed:26300262). Interacts with MCM8 (PubMed:26300262). CC Interacts with PMS2; this interaction promotes MLH1 stability CC (PubMed:11427529, PubMed:22753075, PubMed:39032648). Interacts with CC MBD4 (PubMed:10097147). Interacts with EXO1 (PubMed:11427529, CC PubMed:11429708, PubMed:12414623, PubMed:14676842, PubMed:22753075). CC Interacts with MTMR15/FAN1 (PubMed:20603073). CC {ECO:0000269|PubMed:10097147, ECO:0000269|PubMed:10783165, CC ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:12414623, ECO:0000269|PubMed:14676842, CC ECO:0000269|PubMed:20603073, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:26300262, ECO:0000269|PubMed:39032648}. CC -!- INTERACTION: CC P40692; P63261: ACTG1; NbExp=6; IntAct=EBI-744248, EBI-351292; CC P40692; P07355: ANXA2; NbExp=6; IntAct=EBI-744248, EBI-352622; CC P40692; Q10567-3: AP1B1; NbExp=3; IntAct=EBI-744248, EBI-11978055; CC P40692; P63010-2: AP2B1; NbExp=8; IntAct=EBI-744248, EBI-11529439; CC P40692; Q9BX63: BRIP1; NbExp=21; IntAct=EBI-744248, EBI-3509650; CC P40692; Q9BX70: BTBD2; NbExp=3; IntAct=EBI-744248, EBI-710091; CC P40692; Q5JTZ5: C9orf152; NbExp=3; IntAct=EBI-744248, EBI-18560658; CC P40692; Q8NA61: CBY2; NbExp=6; IntAct=EBI-744248, EBI-741724; CC P40692; Q8NA61-2: CBY2; NbExp=11; IntAct=EBI-744248, EBI-11524851; CC P40692; Q8N5R6: CCDC33; NbExp=4; IntAct=EBI-744248, EBI-740841; CC P40692; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-744248, EBI-17967022; CC P40692; Q96GN5: CDCA7L; NbExp=4; IntAct=EBI-744248, EBI-5278764; CC P40692; O76039: CDKL5; NbExp=4; IntAct=EBI-744248, EBI-1752465; CC P40692; P07858: CTSB; NbExp=6; IntAct=EBI-744248, EBI-715062; CC P40692; P17661: DES; NbExp=6; IntAct=EBI-744248, EBI-1055572; CC P40692; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-744248, EBI-744099; CC P40692; Q86W67: FAM228A; NbExp=3; IntAct=EBI-744248, EBI-12958227; CC P40692; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-744248, EBI-742802; CC P40692; Q86YD7: FAM90A1; NbExp=3; IntAct=EBI-744248, EBI-6658203; CC P40692; Q96NE9: FRMD6; NbExp=3; IntAct=EBI-744248, EBI-741729; CC P40692; Q96NE9-2: FRMD6; NbExp=4; IntAct=EBI-744248, EBI-13213391; CC P40692; Q16658: FSCN1; NbExp=7; IntAct=EBI-744248, EBI-351076; CC P40692; P11142: HSPA8; NbExp=2; IntAct=EBI-744248, EBI-351896; CC P40692; Q9ULR0: ISY1; NbExp=3; IntAct=EBI-744248, EBI-2557660; CC P40692; P52292: KPNA2; NbExp=9; IntAct=EBI-744248, EBI-349938; CC P40692; O15131: KPNA5; NbExp=3; IntAct=EBI-744248, EBI-540602; CC P40692; Q5T749: KPRP; NbExp=3; IntAct=EBI-744248, EBI-10981970; CC P40692; O95232-2: LUC7L3; NbExp=3; IntAct=EBI-744248, EBI-19157865; CC P40692; P43361: MAGEA8; NbExp=7; IntAct=EBI-744248, EBI-10182930; CC P40692; Q8WWY6: MBD3L1; NbExp=3; IntAct=EBI-744248, EBI-12516603; CC P40692; O95243-2: MBD4; NbExp=3; IntAct=EBI-744248, EBI-6448717; CC P40692; Q9UJA3: MCM8; NbExp=2; IntAct=EBI-744248, EBI-8756095; CC P40692; Q9NXL9: MCM9; NbExp=5; IntAct=EBI-744248, EBI-2804985; CC P40692; Q9UHC1: MLH3; NbExp=7; IntAct=EBI-744248, EBI-3893094; CC P40692; Q6PF18: MORN3; NbExp=3; IntAct=EBI-744248, EBI-9675802; CC P40692; P29372-4: MPG; NbExp=3; IntAct=EBI-744248, EBI-10695618; CC P40692; P20585: MSH3; NbExp=5; IntAct=EBI-744248, EBI-1164205; CC P40692; P15173: MYOG; NbExp=12; IntAct=EBI-744248, EBI-3906629; CC P40692; P60323-2: NANOS3; NbExp=3; IntAct=EBI-744248, EBI-18012223; CC P40692; Q9H3P2: NELFA; NbExp=3; IntAct=EBI-744248, EBI-5461341; CC P40692; Q14938-5: NFIX; NbExp=3; IntAct=EBI-744248, EBI-12024662; CC P40692; O00746: NME4; NbExp=3; IntAct=EBI-744248, EBI-744871; CC P40692; O15055: PER2; NbExp=3; IntAct=EBI-744248, EBI-1054296; CC P40692; P78356-2: PIP4K2B; NbExp=3; IntAct=EBI-744248, EBI-11532361; CC P40692; P54277: PMS1; NbExp=8; IntAct=EBI-744248, EBI-2893308; CC P40692; P54278: PMS2; NbExp=24; IntAct=EBI-744248, EBI-1162561; CC P40692; Q96KQ4: PPP1R13B; NbExp=3; IntAct=EBI-744248, EBI-1105153; CC P40692; Q6MZQ0: PRR5L; NbExp=3; IntAct=EBI-744248, EBI-1567866; CC P40692; P25786: PSMA1; NbExp=5; IntAct=EBI-744248, EBI-359352; CC P40692; P26045: PTPN3; NbExp=3; IntAct=EBI-744248, EBI-1047946; CC P40692; Q6NSI4: RADX; NbExp=9; IntAct=EBI-744248, EBI-8634209; CC P40692; Q5RL73: RBM48; NbExp=3; IntAct=EBI-744248, EBI-473821; CC P40692; Q86UC2: RSPH3; NbExp=3; IntAct=EBI-744248, EBI-6873025; CC P40692; Q6RVD6: SPATA8; NbExp=3; IntAct=EBI-744248, EBI-8635958; CC P40692; Q13813: SPTAN1; NbExp=6; IntAct=EBI-744248, EBI-351450; CC P40692; O95926: SYF2; NbExp=3; IntAct=EBI-744248, EBI-2557644; CC P40692; Q5VWN6: TASOR2; NbExp=6; IntAct=EBI-744248, EBI-745958; CC P40692; Q7Z6R9: TFAP2D; NbExp=5; IntAct=EBI-744248, EBI-11952651; CC P40692; Q08117-2: TLE5; NbExp=3; IntAct=EBI-744248, EBI-11741437; CC P40692; P62328: TMSB4X; NbExp=15; IntAct=EBI-744248, EBI-712598; CC P40692; Q96PP4: TSGA13; NbExp=3; IntAct=EBI-744248, EBI-12390276; CC P40692; Q01081: U2AF1; NbExp=3; IntAct=EBI-744248, EBI-632461; CC P40692; O94941: UBOX5; NbExp=7; IntAct=EBI-744248, EBI-751901; CC P40692; O75152: ZC3H11A; NbExp=8; IntAct=EBI-744248, EBI-748480; CC P40692; Q9NU63-3: ZFP57; NbExp=3; IntAct=EBI-744248, EBI-12879708; CC P40692; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-744248, EBI-11419867; CC P40692; Q9UDW3: ZMAT5; NbExp=3; IntAct=EBI-744248, EBI-7850213; CC P40692; Q13360-2: ZNF177; NbExp=3; IntAct=EBI-744248, EBI-12272076; CC P40692; Q9UDV6: ZNF212; NbExp=3; IntAct=EBI-744248, EBI-1640204; CC P40692; Q6S9Z5: ZNF474; NbExp=3; IntAct=EBI-744248, EBI-17269964; CC P40692; Q6NX45: ZNF774; NbExp=3; IntAct=EBI-744248, EBI-10251462; CC P40692; P42843: SKP2; Xeno; NbExp=3; IntAct=EBI-744248, EBI-28370; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11429708, CC ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:21120944, CC ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:30770470}. Chromosome CC {ECO:0000269|PubMed:26300262}. Note=Recruited to chromatin in a MCM9- CC dependent manner. {ECO:0000269|PubMed:26300262}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P40692-1; Sequence=Displayed; CC Name=2; CC IsoId=P40692-2; Sequence=VSP_045201; CC Name=3; CC IsoId=P40692-3; Sequence=VSP_047023; CC -!- TISSUE SPECIFICITY: Colon, lymphocytes, breast, lung, spleen, testis, CC prostate, thyroid, gall bladder and heart. CC -!- PTM: Acetylated (PubMed:30770470). Deacetylated by HDAC6 which prevents CC the MutL alpha complex, formed by the MLH1-PMS2 heterodimer, from being CC recruited to the MutS alpha complex, formed by the MSH2-MSH6 CC heterodimer, leading to tolerance of DNA damage (PubMed:30770470). CC {ECO:0000269|PubMed:30770470}. CC -!- PTM: Ubiquitinated by UBR4; leading to proteasomal degradation. This CC ubiquitination is counteracted by the deubiquitinase USP5. CC {ECO:0000269|PubMed:39032648}. CC -!- DISEASE: Lynch syndrome 2 (LYNCH2) [MIM:609310]: A form of Lynch CC syndrome, an autosomal dominant disease associated with marked increase CC in cancer susceptibility. It is characterized by a familial CC predisposition to early-onset colorectal carcinoma (CRC) and extra- CC colonic tumors of the gastrointestinal, urological and female CC reproductive tracts. Lynch syndrome is reported to be the most common CC form of inherited colorectal cancer in the Western world. Clinically, CC it is often divided into two subgroups. Type I is characterized by CC hereditary predisposition to colorectal cancer, a young age of onset, CC and carcinoma observed in the proximal colon. Type II is characterized CC by increased risk for cancers in certain tissues such as the uterus, CC ovary, breast, stomach, small intestine, skin, and larynx in addition CC to the colon. Diagnosis of classical Lynch syndrome is based on the CC Amsterdam criteria: 3 or more relatives affected by colorectal cancer, CC one a first degree relative of the other two; 2 or more generation CC affected; 1 or more colorectal cancers presenting before 50 years of CC age; exclusion of hereditary polyposis syndromes. The term 'suspected CC Lynch syndrome' or 'incomplete Lynch syndrome' can be used to describe CC families who do not or only partially fulfill the Amsterdam criteria, CC but in whom a genetic basis for colon cancer is strongly suspected. CC {ECO:0000269|PubMed:10323887, ECO:0000269|PubMed:10375096, CC ECO:0000269|PubMed:10386556, ECO:0000269|PubMed:10413423, CC ECO:0000269|PubMed:10480359, ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10627141, ECO:0000269|PubMed:10660333, CC ECO:0000269|PubMed:10671064, ECO:0000269|PubMed:10713887, CC ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:10882759, CC ECO:0000269|PubMed:11139242, ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:11748856, CC ECO:0000269|PubMed:11754112, ECO:0000269|PubMed:11781295, CC ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:11839723, CC ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12095971, CC ECO:0000269|PubMed:12132870, ECO:0000269|PubMed:12200596, CC ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:12373605, CC ECO:0000269|PubMed:12655562, ECO:0000269|PubMed:12658575, CC ECO:0000269|PubMed:14635101, ECO:0000269|PubMed:14961575, CC ECO:0000269|PubMed:15064764, ECO:0000269|PubMed:15139004, CC ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:15365996, CC ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, CC ECO:0000269|PubMed:17301300, ECO:0000269|PubMed:17510385, CC ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, CC ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, CC ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8521398, CC ECO:0000269|PubMed:8566964, ECO:0000269|PubMed:8571956, CC ECO:0000269|PubMed:8574961, ECO:0000269|PubMed:8797773, CC ECO:0000269|PubMed:8872463, ECO:0000269|PubMed:8993976, CC ECO:0000269|PubMed:9048925, ECO:0000269|PubMed:9067757, CC ECO:0000269|PubMed:9218993, ECO:0000269|PubMed:9272156, CC ECO:0000269|PubMed:9298827, ECO:0000269|PubMed:9311737, CC ECO:0000269|PubMed:9326924, ECO:0000269|PubMed:9399661, CC ECO:0000269|PubMed:9559627, ECO:0000269|PubMed:9718327, CC ECO:0000269|PubMed:9833759, ECO:0000269|PubMed:9927034, CC ECO:0000269|Ref.5}. Note=The disease is caused by variants affecting CC the gene represented in this entry. CC -!- DISEASE: Mismatch repair cancer syndrome 1 (MMRCS1) [MIM:276300]: An CC autosomal recessive form of mismatch repair cancer syndrome, a CC childhood cancer predisposition syndrome encompassing a broad tumor CC spectrum. This includes hematological malignancies, central nervous CC system tumors, Lynch syndrome-associated malignancies such as CC colorectal tumors as well as multiple intestinal polyps, embryonic CC tumors and rhabdomyosarcoma. Multiple cafe-au-lait macules, a feature CC reminiscent of neurofibromatosis type 1, are often found as first CC manifestation of the underlying cancer. {ECO:0000269|PubMed:11427529, CC ECO:0000269|PubMed:17440981, ECO:0000269|PubMed:7661930}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Muir-Torre syndrome (MRTES) [MIM:158320]: Rare autosomal CC dominant disorder characterized by sebaceous neoplasms and visceral CC malignancy. {ECO:0000269|PubMed:8751876}. Note=The disease is caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Defects in MLH1 may contribute to lobular carcinoma in CC situ (LCIS), a non-invasive neoplastic disease of the breast. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. Note=Disease susceptibility is associated with CC variants affecting the gene represented in this entry. CC -!- DISEASE: Note=Some epigenetic changes can be transmitted unchanged CC through the germline (termed 'epigenetic inheritance'). Evidence that CC this mechanism occurs in humans is provided by the identification of CC individuals in whom 1 allele of the MLH1 gene is epigenetically CC silenced throughout the soma (implying a germline event). These CC individuals are affected by Lynch syndrome but does not have CC identifiable mutations in MLH1, even though it is silenced, which CC demonstrates that an epimutation can phenocopy a genetic disease. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000269|PubMed:10598809, CC ECO:0000269|PubMed:10882759, ECO:0000269|PubMed:12132870, CC ECO:0000269|PubMed:12655564, ECO:0000269|PubMed:14504054, CC ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:8872463, CC ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9087566, CC ECO:0000269|PubMed:9611074}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the DNA mismatch repair MutL/HexB family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/149/MLH1"; CC -!- WEB RESOURCE: Name=Colon cancer gene variant databases MutL homolog 1 CC (E.coli) (MLH1); Note=Leiden Open Variation Database (LOVD); CC URL="https://databases.lovd.nl/shared/genes/MLH1"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U07343; AAC50285.1; -; mRNA. DR EMBL; U07418; AAA17374.1; -; mRNA. DR EMBL; U40978; AAA82079.1; -; Genomic_DNA. DR EMBL; U40960; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40961; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40962; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40963; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40964; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40965; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40966; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40967; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40968; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40969; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40970; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40971; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40972; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40973; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40974; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40975; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40976; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U40977; AAA82079.1; JOINED; Genomic_DNA. DR EMBL; U17857; AAA85687.1; -; Genomic_DNA. DR EMBL; U17839; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17840; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17841; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17842; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17843; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17844; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17845; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17846; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17847; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17848; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17849; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17851; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17852; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17853; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17854; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17855; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; U17856; AAA85687.1; JOINED; Genomic_DNA. DR EMBL; AY217549; AAO22994.1; -; Genomic_DNA. DR EMBL; AK295359; BAG58325.1; -; mRNA. DR EMBL; AK298324; BAG60576.1; -; mRNA. DR EMBL; AK298583; BAG60773.1; -; mRNA. DR EMBL; AK316074; BAH14445.1; -; mRNA. DR EMBL; AK316264; BAH14635.1; -; mRNA. DR EMBL; AC006583; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC011816; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471055; EAW64483.1; -; Genomic_DNA. DR EMBL; BC006850; AAH06850.1; -; mRNA. DR CCDS; CCDS2663.1; -. [P40692-1] DR CCDS; CCDS54562.1; -. [P40692-3] DR CCDS; CCDS54563.1; -. [P40692-2] DR PIR; S43085; S43085. DR RefSeq; NP_000240.1; NM_000249.4. [P40692-1] DR RefSeq; NP_001161089.1; NM_001167617.3. [P40692-3] DR RefSeq; NP_001161090.1; NM_001167618.3. [P40692-2] DR RefSeq; NP_001161091.1; NM_001167619.3. [P40692-2] DR RefSeq; NP_001245200.1; NM_001258271.1. DR RefSeq; NP_001245202.1; NM_001258273.2. [P40692-2] DR RefSeq; NP_001245203.1; NM_001258274.3. [P40692-2] DR RefSeq; NP_001341544.1; NM_001354615.2. [P40692-2] DR RefSeq; NP_001341545.1; NM_001354616.2. [P40692-2] DR RefSeq; NP_001341546.1; NM_001354617.2. [P40692-2] DR RefSeq; NP_001341547.1; NM_001354618.2. [P40692-2] DR RefSeq; NP_001341548.1; NM_001354619.2. [P40692-2] DR RefSeq; NP_001341549.1; NM_001354620.2. [P40692-3] DR RefSeq; XP_047304109.1; XM_047448153.1. [P40692-2] DR RefSeq; XP_047304110.1; XM_047448154.1. [P40692-2] DR RefSeq; XP_047304111.1; XM_047448155.1. [P40692-2] DR RefSeq; XP_054202541.1; XM_054346566.1. [P40692-2] DR RefSeq; XP_054202542.1; XM_054346567.1. [P40692-2] DR RefSeq; XP_054202543.1; XM_054346568.1. [P40692-2] DR PDB; 3RBN; X-ray; 2.16 A; A/B=486-751. DR PDB; 4P7A; X-ray; 2.30 A; A=1-347. DR PDB; 5U5P; X-ray; 2.17 A; B/C=467-476. DR PDB; 6WBA; X-ray; 2.15 A; B/C=466-476. DR PDB; 6WBB; X-ray; 2.66 A; B/C=466-476. DR PDB; 6WBC; X-ray; 2.15 A; B=466-476. DR PDB; 7M60; X-ray; 2.30 A; B/C=466-476. DR PDBsum; 3RBN; -. DR PDBsum; 4P7A; -. DR PDBsum; 5U5P; -. DR PDBsum; 6WBA; -. DR PDBsum; 6WBB; -. DR PDBsum; 6WBC; -. DR PDBsum; 7M60; -. DR AlphaFoldDB; P40692; -. DR SMR; P40692; -. DR BioGRID; 110438; 261. DR ComplexPortal; CPX-9901; MutLalpha endonuclease complex. DR ComplexPortal; CPX-9941; MutLabeta endonuclease complex. DR ComplexPortal; CPX-9961; MutLgamma endonuclease complex. DR CORUM; P40692; -. DR DIP; DIP-27601N; -. DR FunCoup; P40692; 2633. DR IntAct; P40692; 232. DR MINT; P40692; -. DR STRING; 9606.ENSP00000231790; -. DR GlyCosmos; P40692; 1 site, 1 glycan. DR GlyGen; P40692; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P40692; -. DR MetOSite; P40692; -. DR PhosphoSitePlus; P40692; -. DR BioMuta; MLH1; -. DR DMDM; 730028; -. DR jPOST; P40692; -. DR MassIVE; P40692; -. DR PaxDb; 9606-ENSP00000231790; -. DR PeptideAtlas; P40692; -. DR ProteomicsDB; 19516; -. DR ProteomicsDB; 4266; -. DR ProteomicsDB; 55377; -. [P40692-1] DR Pumba; P40692; -. DR Antibodypedia; 4599; 923 antibodies from 47 providers. DR CPTC; P40692; 3 antibodies. DR DNASU; 4292; -. DR Ensembl; ENST00000231790.8; ENSP00000231790.3; ENSG00000076242.19. [P40692-1] DR Ensembl; ENST00000429117.6; ENSP00000407019.2; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000435176.5; ENSP00000402564.1; ENSG00000076242.19. [P40692-3] DR Ensembl; ENST00000455445.6; ENSP00000398272.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000458205.6; ENSP00000402667.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000466900.6; ENSP00000519069.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000485889.2; ENSP00000518946.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000492474.6; ENSP00000518393.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000536378.5; ENSP00000444286.2; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000539477.6; ENSP00000443665.1; ENSG00000076242.19. [P40692-2] DR Ensembl; ENST00000674019.1; ENSP00000501081.1; ENSG00000076242.19. [P40692-2] DR GeneID; 4292; -. DR KEGG; hsa:4292; -. DR MANE-Select; ENST00000231790.8; ENSP00000231790.3; NM_000249.4; NP_000240.1. DR UCSC; uc003cgl.4; human. [P40692-1] DR AGR; HGNC:7127; -. DR CIViC; 4292; 30 evidence items across 33 molecular profiles. DR ClinPGx; PA240; -. DR CTD; 4292; -. DR DisGeNET; 4292; -. DR GeneCards; MLH1; -. DR GeneReviews; MLH1; -. DR HGNC; HGNC:7127; MLH1. DR HPA; ENSG00000076242; Low tissue specificity. DR MalaCards; MLH1; -. DR MIM; 114500; phenotype. DR MIM; 120436; gene. DR MIM; 158320; phenotype. DR MIM; 276300; phenotype. DR MIM; 608089; phenotype. DR MIM; 609310; phenotype. DR OpenTargets; ENSG00000076242; -. DR Orphanet; 252202; Constitutional mismatch repair deficiency syndrome. DR Orphanet; 144; Lynch syndrome. DR VEuPathDB; HostDB:ENSG00000076242; -. DR eggNOG; KOG1979; Eukaryota. DR GeneTree; ENSGT00800000124177; -. DR InParanoid; P40692; -. DR OMA; ANYHVKK; -. DR OrthoDB; 10263226at2759; -. DR PAN-GO; P40692; 4 GO annotations based on evolutionary models. DR PhylomeDB; P40692; -. DR PathwayCommons; P40692; -. DR Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha). DR Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta). DR Reactome; R-HSA-5545483; Defective Mismatch Repair Associated With MLH1. DR Reactome; R-HSA-5632987; Defective Mismatch Repair Associated With PMS2. DR Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes. DR Reactome; R-HSA-912446; Meiotic recombination. DR SignaLink; P40692; -. DR SIGNOR; P40692; -. DR Agora; ENSG00000076242; -. DR BioGRID-ORCS; 4292; 15 hits in 1172 CRISPR screens. DR CD-CODE; 91857CE7; Nucleolus. DR ChiTaRS; MLH1; human. DR EvolutionaryTrace; P40692; -. DR GeneWiki; MLH1; -. DR GenomeRNAi; 4292; -. DR Pharos; P40692; Tbio. DR PRO; PR:P40692; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P40692; protein. DR Bgee; ENSG00000076242; Expressed in tibialis anterior and 210 other cell types or tissues. DR ExpressionAtlas; P40692; baseline and differential. DR GO; GO:0005712; C:chiasma; IEA:Ensembl. DR GO; GO:0005694; C:chromosome; ISS:UniProtKB. DR GO; GO:0005715; C:late recombination nodule; IEA:Ensembl. DR GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0032389; C:MutLalpha complex; IBA:GO_Central. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0000795; C:synaptonemal complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IBA:GO_Central. DR GO; GO:0140664; F:ATP-dependent DNA damage sensor activity; IEA:InterPro. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0008047; F:enzyme activator activity; IDA:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0032137; F:guanine/thymine mispair binding; IEA:Ensembl. DR GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IEA:Ensembl. DR GO; GO:0016321; P:female meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0007129; P:homologous chromosome pairing at meiosis; IEA:Ensembl. DR GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl. DR GO; GO:0045190; P:isotype switching; IEA:Ensembl. DR GO; GO:0007060; P:male meiosis chromosome segregation; IEA:Ensembl. DR GO; GO:0043060; P:meiotic metaphase I homologous chromosome alignment; IEA:Ensembl. DR GO; GO:0051257; P:meiotic spindle midzone assembly; IEA:Ensembl. DR GO; GO:0045141; P:meiotic telomere clustering; IEA:Ensembl. DR GO; GO:0006298; P:mismatch repair; IGI:MGI. DR GO; GO:0045950; P:negative regulation of mitotic recombination; IEA:Ensembl. DR GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; IEA:Ensembl. DR GO; GO:0048477; P:oogenesis; IEA:Ensembl. DR GO; GO:0048298; P:positive regulation of isotype switching to IgA isotypes; IEA:Ensembl. DR GO; GO:0048304; P:positive regulation of isotype switching to IgG isotypes; IEA:Ensembl. DR GO; GO:0000712; P:resolution of meiotic recombination intermediates; IEA:Ensembl. DR GO; GO:0009617; P:response to bacterium; IEA:Ensembl. DR GO; GO:0016446; P:somatic hypermutation of immunoglobulin genes; IBA:GO_Central. DR GO; GO:0007283; P:spermatogenesis; IEA:Ensembl. DR CDD; cd16926; HATPase_MutL-MLH-PMS-like; 1. DR CDD; cd03483; MutL_Trans_MLH1; 1. DR DisProt; DP03062; -. DR FunFam; 3.30.230.10:FF:000014; DNA mismatch repair protein Mlh1; 1. DR FunFam; 3.30.565.10:FF:000034; DNA mismatch repair protein mlh1, putative; 1. DR Gene3D; 3.30.230.10; -; 1. DR Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1. DR InterPro; IPR014762; DNA_mismatch_repair_CS. DR InterPro; IPR013507; DNA_mismatch_S5_2-like. DR InterPro; IPR036890; HATPase_C_sf. DR InterPro; IPR032189; Mlh1_C. DR InterPro; IPR002099; MutL/Mlh/PMS. DR InterPro; IPR038973; MutL/Mlh/Pms-like. DR InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF. DR InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr. DR NCBIfam; TIGR00585; mutl; 1. DR PANTHER; PTHR10073; DNA MISMATCH REPAIR PROTEIN MLH, PMS, MUTL; 1. DR PANTHER; PTHR10073:SF12; DNA MISMATCH REPAIR PROTEIN MLH1; 1. DR Pfam; PF01119; DNA_mis_repair; 1. DR Pfam; PF13589; HATPase_c_3; 1. DR Pfam; PF16413; Mlh1_C; 1. DR SMART; SM01340; DNA_mis_repair; 1. DR SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1. DR SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1. DR PROSITE; PS00058; DNA_MISMATCH_REPAIR_1; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle; KW Chromosome; Disease variant; DNA damage; DNA repair; KW Hereditary nonpolyposis colorectal cancer; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22223895" FT CHAIN 2..756 FT /note="DNA mismatch repair protein Mlh1" FT /id="PRO_0000178000" FT REGION 355..378 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 400..491 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 410..650 FT /note="Interaction with EXO1" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:12414623, FT ECO:0000269|PubMed:14676842, ECO:0000269|PubMed:22753075" FT MOTIF 471..474 FT /note="Nuclear localization signal" FT /evidence="ECO:0000269|PubMed:29175432" FT COMPBIAS 362..375 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 443..457 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 63 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 82..84 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT BINDING 100..104 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:26249686, FT ECO:0007744|PDB:4P7A" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22223895" FT MOD_RES 33 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 241 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 361 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 377 FT /note="N6-acetyllysine" FT /evidence="ECO:0000269|PubMed:30770470" FT MOD_RES 477 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..241 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045201" FT VAR_SEQ 1..101 FT /note="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKSTSIQVIVK FT EGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRG -> MAF FT (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_047023" FT VARIANT 18 FT /note="R -> C (in LYNCH2; dbSNP:rs367654552)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022663" FT VARIANT 19 FT /note="I -> F (in LYNCH2; dbSNP:rs63750648)" FT /evidence="ECO:0000269|PubMed:12362047" FT /id="VAR_043383" FT VARIANT 21 FT /note="A -> V (in LYNCH2; dbSNP:rs63750706)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_043384" FT VARIANT 22 FT /note="G -> A (in dbSNP:rs41295280)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038023" FT VARIANT 25 FT /note="I -> F (in LYNCH2; dbSNP:rs63749838)" FT /evidence="ECO:0000269|PubMed:10386556" FT /id="VAR_043385" FT VARIANT 28 FT /note="P -> L (in LYNCH2; loss of protein expression; FT normal interaction with PMS2 and EXO1; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63750792)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9298827" FT /id="VAR_004433" FT VARIANT 29 FT /note="A -> S (in LYNCH2; uncertain significance; acts FT functionally like the wild-type protein; dbSNP:rs63750656)" FT /evidence="ECO:0000269|PubMed:12658575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043386" FT VARIANT 31 FT /note="A -> C (in LYNCH2; decreased mismatch repair FT activity; requires 2 nucleotide substitutions; FT dbSNP:rs63749994)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076338" FT VARIANT 32 FT /note="I -> V (in dbSNP:rs2020872)" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_014876" FT VARIANT 35 FT /note="M -> K (in LYNCH2; uncertain significance; FT dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043387" FT VARIANT 35 FT /note="M -> N (in MMRCS1; requires 2 nucleotide FT substitutions; dbSNP:rs121912965)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:17440981" FT /id="VAR_043388" FT VARIANT 35 FT /note="M -> R (in LYNCH2; dbSNP:rs63749906)" FT /evidence="ECO:0000269|PubMed:8521398" FT /id="VAR_004434" FT VARIANT 37 FT /note="E -> ELNH (found in an endometrial cancer sample; FT somatic mutation)" FT /id="VAR_004435" FT VARIANT 37 FT /note="E -> K (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; dbSNP:rs63751012)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076339" FT VARIANT 38 FT /note="N -> H (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63750580)" FT /evidence="ECO:0000269|PubMed:12373605, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_043389" FT VARIANT 38 FT /note="N -> K (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs267607706)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076340" FT VARIANT 41 FT /note="D -> G (in LYNCH2; dbSNP:rs63751094)" FT /evidence="ECO:0000269|PubMed:15365996" FT /id="VAR_043390" FT VARIANT 41 FT /note="D -> H (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607713)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054522" FT VARIANT 44 FT /note="S -> F (in LYNCH2; no effect on MLH1 splicing; loss FT of mismatch repair activity; dbSNP:rs63751109)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9326924" FT /id="VAR_004436" FT VARIANT 45..47 FT /note="TSI -> CF (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_043391" FT VARIANT 54 FT /note="G -> E (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63751267)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012902" FT VARIANT 62 FT /note="Q -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751428)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004437" FT VARIANT 63 FT /note="D -> E (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs587778955)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043392" FT VARIANT 64 FT /note="N -> S (in LYNCH2; dbSNP:rs63750952)" FT /evidence="ECO:0000269|PubMed:9311737" FT /id="VAR_004438" FT VARIANT 67 FT /note="G -> E (in CRC; dbSNP:rs63749939)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038024" FT VARIANT 67 FT /note="G -> R (in LYNCH2; no effect on MLH1 splicing; FT decreased mismatch repair activity; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:14961575, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9067757, ECO:0000269|PubMed:9833759" FT /id="VAR_004439" FT VARIANT 67 FT /note="G -> W (in LYNCH2; dbSNP:rs63750206)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9927034" FT /id="VAR_012903" FT VARIANT 68 FT /note="I -> N (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750281)" FT /evidence="ECO:0000269|PubMed:14961575" FT /id="VAR_004440" FT VARIANT 69 FT /note="R -> K (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751661)" FT /evidence="ECO:0000269|PubMed:10627141" FT /id="VAR_004441" FT VARIANT 71 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043393" FT VARIANT 77 FT /note="C -> R (in LYNCH2; decreased mismatch repair FT activity; loss of nuclear localization; normal interaction FT with PMS2; dbSNP:rs63749859)" FT /evidence="ECO:0000269|PubMed:10660333, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004442" FT VARIANT 77 FT /note="C -> Y (in CRC; sporadic; early onset; FT dbSNP:rs63750437)" FT /evidence="ECO:0000269|PubMed:9032648" FT /id="VAR_012904" FT VARIANT 80 FT /note="F -> V (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63749990)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012905" FT VARIANT 84 FT /note="K -> E (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750641)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_012906" FT VARIANT 93 FT /note="S -> G (normal interaction with PMS2; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs41295282)" FT /evidence="ECO:0000269|PubMed:10671064, FT ECO:0000269|PubMed:11793442, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_004443" FT VARIANT 98 FT /note="G -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607725)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054523" FT VARIANT 101 FT /note="G -> D (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607727)" FT /evidence="ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:18561205" FT /id="VAR_022664" FT VARIANT 101 FT /note="G -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607726)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054524" FT VARIANT 102 FT /note="E -> K (in LYNCH2; dbSNP:rs63750453)" FT /evidence="ECO:0000269|PubMed:17510385" FT /id="VAR_043394" FT VARIANT 106 FT /note="S -> R (in gastric cancer; uncertain significance; FT dbSNP:rs63750297)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043395" FT VARIANT 107 FT /note="I -> R (in LYNCH2; decreased mismatch repair FT activity; normal interaction with PMS2; loss of protein FT expression; loss of nuclear localization; FT dbSNP:rs63750507)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004444" FT VARIANT 109 FT /note="H -> P (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs587779004)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076341" FT VARIANT 109 FT /note="H -> Q (in gastric cancer; uncertain significance; FT dbSNP:rs63749803)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043396" FT VARIANT 111 FT /note="A -> P (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs587779005)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076342" FT VARIANT 111 FT /note="A -> V (in LYNCH2; dbSNP:rs63750539)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:16451135" FT /id="VAR_012907" FT VARIANT 116 FT /note="T -> K (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054525" FT VARIANT 116 FT /note="T -> R (no effect on protein expression; FT dbSNP:rs63750465)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079812" FT VARIANT 117 FT /note="T -> M (in LYNCH2; decreased mismatch repair FT activity; no effect on MLH1 splicing; fails to interact FT with PMS2 and EXO1; loss of nuclear localization; FT dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11429708, ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:8566964" FT /id="VAR_004445" FT VARIANT 117 FT /note="T -> R (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750781)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_004446" FT VARIANT 126 FT /note="Y -> N (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs200076893)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054526" FT VARIANT 128 FT /note="A -> P (in LYNCH2; dbSNP:rs63750866)" FT /evidence="ECO:0000269|PubMed:9218993" FT /id="VAR_012908" FT VARIANT 132 FT /note="D -> H (decreased but not abolished ATPase activity; FT dbSNP:rs28930073)" FT /evidence="ECO:0000269|PubMed:15184898" FT /id="VAR_022665" FT VARIANT 155 FT /note="L -> R (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750891)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043397" FT VARIANT 182 FT /note="R -> G (in LYNCH2; incomplete; dbSNP:rs63750211)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:9399661" FT /id="VAR_012909" FT VARIANT 182 FT /note="R -> K (in LYNCH2; dbSNP:rs587779021)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022666" FT VARIANT 185 FT /note="V -> G (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing; FT dbSNP:rs63750515)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_004447" FT VARIANT 185 FT /note="V -> L (in LYNCH2; uncertain significance; FT dbSNP:rs63750012)" FT /evidence="ECO:0000269|PubMed:12658575" FT /id="VAR_043398" FT VARIANT 193 FT /note="S -> P (in LYNCH2; dbSNP:rs63751021)" FT /evidence="ECO:0000269|PubMed:10660333" FT /id="VAR_004448" FT VARIANT 213 FT /note="V -> L (no effect on protein expression; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079813" FT VARIANT 213 FT /note="V -> M (no effect on MLH1 splicing; FT dbSNP:rs2308317)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944, FT ECO:0000269|Ref.5" FT /id="VAR_012910" FT VARIANT 215 FT /note="N -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607775)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054527" FT VARIANT 216 FT /note="I -> S (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607776)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054528" FT VARIANT 217 FT /note="R -> C (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; dbSNP:rs4986984)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:8797773, FT ECO:0000269|PubMed:9559627" FT /id="VAR_004449" FT VARIANT 217 FT /note="R -> G (in dbSNP:rs4986984)" FT /id="VAR_020469" FT VARIANT 219 FT /note="I -> V (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs1799977)" FT /evidence="ECO:0000269|PubMed:10375096, FT ECO:0000269|PubMed:10777691, ECO:0000269|PubMed:11754112, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:12200596, ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9032648, ECO:0000269|PubMed:9067757, FT ECO:0000269|PubMed:9087566, ECO:0000269|PubMed:9218993, FT ECO:0000269|PubMed:9833759, ECO:0000269|Ref.5" FT /id="VAR_004450" FT VARIANT 226..295 FT /note="Missing (in LYNCH2)" FT /id="VAR_004452" FT VARIANT 226 FT /note="R -> L (in LYNCH2; dbSNP:rs63751711)" FT /evidence="ECO:0000269|PubMed:8566964" FT /id="VAR_004451" FT VARIANT 233 FT /note="Missing (in LYNCH2; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076343" FT VARIANT 234 FT /note="E -> G (in LYNCH2; uncertain significance; FT dbSNP:rs63750696)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043399" FT VARIANT 244 FT /note="G -> D (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:11781295, FT ECO:0000269|PubMed:12658575, ECO:0000269|PubMed:9218993" FT /id="VAR_012911" FT VARIANT 244 FT /note="G -> V (in CRC; sporadic; somatic mutation; FT uncertain significance; dbSNP:rs63750303)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012912" FT VARIANT 247 FT /note="S -> P (in LYNCH2; decreased mismatch repair FT activity; loss of protein expression; loss of nuclear FT localization; dbSNP:rs63750948)" FT /evidence="ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944" FT /id="VAR_043400" FT VARIANT 260 FT /note="L -> F (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs63750642)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054529" FT VARIANT 260 FT /note="L -> R (in CRC; dbSNP:rs63751283)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043401" FT VARIANT 262 FT /note="Missing (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012913" FT VARIANT 264 FT /note="H -> L (no effect on protein expression; FT dbSNP:rs63751664)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079814" FT VARIANT 264 FT /note="H -> Y (in LYNCH2; dbSNP:rs63751597)" FT /evidence="ECO:0000269|PubMed:10413423" FT /id="VAR_043402" FT VARIANT 265 FT /note="R -> C (in LYNCH2; results in partial MLH1 exon 10 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; no effect on nuclear localization; FT dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_054530" FT VARIANT 265 FT /note="R -> H (risk factor for LYNCH2; results in partial FT MLH1 exon 10 skipping on ex vivo splicing assay; decreased FT mismatch repair activity; dbSNP:rs63751448)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:8993976" FT /id="VAR_012914" FT VARIANT 265 FT /note="R -> S (in LYNCH2; decreased mismatch repair FT activity; dbSNP:rs63751194)" FT /evidence="ECO:0000269|PubMed:20020535" FT /id="VAR_076344" FT VARIANT 268 FT /note="E -> G (in CRC; benign; dbSNP:rs63750650)" FT /evidence="ECO:0000269|PubMed:9611074" FT /id="VAR_012915" FT VARIANT 282 FT /note="A -> G (in LYNCH2; likely benign; dbSNP:rs63750360)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043403" FT VARIANT 292 FT /note="L -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750517)" FT /evidence="ECO:0000269|PubMed:12362047, FT ECO:0000269|PubMed:16451135" FT /id="VAR_043404" FT VARIANT 295 FT /note="S -> T (in LYNCH2; uncertain significance; FT dbSNP:rs63750144)" FT /evidence="ECO:0000269|PubMed:9399661" FT /id="VAR_012916" FT VARIANT 304 FT /note="D -> V (in LYNCH2; dbSNP:rs63750993)" FT /evidence="ECO:0000269|PubMed:10882759" FT /id="VAR_043405" FT VARIANT 309 FT /note="P -> S (in dbSNP:rs267607808)" FT /evidence="ECO:0000269|PubMed:18033691" FT /id="VAR_038025" FT VARIANT 320 FT /note="E -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607811)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054531" FT VARIANT 321 FT /note="S -> I (in LYNCH2; uncertain significance; FT dbSNP:rs63750286)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043406" FT VARIANT 325..327 FT /note="Missing (in CRC)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043407" FT VARIANT 325 FT /note="R -> Q (in dbSNP:rs63750268)" FT /evidence="ECO:0000269|PubMed:9087566" FT /id="VAR_012917" FT VARIANT 326 FT /note="V -> A (in LYNCH2; benign; no decrease in mismatch FT repair activity; dbSNP:rs63751049)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11781295, ECO:0000269|PubMed:18561205" FT /id="VAR_004453" FT VARIANT 329 FT /note="H -> P (in LYNCH2; loss of protein expression; loss FT of nuclear localization; dbSNP:rs63750710)" FT /evidence="ECO:0000269|PubMed:10323887, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:9272156" FT /id="VAR_012918" FT VARIANT 330 FT /note="Missing (in LYNCH2; results in weak MLH1 exon 11 FT skipping on ex vivo splicing assay; decreased mismatch FT repair activity; loss of protein expression; loss of FT nuclear localization; dbSNP:rs63751197)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_043408" FT VARIANT 338 FT /note="N -> S (in LYNCH2; dbSNP:rs63751467)" FT /evidence="ECO:0000269|PubMed:12095971" FT /id="VAR_043409" FT VARIANT 379 FT /note="Y -> C (in LYNCH2; dbSNP:rs143009528)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022667" FT VARIANT 384 FT /note="V -> D (probable risk factor for HNPCC in some FT populations; dbSNP:rs63750447)" FT /evidence="ECO:0000269|PubMed:10777691, FT ECO:0000269|PubMed:8609062, ECO:0000269|PubMed:9526167" FT /id="VAR_004454" FT VARIANT 385 FT /note="R -> C (in LYNCH2; uncertain significance; FT dbSNP:rs63750760)" FT /evidence="ECO:0000269|PubMed:11839723" FT /id="VAR_043410" FT VARIANT 385 FT /note="R -> P (in LYNCH2; uncertain significance; FT dbSNP:rs63750430)" FT /evidence="ECO:0000269|PubMed:10573010" FT /id="VAR_043411" FT VARIANT 389 FT /note="R -> W (in LYNCH2; uncertain significance; no effect FT on nuclear localization; normal interaction with PMS2 and FT EXO1; dbSNP:rs61751644)" FT /evidence="ECO:0000269|PubMed:22753075" FT /id="VAR_076345" FT VARIANT 403 FT /note="P -> S (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs587778897)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076346" FT VARIANT 406 FT /note="S -> N (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs41294980)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9087566" FT /id="VAR_012919" FT VARIANT 423 FT /note="R -> T (no effect on protein expression; FT dbSNP:rs370687064)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079815" FT VARIANT 441 FT /note="A -> T (in LYNCH2; benign; dbSNP:rs63750365)" FT /evidence="ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:9326924" FT /id="VAR_012920" FT VARIANT 443 FT /note="K -> Q (in LYNCH2; uncertain significance; no FT decrease in mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs34213726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043412" FT VARIANT 460 FT /note="E -> A (in LYNCH2; uncertain significance; FT dbSNP:rs202038499)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076347" FT VARIANT 472 FT /note="R -> I (in CRC; uncertain significance; FT dbSNP:rs63750498)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043413" FT VARIANT 474 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63751083)" FT /evidence="ECO:0000269|PubMed:17510385, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043414" FT VARIANT 474 FT /note="R -> W (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs147939838)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054532" FT VARIANT 485 FT /note="D -> E (in LYNCH2; dbSNP:rs63750956)" FT /evidence="ECO:0000269|PubMed:10375096" FT /id="VAR_043415" FT VARIANT 485 FT /note="D -> H (in LYNCH2; uncertain significance; FT dbSNP:rs63750314)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043416" FT VARIANT 492 FT /note="A -> T (in LYNCH2; also found in sporadic colorectal FT cancer; dbSNP:rs63751145)" FT /evidence="ECO:0000269|PubMed:8872463" FT /id="VAR_004455" FT VARIANT 506 FT /note="V -> A (in LYNCH2; dbSNP:rs63749909)" FT /evidence="ECO:0000269|PubMed:8574961" FT /id="VAR_004456" FT VARIANT 539 FT /note="A -> D (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607843)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054533" FT VARIANT 542 FT /note="Q -> L (in LYNCH2; type II; decreased mismatch FT repair activity; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004457" FT VARIANT 542 FT /note="Q -> P (in LYNCH2; dbSNP:rs63750511)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043417" FT VARIANT 549 FT /note="L -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750289)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:8797773" FT /id="VAR_012921" FT VARIANT 550 FT /note="L -> P (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750193)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043418" FT VARIANT 551 FT /note="N -> T (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63750271)" FT /evidence="ECO:0000269|PubMed:18561205, FT ECO:0000269|PubMed:9399661, ECO:0000269|PubMed:9833759" FT /id="VAR_012922" FT VARIANT 559 FT /note="L -> R (in LYNCH2; uncertain significance; FT dbSNP:rs63750059)" FT /evidence="ECO:0000269|PubMed:14635101" FT /id="VAR_022668" FT VARIANT 565 FT /note="I -> F (in LYNCH2; dbSNP:rs63750062)" FT /evidence="ECO:0000269|PubMed:9833759" FT /id="VAR_012923" FT VARIANT 574 FT /note="L -> P (in LYNCH2; type I; abrogates interaction FT with EXO1; loss of protein expression; dbSNP:rs63751608)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:15365995, ECO:0000269|PubMed:39032648, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8797773" FT /id="VAR_004458" FT VARIANT 578..632 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076348" FT VARIANT 578 FT /note="E -> G (in LYNCH2 and CRC; benign; no decrease in FT mismatch repair activity; no effect on nuclear FT localization; dbSNP:rs63751612)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:22753075" FT /id="VAR_004459" FT VARIANT 582 FT /note="L -> F (in LYNCH2; decreased mismatch repair FT activity; no effect on nuclear localization; FT dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:22753075" FT /id="VAR_076349" FT VARIANT 582 FT /note="L -> V (in LYNCH2; type II; dbSNP:rs63751713)" FT /evidence="ECO:0000269|PubMed:7757073" FT /id="VAR_004460" FT VARIANT 585 FT /note="L -> R (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607865)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054534" FT VARIANT 586 FT /note="A -> P (in LYNCH2; dbSNP:rs63751176)" FT /evidence="ECO:0000269|PubMed:12655562" FT /id="VAR_015689" FT VARIANT 588 FT /note="L -> P (in LYNCH2; dbSNP:rs63750575)" FT /evidence="ECO:0000269|PubMed:10777691" FT /id="VAR_012924" FT VARIANT 589 FT /note="A -> D (in LYNCH2; decreased mismatch repair FT activity; loss of interaction with PMS2 and EXO1; loss of FT protein expression; may lose nuclear localization; FT dbSNP:rs63750016)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:39032648" FT /id="VAR_043419" FT VARIANT 596 FT /note="Missing (in LYNCH2)" FT /id="VAR_043420" FT VARIANT 601 FT /note="D -> G (in CRC; uncertain significance; FT dbSNP:rs63750718)" FT /evidence="ECO:0000269|PubMed:12655564" FT /id="VAR_043421" FT VARIANT 603 FT /note="P -> R (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs63750876)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18561205" FT /id="VAR_012925" FT VARIANT 607 FT /note="L -> H (in LYNCH2; likely benign; no effect on MLH1 FT splicing; dbSNP:rs41295284)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11369138, ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012926" FT VARIANT 612 FT /note="Missing (in LYNCH2; loss of protein expression; loss FT of nuclear localization)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043422" FT VARIANT 616 FT /note="Missing (in LYNCH2 and MMRCS1; abrogates interaction FT with EXO1; loss of protein expression; loss of nuclear FT localization; no effect on MLH1 splicing)" FT /evidence="ECO:0000269|PubMed:10480359, FT ECO:0000269|PubMed:11427529, ECO:0000269|PubMed:14635101, FT ECO:0000269|PubMed:14961575, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:7661930, FT ECO:0000269|PubMed:8571956, ECO:0000269|PubMed:8872463, FT ECO:0000269|PubMed:8993976, ECO:0000269|PubMed:9311737" FT /id="VAR_004461" FT VARIANT 618 FT /note="K -> A (in LYNCH2; benign; interacts weakly with FT PMS2; no decrease in mismatch repair activity; no effect on FT nuclear localization; requires 2 nucleotide substitutions; FT dbSNP:rs35502531)" FT /evidence="ECO:0000269|PubMed:10598809, FT ECO:0000269|PubMed:10713887, ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11870161, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:12373605, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004462" FT VARIANT 618 FT /note="K -> R (in CRC; likely benign; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043424" FT VARIANT 618 FT /note="K -> T (in LYNCH2; benign; type II; loss of nuclear FT localization; dbSNP:rs63750449)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11839723, ECO:0000269|PubMed:12095971, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:7757073, ECO:0000269|PubMed:8872463" FT /id="VAR_004463" FT VARIANT 618 FT /note="Missing (in LYNCH2; dbSNP:rs63751247)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043423" FT VARIANT 619 FT /note="A -> P (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607866)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054535" FT VARIANT 622 FT /note="L -> H (in LYNCH2; dbSNP:rs63750693)" FT /evidence="ECO:0000269|PubMed:11748856" FT /id="VAR_012927" FT VARIANT 623 FT /note="A -> P (in LYNCH2; uncertain significance; FT dbSNP:rs587778951)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043425" FT VARIANT 626..627 FT /note="FS -> ST (in LYNCH2)" FT /evidence="ECO:0000269|PubMed:9048925" FT /id="VAR_004464" FT VARIANT 631 FT /note="D -> A (in LYNCH2; uncertain significance; FT dbSNP:rs63750240)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043426" FT VARIANT 633..663 FT /note="Missing (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2; loss of FT protein expression; loss of nuclear localization)" FT /evidence="ECO:0000269|PubMed:21120944" FT /id="VAR_076350" FT VARIANT 635 FT /note="N -> K (in gastric cancer; uncertain significance; FT dbSNP:rs63751047)" FT /evidence="ECO:0000269|PubMed:12132870" FT /id="VAR_043427" FT VARIANT 636 FT /note="L -> P (in LYNCH2; dbSNP:rs63750825)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043428" FT VARIANT 640 FT /note="P -> L (risk factor for LYNCH2; no effect on MLH1 FT splicing; dbSNP:rs267607875)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054536" FT VARIANT 640 FT /note="P -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs63749792)" FT /evidence="ECO:0000269|PubMed:15365995, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043429" FT VARIANT 646 FT /note="Y -> C (in LYNCH2; defective in interaction with FT PMS2 and EXO1; no decrease in mismatch repair activity; FT dbSNP:rs35045067)" FT /evidence="ECO:0000269|PubMed:11870161, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_043430" FT VARIANT 648 FT /note="P -> L (in LYNCH2; defective in interaction with FT PMS2 and EXO1; may lose nuclear localization; loss of FT protein expression; no decrease in mismatch repair FT activity; dbSNP:rs63750610)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075" FT /id="VAR_012928" FT VARIANT 648 FT /note="P -> S (in LYNCH2; the protein is unstable; loss of FT nuclear localization; loss of protein expression; no FT decrease in mismatch repair activity; dbSNP:rs63750899)" FT /evidence="ECO:0000269|PubMed:11839723, FT ECO:0000269|PubMed:15139004, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_022669" FT VARIANT 654 FT /note="P -> L (in LYNCH2; decreased mismatch repair FT activity; defective in interaction with PMS2 and EXO1; loss FT of protein expression; may lose nuclear localization; FT dbSNP:rs63750726)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075" FT /id="VAR_043431" FT VARIANT 655 FT /note="I -> V (in LYNCH2; likely benign; also found in an FT endometrial cancer sample; no effect on MLH1 splicing; FT dbSNP:rs55907433)" FT /evidence="ECO:0000269|PubMed:12115348, FT ECO:0000269|PubMed:18561205" FT /id="VAR_043432" FT VARIANT 656 FT /note="F -> S (in LYNCH2; no effect on MLH1 splicing; FT dbSNP:rs267607876)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054537" FT VARIANT 657 FT /note="Missing (in LYNCH2; uncertain significance)" FT /evidence="ECO:0000269|PubMed:16451135" FT /id="VAR_043433" FT VARIANT 659 FT /note="R -> L (in LYNCH2; dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:10713887, FT ECO:0000269|PubMed:11427529" FT /id="VAR_012929" FT VARIANT 659 FT /note="R -> P (in LYNCH2; interacts only very weakly with FT PMS2; abrogates interaction with EXO1; decreased mismatch FT repair activity; may lose nuclear localization; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:11793442, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:20020535, FT ECO:0000269|PubMed:21120944, ECO:0000269|PubMed:22753075, FT ECO:0000269|PubMed:9311737" FT /id="VAR_004465" FT VARIANT 659 FT /note="R -> Q (in LYNCH2; uncertain significance; FT dbSNP:rs63749900)" FT /evidence="ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:21120944" FT /id="VAR_043434" FT VARIANT 662 FT /note="T -> P (in LYNCH2; dbSNP:rs587778964)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:11754112" FT /id="VAR_012930" FT VARIANT 666 FT /note="W -> R (in LYNCH2; uncertain significance; no effect FT on MLH1 splicing; dbSNP:rs267607887)" FT /evidence="ECO:0000269|PubMed:18561205" FT /id="VAR_054538" FT VARIANT 681 FT /note="A -> T (in LYNCH2 and CRC; abrogates interaction FT with EXO1; no decrease in mismatch repair activity; FT dbSNP:rs63750217)" FT /evidence="ECO:0000269|PubMed:11427529, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16083711, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:18561205, ECO:0000269|PubMed:21120944" FT /id="VAR_004466" FT VARIANT 687 FT /note="R -> W (in LYNCH2; dbSNP:rs63751275)" FT /evidence="ECO:0000269|PubMed:11748856, FT ECO:0000269|PubMed:12362047, ECO:0000269|PubMed:16451135, FT ECO:0000269|PubMed:21120944" FT /id="VAR_012931" FT VARIANT 689 FT /note="Q -> R (in LYNCH2; benign; dbSNP:rs63750702)" FT /evidence="ECO:0000269|PubMed:11726306, FT ECO:0000269|PubMed:18033691, ECO:0000269|PubMed:18561205" FT /id="VAR_012932" FT VARIANT 716 FT /note="V -> M (no decrease in mismatch repair activity; no FT effect on nuclear localization; dbSNP:rs35831931)" FT /evidence="ECO:0000269|PubMed:10573010, FT ECO:0000269|PubMed:11726306, ECO:0000269|PubMed:12200596, FT ECO:0000269|PubMed:16083711, ECO:0000269|PubMed:18033691, FT ECO:0000269|PubMed:20020535, ECO:0000269|PubMed:21120944, FT ECO:0000269|PubMed:22753075, ECO:0000269|PubMed:9833759" FT /id="VAR_012933" FT VARIANT 718 FT /note="H -> Y (in LYNCH2; benign; dbSNP:rs2020873)" FT /evidence="ECO:0000269|PubMed:10386556, FT ECO:0000269|PubMed:12095971, ECO:0000269|PubMed:18033691" FT /id="VAR_004467" FT VARIANT 719 FT /note="I -> INVFHI (in LYNCH2)" FT /id="VAR_043435" FT VARIANT 724 FT /note="L -> M (in LYNCH2; dbSNP:rs63749875)" FT /evidence="ECO:0000269|PubMed:15365995" FT /id="VAR_043436" FT VARIANT 725 FT /note="R -> H (reduces by 60% protein expression; FT dbSNP:rs566928243)" FT /evidence="ECO:0000269|PubMed:28494185" FT /id="VAR_079816" FT VARIANT 729 FT /note="L -> V (in dbSNP:rs1800149)" FT /id="VAR_004468" FT VARIANT 749 FT /note="L -> P (in CRC; dbSNP:rs267607894)" FT /evidence="ECO:0000269|PubMed:14504054" FT /id="VAR_043437" FT VARIANT 751 FT /note="K -> R (in LYNCH2; likely benign; FT dbSNP:rs140195825)" FT /evidence="ECO:0000269|PubMed:11139242, FT ECO:0000269|PubMed:16451135, ECO:0000269|PubMed:18033691" FT /id="VAR_012934" FT VARIANT 755 FT /note="R -> W (in HNPCC; incomplete; dbSNP:rs267607900)" FT /evidence="ECO:0000269|PubMed:10480359" FT /id="VAR_012935" FT MUTAGEN 33 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 241, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 33 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-241, R-361 and R- FT 377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-361 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 241 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-361 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 361 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-377." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->Q: Abolishes acetylation; when associated with Q- FT 33, Q-241 and Q-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 377 FT /note="K->R: Abolishes acetylation and binding affinity for FT MSH6 and MSH2; when associated with R-33, R-241 and R-361." FT /evidence="ECO:0000269|PubMed:30770470" FT MUTAGEN 471 FT /note="K->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT MUTAGEN 472 FT /note="R->N: Affects binding to importins alpha, including FT KPNA2, hence may affect import to the nucleus." FT /evidence="ECO:0000269|PubMed:29175432" FT CONFLICT 352 FT /note="L -> H (in Ref. 6; BAG60773)" FT /evidence="ECO:0000305" FT CONFLICT 708..711 FT /note="Missing (in Ref. 4; AAA85687)" FT /evidence="ECO:0000305" FT HELIX 13..25 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 28..41 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 45..52 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 53..56 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 57..63 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 70..72 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 73..77 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 103..109 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 110..118 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 122..131 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 134..137 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 140..142 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 146..154 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 155..158 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 160..165 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 169..186 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 187..189 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 190..196 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 203..205 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 212..220 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 222..225 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 228..235 FT /evidence="ECO:0007829|PDB:4P7A" FT TURN 236..239 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 240..247 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 253..255 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 270..281 FT /evidence="ECO:0007829|PDB:4P7A" FT STRAND 291..298 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 322..335 FT /evidence="ECO:0007829|PDB:4P7A" FT HELIX 504..516 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 519..526 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 529..543 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 546..551 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 552..566 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 572..581 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 582..590 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 593..595 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 604..626 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 634..641 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 650..652 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 653..662 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 669..684 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 688..690 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 712..718 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 720..724 FT /evidence="ECO:0007829|PDB:3RBN" FT HELIX 732..735 FT /evidence="ECO:0007829|PDB:3RBN" FT STRAND 737..745 FT /evidence="ECO:0007829|PDB:3RBN" SQ SEQUENCE 756 AA; 84601 MW; C9231FC406C2CA20 CRC64; MSFVAGVIRR LDETVVNRIA AGEVIQRPAN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ IQDNGTGIRK EDLDIVCERF TTSKLQSFED LASISTYGFR GEALASISHV AHVTITTKTA DGKCAYRASY SDGKLKAPPK PCAGNQGTQI TVEDLFYNIA TRRKALKNPS EEYGKILEVV GRYSVHNAGI SFSVKKQGET VADVRTLPNA STVDNIRSIF GNAVSRELIE IGCEDKTLAF KMNGYISNAN YSVKKCIFLL FINHRLVEST SLRKAIETVY AAYLPKNTHP FLYLSLEISP QNVDVNVHPT KHEVHFLHEE SILERVQQHI ESKLLGSNSS RMYFTQTLLP GLAGPSGEMV KSTTSLTSSS TSGSSDKVYA HQMVRTDSRE QKLDAFLQPL SKPLSSQPQA IVTEDKTDIS SGRARQQDEE MLELPAPAEV AAKNQSLEGD TTKGTSEMSE KRGPTSSNPR KRHREDSDVE MVEDDSRKEM TAACTPRRRI INLTSVLSLQ EEINEQGHEV LREMLHNHSF VGCVNPQWAL AQHQTKLYLL NTTKLSEELF YQILIYDFAN FGVLRLSEPA PLFDLAMLAL DSPESGWTEE DGPKEGLAEY IVEFLKKKAE MLADYFSLEI DEEGNLIGLP LLIDNYVPPL EGLPIFILRL ATEVNWDEEK ECFESLSKEC AMFYSIRKQY ISEESTLSGQ QSEVPGSIPN SWKWTVEHIV YKALRSHILP PKHFTEDGNI LQLANLPDLY KVFERC // ID MTOR_HUMAN Reviewed; 2549 AA. AC P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 243. DE RecName: Full=Serine/threonine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423}; DE AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1; DE AltName: Full=FKBP12-rapamycin complex-associated protein; DE AltName: Full=Mammalian target of rapamycin; DE Short=mTOR; DE AltName: Full=Mechanistic target of rapamycin; DE AltName: Full=Rapamycin and FKBP12 target 1; DE AltName: Full=Rapamycin target protein 1; DE AltName: Full=Tyrosine-protein kinase mTOR {ECO:0000305}; DE EC=2.7.10.2 {ECO:0000305|PubMed:26584640}; GN Name=MTOR {ECO:0000312|HGNC:HGNC:3942}; GN Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Brain; RX PubMed=8008069; DOI=10.1038/369756a0; RA Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., RA Schreiber S.L.; RT "A mammalian protein targeted by G1-arresting rapamycin-receptor complex."; RL Nature 369:756-758(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA]. RX PubMed=9653645; DOI=10.1006/geno.1997.5186; RA Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.; RT "Molecular cloning and expression analysis of five novel genes in RT chromosome 1p36."; RL Genomics 50:187-198(1998). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M., Ohara R., RA Okazaki N., Koga H., Nagase T., Ohara O.; RT "Preparation of a set of expression-ready clones of mammalian long cDNAs RT encoding large proteins by the ORF trap cloning method."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Cerebellum; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549. RX PubMed=11426320; DOI=10.1038/sj.gene.6363745; RA Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C., RA Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S., RA Fujita T., Schwaeble W.; RT "The human gene for mannan-binding lectin-associated serine protease-2 RT (MASP-2), the effector component of the lectin route of complement RT activation, is part of a tightly linked gene cluster on chromosome 1p36.2- RT 3."; RL Genes Immun. 2:119-127(2001). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY. RC TISSUE=B-cell; RX PubMed=7809080; DOI=10.1073/pnas.91.26.12574; RA Chiu M.I., Katz H., Berlin V.; RT "RAPT1, a mammalian homolog of yeast Tor, interacts with the RT FKBP12/rapamycin complex."; RL Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994). RN [8] RP SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION. RX PubMed=9434772; DOI=10.1006/bbrc.1997.7878; RA Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M., Alarcon C.M., RA Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.; RT "Expression, enzyme activity, and subcellular localization of mammalian RT target of rapamycin in insulin-responsive cells."; RL Biochem. Biophys. Res. Commun. 241:704-709(1997). RN [9] RP INTERACTION WITH UBQLN1. RX PubMed=11853878; DOI=10.1016/s0167-4889(01)00164-1; RA Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.; RT "Characterization of ubiquilin 1, an mTOR-interacting protein."; RL Biochim. Biophys. Acta 1542:41-56(2002). RN [10] RP FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, CATALYTIC ACTIVITY, FUNCTION IN RP PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR. RX PubMed=12150925; DOI=10.1016/s0092-8674(02)00808-5; RA Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "mTOR interacts with raptor to form a nutrient-sensitive complex that RT signals to the growth machinery."; RL Cell 110:163-175(2002). RN [11] RP FUNCTION, AND INTERACTION WITH RPTOR. RX PubMed=12150926; DOI=10.1016/s0092-8674(02)00833-4; RA Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., RA Tokunaga C., Avruch J., Yonezawa K.; RT "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR RT action."; RL Cell 110:177-189(2002). RN [12] RP INTERACTION WITH CLIP1, FUNCTION IN PHOSPHORYLATION OF CLIP1, AND CATALYTIC RP ACTIVITY. RX PubMed=12231510; DOI=10.1093/embo-reports/kvf197; RA Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F.; RT "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase."; RL EMBO Rep. 3:988-994(2002). RN [13] RP FUNCTION IN PHOSPHORYLATION OF RPS6KB2, AND CATALYTIC ACTIVITY. RX PubMed=12087098; DOI=10.1074/jbc.m204080200; RA Park I.H., Bachmann R., Shirazi H., Chen J.; RT "Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin."; RL J. Biol. Chem. 277:31423-31429(2002). RN [14] RP INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP TISSUE SPECIFICITY. RX PubMed=12408816; DOI=10.1016/s1097-2765(02)00636-6; RA Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., RA Bonenfant D., Oppliger W., Jenoe P., Hall M.N.; RT "Two TOR complexes, only one of which is rapamycin sensitive, have distinct RT roles in cell growth control."; RL Mol. Cell 10:457-468(2002). RN [15] RP SUBCELLULAR LOCATION. RX PubMed=11930000; DOI=10.1073/pnas.261702698; RA Desai B.N., Myers B.R., Schreiber S.L.; RT "FKBP12-rapamycin-associated protein associates with mitochondria and RT senses osmotic stress via mitochondrial dysfunction."; RL Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002). RN [16] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY. RX PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2; RA Inoki K., Zhu T., Guan K.L.; RT "TSC2 mediates cellular energy response to control cell growth and RT survival."; RL Cell 115:577-590(2003). RN [17] RP FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH MLST8. RX PubMed=12718876; DOI=10.1016/s1097-2765(03)00114-x; RA Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "GbetaL, a positive regulator of the rapamycin-sensitive pathway required RT for the nutrient-sensitive interaction between raptor and mTOR."; RL Mol. Cell 11:895-904(2003). RN [18] RP FUNCTION IN PHOSPHORYLATION OF PRKCA, CATALYTIC ACTIVITY, FUNCTION IN RP REGULATION OF THE ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, RP AND INTERACTION WITH RICTOR. RX PubMed=15268862; DOI=10.1016/j.cub.2004.06.054; RA Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R., RA Erdjument-Bromage H., Tempst P., Sabatini D.M.; RT "Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive RT and raptor-independent pathway that regulates the cytoskeleton."; RL Curr. Biol. 14:1296-1302(2004). RN [19] RP ACTIVITY REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA. RX PubMed=15545625; DOI=10.1101/gad.1256804; RA Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., RA Witters L.A., Ellisen L.W., Kaelin W.G. Jr.; RT "Regulation of mTOR function in response to hypoxia by REDD1 and the RT TSC1/TSC2 tumor suppressor complex."; RL Genes Dev. 18:2893-2904(2004). RN [20] RP SUBCELLULAR LOCATION. RX PubMed=14578359; DOI=10.1074/jbc.m305912200; RA Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.; RT "FKBP12-rapamycin-associated protein or mammalian target of rapamycin RT (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi RT apparatus."; RL J. Biol. Chem. 279:772-778(2004). RN [21] RP FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, CATALYTIC ACTIVITY, RP FUNCTION IN PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX, RP INTERACTION WITH RICTOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION. RX PubMed=15467718; DOI=10.1038/ncb1183; RA Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N.; RT "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin RT insensitive."; RL Nat. Cell Biol. 6:1122-1128(2004). RN [22] RP PHOSPHORYLATION AT SER-2448. RX PubMed=15899889; DOI=10.1074/jbc.m501707200; RA Chiang G.G., Abraham R.T.; RT "Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is RT mediated by p70S6 kinase."; RL J. Biol. Chem. 280:25485-25490(2005). RN [23] RP PHOSPHORYLATION AT THR-2446 AND SER-2448. RX PubMed=15905173; DOI=10.1074/jbc.m504045200; RA Holz M.K., Blenis J.; RT "Identification of S6 kinase 1 as a novel mammalian target of rapamycin RT (mTOR)-phosphorylating kinase."; RL J. Biol. Chem. 280:26089-26093(2005). RN [24] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=15718470; DOI=10.1126/science.1106148; RA Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.; RT "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex."; RL Science 307:1098-1101(2005). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=17517883; DOI=10.1074/jbc.m702636200; RA Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., RA Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K.; RT "The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological RT substrate of mammalian target of rapamycin complex 1."; RL J. Biol. Chem. 282:20329-20339(2007). RN [26] RP IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5. RX PubMed=17599906; DOI=10.1074/jbc.m704343200; RA Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I., RA Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.; RT "PRR5, a novel component of mTOR complex 2, regulates platelet-derived RT growth factor receptor beta expression and signaling."; RL J. Biol. Chem. 282:25604-25612(2007). RN [27] RP INTERACTION WITH AKT1S1, AND ACTIVITY REGULATION. RX PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003; RA Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., RA Spooner E., Carr S.A., Sabatini D.M.; RT "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase."; RL Mol. Cell 25:903-915(2007). RN [28] RP IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, CATALYTIC ACTIVITY, AND RP FUNCTION IN PHOSPHORYLATION OF RPS6KB1 AND SGK1. RX PubMed=18925875; DOI=10.1042/bj20081668; RA Garcia-Martinez J.M., Alessi D.R.; RT "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and RT activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)."; RL Biochem. J. 416:375-385(2008). RN [29] RP FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH. RX PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007; RA Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., RA Griffiths J.R., Chung Y.L., Schulze A.; RT "SREBP activity is regulated by mTORC1 and contributes to Akt-dependent RT cell growth."; RL Cell Metab. 8:224-236(2008). RN [30] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=18372248; DOI=10.1074/jbc.m800723200; RA Wang L., Harris T.E., Lawrence J.C. Jr.; RT "Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by RT mammalian target of rapamycin complex 1 (mTORC1)-mediated RT phosphorylation."; RL J. Biol. Chem. 283:15619-15627(2008). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [32] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [33] RP FUNCTION, ACTIVITY REGULATION, AND SUBCELLULAR LOCATION. RX PubMed=18497260; DOI=10.1126/science.1157535; RA Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., RA Bar-Peled L., Sabatini D.M.; RT "The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1."; RL Science 320:1496-1501(2008). RN [34] RP INTERACTION WITH DEPTOR, AND ACTIVITY REGULATION. RX PubMed=19446321; DOI=10.1016/j.cell.2009.03.046; RA Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., RA Gray N.S., Sabatini D.M.; RT "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma RT cells and required for their survival."; RL Cell 137:873-886(2009). RN [35] RP PHOSPHORYLATION AT SER-1261, AND ACTIVITY REGULATION. RX PubMed=19487463; DOI=10.1128/mcb.01665-08; RA Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., RA Feener E.P., Ballif B.A., Fingar D.C.; RT "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and RT cell growth."; RL Mol. Cell. Biol. 29:4308-4324(2009). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [37] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [38] RP PHOSPHORYLATION AT SER-2448. RX PubMed=19145465; DOI=10.1007/s00726-008-0230-7; RA Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.; RT "mTOR phosphorylated at S2448 binds to raptor and rictor."; RL Amino Acids 38:223-228(2010). RN [39] RP SUBCELLULAR LOCATION, AND ACTIVITY REGULATION. RX PubMed=20381137; DOI=10.1016/j.cell.2010.02.024; RA Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M.; RT "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is RT necessary for its activation by amino acids."; RL Cell 141:290-303(2010). RN [40] RP FUNCTION IN PHOSPHORYLATION OF DAP, FUNCTION IN AUTOPHAGY, AND CATALYTIC RP ACTIVITY. RX PubMed=20537536; DOI=10.1016/j.cub.2010.04.041; RA Koren I., Reem E., Kimchi A.; RT "DAP1, a novel substrate of mTOR, negatively regulates autophagy."; RL Curr. Biol. 20:1093-1098(2010). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-2481. RX PubMed=20022946; DOI=10.1074/jbc.m109.096222; RA Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., RA Fingar D.C.; RT "mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic RT activity and clarifies rapamycin mechanism of action."; RL J. Biol. Chem. 285:7866-7879(2010). RN [42] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=21376236; DOI=10.1016/j.cell.2011.02.014; RA Zinzalla V., Stracka D., Oppliger W., Hall M.N.; RT "Activation of mTORC2 by association with the ribosome."; RL Cell 144:757-768(2011). RN [43] RP INTERACTION WITH TTI1. RX PubMed=20810650; DOI=10.1101/gad.1934210; RA Hurov K.E., Cotta-Ramusino C., Elledge S.J.; RT "A genetic screen identifies the Triple T complex required for DNA damage RT signaling and ATM and ATR stability."; RL Genes Dev. 24:1939-1950(2010). RN [44] RP INTERACTION WITH TELO2. RX PubMed=20801936; DOI=10.1101/gad.1956410; RA Takai H., Xie Y., de Lange T., Pavletich N.P.; RT "Tel2 structure and function in the Hsp90-dependent maturation of mTOR and RT ATR complexes."; RL Genes Dev. 24:2019-2030(2010). RN [45] RP INTERACTION WITH TELO2 AND TTI1. RX PubMed=20427287; DOI=10.1074/jbc.m110.121699; RA Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K., RA Iemura S., Natsume T., Mizushima N.; RT "Tti1 and Tel2 are critical factors in mammalian target of rapamycin RT complex assembly."; RL J. Biol. Chem. 285:20109-20116(2010). RN [46] RP FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, FUNCTION IN RP PHOSPHORYLATION OF MAF1, AND CATALYTIC ACTIVITY. RX PubMed=20516213; DOI=10.1128/mcb.00319-10; RA Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W., RA Reina J.H., Hall M.N., Hernandez N.; RT "mTORC1 directly phosphorylates and regulates human MAF1."; RL Mol. Cell. Biol. 30:3749-3757(2010). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [48] RP SUBCELLULAR LOCATION. RX PubMed=21867682; DOI=10.1016/j.bbrc.2011.08.034; RA Boulbes D.R., Shaiken T., Sarbassov D.D.; RT "Endoplasmic reticulum is a main localization site of mTORC2."; RL Biochem. Biophys. Res. Commun. 413:46-52(2011). RN [49] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [50] RP PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF RP SER-2159 AND THR-2164. RX PubMed=21576368; DOI=10.1128/mcb.05437-11; RA Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., RA Fingar D.C.; RT "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, RT and cell cycle progression."; RL Mol. Cell. Biol. 31:2787-2801(2011). RN [51] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [52] RP FUNCTION IN PHOSPHORYLATION OF GRB10, CATALYTIC ACTIVITY, AND FUNCTION IN RP INSR-DEPENDENT SIGNALING. RX PubMed=21659604; DOI=10.1126/science.1199498; RA Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., RA Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M.; RT "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated RT inhibition of growth factor signaling."; RL Science 332:1317-1322(2011). RN [53] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22576015; DOI=10.4161/auto.19653; RA Martina J.A., Chen Y., Gucek M., Puertollano R.; RT "MTORC1 functions as a transcriptional regulator of autophagy by preventing RT nuclear transport of TFEB."; RL Autophagy 8:903-914(2012). RN [54] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22343943; DOI=10.1038/emboj.2012.32; RA Settembre C., Zoncu R., Medina D.L., Vetrini F., Erdin S., Erdin S., RA Huynh T., Ferron M., Karsenty G., Vellard M.C., Facchinetti V., RA Sabatini D.M., Ballabio A.; RT "A lysosome-to-nucleus signalling mechanism senses and regulates the RT lysosome via mTOR and TFEB."; RL EMBO J. 31:1095-1108(2012). RN [55] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22692423; DOI=10.1126/scisignal.2002790; RA Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., RA Angarola B., Walther T.C., Ferguson S.M.; RT "The transcription factor TFEB links mTORC1 signaling to transcriptional RT control of lysosome homeostasis."; RL Sci. Signal. 5:RA42-RA42(2012). RN [56] RP INTERACTION WITH HTR6. RX PubMed=23027611; DOI=10.1002/emmm.201201410; RA Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F., Watson D.J., RA Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P., Herve D., RA Fone K.C., Bockaert J., Millan M.J., Marin P.; RT "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed RT cognition in schizophrenia."; RL EMBO Mol. Med. 4:1043-1056(2012). RN [57] RP ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [58] RP FUNCTION, AND INTERACTION WITH TPCN1 AND TPCN2. RX PubMed=23394946; DOI=10.1016/j.cell.2013.01.023; RA Cang C., Zhou Y., Navarro B., Seo Y.J., Aranda K., Shi L., RA Battaglia-Hsu S., Nissim I., Clapham D.E., Ren D.; RT "mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to RT metabolic state."; RL Cell 152:778-790(2013). RN [59] RP FUNCTION. RX PubMed=23426360; DOI=10.1074/jbc.m112.441493; RA Eaton J.M., Mullins G.R., Brindley D.N., Harris T.E.; RT "Phosphorylation of lipin 1 and charge on the phosphatidic acid head group RT control its phosphatidic acid phosphatase activity and membrane RT association."; RL J. Biol. Chem. 288:9933-9945(2013). RN [60] RP INTERACTION WITH BRAT1. RX PubMed=25657994; RA So E.Y., Ouchi T.; RT "The potential role of BRCA1-associated ATM activator-1 (BRAT1) in RT regulation of mTOR."; RL J. Cancer Biol. Res. 1:0-0(2013). RN [61] RP PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173. RX PubMed=24247430; DOI=10.1083/jcb.201305103; RA Halova L., Du W., Kirkham S., Smith D.L., Petersen J.; RT "Phosphorylation of the TOR ATP binding domain by AGC kinase constitutes a RT novel mode of TOR inhibition."; RL J. Cell Biol. 203:595-604(2013). RN [62] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [63] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=23524951; DOI=10.1038/ncb2708; RA Nazio F., Strappazzon F., Antonioli M., Bielli P., Cianfanelli V., RA Bordi M., Gretzmeier C., Dengjel J., Piacentini M., Fimia G.M., Cecconi F.; RT "mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self- RT association and function through AMBRA1 and TRAF6."; RL Nat. Cell Biol. 15:406-416(2013). RN [64] RP INTERACTION WITH NBN. RX PubMed=23762398; DOI=10.1371/journal.pone.0065586; RA Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C., Wu K.J.; RT "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through specific RT domains."; RL PLoS ONE 8:E65586-E65586(2013). RN [65] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429704; DOI=10.1126/science.1228771; RA Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., RA Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.; RT "Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine RT synthesis."; RL Science 339:1320-1323(2013). RN [66] RP FUNCTION, AND REGULATION OF PYRIMIDINE SYNTHESIS. RX PubMed=23429703; DOI=10.1126/science.1228792; RA Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.; RT "Stimulation of de novo pyrimidine synthesis by growth signaling through RT mTOR and S6K1."; RL Science 339:1323-1328(2013). RN [67] RP FUNCTION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=24403073; DOI=10.1074/jbc.m113.482067; RA Coffman K., Yang B., Lu J., Tetlow A.L., Pelliccio E., Lu S., Guo D.C., RA Tang C., Dong M.Q., Tamanoi F.; RT "Characterization of the Raptor/4E-BP1 interaction by chemical cross- RT linking coupled with mass spectrometry analysis."; RL J. Biol. Chem. 289:4723-4734(2014). RN [68] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [69] RP FUNCTION. RX PubMed=24670654; DOI=10.1038/nature13079; RA Liu P., Begley M., Michowski W., Inuzuka H., Ginzberg M., Gao D., Tsou P., RA Gan W., Papa A., Kim B.M., Wan L., Singh A., Zhai B., Yuan M., Wang Z., RA Gygi S.P., Lee T.H., Lu K.P., Toker A., Pandolfi P.P., Asara J.M., RA Kirschner M.W., Sicinski P., Cantley L., Wei W.; RT "Cell-cycle-regulated activation of Akt kinase by phosphorylation at its RT carboxyl terminus."; RL Nature 508:541-545(2014). RN [70] RP FUNCTION. RX PubMed=24448649; DOI=10.1126/scisignal.2004754; RA Martina J.A., Diab H.I., Lishu L., Jeong-A L., Patange S., Raben N., RA Puertollano R.; RT "The nutrient-responsive transcription factor TFE3 promotes autophagy, RT lysosomal biogenesis, and clearance of cellular debris."; RL Sci. Signal. 7:ra9-ra9(2014). RN [71] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=25851998; DOI=10.1002/ajmg.a.37070; RA Baynam G., Overkov A., Davis M., Mina K., Schofield L., Allcock R., RA Laing N., Cook M., Dawkins H., Goldblatt J.; RT "A germline MTOR mutation in Aboriginal Australian siblings with RT intellectual disability, dysmorphism, macrocephaly, and small thoraces."; RL Am. J. Med. Genet. A 167:1659-1667(2015). RN [72] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 ASP-1459; PRO-1460; RP PHE-2215 AND TYR-2215, AND CHARACTERIZATION OF VARIANTS FCORD2 ASP-1459; RP PRO-1460; PHE-2215 AND TYR-2215. RX PubMed=26018084; DOI=10.1002/ana.24444; RA Nakashima M., Saitsu H., Takei N., Tohyama J., Kato M., Kitaura H., RA Shiina M., Shirozu H., Masuda H., Watanabe K., Ohba C., Tsurusaki Y., RA Miyake N., Zheng Y., Sato T., Takebayashi H., Ogata K., Kameyama S., RA Kakita A., Matsumoto N.; RT "Somatic mutations in the MTOR gene cause focal cortical dysplasia type RT IIb."; RL Ann. Neurol. 78:375-386(2015). RN [73] RP INVOLVEMENT IN SKS, VARIANT SKS LYS-1799, AND CHARACTERIZATION OF VARIANT RP SKS LYS-1799. RX PubMed=26542245; DOI=10.1186/s12881-015-0240-8; RA Mroske C., Rasmussen K., Shinde D.N., Huether R., Powis Z., Lu H.M., RA Baxter R.M., McPherson E., Tang S.; RT "Germline activating MTOR mutation arising through gonadal mosaicism in two RT brothers with megalencephaly and neurodevelopmental abnormalities."; RL BMC Med. Genet. 16:102-102(2015). RN [74] RP FUNCTION IN PHOSPHORYLATION OF AMBRA1. RX PubMed=25438055; DOI=10.1038/ncb3072; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RT "AMBRA1 links autophagy to cell proliferation and tumorigenesis by RT promoting c-Myc dephosphorylation and degradation."; RL Nat. Cell Biol. 17:20-30(2015). RN [75] RP ERRATUM OF PUBMED:25438055. RX PubMed=25925585; DOI=10.1038/ncb3171; RA Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., RA Gherardini P.F., De Zio D., Nazio F., Antonioli M., D'Orazio M., Skobo T., RA Bordi M., Rohde M., Dalla Valle L., Helmer-Citterich M., Gretzmeier C., RA Dengjel J., Fimia G.M., Piacentini M., Di Bartolomeo S., Velasco G., RA Cecconi F.; RL Nat. Cell Biol. 17:706-706(2015). RN [76] RP FUNCTION, INVOLVEMENT IN FCORD2, VARIANTS FCORD2 HIS-624; ASP-1450; RP ARG-1483; HIS-1709; LYS-1977; CYS-2193; PHE-2215; GLN-2427 AND PRO-2427, RP AND CHARACTERIZATION OF VARIANTS FCORD2 ARG-1483; GLN-2427 AND PRO-2427. RX PubMed=25799227; DOI=10.1038/nm.3824; RA Lim J.S., Kim W.I., Kang H.C., Kim S.H., Park A.H., Park E.K., Cho Y.W., RA Kim S., Kim H.M., Kim J.A., Kim J., Rhee H., Kang S.G., Kim H.D., Kim D., RA Kim D.S., Lee J.H.; RT "Brain somatic mutations in MTOR cause focal cortical dysplasia type II RT leading to intractable epilepsy."; RL Nat. Med. 21:395-400(2015). RN [77] RP ACTIVITY REGULATION. RX PubMed=25561175; DOI=10.1038/nature14107; RA Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M., RA Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L., Bruckner M., RA Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W., Heinz L.X., RA Kraft C., Bennett K.L., Indiveri C., Huber L.A., Superti-Furga G.; RT "SLC38A9 is a component of the lysosomal amino acid sensing machinery that RT controls mTORC1."; RL Nature 519:477-481(2015). RN [78] RP INVOLVEMENT IN FCORD2, AND VARIANT FCORD2 GLY-1456. RX PubMed=25878179; DOI=10.1212/wnl.0000000000001594; RA Leventer R.J., Scerri T., Marsh A.P., Pope K., Gillies G., Maixner W., RA MacGregor D., Harvey A.S., Delatycki M.B., Amor D.J., Crino P., Bahlo M., RA Lockhart P.J.; RT "Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in RT MTOR."; RL Neurology 84:2029-2032(2015). RN [79] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [80] RP ACTIVITY REGULATION. RX PubMed=25567906; DOI=10.1126/science.1257132; RA Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., RA Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T., Bar-Peled L., RA Zoncu R., Straub C., Kim C., Park J., Sabatini B.L., Sabatini D.M.; RT "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine RT sufficiency to mTORC1."; RL Science 347:188-194(2015). RN [81] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=26584640; DOI=10.1038/cr.2015.133; RA Yin Y., Hua H., Li M., Liu S., Kong Q., Shao T., Wang J., Luo Y., Wang Q., RA Luo T., Jiang Y.; RT "mTORC2 promotes type I insulin-like growth factor receptor and insulin RT receptor activation through the tyrosine kinase activity of mTOR."; RL Cell Res. 26:46-65(2016). RN [82] RP INTERACTION WITH WAC. RX PubMed=26812014; DOI=10.1016/j.devcel.2015.12.019; RA David-Morrison G., Xu Z., Rui Y.N., Charng W.L., Jaiswal M., Yamamoto S., RA Xiong B., Zhang K., Sandoval H., Duraine L., Zuo Z., Zhang S., Bellen H.J.; RT "WAC regulates mTOR activity by acting as an adaptor for the TTT and RT Pontin/Reptin complexes."; RL Dev. Cell 36:139-151(2016). RN [83] RP SUBCELLULAR LOCATION. RX PubMed=27623384; DOI=10.1016/j.devcel.2016.08.001; RA Krishna S., Palm W., Lee Y., Yang W., Bandyopadhyay U., Xu H., Florey O., RA Thompson C.B., Overholtzer M.; RT "PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following RT Engulfment."; RL Dev. Cell 38:536-547(2016). RN [84] RP INVOLVEMENT IN FCORD2, VARIANTS GLU-1376 AND VAL-2501, VARIANTS FCORD2 RP SER-1459; PRO-1460; PHE-2215 AND TYR-2215, AND VARIANTS SKS ARG-1490; RP ILE-1595; THR-1832; CYS-1888 AND ILE-2327. RX PubMed=27830187; DOI=10.1212/nxg.0000000000000118; RA Moeller R.S., Weckhuysen S., Chipaux M., Marsan E., Taly V., Bebin E.M., RA Hiatt S.M., Prokop J.W., Bowling K.M., Mei D., Conti V., de la Grange P., RA Ferrand-Sorbets S., Dorfmueller G., Lambrecq V., Larsen L.H., Leguern E., RA Guerrini R., Rubboli G., Cooper G.M., Baulac S.; RT "Germline and somatic mutations in the MTOR gene in focal cortical RT dysplasia and epilepsy."; RL Neurol. Genet. 2:E118-E118(2016). RN [85] RP FUNCTION. RX PubMed=30171069; DOI=10.1074/jbc.ra118.005354; RA Choppara S., Ganga S., Manne R., Dutta P., Singh S., Santra M.K.; RT "The SCFFBXO46 ubiquitin ligase complex mediates degradation of the tumor RT suppressor FBXO31 and thereby prevents premature cellular senescence."; RL J. Biol. Chem. 293:16291-16306(2018). RN [86] RP SUBCELLULAR LOCATION, AND INTERACTION WITH MEAK7. RX PubMed=29750193; DOI=10.1126/sciadv.aao5838; RA Nguyen J.T., Ray C., Fox A.L., Mendonca D.B., Kim J.K., Krebsbach P.H.; RT "Mammalian EAK-7 activates alternative mTOR signaling to regulate cell RT proliferation and migration."; RL Sci. Adv. 4:EAAO5838-EAAO5838(2018). RN [87] RP FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT SER-2159, AND MUTAGENESIS RP OF SER-2159. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [88] RP INTERACTION WITH TM4SF5, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-2357 RP AND VAL-2364. RX PubMed=30956113; DOI=10.1016/j.cmet.2019.03.005; RA Jung J.W., Macalino S.J.Y., Cui M., Kim J.E., Kim H.J., Song D.G., RA Nam S.H., Kim S., Choi S., Lee J.W.; RT "Transmembrane 4 L six family member 5 senses arginine for mTORC1 RT signaling."; RL Cell Metab. 29:1306-1319(2019). RN [89] RP FUNCTION. RX PubMed=30704899; DOI=10.1016/j.molcel.2018.12.017; RA Cheng X., Ma X., Zhu Q., Song D., Ding X., Li L., Jiang X., Wang X., RA Tian R., Su H., Shen Z., Chen S., Liu T., Gong W., Liu W., Sun Q.; RT "Pacer is a mediator of mTORC1 and GSK3-TIP60 signaling in regulation of RT autophagosome maturation and lipid metabolism."; RL Mol. Cell 73:1-15(2019). RN [90] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=31112131; DOI=10.7554/elife.43038; RA Jewell J.L., Fu V., Hong A.W., Yu F.X., Meng D., Melick C.H., Wang H., RA Lam W.M., Yuan H.X., Taylor S.S., Guan K.L.; RT "GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor."; RL Elife 8:0-0(2019). RN [91] RP FUNCTION. RX PubMed=31695197; DOI=10.1038/s41586-019-1738-6; RA MacVicar T., Ohba Y., Nolte H., Mayer F.C., Tatsuta T., Sprenger H.G., RA Lindner B., Zhao Y., Li J., Bruns C., Krueger M., Habich M., Riemer J., RA Schwarzer R., Pasparakis M., Henschke S., Bruening J.C., Zamboni N., RA Langer T.; RT "Lipid signalling drives proteolytic rewiring of mitochondria by YME1L."; RL Nature 575:361-365(2019). RN [92] RP INTERACTION WITH GPR137B. RX PubMed=31036939; DOI=10.1038/s41556-019-0321-6; RA Gan L., Seki A., Shen K., Iyer H., Han K., Hayer A., Wollman R., Ge X., RA Lin J.R., Dey G., Talbot W.S., Meyer T.; RT "The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 RT localization and activity."; RL Nat. Cell Biol. 21:614-626(2019). RN [93] RP FUNCTION. RX PubMed=31601708; DOI=10.1126/science.aay0166; RA Rogala K.B., Gu X., Kedir J.F., Abu-Remaileh M., Bianchi L.F., RA Bottino A.M.S., Dueholm R., Niehaus A., Overwijn D., Fils A.P., Zhou S.X., RA Leary D., Laqtom N.N., Brignole E.J., Sabatini D.M.; RT "Structural basis for the docking of mTORC1 on the lysosomal surface."; RL Science 366:468-475(2019). RN [94] RP INTERACTION WITH RICTOR. RX PubMed=33378666; DOI=10.1016/j.celrep.2020.108564; RA Wrobel L., Siddiqi F.H., Hill S.M., Son S.M., Karabiyik C., Kim H., RA Rubinsztein D.C.; RT "mTORC2 Assembly Is Regulated by USP9X-Mediated Deubiquitination of RT RICTOR."; RL Cell Rep. 33:108564-108564(2020). RN [95] RP FUNCTION, AND ACTIVITY REGULATION. RX PubMed=32612235; DOI=10.1038/s41586-020-2444-0; RA Napolitano G., Di Malta C., Esposito A., de Araujo M.E.G., Pece S., RA Bertalot G., Matarese M., Benedetti V., Zampelli A., Stasyk T., RA Siciliano D., Venuta A., Cesana M., Vilardo C., Nusco E., Monfregola J., RA Calcagni A., Di Fiore P.P., Huber L.A., Ballabio A.; RT "A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dube syndrome."; RL Nature 585:597-602(2020). RN [96] RP FUNCTION. RX PubMed=32561715; DOI=10.1038/s41467-020-16886-2; RA Son S.M., Park S.J., Stamatakou E., Vicinanza M., Menzies F.M., RA Rubinsztein D.C.; RT "Leucine regulates autophagy via acetylation of the mTORC1 component RT raptor."; RL Nat. Commun. 11:3148-3148(2020). RN [97] RP INTERACTION WITH NCKAP1L. RX PubMed=32647003; DOI=10.1126/science.aay5663; RA Cook S.A., Comrie W.A., Poli M.C., Similuk M., Oler A.J., Faruqi A.J., RA Kuhns D.B., Yang S., Vargas-Hernandez A., Carisey A.F., Fournier B., RA Anderson D.E., Price S., Smelkinson M., Abou Chahla W., Forbes L.R., RA Mace E.M., Cao T.N., Coban-Akdemir Z.H., Jhangiani S.N., Muzny D.M., RA Gibbs R.A., Lupski J.R., Orange J.S., Cuvelier G.D.E., Al Hassani M., RA Al Kaabi N., Al Yafei Z., Jyonouchi S., Raje N., Caldwell J.W., Huang Y., RA Burkhardt J.K., Latour S., Chen B., ElGhazali G., Rao V.K., Chinn I.K., RA Lenardo M.J.; RT "HEM1 deficiency disrupts mTORC2 and F-actin control in inherited RT immunodysregulatory disease."; RL Science 369:202-207(2020). RN [98] RP FUNCTION. RX PubMed=34289345; DOI=10.1016/j.cell.2021.06.028; RA Evavold C.L., Hafner-Bratkovic I., Devant P., D'Andrea J.M., Ngwa E.M., RA Borsic E., Doench J.G., LaFleur M.W., Sharpe A.H., Thiagarajah J.R., RA Kagan J.C.; RT "Control of gasdermin D oligomerization and pyroptosis by the Ragulator- RT Rag-mTORC1 pathway."; RL Cell 184:4495-4511(2021). RN [99] RP INTERACTION WITH SLC38A7. RX PubMed=35561222; DOI=10.1073/pnas.2123261119; RA Meng D., Yang Q., Jeong M.H., Curukovic A., Tiwary S., Melick C.H., RA Lama-Sherpa T.D., Wang H., Huerta-Rosario M., Urquhart G., Zacharias L.G., RA Lewis C., DeBerardinis R.J., Jewell J.L.; RT "SNAT7 regulates mTORC1 via macropinocytosis."; RL Proc. Natl. Acad. Sci. U.S.A. 119:e2123261119-e2123261119(2022). RN [100] RP INTERACTION WITH TSPAN8. RX PubMed=35904232; DOI=10.1002/cbin.11870; RA Zhuang L., Jin G., Hu X., Yang Q., Pei X., Zhao W.; RT "TSPAN8 alleviates high glucose-induced apoptosis and autophagy via RT targeting mTORC2."; RL Cell Biol. Int. 46:1693-1703(2022). RN [101] RP FUNCTION. RX PubMed=36691768; DOI=10.15252/embj.2022112344; RA Shetty S., Hofstetter J., Battaglioni S., Ritz D., Hall M.N.; RT "TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to RT activate dormant ribosomes."; RL EMBO J. 42:e112344-e112344(2023). RN [102] RP SUBCELLULAR LOCATION. RX PubMed=37057673; DOI=10.1016/j.gim.2023.100838; RA Reijnders M.R.F., Seibt A., Brugger M., Lamers I.J.C., Ott T., Klaas O., RA Horvath J., Rose A.M.S., Craghill I.M., Brunet T., Graf E., Mayerhanser K., RA Hellebrekers D., Pauck D., Neuen-Jacob E., Rodenburg R.J.T., Wieczorek D., RA Klee D., Mayatepek E., Driessen G., Bindermann R., Averdunk L., RA Lohmeier K., Sinnema M., Stegmann A.P.A., Roepman R., Poulter J.A., RA Distelmaier F.; RT "De novo missense variants in RRAGC lead to a fatal mTORopathy of early RT childhood."; RL Genet. Med. 25:100838-100838(2023). RN [103] RP FUNCTION. RX PubMed=36608670; DOI=10.1016/j.molcel.2022.12.013; RA Nardone C., Palanski B.A., Scott D.C., Timms R.T., Barber K.W., Gu X., RA Mao A., Leng Y., Watson E.V., Schulman B.A., Cole P.A., Elledge S.J.; RT "A central role for regulated protein stability in the control of TFE3 and RT MITF by nutrients."; RL Mol. Cell 83:57-73(2023). RN [104] RP FUNCTION, UBIQUITINATION AT LYS-2066, AND MUTAGENESIS OF LYS-2066. RX PubMed=37979583; DOI=10.1016/j.cmet.2023.10.016; RA Ge M.K., Zhang C., Zhang N., He P., Cai H.Y., Li S., Wu S., Chu X.L., RA Zhang Y.X., Ma H.M., Xia L., Yang S., Yu J.X., Yao S.Y., Zhou X.L., Su B., RA Chen G.Q., Shen S.M.; RT "The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid RT insufficiency."; RL Cell Metab. 35:2216-2230.e8(2023). RN [105] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=37751742; DOI=10.1016/j.molcel.2023.08.032; RA He L., Chen J., Deng P., Huang S., Liu P., Wang C., Huang X., Li Y., RA Chen B., Shi D., Xiao Y., Chen X., Ouyang Y., Song L., Lin C.; RT "Lysosomal cyst(e)ine storage potentiates tolerance to oxidative stress in RT cancer cells."; RL Mol. Cell 83:3502-3519(2023). RN [106] RP X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=8662507; DOI=10.1126/science.273.5272.239; RA Choi J., Chen J., Schreiber S.L., Clardy J.; RT "Structure of the FKBP12-rapamycin complex interacting with the binding RT domain of human FRAP."; RL Science 273:239-242(1996). RN [107] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH FKBP1A RP AND INHIBITOR RAPAMYCIN, AND ACTIVITY REGULATION. RX PubMed=10089303; DOI=10.1107/s0907444998014747; RA Liang J., Choi J., Clardy J.; RT "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A RT resolution."; RL Acta Crystallogr. D 55:736-744(1999). RN [108] RP 3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS. RX PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002; RA Knutson B.A.; RT "Insights into the domain and repeat architecture of target of rapamycin."; RL J. Struct. Biol. 170:354-363(2010). RN [109] RP STRUCTURE BY ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND RP SUBUNIT. RX PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017; RA Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.; RT "Structure of the human mTOR complex I and its implications for rapamycin RT inhibition."; RL Mol. Cell 38:768-774(2010). RN [110] RP X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH MLST8, RP SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340. RX PubMed=23636326; DOI=10.1038/nature12122; RA Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P.; RT "mTOR kinase structure, mechanism and regulation."; RL Nature 497:217-223(2013). RN [111] {ECO:0007744|PDB:5H64} RP STRUCTURE BY ELECTRON MICROSCOPY (4.40 ANGSTROMS) IN COMPLEX WITH RPTOR AND RP MLST8, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=27909983; DOI=10.1007/s13238-016-0346-6; RA Yang H., Wang J., Liu M., Chen X., Huang M., Tan D., Dong M.Q., Wong C.C., RA Wang J., Xu Y., Wang H.W.; RT "4.4 Aa Resolution Cryo-EM structure of human mTOR Complex 1."; RL Protein Cell 7:878-887(2016). RN [112] {ECO:0007744|PDB:5FLC} RP STRUCTURE BY ELECTRON MICROSCOPY (5.90 ANGSTROMS) IN COMPLEX WITH MLST8. RX PubMed=26678875; DOI=10.1126/science.aaa3870; RA Aylett C.H., Sauer E., Imseng S., Boehringer D., Hall M.N., Ban N., RA Maier T.; RT "Architecture of human mTOR complex 1."; RL Science 351:48-52(2016). RN [113] {ECO:0007744|PDB:5WBH, ECO:0007744|PDB:5WBU, ECO:0007744|PDB:5WBY, ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX} RP STRUCTURE BY ELECTRON MICROSCOPY (3.43 ANGSTROMS) IN COMPLEX WITH ATP; RP MAGNESIUM; MLST8; RPTOR; RHEB; AKT1S1; RPS6KB1 AND EIF4EBP1, FUNCTION, RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 RP COMPLEX. RX PubMed=29236692; DOI=10.1038/nature25023; RA Yang H., Jiang X., Li B., Yang H.J., Miller M., Yang A., Dhar A., RA Pavletich N.P.; RT "Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40."; RL Nature 552:368-373(2017). RN [114] {ECO:0007744|PDB:5ZCS} RP STRUCTURE BY ELECTRON MICROSCOPY (4.90 ANGSTROMS) OF THE MTORC2 COMPLEX, RP AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=29567957; DOI=10.1038/s41422-018-0029-3; RA Chen X., Liu M., Tian Y., Li J., Qi Y., Zhao D., Wu Z., Huang M., RA Wong C.C.L., Wang H.W., Wang J., Yang H., Xu Y.; RT "Cryo-EM structure of human mTOR complex 2."; RL Cell Res. 28:518-528(2018). RN [115] RP STRUCTURE BY ELECTRON MICROSCOPY OF THE MTORC2 COMPLEX, AND IDENTIFICATION RP IN THE MTORC2 COMPLEX. RX PubMed=29424687; DOI=10.7554/elife.33101; RA Stuttfeld E., Aylett C.H., Imseng S., Boehringer D., Scaiola A., Sauer E., RA Hall M.N., Maier T., Ban N.; RT "Architecture of the human mTORC2 core complex."; RL Elife 7:0-0(2018). RN [116] {ECO:0007744|PDB:6SB0, ECO:0007744|PDB:6SB2} RP STRUCTURE BY ELECTRON MICROSCOPY (5.50 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; RPTOR; MLST8 AND AKT1S1, IDENTIFICATION IN THE MTORC1 COMPLEX, AND RP SUBCELLULAR LOCATION. RX PubMed=31601764; DOI=10.1126/science.aax3939; RA Anandapadamanaban M., Masson G.R., Perisic O., Berndt A., Kaufman J., RA Johnson C.M., Santhanam B., Rogala K.B., Sabatini D.M., Williams R.L.; RT "Architecture of human Rag GTPase heterodimers and their complex with RT mTORC1."; RL Science 366:203-210(2019). RN [117] {ECO:0007744|PDB:6ZWM, ECO:0007744|PDB:6ZWO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF THE MTORC2 COMPLEX IN RP COMPLEX WITH 1D-MYO-INOSITOL HEXAKISPHOSPHATE, AND IDENTIFICATION IN THE RP MTORC2 COMPLEX. RX PubMed=33158864; DOI=10.1126/sciadv.abc1251; RA Scaiola A., Mangia F., Imseng S., Boehringer D., Berneiser K., RA Shimobayashi M., Stuttfeld E., Hall M.N., Ban N., Maier T.; RT "The 3.2-Aa resolution structure of human mTORC2."; RL Sci. Adv. 6:0-0(2020). RN [118] {ECO:0007744|PDB:7PE7, ECO:0007744|PDB:7PE8, ECO:0007744|PDB:7PE9, ECO:0007744|PDB:7PEA, ECO:0007744|PDB:7PEB, ECO:0007744|PDB:7PEC} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 1-230 IN COMPLEX WITH DEPTOR; RP MLST8; MAPKAP1; RICTOR AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN RP THE MTORC1 COMPLEX, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=34519268; DOI=10.7554/elife.70871; RA Waelchli M., Berneiser K., Mangia F., Imseng S., Craigie L.M., RA Stuttfeld E., Hall M.N., Maier T.; RT "Regulation of human mTOR complexes by DEPTOR."; RL Elife 10:0-0(2021). RN [119] {ECO:0007744|PDB:7OWG} RP STRUCTURE BY ELECTRON MICROSCOPY (4.70 ANGSTROMS) IN COMPLEX WITH DEPTOR; RP MLST8 AND RPTOR, ACTIVITY REGULATION, IDENTIFICATION IN THE MTORC1 COMPLEX, RP AND FUNCTION. RX PubMed=34519269; DOI=10.7554/elife.68799; RA Heimhalt M., Berndt A., Wagstaff J., Anandapadamanaban M., Perisic O., RA Maslen S., McLaughlin S., Yu C.W., Masson G.R., Boland A., Ni X., RA Yamashita K., Murshudov G.N., Skehel M., Freund S.M., Williams R.L.; RT "Bipartite binding and partial inhibition links DEPTOR and mTOR in a RT mutually antagonistic embrace."; RL Elife 10:0-0(2021). RN [120] {ECO:0007744|PDB:7TZO} RP STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF THE MTORC2 COMPLEX, RP FUNCTION, AND IDENTIFICATION IN THE MTORC2 COMPLEX. RX PubMed=35926713; DOI=10.1016/j.jbc.2022.102288; RA Yu Z., Chen J., Takagi E., Wang F., Saha B., Liu X., Joubert L.M., RA Gleason C.E., Jin M., Li C., Nowotny C., Agard D., Cheng Y., Pearce D.; RT "Interactions between mTORC2 core subunits Rictor and mSin1 dictate RT selective and context-dependent phosphorylation of substrate kinases SGK1 RT and Akt."; RL J. Biol. Chem. 298:102288-102288(2022). RN [121] {ECO:0007744|PDB:7UXC, ECO:0007744|PDB:7UXH} RP STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS) IN COMPLEX WITH RRAGA; RP RRAGC; LAMTOR1; LAMTOR2; LAMTOR3; LAMTOR4; LAMTOR5; RPTOR; MLST8 AND TFEB, RP FUNCTION, ACTIVITY REGULATION, AND IDENTIFICATION IN THE MTORC1 COMPLEX. RX PubMed=36697823; DOI=10.1038/s41586-022-05652-7; RA Cui Z., Napolitano G., de Araujo M.E.G., Esposito A., Monfregola J., RA Huber L.A., Ballabio A., Hurley J.H.; RT "Structure of the lysosomal mTORC1-TFEB-Rag-Ragulator megacomplex."; RL Nature 614:572-579(2023). RN [122] RP VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134; RP PHE-1178; VAL-2011; TYR-2215 AND LEU-2476. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [123] RP VARIANTS PHE-2220 AND ALA-2406. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). CC -!- FUNCTION: Serine/threonine protein kinase which is a central regulator CC of cellular metabolism, growth and survival in response to hormones, CC growth factors, nutrients, energy and stress signals (PubMed:12087098, CC PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, CC PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, CC PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, CC PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, CC PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, CC PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, CC PubMed:34519269, PubMed:37751742). MTOR directly or indirectly CC regulates the phosphorylation of at least 800 proteins CC (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, CC PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, CC PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, CC PubMed:37751742). Functions as part of 2 structurally and functionally CC distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) CC (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, CC PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, CC PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to CC nutrients, growth factors or amino acids, mTORC1 is recruited to the CC lysosome membrane and promotes protein, lipid and nucleotide synthesis CC by phosphorylating key regulators of mRNA translation and ribosome CC synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, CC PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, CC PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, CC PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, CC PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, CC PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, CC PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release CC of its inhibition toward the elongation initiation factor 4E (eiF4E) CC (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and CC activates RPS6KB1 and RPS6KB2 that promote protein synthesis by CC modulating the activity of their downstream targets including ribosomal CC protein S6, eukaryotic translation initiation factor EIF4B, and the CC inhibitor of translation initiation PDCD4 (PubMed:12087098, CC PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). CC Stimulates the pyrimidine biosynthesis pathway, both by acute CC regulation through RPS6KB1-mediated phosphorylation of the biosynthetic CC enzyme CAD, and delayed regulation, through transcriptional enhancement CC of the pentose phosphate pathway which produces 5-phosphoribosyl-1- CC pyrophosphate (PRPP), an allosteric activator of CAD at a later step in CC synthesis, this function is dependent on the mTORC1 complex CC (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by CC activating RNA polymerase III-dependent transcription through CC phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor CC (PubMed:20516213). Activates dormant ribosomes by mediating CC phosphorylation of SERBP1, leading to SERBP1 inactivation and CC reactivation of translation (PubMed:36691768). In parallel to protein CC synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and CC LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also CC regulate mitochondrial biogenesis through regulation of PPARGC1A (By CC similarity). In the same time, mTORC1 inhibits catabolic pathways: CC negatively regulates autophagy through phosphorylation of ULK1 CC (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at CC 'Ser-758', disrupting the interaction with AMPK and preventing CC activation of ULK1 (PubMed:32561715). Also prevents autophagy through CC phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also CC prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich CC conditions (PubMed:30704899). Prevents autophagy by mediating CC phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate CC ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA CC (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on CC upstream growth factor signaling that includes phosphorylation and CC activation of GRB10 a INSR-dependent signaling suppressor CC (PubMed:21659604). Among other potential targets mTORC1 may CC phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The CC mTORC1 complex is inhibited in response to starvation and amino acid CC depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, CC PubMed:31695197). The non-canonical mTORC1 complex, which acts CC independently of RHEB, specifically mediates phosphorylation of MiT/TFE CC factors MITF, TFEB and TFE3 in the presence of nutrients, promoting CC their cytosolic retention and inactivation (PubMed:22343943, CC PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, CC PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, CC inhibition of mTORC1 induces dephosphorylation and nuclear CC translocation of TFEB and TFE3, promoting their transcription factor CC activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, CC PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex CC regulates pyroptosis in macrophages by promoting GSDMD oligomerization CC (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits CC mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces CC signals from growth factors to pathways involved in proliferation, CC cytoskeletal organization, lipogenesis and anabolic output CC (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, CC PubMed:29567957, PubMed:35926713). In response to growth factors, CC mTORC2 phosphorylates and activates AGC protein kinase family members, CC including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and CC SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, CC PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In CC contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). CC mTORC2 plays a critical role in AKT1 activation by mediating CC phosphorylation of different sites depending on the context, such as CC 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the CC phosphorylation of the activation loop of AKT1 on 'Thr-308' by CC PDPK1/PDK1 which is a prerequisite for full activation CC (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, CC PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at CC 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin CC cytoskeleton, through phosphorylation of PRKCA, PXN and activation of CC the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or CC RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various CC proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By CC similarity). May also regulate insulin signaling by acting as a CC tyrosine protein kinase that catalyzes phosphorylation of IGF1R and CC INSR; additional evidence are however required to confirm this result CC in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting CC the expression of CEBPB isoforms (By similarity). Plays an important CC regulatory role in the circadian clock function; regulates period CC length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and CC liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, CC ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, CC ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, CC ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, CC ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, CC ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, CC ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, CC ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, CC ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, CC ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, CC ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, CC ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, CC ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, CC ECO:0000269|PubMed:29150432}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15718470, CC ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, CC ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, CC ECO:0000269|PubMed:37751742}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2; CC Evidence={ECO:0000305|PubMed:26584640}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597; CC Evidence={ECO:0000305|PubMed:26584640}; CC -!- ACTIVITY REGULATION: The mTORC1 complex is activated in response to CC nutrients, growth factors or amino acids: activation requires CC relocalization of the mTORC1 complex to lysosomes that is mediated by CC the Ragulator complex, SLC38A9, and the Rag GTPases RagA/RRAGA, CC RagB/RRAGB, RagC/RRAGC and RagD/RRAGD (PubMed:18497260, CC PubMed:20381137, PubMed:25561175, PubMed:25567906). Activation of CC mTORC1 by growth factors such as insulin involves AKT1-mediated CC phosphorylation of TSC1-TSC2, which leads to the activation of the RHEB CC GTPase a potent activator of the protein kinase activity of mTORC1 CC (PubMed:14651849, PubMed:15545625, PubMed:29236692). Insulin-stimulated CC and amino acid-dependent phosphorylation at Ser-1261 promotes CC autophosphorylation and the activation of mTORC1 (PubMed:19487463). On CC the other hand, low cellular energy levels can inhibit mTORC1 through CC activation of PRKAA1 while hypoxia inhibits mTORC1 through a REDD1- CC dependent mechanism which may also require PRKAA1 (PubMed:14651849, CC PubMed:15545625). The kinase activity of MTOR within the mTORC1 complex CC is positively regulated by MLST8 (PubMed:12718876). The kinase activity CC of MTOR is inhibited by DEPTOR and AKT1S1 (PubMed:17386266, CC PubMed:19446321, PubMed:29236692, PubMed:34519268, PubMed:34519269). CC The non-canonical mTORC1 complex is independent of the RHEB GTPase and CC specifically mediates phosphorylation of MiT/TFE factors TFEB and TFE3 CC but not other mTORC1 substrates: it is activated by FLCN, which CC activates Rag GTPases RagC/RRAGC and RagD/RRAGD (PubMed:32612235, CC PubMed:36697823). MTOR is the target of the immunosuppressive and anti- CC cancer drug rapamycin which acts in complex with FKBP1A/FKBP12, and CC specifically inhibits its kinase activity (PubMed:10089303, CC PubMed:8662507). mTORC2 is also activated by growth factors, but seems CC to be nutrient-insensitive (PubMed:15467718). mTORC2 associates and is CC directly activated by ribosomes (PubMed:21376236). mTORC2 may also be CC regulated by RHEB but in an indirect manner through the PI3K signaling CC pathway (PubMed:15467718). {ECO:0000269|PubMed:10089303, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, CC ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:19487463, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:21376236, CC ECO:0000269|PubMed:25561175, ECO:0000269|PubMed:25567906, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:32612235, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:8662507}. CC -!- SUBUNIT: Part of the mechanistic target of rapamycin complex 1 (mTORC1) CC which contains MTOR, MLST8 and RPTOR (PubMed:12150925, PubMed:12150926, CC PubMed:12408816, PubMed:12718876, PubMed:18925875, PubMed:20542007, CC PubMed:23636326, PubMed:24403073, PubMed:26678875, PubMed:27909983, CC PubMed:29236692, PubMed:31601764, PubMed:34519268, PubMed:34519269, CC PubMed:36697823). The mTORC1 complex is a 1 Md obligate dimer of two CC stoichiometric heterotetramers with overall dimensions of 290 A x 210 A CC x 135 A (PubMed:20542007, PubMed:23636326). It has a rhomboid shape and CC a central cavity, the dimeric interfaces are formed by interlocking CC interactions between the two MTOR and the two RPTOR subunits CC (PubMed:20542007, PubMed:23636326, PubMed:27909983). The MLST8 subunit CC forms distal foot-like protuberances, and contacts only one MTOR within CC the complex, while the small AKT1S1/PRAS40 localizes to the midsection CC of the central core, in close proximity to RPTOR (PubMed:20542007, CC PubMed:23636326, PubMed:27909983, PubMed:29236692). mTORC1 associates CC with AKT1S1/PRAS40, which inhibits its activity by blocking MTOR CC substrate-recruitment site (PubMed:17386266, PubMed:29236692). CC Component of the mechanistic target of rapamycin complex 2 (mTORC2), CC consisting in two heterotretramers composed of MTOR, MLST8, RICTOR and CC MAPKAP1/SIN1 (PubMed:15268862, PubMed:15467718, PubMed:17599906, CC PubMed:18925875, PubMed:29424687, PubMed:29567957, PubMed:33158864, CC PubMed:35926713). Interacts with PLPP7 and PML (By similarity). CC Interacts with PRR5 and RICTOR; the interaction is direct within the CC mTORC2 complex and interaction with RICTOR is enhanced by CC deubiquitination of RICTOR by USP9X (PubMed:17599906, PubMed:33378666, CC PubMed:29424687, PubMed:34519268). mTORC1 and mTORC2 associate with CC DEPTOR, which regulates their activity (PubMed:19446321, CC PubMed:34519268, PubMed:34519269). Interacts with WAC; WAC positively CC regulates MTOR activity by promoting the assembly of the TTT complex CC composed of TELO2, TTI1 and TTI2 and the RUVBL complex composed of CC RUVBL1 and RUVBL2 into the TTT-RUVBL complex which leads to the CC dimerization of the mTORC1 complex and its subsequent activation CC (PubMed:26812014). Interacts with UBQLN1 (PubMed:11853878). Interacts CC with TTI1 and TELO2 (PubMed:20427287, PubMed:20801936, CC PubMed:20810650). Interacts with CLIP1; phosphorylates and regulates CC CLIP1 (PubMed:12231510). Interacts with NBN (PubMed:23762398). CC Interacts with HTR6 (PubMed:23027611). Interacts with BRAT1 CC (PubMed:25657994). Interacts with MEAK7 (via C-terminal domain); the CC interaction increases upon nutrient stimulation (PubMed:29750193). CC Interacts with TM4SF5; the interaction is positively regulated by CC arginine and is negatively regulated by leucine (PubMed:30956113). CC Interacts with GPR137B (PubMed:31036939). Interacts with NCKAP1L CC (PubMed:32647003). Interacts with TPCN1 and TPCN2; the interaction is CC required for TPCN1 and TPCN2 sensitivity to ATP (PubMed:23394946). CC Interacts with ATP6V1A and with CRYAB, forming a ternary complex (By CC similarity). Interacts with SLC38A7; this interaction mediates the CC recruitment of mTORC1 to the lysosome and its subsequent activation CC (PubMed:35561222). Interacts with TSPAN8 (PubMed:35904232). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:11853878, CC ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, CC ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12408816, CC ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:15268862, CC ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:17386266, CC ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:18925875, CC ECO:0000269|PubMed:19446321, ECO:0000269|PubMed:20427287, CC ECO:0000269|PubMed:20542007, ECO:0000269|PubMed:20801936, CC ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:23027611, CC ECO:0000269|PubMed:23394946, ECO:0000269|PubMed:23636326, CC ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:24403073, CC ECO:0000269|PubMed:25657994, ECO:0000269|PubMed:26678875, CC ECO:0000269|PubMed:26812014, ECO:0000269|PubMed:27909983, CC ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, CC ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31036939, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:32647003, CC ECO:0000269|PubMed:33158864, ECO:0000269|PubMed:33378666, CC ECO:0000269|PubMed:34519268, ECO:0000269|PubMed:34519269, CC ECO:0000269|PubMed:35561222, ECO:0000269|PubMed:35904232, CC ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36697823}. CC -!- INTERACTION: CC P42345; P31749: AKT1; NbExp=6; IntAct=EBI-359260, EBI-296087; CC P42345; Q07817-1: BCL2L1; NbExp=4; IntAct=EBI-359260, EBI-287195; CC P42345; Q6UXB4: CLEC4G; NbExp=4; IntAct=EBI-359260, EBI-2114729; CC P42345; Q8TB45: DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040; CC P42345; Q13541: EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090; CC P42345; Q969H0: FBXW7; NbExp=5; IntAct=EBI-359260, EBI-359574; CC P42345; P62942: FKBP1A; NbExp=5; IntAct=EBI-359260, EBI-1027571; CC P42345; P24522: GADD45A; NbExp=4; IntAct=EBI-359260, EBI-448167; CC P42345; Q8WUA4: GTF3C2; NbExp=3; IntAct=EBI-359260, EBI-1237062; CC P42345; Q9BVC4: MLST8; NbExp=7; IntAct=EBI-359260, EBI-1387471; CC P42345; Q9BVC4-1: MLST8; NbExp=7; IntAct=EBI-359260, EBI-16056342; CC P42345; Q13615: MTMR3; NbExp=3; IntAct=EBI-359260, EBI-371938; CC P42345; P42345: MTOR; NbExp=2; IntAct=EBI-359260, EBI-359260; CC P42345; Q9Y4G2: PLEKHM1; NbExp=6; IntAct=EBI-359260, EBI-473814; CC P42345; Q8TCU6: PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542; CC P42345; P62820: RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845; CC P42345; Q15382: RHEB; NbExp=4; IntAct=EBI-359260, EBI-1055287; CC P42345; Q6R327: RICTOR; NbExp=37; IntAct=EBI-359260, EBI-1387196; CC P42345; Q8N122: RPTOR; NbExp=48; IntAct=EBI-359260, EBI-1567928; CC P42345; Q96EB6: SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965; CC P42345; O14894: TM4SF5; NbExp=7; IntAct=EBI-359260, EBI-19125949; CC P42345; Q92544: TM9SF4; NbExp=4; IntAct=EBI-359260, EBI-6138615; CC P42345; Q8NHX9: TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949; CC P42345; O75385: ULK1; NbExp=7; IntAct=EBI-359260, EBI-908831; CC P42345; P63104: YWHAZ; NbExp=3; IntAct=EBI-359260, EBI-347088; CC -!- SUBCELLULAR LOCATION: Lysosome membrane {ECO:0000269|PubMed:18497260, CC ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131, CC ECO:0000269|PubMed:31601764, ECO:0000269|PubMed:37057673}; Peripheral CC membrane protein {ECO:0000269|PubMed:30956113, CC ECO:0000269|PubMed:31112131}; Cytoplasmic side CC {ECO:0000269|PubMed:30956113, ECO:0000269|PubMed:31112131}. Endoplasmic CC reticulum membrane {ECO:0000269|PubMed:14578359}; Peripheral membrane CC protein {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Golgi apparatus membrane CC {ECO:0000269|PubMed:14578359}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:14578359}. Cell membrane CC {ECO:0000269|PubMed:21867682}; Peripheral membrane protein CC {ECO:0000269|PubMed:14578359}. Mitochondrion outer membrane CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}; Peripheral CC membrane protein {ECO:0000269|PubMed:11930000, CC ECO:0000269|PubMed:14578359}; Cytoplasmic side CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:14578359}. Cytoplasm CC {ECO:0000269|PubMed:11930000, ECO:0000269|PubMed:18497260}. Nucleus CC {ECO:0000250|UniProtKB:Q9JLN9}. Nucleus, PML body CC {ECO:0000250|UniProtKB:Q9JLN9}. Microsome membrane CC {ECO:0000269|PubMed:9434772}. Cytoplasmic vesicle, phagosome CC {ECO:0000269|PubMed:27623384}. Note=Shuttles between cytoplasm and CC nucleus. Accumulates in the nucleus in response to hypoxia (By CC similarity). Targeting to lysosomes depends on amino acid availability CC and RRAGA and RRAGB (PubMed:18497260, PubMed:20381137). Lysosome CC targeting also depends on interaction with MEAK7. Translocates to the CC lysosome membrane in the presence of TM4SF5 (PubMed:30956113). The CC mTORC2 complex localizes to membranes: mTORC2 is active at the plasma CC membrane, endoplasmic reticulum membrane and lysosomes CC (PubMed:21867682). {ECO:0000250|UniProtKB:Q9JLN9, CC ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:20381137, CC ECO:0000269|PubMed:21867682, ECO:0000269|PubMed:29750193, CC ECO:0000269|PubMed:30956113}. CC -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest levels CC in testis. {ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:7809080}. CC -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but has a CC highly restricted catalytic center. {ECO:0000269|PubMed:23636326}. CC -!- DOMAIN: The FAT domain forms three discontinuous subdomains of alpha- CC helical TPR repeats plus a single subdomain of HEAT repeats. The four CC domains pack sequentially to form a C-shaped a-solenoid that clamps CC onto the kinase domain (PubMed:23636326). CC {ECO:0000269|PubMed:23636326}. CC -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2 (PubMed:15467718, CC PubMed:20022946, PubMed:9434772). Phosphorylation at Ser-1261, Ser-2159 CC and Thr-2164 promotes autophosphorylation (PubMed:19487463). CC Phosphorylated at Ser-2448 by RPS6KB1 (PubMed:15899889, CC PubMed:15905173, PubMed:19145465). Phosphorylation in the kinase domain CC modulates the interactions of MTOR with RPTOR and AKT1S1/PRAS40 and CC leads to increased intrinsic mTORC1 kinase activity (PubMed:15905173, CC PubMed:19145465, PubMed:21576368). Phosphorylation at Ser-2159 by TBK1 CC in response to growth factors and pathogen recognition receptors CC promotes mTORC1 activity (PubMed:29150432). Phosphorylation at Ser-2159 CC by TBK1 in response to EGF growth factor promotes mTORC2 activity, CC leading to AKT1 phosphorylation and activation (By similarity). CC Phosphorylation at Thr-2173 in the ATP-binding region by AKT1 strongly CC reduces kinase activity (PubMed:24247430). CC {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:15467718, CC ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, CC ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20022946, CC ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:24247430, CC ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:9434772}. CC -!- PTM: Ubiquitinated at Lys-2066 by the SCF(FBXO22) complex via 'Lys-27'- CC linked ubiquitination prevents mTORC1 substrate recruitment. CC {ECO:0000269|PubMed:37979583}. CC -!- DISEASE: Smith-Kingsmore syndrome (SKS) [MIM:616638]: An autosomal CC dominant syndrome characterized by intellectual disability, CC macrocephaly, seizures, umbilical hernia, and facial dysmorphic CC features. {ECO:0000269|PubMed:25851998, ECO:0000269|PubMed:26542245, CC ECO:0000269|PubMed:27830187}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Focal cortical dysplasia 2 (FCORD2) [MIM:607341]: A form of CC focal cortical dysplasia, a malformation of cortical development that CC results in medically refractory epilepsy in the pediatric population CC and in adults. FCORD2 is a severe form, with onset usually in CC childhood, characterized by disrupted cortical lamination and specific CC cytological abnormalities. It is classified in 2 subtypes: type IIA CC characterized by dysmorphic neurons and lack of balloon cells; type IIB CC with dysmorphic neurons and balloon cells. CC {ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:25878179, CC ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC39933.1; Type=Frameshift; Evidence={ECO:0000305}; CC Sequence=BAE06077.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40639/FRAP1"; CC -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin entry; CC URL="https://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L34075; AAA58486.1; -; mRNA. DR EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA. DR EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA. DR EMBL; AL109811; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391561; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL049653; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC117166; AAI17167.1; -; mRNA. DR EMBL; AJ300188; CAC15570.1; -; Genomic_DNA. DR EMBL; L35478; AAC41713.1; -; mRNA. DR CCDS; CCDS127.1; -. DR PIR; S45340; S45340. DR RefSeq; NP_001373429.1; NM_001386500.1. DR RefSeq; NP_004949.1; NM_004958.4. DR PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114. DR PDB; 1FAP; X-ray; 2.70 A; B=2018-2112. DR PDB; 1NSG; X-ray; 2.20 A; B=2019-2112. DR PDB; 2FAP; X-ray; 2.20 A; B=2019-2112. DR PDB; 2GAQ; NMR; -; A=2015-2114. DR PDB; 2NPU; NMR; -; A=2015-2114. DR PDB; 2RSE; NMR; -; B=2019-2112. DR PDB; 3FAP; X-ray; 1.85 A; B=2019-2112. DR PDB; 3JBZ; EM; 28.00 A; A=1385-2549. DR PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114. DR PDB; 4DRI; X-ray; 1.45 A; B=2025-2114. DR PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114. DR PDB; 4FAP; X-ray; 2.80 A; B=2019-2112. DR PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549. DR PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549. DR PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549. DR PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549. DR PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549. DR PDB; 5FLC; EM; 5.90 A; B/F=1382-2549. DR PDB; 5GPG; X-ray; 1.67 A; B=2021-2112. DR PDB; 5H64; EM; 4.40 A; A/a=1-2549. DR PDB; 5WBH; X-ray; 1.75 A; A/B/C/D/E=2018-2114. DR PDB; 5WBU; X-ray; 3.42 A; A/B=1376-2549. DR PDB; 5WBY; X-ray; 3.10 A; A/B=1376-2549. DR PDB; 5ZCS; EM; 4.90 A; A/B=1-2549. DR PDB; 6BCU; EM; 3.43 A; A/B=1-2549. DR PDB; 6BCX; EM; 3.00 A; A/B=1-2549. DR PDB; 6M4U; X-ray; 2.20 A; B/F=2021-2113. DR PDB; 6M4W; X-ray; 3.11 A; G/H/I=2021-2113. DR PDB; 6SB0; EM; 5.50 A; A/B=60-2549. DR PDB; 6SB2; EM; 6.20 A; A/B=54-2549. DR PDB; 6ZWM; EM; 3.20 A; A/B=1-2549. DR PDB; 6ZWO; EM; 3.00 A; B=1-2549. DR PDB; 7EPD; EM; 3.90 A; B=2019-2114. DR PDB; 7OWG; EM; 4.70 A; B=1-2549. DR PDB; 7PE7; EM; 3.41 A; A/B=1-2549. DR PDB; 7PE8; EM; 3.20 A; A=1-2549. DR PDB; 7PE9; EM; 3.70 A; A=1-2549. DR PDB; 7PEA; EM; 4.07 A; A/B=1-2549. DR PDB; 7PEB; EM; 3.67 A; A=1-2549. DR PDB; 7PEC; EM; 4.24 A; A=1-2549. DR PDB; 7TZO; EM; 3.28 A; A/B=1-2549. DR PDB; 7UXC; EM; 3.20 A; A=1-2549. DR PDB; 7UXH; EM; 3.20 A; A/C=1-2549. DR PDB; 8ER6; X-ray; 2.81 A; B/D/F=2019-2112. DR PDB; 8ER7; X-ray; 3.07 A; B/D/F=2019-2112. DR PDB; 8ERA; EM; 2.86 A; A=1-2549. DR PDB; 8PPZ; X-ray; 1.85 A; B=2025-2114. DR PDB; 8RCH; EM; 4.00 A; A/B=1-2549. DR PDB; 8RCK; EM; 3.40 A; B=1-2549. DR PDB; 8RCN; EM; 3.10 A; B=1-2549. DR PDB; 9F44; EM; 3.68 A; A/B=1-2549. DR PDB; 9F45; EM; 3.74 A; A/B=1-2549. DR PDBsum; 1AUE; -. DR PDBsum; 1FAP; -. DR PDBsum; 1NSG; -. DR PDBsum; 2FAP; -. DR PDBsum; 2GAQ; -. DR PDBsum; 2NPU; -. DR PDBsum; 2RSE; -. DR PDBsum; 3FAP; -. DR PDBsum; 3JBZ; -. DR PDBsum; 4DRH; -. DR PDBsum; 4DRI; -. DR PDBsum; 4DRJ; -. DR PDBsum; 4FAP; -. DR PDBsum; 4JSN; -. DR PDBsum; 4JSP; -. DR PDBsum; 4JSV; -. DR PDBsum; 4JSX; -. DR PDBsum; 4JT5; -. DR PDBsum; 4JT6; -. DR PDBsum; 5FLC; -. DR PDBsum; 5GPG; -. DR PDBsum; 5H64; -. DR PDBsum; 5WBH; -. DR PDBsum; 5WBU; -. DR PDBsum; 5WBY; -. DR PDBsum; 5ZCS; -. DR PDBsum; 6BCU; -. DR PDBsum; 6BCX; -. DR PDBsum; 6M4U; -. DR PDBsum; 6M4W; -. DR PDBsum; 6SB0; -. DR PDBsum; 6SB2; -. DR PDBsum; 6ZWM; -. DR PDBsum; 6ZWO; -. DR PDBsum; 7EPD; -. DR PDBsum; 7OWG; -. DR PDBsum; 7PE7; -. DR PDBsum; 7PE8; -. DR PDBsum; 7PE9; -. DR PDBsum; 7PEA; -. DR PDBsum; 7PEB; -. DR PDBsum; 7PEC; -. DR PDBsum; 7TZO; -. DR PDBsum; 7UXC; -. DR PDBsum; 7UXH; -. DR PDBsum; 8ER6; -. DR PDBsum; 8ER7; -. DR PDBsum; 8ERA; -. DR PDBsum; 8PPZ; -. DR PDBsum; 8RCH; -. DR PDBsum; 8RCK; -. DR PDBsum; 8RCN; -. DR PDBsum; 9F44; -. DR PDBsum; 9F45; -. DR AlphaFoldDB; P42345; -. DR BMRB; P42345; -. DR EMDB; EMD-10132; -. DR EMDB; EMD-10133; -. DR EMDB; EMD-11488; -. DR EMDB; EMD-11489; -. DR EMDB; EMD-11490; -. DR EMDB; EMD-11491; -. DR EMDB; EMD-11492; -. DR EMDB; EMD-13097; -. DR EMDB; EMD-13347; -. DR EMDB; EMD-13348; -. DR EMDB; EMD-13349; -. DR EMDB; EMD-13350; -. DR EMDB; EMD-13351; -. DR EMDB; EMD-13352; -. DR EMDB; EMD-19052; -. DR EMDB; EMD-19053; -. DR EMDB; EMD-19056; -. DR EMDB; EMD-26213; -. DR EMDB; EMD-26857; -. DR EMDB; EMD-26861; -. DR EMDB; EMD-28551; -. DR EMDB; EMD-3212; -. DR EMDB; EMD-3213; -. DR EMDB; EMD-50183; -. DR EMDB; EMD-50184; -. DR EMDB; EMD-6668; -. DR EMDB; EMD-6913; -. DR EMDB; EMD-7086; -. DR EMDB; EMD-7087; -. DR SMR; P42345; -. DR BioGRID; 108757; 392. DR ComplexPortal; CPX-4402; mTORC2 complex. DR ComplexPortal; CPX-503; mTORC1 complex. DR CORUM; P42345; -. DR DIP; DIP-790N; -. DR FunCoup; P42345; 4303. DR IntAct; P42345; 203. DR MINT; P42345; -. DR STRING; 9606.ENSP00000354558; -. DR BindingDB; P42345; -. DR ChEMBL; CHEMBL2842; -. DR DrugBank; DB12180; Apitolisib. DR DrugBank; DB12774; AZD-8055. DR DrugBank; DB14846; Bimiralisib. DR DrugBank; DB11651; Dactolisib. DR DrugBank; DB01590; Everolimus. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB13072; GDC-0349. DR DrugBank; DB11896; Gedatolisib. DR DrugBank; DB11978; Glasdegib. DR DrugBank; DB11962; GSK-1059615. DR DrugBank; DB12167; LY-3023414. DR DrugBank; DB13062; ME-344. DR DrugBank; DB19085; Novolimus. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB12570; Onatasertib. DR DrugBank; DB12387; OSI-027. DR DrugBank; DB11974; PF-04691502. DR DrugBank; DB00337; Pimecrolimus. DR DrugBank; DB08052; PP-121. DR DrugBank; DB06233; Ridaforolimus. DR DrugBank; DB04974; Rimiducid. DR DrugBank; DB12681; Salirasib. DR DrugBank; DB11836; Sapanisertib. DR DrugBank; DB05210; SF1126. DR DrugBank; DB00877; Sirolimus. DR DrugBank; DB06287; Temsirolimus. DR DrugBank; DB11925; Vistusertib. DR DrugBank; DB12400; Voxtalisib. DR DrugBank; DB12986; VS-5584. DR DrugBank; DB05241; XL765. DR DrugBank; DB18761; Zotarolimus. DR DrugCentral; P42345; -. DR GuidetoPHARMACOLOGY; 2109; -. DR GlyGen; P42345; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P42345; -. DR MetOSite; P42345; -. DR PhosphoSitePlus; P42345; -. DR SwissPalm; P42345; -. DR BioMuta; MTOR; -. DR DMDM; 1169735; -. DR CPTAC; CPTAC-1360; -. DR CPTAC; CPTAC-1361; -. DR CPTAC; CPTAC-3133; -. DR CPTAC; CPTAC-3134; -. DR CPTAC; CPTAC-5752; -. DR CPTAC; CPTAC-5753; -. DR CPTAC; CPTAC-5754; -. DR CPTAC; CPTAC-5755; -. DR CPTAC; CPTAC-5756; -. DR CPTAC; CPTAC-5793; -. DR CPTAC; CPTAC-5794; -. DR CPTAC; CPTAC-5795; -. DR CPTAC; CPTAC-5796; -. DR CPTAC; CPTAC-5797; -. DR CPTAC; CPTAC-5798; -. DR CPTAC; CPTAC-5799; -. DR CPTAC; CPTAC-5800; -. DR CPTAC; non-CPTAC-5421; -. DR CPTAC; non-CPTAC-5422; -. DR CPTAC; non-CPTAC-5423; -. DR CPTAC; non-CPTAC-5424; -. DR CPTAC; non-CPTAC-5425; -. DR CPTAC; non-CPTAC-5560; -. DR CPTAC; non-CPTAC-5561; -. DR CPTAC; non-CPTAC-5562; -. DR CPTAC; non-CPTAC-5563; -. DR CPTAC; non-CPTAC-5709; -. DR CPTAC; non-CPTAC-5710; -. DR CPTAC; non-CPTAC-5711; -. DR CPTAC; non-CPTAC-5712; -. DR jPOST; P42345; -. DR MassIVE; P42345; -. DR PaxDb; 9606-ENSP00000354558; -. DR PeptideAtlas; P42345; -. DR ProteomicsDB; 55511; -. DR Pumba; P42345; -. DR Antibodypedia; 3566; 1829 antibodies from 54 providers. DR CPTC; P42345; 10 antibodies. DR DNASU; 2475; -. DR Ensembl; ENST00000361445.9; ENSP00000354558.4; ENSG00000198793.15. DR Ensembl; ENST00000703143.2; ENSP00000515200.2; ENSG00000198793.15. DR GeneID; 2475; -. DR KEGG; hsa:2475; -. DR MANE-Select; ENST00000361445.9; ENSP00000354558.4; NM_004958.4; NP_004949.1. DR UCSC; uc001asd.4; human. DR AGR; HGNC:3942; -. DR CIViC; 2475; 31 evidence items across 26 molecular profiles. DR ClinPGx; PA28360; -. DR CTD; 2475; -. DR DisGeNET; 2475; -. DR GeneCards; MTOR; -. DR HGNC; HGNC:3942; MTOR. DR HPA; ENSG00000198793; Low tissue specificity. DR MalaCards; MTOR; -. DR MIM; 601231; gene. DR MIM; 607341; phenotype. DR MIM; 616638; phenotype. DR OpenTargets; ENSG00000198793; -. DR Orphanet; 99802; Hemimegalencephaly. DR Orphanet; 269001; Isolated focal cortical dysplasia type IIa. DR Orphanet; 269008; Isolated focal cortical dysplasia type IIb. DR Orphanet; 457485; Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome. DR VEuPathDB; HostDB:ENSG00000198793; -. DR eggNOG; KOG0891; Eukaryota. DR GeneTree; ENSGT00930000151037; -. DR HOGENOM; CLU_000178_7_1_1; -. DR InParanoid; P42345; -. DR OMA; MRQHSAK; -. DR OrthoDB; 2250022at2759; -. DR PAN-GO; P42345; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42345; -. DR PathwayCommons; P42345; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-1632852; Macroautophagy. DR Reactome; R-HSA-165159; MTOR signalling. DR Reactome; R-HSA-166208; mTORC1-mediated signalling. DR Reactome; R-HSA-3371571; HSF1-dependent transactivation. DR Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK. DR Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling. DR Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer. DR Reactome; R-HSA-6804757; Regulation of TP53 Degradation. DR Reactome; R-HSA-8943724; Regulation of PTEN gene transcription. DR Reactome; R-HSA-9639288; Amino acids regulate mTORC1. DR Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells. DR SABIO-RK; P42345; -. DR SignaLink; P42345; -. DR SIGNOR; P42345; -. DR Agora; ENSG00000198793; -. DR BioGRID-ORCS; 2475; 805 hits in 1184 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; DEE660B4; Stress granule. DR ChiTaRS; MTOR; human. DR EvolutionaryTrace; P42345; -. DR GeneWiki; Mammalian_target_of_rapamycin; -. DR GenomeRNAi; 2475; -. DR Pharos; P42345; Tclin. DR PRO; PR:P42345; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P42345; protein. DR Bgee; ENSG00000198793; Expressed in primordial germ cell in gonad and 132 other cell types or tissues. DR ExpressionAtlas; P42345; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0012505; C:endomembrane system; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB. DR GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell. DR GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB. DR GO; GO:0005764; C:lysosome; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005635; C:nuclear envelope; IDA:CACAO. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0045335; C:phagocytic vesicle; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB. DR GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0000822; F:inositol hexakisphosphate binding; IDA:UniProtKB. DR GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IDA:WormBase. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0043022; F:ribosome binding; IDA:UniProtKB. DR GO; GO:0001002; F:RNA polymerase III type 1 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001003; F:RNA polymerase III type 2 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001006; F:RNA polymerase III type 3 promoter sequence-specific DNA binding; IDA:UniProtKB. DR GO; GO:0001156; F:TFIIIC-class transcription factor complex binding; IDA:UniProtKB. DR GO; GO:0044325; F:transmembrane transporter binding; IEA:Ensembl. DR GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl. DR GO; GO:0043276; P:anoikis; NAS:ParkinsonsUK-UCL. DR GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl. DR GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0055013; P:cardiac muscle cell development; IEA:Ensembl. DR GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl. DR GO; GO:0030030; P:cell projection organization; IEA:Ensembl. DR GO; GO:0034198; P:cellular response to amino acid starvation; IDA:UniProtKB. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:CAFA. DR GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB. DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:UniProt. DR GO; GO:0071233; P:cellular response to L-leucine; IDA:CAFA. DR GO; GO:1990253; P:cellular response to leucine starvation; IDA:CAFA. DR GO; GO:0061431; P:cellular response to methionine; IDA:UniProt. DR GO; GO:0031670; P:cellular response to nutrient; IDA:UniProt. DR GO; GO:0031669; P:cellular response to nutrient levels; IDA:UniProt. DR GO; GO:0071470; P:cellular response to osmotic stress; NAS:ComplexPortal. DR GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB. DR GO; GO:0007010; P:cytoskeleton organization; NAS:ComplexPortal. DR GO; GO:0006974; P:DNA damage response; NAS:ComplexPortal. DR GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl. DR GO; GO:0007281; P:germ cell development; IEA:Ensembl. DR GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl. DR GO; GO:0003179; P:heart valve morphogenesis; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; IEA:Ensembl. DR GO; GO:0016236; P:macroautophagy; IEA:Ensembl. DR GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl. DR GO; GO:0043066; P:negative regulation of apoptotic process; NAS:ComplexPortal. DR GO; GO:0010507; P:negative regulation of autophagy; IDA:UniProtKB. DR GO; GO:0070885; P:negative regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl. DR GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl. DR GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProt. DR GO; GO:1905672; P:negative regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016242; P:negative regulation of macroautophagy; IDA:MGI. DR GO; GO:1900181; P:negative regulation of protein localization to nucleus; IDA:UniProtKB. DR GO; GO:0019228; P:neuronal action potential; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl. DR GO; GO:0030307; P:positive regulation of cell growth; NAS:ComplexPortal. DR GO; GO:1904690; P:positive regulation of cytoplasmic translational initiation; TAS:ARUK-UCL. DR GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0045821; P:positive regulation of glycolytic process; NAS:ComplexPortal. DR GO; GO:0051549; P:positive regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl. DR GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB. DR GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:1905857; P:positive regulation of pentose-phosphate shunt; NAS:ComplexPortal. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; TAS:Reactome. DR GO; GO:1900029; P:positive regulation of ruffle assembly; IEA:Ensembl. DR GO; GO:0062027; P:positive regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process; IDA:UniProt. DR GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl. DR GO; GO:0045945; P:positive regulation of transcription by RNA polymerase III; IMP:UniProtKB. DR GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB. DR GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB. DR GO; GO:0045948; P:positive regulation of translational initiation; IDA:UniProt. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:UniProtKB. DR GO; GO:1903691; P:positive regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0009791; P:post-embryonic development; IEA:Ensembl. DR GO; GO:0031648; P:protein destabilization; IDA:UniProt. DR GO; GO:0050821; P:protein stabilization; ISS:UniProt. DR GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB. DR GO; GO:2000785; P:regulation of autophagosome assembly; IDA:UniProt. DR GO; GO:0001558; P:regulation of cell growth; IDA:UniProtKB. DR GO; GO:0008361; P:regulation of cell size; IMP:CAFA. DR GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:1904059; P:regulation of locomotor rhythm; ISS:UniProtKB. DR GO; GO:1905671; P:regulation of lysosome organization; IDA:UniProtKB. DR GO; GO:0016241; P:regulation of macroautophagy; TAS:Reactome. DR GO; GO:0090559; P:regulation of membrane permeability; IEA:Ensembl. DR GO; GO:0031641; P:regulation of myelination; IEA:Ensembl. DR GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0043200; P:response to amino acid; IDA:UniProtKB. DR GO; GO:0009408; P:response to heat; IEA:Ensembl. DR GO; GO:0031667; P:response to nutrient levels; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; IEA:Ensembl. DR GO; GO:0031295; P:T cell costimulation; TAS:Reactome. DR GO; GO:0002296; P:T-helper 1 cell lineage commitment; IEA:Ensembl. DR GO; GO:0031929; P:TOR signaling; IMP:UniProtKB. DR GO; GO:0038202; P:TORC1 signaling; IDA:UniProtKB. DR GO; GO:0038203; P:TORC2 signaling; IDA:UniProtKB. DR GO; GO:0097700; P:vascular endothelial cell response to laminar fluid shear stress; TAS:Reactome. DR GO; GO:0050882; P:voluntary musculoskeletal movement; IEA:Ensembl. DR CDD; cd05169; PIKKc_TOR; 1. DR DisProt; DP03874; -. DR FunFam; 1.10.1070.11:FF:000074; DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1); 1. DR FunFam; 1.10.1070.11:FF:000058; MTOR isoform 6; 1. DR FunFam; 1.25.10.10:FF:000060; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000094; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.25.10.10:FF:000532; Serine/threonine-protein kinase mTOR; 1. DR FunFam; 1.20.120.150:FF:000001; Serine/threonine-protein kinase TOR; 1. DR FunFam; 1.25.10.10:FF:000083; Serine/threonine-protein kinase TOR; 1. DR FunFam; 3.30.1010.10:FF:000004; Serine/threonine-protein kinase TOR; 1. DR Gene3D; 1.20.120.150; FKBP12-rapamycin binding domain; 1. DR Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 4. DR Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1. DR Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1. DR Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1. DR IDEAL; IID00598; -. DR InterPro; IPR011989; ARM-like. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR050517; DDR_Repair_Kinase. DR InterPro; IPR003152; FATC_dom. DR InterPro; IPR009076; FRB_dom. DR InterPro; IPR036738; FRB_sf. DR InterPro; IPR057564; HEAT_ATR. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024585; mTOR_dom. DR InterPro; IPR000403; PI3/4_kinase_cat_dom. DR InterPro; IPR036940; PI3/4_kinase_cat_sf. DR InterPro; IPR018936; PI3/4_kinase_CS. DR InterPro; IPR003151; PIK-rel_kinase_FAT. DR InterPro; IPR014009; PIK_FAT. DR InterPro; IPR026683; TOR_cat. DR InterPro; IPR011990; TPR-like_helical_dom_sf. DR PANTHER; PTHR11139; ATAXIA TELANGIECTASIA MUTATED ATM -RELATED; 1. DR PANTHER; PTHR11139:SF9; SERINE_THREONINE-PROTEIN KINASE MTOR; 1. DR Pfam; PF02259; FAT; 1. DR Pfam; PF02260; FATC; 1. DR Pfam; PF08771; FRB_dom; 1. DR Pfam; PF23593; HEAT_ATR; 1. DR Pfam; PF11865; mTOR_dom; 1. DR Pfam; PF00454; PI3_PI4_kinase; 1. DR SMART; SM01346; DUF3385; 1. DR SMART; SM01343; FATC; 1. DR SMART; SM00146; PI3Kc; 1. DR SMART; SM01345; Rapamycin_bind; 1. DR SUPFAM; SSF48371; ARM repeat; 2. DR SUPFAM; SSF47212; FKBP12-rapamycin-binding domain of FKBP-rapamycin-associated protein (FRAP); 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51189; FAT; 1. DR PROSITE; PS51190; FATC; 1. DR PROSITE; PS00915; PI3_4_KINASE_1; 1. DR PROSITE; PS00916; PI3_4_KINASE_2; 1. DR PROSITE; PS50290; PI3_4_KINASE_3; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Cell membrane; Cytoplasm; KW Cytoplasmic vesicle; Disease variant; Endoplasmic reticulum; Epilepsy; KW Golgi apparatus; Intellectual disability; Isopeptide bond; Kinase; KW Lysosome; Membrane; Microsome; Mitochondrion; Mitochondrion outer membrane; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; TPR repeat; KW Transferase; Ubl conjugation. FT CHAIN 1..2549 FT /note="Serine/threonine-protein kinase mTOR" FT /id="PRO_0000088808" FT REPEAT 16..53 FT /note="HEAT 1" FT REPEAT 55..99 FT /note="HEAT 2" FT REPEAT 100..137 FT /note="HEAT 3" FT REPEAT 138..179 FT /note="HEAT 4" FT REPEAT 180..220 FT /note="HEAT 5" FT REPEAT 222..276 FT /note="HEAT 6" FT REPEAT 277..313 FT /note="HEAT 7" FT REPEAT 314..364 FT /note="HEAT 8" FT REPEAT 365..409 FT /note="HEAT 9" FT REPEAT 410..445 FT /note="HEAT 10" FT REPEAT 446..494 FT /note="HEAT 11" FT REPEAT 495..529 FT /note="HEAT 12" FT REPEAT 530..563 FT /note="HEAT 13" FT REPEAT 564..596 FT /note="HEAT 14" FT REPEAT 597..636 FT /note="HEAT 15" FT REPEAT 637..683 FT /note="HEAT 16" FT REPEAT 686..724 FT /note="HEAT 17" FT REPEAT 727..766 FT /note="HEAT 18" FT REPEAT 769..811 FT /note="HEAT 19" FT REPEAT 814..853 FT /note="HEAT 20" FT REPEAT 857..893 FT /note="HEAT 21" FT REPEAT 894..942 FT /note="HEAT 22" FT REPEAT 943..988 FT /note="HEAT 23" FT REPEAT 989..1027 FT /note="HEAT 24" FT REPEAT 1029..1068 FT /note="HEAT 25" FT REPEAT 1069..1105 FT /note="HEAT 26" FT REPEAT 1106..1144 FT /note="HEAT 27" FT REPEAT 1145..1188 FT /note="HEAT 28" FT REPEAT 1189..1225 FT /note="HEAT 29" FT REPEAT 1226..1273 FT /note="HEAT 30" FT REPEAT 1274..1311 FT /note="HEAT 31" FT REPEAT 1312..1345 FT /note="HEAT 32" FT REPEAT 1346..1382 FT /note="TPR 1" FT DOMAIN 1382..1982 FT /note="FAT" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534" FT REPEAT 1383..1408 FT /note="TPR 2" FT REPEAT 1409..1442 FT /note="TPR 3" FT REPEAT 1443..1473 FT /note="TPR 4" FT REPEAT 1474..1507 FT /note="TPR 5" FT REPEAT 1508..1541 FT /note="TPR 6" FT REPEAT 1542..1574 FT /note="TPR 7" FT REPEAT 1575..1614 FT /note="TPR 8" FT REPEAT 1615..1649 FT /note="TPR 9" FT REPEAT 1650..1693 FT /note="TPR 10" FT REPEAT 1694..1731 FT /note="TPR 11" FT REPEAT 1732..1786 FT /note="TPR 12" FT REPEAT 1787..1846 FT /note="TPR 13" FT REPEAT 1898..1930 FT /note="TPR 14" FT REPEAT 1931..1970 FT /note="TPR 15" FT REPEAT 1971..2005 FT /note="TPR 16" FT DOMAIN 2156..2469 FT /note="PI3K/PI4K catalytic" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT DOMAIN 2517..2549 FT /note="FATC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00534, FT ECO:0000255|PROSITE-ProRule:PRU00535" FT REGION 1..651 FT /note="Interaction with NBN" FT /evidence="ECO:0000269|PubMed:23762398" FT REGION 1812..1867 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2012..2144 FT /note="Sufficient for interaction with the FKBP1A/rapamycin FT complex" FT /evidence="ECO:0000250|UniProtKB:Q9JLN9" FT REGION 2162..2168 FT /note="G-loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2258..2296 FT /note="Interaction with MLST8" FT REGION 2335..2343 FT /note="Catalytic loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT REGION 2355..2380 FT /note="Activation loop" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00269" FT COMPBIAS 1820..1860 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 1662 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1702 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 1749 FT /ligand="1D-myo-inositol hexakisphosphate" FT /ligand_id="ChEBI:CHEBI:58130" FT /evidence="ECO:0000269|PubMed:33158864, FT ECO:0007744|PDB:6ZWM" FT BINDING 2165 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2167 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2185 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2187 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2190 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2225 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2238 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2239 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2240 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2245 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2343 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT BINDING 2345 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2356 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCU, ECO:0007744|PDB:6BCX" FT BINDING 2357 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:29236692, FT ECO:0007744|PDB:6BCX" FT MOD_RES 1 FT /note="N-acetylmethionine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 567 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:20068231" FT MOD_RES 1162 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1218 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:19487463, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2159 FT /note="Phosphoserine; by TBK1" FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MOD_RES 2164 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:21576368" FT MOD_RES 2173 FT /note="Phosphothreonine; by PKB/AKT1" FT /evidence="ECO:0000269|PubMed:24247430" FT MOD_RES 2446 FT /note="Phosphothreonine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15905173" FT MOD_RES 2448 FT /note="Phosphoserine; by RPS6KB1" FT /evidence="ECO:0000269|PubMed:15899889, FT ECO:0000269|PubMed:15905173, ECO:0000269|PubMed:19145465, FT ECO:0007744|PubMed:24275569" FT MOD_RES 2478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2481 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:20022946, FT ECO:0000269|PubMed:21576368, ECO:0007744|PubMed:18669648" FT CROSSLNK 2066 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:37979583" FT VARIANT 8 FT /note="A -> S (in a lung large cell carcinoma sample; FT somatic mutation; dbSNP:rs748801456)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041537" FT VARIANT 135 FT /note="M -> T (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041538" FT VARIANT 624 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs913197212)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078824" FT VARIANT 1083 FT /note="M -> V (in dbSNP:rs56164650)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041539" FT VARIANT 1134 FT /note="A -> V (in dbSNP:rs28730685)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041540" FT VARIANT 1178 FT /note="S -> F (in dbSNP:rs55975118)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041541" FT VARIANT 1376 FT /note="D -> E (found in a patient with focal epilepsy; FT uncertain significance; dbSNP:rs975577894)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078825" FT VARIANT 1450 FT /note="Y -> D (in FCORD2; somatic mutation)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078826" FT VARIANT 1456 FT /note="W -> G (in FCORD2; somatic mutation; FT dbSNP:rs1085307114)" FT /evidence="ECO:0000269|PubMed:25878179" FT /id="VAR_078827" FT VARIANT 1459 FT /note="A -> D (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1644347782)" FT /evidence="ECO:0000269|PubMed:26018084" FT /id="VAR_078828" FT VARIANT 1459 FT /note="A -> S (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs1644347846)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078829" FT VARIANT 1460 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs1057519779)" FT /evidence="ECO:0000269|PubMed:26018084, FT ECO:0000269|PubMed:27830187" FT /id="VAR_078830" FT VARIANT 1483 FT /note="C -> R (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1057519914)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078831" FT VARIANT 1490 FT /note="W -> R (in SKS; dbSNP:rs2100566800)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078832" FT VARIANT 1595 FT /note="M -> I (in SKS; dbSNP:rs869312671)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078833" FT VARIANT 1709 FT /note="R -> H (in FCORD2; uncertain significance; somatic FT mutation; dbSNP:rs587777895)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078834" FT VARIANT 1799 FT /note="E -> K (in SKS; results in increased mTOR signaling; FT dbSNP:rs863225264)" FT /evidence="ECO:0000269|PubMed:25851998, FT ECO:0000269|PubMed:26542245" FT /id="VAR_075072" FT VARIANT 1832 FT /note="A -> T (in SKS; dbSNP:rs369088781)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078835" FT VARIANT 1888 FT /note="F -> C (in SKS; dbSNP:rs869312666)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078836" FT VARIANT 1977 FT /note="T -> K (in FCORD2; somatic mutation; FT dbSNP:rs587777893)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078837" FT VARIANT 2011 FT /note="M -> V (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs2100412651)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041542" FT VARIANT 2193 FT /note="R -> C (in FCORD2; somatic mutation; FT dbSNP:rs1642723200)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078838" FT VARIANT 2215 FT /note="S -> F (in FCORD2; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:25799227, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_078839" FT VARIANT 2215 FT /note="S -> Y (in FCORD2; also found in a colorectal FT adenocarcinoma sample; somatic mutation; increased TOR FT signaling; dbSNP:rs587777894)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:27830187" FT /id="VAR_041543" FT VARIANT 2220 FT /note="L -> F (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100381099)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064733" FT VARIANT 2327 FT /note="M -> I (in SKS; dbSNP:rs878855328)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078840" FT VARIANT 2406 FT /note="V -> A (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs2100316251)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064734" FT VARIANT 2427 FT /note="L -> P (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078841" FT VARIANT 2427 FT /note="L -> Q (in FCORD2; somatic mutation; increased TOR FT signaling; increased kinase activity; dbSNP:rs1085307113)" FT /evidence="ECO:0000269|PubMed:25799227" FT /id="VAR_078842" FT VARIANT 2476 FT /note="P -> L (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041544" FT VARIANT 2501 FT /note="I -> V (found in a patient with non-lesional FT nocturnal frontal epilepsy; uncertain significance; FT dbSNP:rs968817513)" FT /evidence="ECO:0000269|PubMed:27830187" FT /id="VAR_078843" FT MUTAGEN 2066 FT /note="K->R: Complete loss ubiquitination by the FT SCF(FBXO22) complex." FT /evidence="ECO:0000269|PubMed:37979583" FT MUTAGEN 2159 FT /note="S->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2164. Reduced FT activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2159 FT /note="S->D: Mimics phosphorylation; leading to stronger FT phosphorylation of RPS6KB1; when associated with E-2164. FT Increased activity of the mTORC1 complex." FT /evidence="ECO:0000269|PubMed:21576368, FT ECO:0000269|PubMed:29150432" FT MUTAGEN 2164 FT /note="T->A: Reduces mTORC1-associated S-2481 FT autophosphorylation; when associated with A-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2164 FT /note="T->E: Stronger phosphorylation of RPS6KB1; when FT associated with D-2159." FT /evidence="ECO:0000269|PubMed:21576368" FT MUTAGEN 2173 FT /note="T->A: Increased mTOR kinase activity." FT /evidence="ECO:0000269|PubMed:24247430" FT MUTAGEN 2340 FT /note="H->A: Barely detectable kinase activity." FT /evidence="ECO:0000269|PubMed:23636326" FT MUTAGEN 2357 FT /note="D->E: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with I-2364." FT /evidence="ECO:0000269|PubMed:30956113" FT MUTAGEN 2364 FT /note="V->I: Kinase-dead mutant, loss of interaction with FT TM4SF5 and loss of lysosome membrane localization; when FT associated with E-2357." FT /evidence="ECO:0000269|PubMed:30956113" FT CONFLICT 353 FT /note="K -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 359 FT /note="S -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 364 FT /note="D -> N (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 390 FT /note="M -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 430 FT /note="R -> L (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 455..457 FT /note="VLD -> GVE (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 461 FT /note="A -> G (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 482..484 FT /note="VFT -> FFN (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 489 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 513 FT /note="L -> I (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 539 FT /note="L -> V (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 553 FT /note="R -> C (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT CONFLICT 857 FT /note="P -> L (in Ref. 3; BAE06077)" FT /evidence="ECO:0000305" FT CONFLICT 1075 FT /note="I -> S (in Ref. 2; AAC39933)" FT /evidence="ECO:0000305" FT HELIX 19..29 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 38..52 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 61..73 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 83..93 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 94..96 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 102..114 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 115..117 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 123..134 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 141..155 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 165..178 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 180..183 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 184..186 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 188..197 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 204..222 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 234..245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 259..275 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 277..288 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 357..360 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 362..375 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 376..378 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 380..382 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 387..402 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 404..409 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 413..424 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 427..443 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 446..448 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 449..451 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 452..462 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 463..465 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 479..490 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 495..497 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 499..510 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 517..527 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:6ZWM" FT HELIX 533..548 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 580..588 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 601..611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 616..629 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 646..648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 649..665 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 667..669 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 670..677 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 681..683 FT /evidence="ECO:0007829|PDB:6ZWM" FT TURN 685..688 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 690..699 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 706..717 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 718..721 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 723..742 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 749..762 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 765..767 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 769..771 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 772..783 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 792..808 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 811..813 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 814..816 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 817..828 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 831..833 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 838..851 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 856..860 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 864..870 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 871..873 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 878..891 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 896..902 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 934..937 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 943..958 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 964..982 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 986..989 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 990..1002 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1006..1008 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1009..1023 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1024..1030 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1031..1040 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1046..1062 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1065..1069 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1071..1083 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1088..1090 FT /evidence="ECO:0007829|PDB:7PE8" FT HELIX 1091..1103 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1104..1107 FT /evidence="ECO:0007829|PDB:7UXC" FT TURN 1108..1110 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1111..1123 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1125..1127 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1129..1142 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1143..1145 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1150..1152 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1153..1163 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1167..1169 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1170..1182 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1185..1191 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1192..1202 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1207..1218 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1222..1226 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1229..1237 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1263..1269 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1277..1293 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1298..1301 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1304..1309 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1311..1315 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1318..1328 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1331..1347 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1351..1366 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1367..1369 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1375..1379 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1380..1390 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1393..1406 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1410..1422 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1426..1439 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1441..1444 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1447..1452 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1456..1469 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1474..1487 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1490..1499 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1501..1504 FT /evidence="ECO:0007829|PDB:6ZWO" FT HELIX 1506..1523 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1526..1533 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1538..1540 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1541..1553 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1557..1579 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1584..1586 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1587..1602 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1603..1605 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:4JSP" FT HELIX 1609..1611 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1612..1623 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1630..1640 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1641..1643 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1646..1648 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1650..1662 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1666..1677 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1681..1683 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1685..1687 FT /evidence="ECO:0007829|PDB:6ZWO" FT STRAND 1691..1693 FT /evidence="ECO:0007829|PDB:7UXC" FT HELIX 1694..1706 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1710..1730 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1737..1758 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1759..1762 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1766..1768 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1769..1782 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1783..1785 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 1787..1809 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1810..1813 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1868..1877 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1878..1880 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1881..1893 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 1896..1898 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1900..1913 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1917..1929 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1933..1935 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1936..1938 FT /evidence="ECO:0007829|PDB:7PE7" FT HELIX 1939..1943 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1944..1947 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1951..1966 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 1970..1972 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1973..1980 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 1985..1999 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2005..2019 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2020..2022 FT /evidence="ECO:0007829|PDB:2NPU" FT HELIX 2025..2039 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2044..2058 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2065..2091 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2094..2111 FT /evidence="ECO:0007829|PDB:4DRI" FT HELIX 2115..2117 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2120..2122 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2123..2126 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2128..2132 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2137..2139 FT /evidence="ECO:0007829|PDB:6ZWO" FT TURN 2141..2143 FT /evidence="ECO:0007829|PDB:5WBY" FT STRAND 2146..2148 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2152..2156 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2158..2162 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2164..2167 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2170..2179 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2181..2187 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2194..2210 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2213..2216 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2217..2219 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2227..2229 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2231..2233 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2235..2238 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2241..2245 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2246..2256 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2263..2271 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2273..2277 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2280..2292 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2298..2305 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2308..2310 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2311..2334 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2341..2343 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2344..2350 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2353..2355 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2362..2364 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2365..2367 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2369..2371 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2381..2385 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2392..2394 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2395..2409 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2411..2422 FT /evidence="ECO:0007829|PDB:8ERA" FT TURN 2425..2428 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2429..2432 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2433..2435 FT /evidence="ECO:0007829|PDB:5WBY" FT HELIX 2493..2509 FT /evidence="ECO:0007829|PDB:8ERA" FT STRAND 2512..2516 FT /evidence="ECO:0007829|PDB:4JT5" FT HELIX 2521..2532 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2535..2539 FT /evidence="ECO:0007829|PDB:8ERA" FT HELIX 2543..2545 FT /evidence="ECO:0007829|PDB:8ERA" SQ SEQUENCE 2549 AA; 288892 MW; 7D9AD6E784882AB4 CRC64; MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD VPTQVELLIK QATSHENLCQ CYIGWCPFW // ID TAF1_HUMAN Reviewed; 1893 AA. AC P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1; Q70Q86; AC Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03; DT 01-MAY-1991, integrated into UniProtKB/Swiss-Prot. DT 08-NOV-2023, sequence version 3. DT 28-JAN-2026, entry version 249. DE RecName: Full=Transcription initiation factor TFIID subunit 1 {ECO:0000305}; DE EC=2.3.1.48 {ECO:0000269|PubMed:15870300}; DE EC=2.7.11.1; DE AltName: Full=Cell cycle gene 1 protein; DE AltName: Full=TBP-associated factor 250 kDa; DE Short=p250; DE AltName: Full=Transcription initiation factor TFIID 250 kDa subunit; DE Short=TAF(II)250; DE Short=TAFII-250; DE Short=TAFII250; GN Name=TAF1 {ECO:0000312|HGNC:HGNC:11535}; Synonyms=BA2R, CCG1, CCGS, TAF2A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION. RC TISSUE=Laryngeal carcinoma; RX PubMed=2038334; DOI=10.1128/mcb.11.6.3317-3325.1991; RA Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.; RT "The human CCG1 gene, essential for progression of the G1 phase, encodes a RT 210-kilodalton nuclear DNA-binding protein."; RL Mol. Cell. Biol. 11:3317-3325(1991). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND TAFS. RX PubMed=7680771; DOI=10.1038/362175a0; RA Ruppert S., Wang E.H., Tjian R.; RT "Cloning and expression of human TAFII250: a TBP-associated factor RT implicated in cell-cycle regulation."; RL Nature 362:175-179(1993). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3. RC TISSUE=Brain; RX PubMed=17273961; DOI=10.1086/512129; RA Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S., Matsumoto S., RA Tabuena M.D., Maranon E., Dantes M., Lee L.V., Ogasawara K., Tooyama I., RA Akatsu H., Nishimura M., Tamiya G.; RT "Reduced neuron-specific expression of the TAF1 gene is associated with X- RT linked dystonia-parkinsonism."; RL Am. J. Hum. Genet. 80:393-406(2007). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANT VAL-290. RG NIEHS SNPs program; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15772651; DOI=10.1038/nature03440; RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C., RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., RA Rogers J., Bentley D.R.; RT "The DNA sequence of the human X chromosome."; RL Nature 434:325-337(2005). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 61-1604 (ISOFORM 1). RX PubMed=3169001; DOI=10.1002/j.1460-2075.1988.tb02996.x; RA Sekiguchi T., Miyata T., Nishimoto T.; RT "Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which RT complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the RT BHK cell line."; RL EMBO J. 7:1683-1687(1988). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 858-1893 (ISOFORM 4). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1368-1893 (ISOFORMS 2A; 2C; 2D AND 2E), RP NUCLEOTIDE SEQUENCE [MRNA] OF 1519-1893 (ISOFORM 16), NUCLEOTIDE SEQUENCE RP [MRNA] OF 1749-1893 (ISOFORM 15), AND INVOLVEMENT IN DYT3. RC TISSUE=Fetal brain; RX PubMed=12928496; DOI=10.1073/pnas.1831949100; RA Nolte D., Niemann S., Muller U.; RT "Specific sequence changes in multiple transcript system DYT3 are RT associated with X-linked dystonia parkinsonism."; RL Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003). RN [9] RP SEQUENCE REVISION (ISOFORMS 2A; 2C; 2D AND 2E), NUCLEOTIDE SEQUENCE [MRNA] RP OF 1368-1893 (ISOFORMS 2E; 2G; 2H AND 2I), AND ALTERNATIVE SPLICING. RX PubMed=17952504; DOI=10.1007/s00335-007-9063-z; RA Herzfeld T., Nolte D., Muller U.; RT "Structural and functional analysis of the human TAF1/DYT3 multiple RT transcript system."; RL Mamm. Genome 18:787-795(2007). RN [10] RP FUNCTION. RX PubMed=8450888; DOI=10.1038/362179a0; RA Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M., RA Roeder R.G.; RT "The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle RT regulatory protein CCG1."; RL Nature 362:179-181(1993). RN [11] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-137 AND SER-328, AND RP ATP-BINDING. RX PubMed=8625415; DOI=10.1016/s0092-8674(00)81055-7; RA Dikstein R., Ruppert S., Tjian R.; RT "TAFII250 is a bipartite protein kinase that phosphorylates the base RT transcription factor RAP74."; RL Cell 84:781-790(1996). RN [12] RP INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION). RX PubMed=8647434; DOI=10.1101/gad.10.11.1369; RA Damania B., Alwine J.C.; RT "TAF-like function of SV40 large T antigen."; RL Genes Dev. 10:1369-1381(1996). RN [13] RP INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION). RX PubMed=8649420; DOI=10.1128/mcb.16.6.3085; RA Carrozza M.J., DeLuca N.A.; RT "Interaction of the viral activator protein ICP4 with TFIID through RT TAF250."; RL Mol. Cell. Biol. 16:3085-3093(1996). RN [14] RP FUNCTION, AND MUTAGENESIS. RX PubMed=9660973; DOI=10.1016/s1097-2765(00)80089-1; RA O'Brien T., Tjian R.; RT "Functional analysis of the human TAFII250 N-terminal kinase domain."; RL Mol. Cell 1:905-911(1998). RN [15] RP FUNCTION, ACTIVITY REGULATION, INTERACTION WITH RB1, AND ATP-BINDING. RX PubMed=9858607; DOI=10.1128/mcb.19.1.846; RA Siegert J.L., Robbins P.D.; RT "Rb inhibits the intrinsic kinase activity of TATA-binding protein- RT associated factor TAFII250."; RL Mol. Cell. Biol. 19:846-854(1999). RN [16] RP INTERACTION WITH ASF1A. RX PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x; RA Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.; RT "A human homologue of yeast anti-silencing factor has histone chaperone RT activity."; RL Genes Cells 5:221-233(2000). RN [17] RP FUNCTION. RX PubMed=11278496; DOI=10.1074/jbc.m009385200; RA Solow S., Salunek M., Ryan R., Lieberman P.M.; RT "Taf(II) 250 phosphorylates human transcription factor IIA on serine RT residues important for TBP binding and transcription activity."; RL J. Biol. Chem. 276:15886-15892(2001). RN [18] RP ACTIVITY REGULATION, AND INTERACTION WITH TAF7. RX PubMed=11592977; DOI=10.1073/pnas.211444798; RA Gegonne A., Weissman J.D., Singer D.S.; RT "TAFII55 binding to TAFII250 inhibits its acetyltransferase activity."; RL Proc. Natl. Acad. Sci. U.S.A. 98:12432-12437(2001). RN [19] RP INTERACTION WITH ASF1A. RX PubMed=12093919; DOI=10.1073/pnas.142627899; RA Chimura T., Kuzuhara T., Horikoshi M.; RT "Identification and characterization of CIA/ASF1 as an interactor of RT bromodomains associated with TFIID."; RL Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002). RN [20] RP INTERACTION WITH ASF1A AND ASF1B. RX PubMed=12842904; DOI=10.1074/jbc.m303549200; RA Umehara T., Horikoshi M.; RT "Transcription initiation factor IID-interactive histone chaperone CIA-II RT implicated in mammalian spermatogenesis."; RL J. Biol. Chem. 278:35660-35667(2003). RN [21] RP FUNCTION, AND INTERACTION WITH TP53. RX PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6; RA Li H.-H., Li A.G., Sheppard H.M., Liu X.; RT "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for RT TAF1 in cell G1 progression."; RL Mol. Cell 13:867-878(2004). RN [22] RP IDENTIFICATION IN THE MLL1/MLL COMPLEX. RX PubMed=15960975; DOI=10.1016/j.cell.2005.04.031; RA Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., RA Allis C.D., Chait B.T., Hess J.L., Roeder R.G.; RT "Physical association and coordinate function of the H3 K4 RT methyltransferase MLL1 and the H4 K16 acetyltransferase MOF."; RL Cell 121:873-885(2005). RN [23] RP HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-742 AND RP 848-MET--ASP-850. RX PubMed=15870300; DOI=10.1128/mcb.25.10.4321-4332.2005; RA Hilton T.L., Li Y., Dunphy E.L., Wang E.H.; RT "TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 RT promoter."; RL Mol. Cell. Biol. 25:4321-4332(2005). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1847, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1721 (ISOFORMS 2A AND 4), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1723 (ISOFORM 2G), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1718 (ISOFORM 16), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [27] RP ACTIVITY REGULATION. RX PubMed=22711989; DOI=10.1128/mcb.00416-12; RA Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.; RT "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene RT transcription by TFIID subunits TAF1 and TAF7."; RL Mol. Cell. Biol. 32:3358-3369(2012). RN [28] RP MISCELLANEOUS. RX PubMed=23184149; DOI=10.1093/hmg/dds499; RA Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L., Muller U.; RT "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific RT sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and RT dopamine metabolism."; RL Hum. Mol. Genet. 22:941-951(2013). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-328, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [30] RP SUBCELLULAR LOCATION. RX PubMed=25593309; DOI=10.1101/gad.252189.114; RA Gong F., Chiu L.Y., Cox B., Aymard F., Clouaire T., Leung J.W., RA Cammarata M., Perez M., Agarwal P., Brodbelt J.S., Legube G., Miller K.M.; RT "Screen identifies bromodomain protein ZMYND8 in chromatin recognition of RT transcription-associated DNA damage that promotes homologous RT recombination."; RL Genes Dev. 29:197-211(2015). RN [31] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-570 AND LYS-583, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [32] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1380-1659. RX PubMed=10827952; DOI=10.1126/science.288.5470.1422; RA Jacobson R.H., Ladurner A.G., King D.S., Tjian R.; RT "Structure and function of a human TAFII250 double bromodomain module."; RL Science 288:1422-1425(2000). RN [33] RP X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1522-1656, AND SUBUNIT. RX PubMed=22464331; DOI=10.1016/j.cell.2012.02.013; RA Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., RA Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T., RA Gingras A.C., Arrowsmith C.H., Knapp S.; RT "Histone recognition and large-scale structural analysis of the human RT bromodomain family."; RL Cell 149:214-231(2012). RN [34] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 600-1236 IN COMPLEX WITH TAF7, RP FUNCTION, AND INTERACTION WITH TAF7. RX PubMed=25412659; DOI=10.1038/cr.2014.148; RA Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.; RT "Crystal structure of a TAF1-TAF7 complex in human transcription factor IID RT reveals a promoter binding module."; RL Cell Res. 24:1433-1444(2014). RN [35] RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1518-1659 IN COMPLEX WITH RP CROTONYLATED OR BUTYRYLATED HISTONE H4. RX PubMed=26365797; DOI=10.1016/j.str.2015.08.004; RA Flynn E.M., Huang O.W., Poy F., Oppikofer M., Bellon S.F., Tang Y., RA Cochran A.G.; RT "A subset of human bromodomains recognizes butyryllysine and crotonyllysine RT histone peptide modifications."; RL Structure 23:1801-1814(2015). RN [36] RP STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR RP LOCATION. RX PubMed=27007846; DOI=10.1038/nature17394; RA Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.; RT "Structure of promoter-bound TFIID and model of human pre-initiation RT complex assembly."; RL Nature 531:604-609(2016). RN [37] {ECO:0007744|PDB:6FIC} RP X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 1380-1659. RA Mathea S., Suh J.L., Salah E., Tallant C., Siejka P., Pike A.C.W., RA von Delft F., Arrowsmith C.H., Edwards A.M., Bountra C., James L.I., RA Frye S.V., Knapp S.; RT "Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem."; RL Submitted (JAN-2018) to the PDB data bank. RN [38] {ECO:0007744|PDB:6P39, ECO:0007744|PDB:6P3A} RP X-RAY CRYSTALLOGRAPHY (2.94 ANGSTROMS) OF 1521-1656. RA Seo H.-S., Dhe-Paganon S.; RT "Crystal Structure Analysis of TAF1 Bromodomain."; RL Submitted (MAY-2019) to the PDB data bank. RN [39] {ECO:0007744|PDB:7JJG} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ATR kinase inhibitor AZ20."; RL Submitted (JUL-2020) to the PDB data bank. RN [40] {ECO:0007744|PDB:7JJH} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human RT TAF1."; RL Submitted (JUL-2020) to the PDB data bank. RN [41] {ECO:0007744|PDB:7JSP} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT the ATR kinase inhibitor AZD6738."; RL Submitted (AUG-2020) to the PDB data bank. RN [42] {ECO:0007744|PDB:7JTC} RP X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT ZS1-322."; RL Submitted (AUG-2020) to the PDB data bank. RN [43] {ECO:0007744|PDB:7K03} RP X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 RT bound to ATR kinase inhibitor AZD6738."; RL Submitted (SEP-2020) to the PDB data bank. RN [44] {ECO:0007744|PDB:7K0D} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to mTORC1/2 inhibitor AZD3147."; RL Submitted (SEP-2020) to the PDB data bank. RN [45] {ECO:0007744|PDB:7K0U} RP X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT PLK1 kinase inhibitor BI2536."; RL Submitted (SEP-2020) to the PDB data bank. RN [46] {ECO:0007744|PDB:7K1P} RP X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT bromosporine."; RL Submitted (SEP-2020) to the PDB data bank. RN [47] {ECO:0007744|PDB:7K27} RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ATR inhibitor AZ20."; RL Submitted (SEP-2020) to the PDB data bank. RN [48] {ECO:0007744|PDB:7K3O} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the unliganded second bromodomain (BD2) of human RT TAF1."; RL Submitted (SEP-2020) to the PDB data bank. RN [49] {ECO:0007744|PDB:7K42} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1522-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to RT dioxane."; RL Submitted (SEP-2020) to the PDB data bank. RN [50] {ECO:0007744|PDB:7K6F} RP X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 1394-1656. RA Karim M.R., Bikowitz M.J., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in RT complex with MES (2-(N-morpholino)ethanesulfonic acid)."; RL Submitted (SEP-2020) to the PDB data bank. RN [51] {ECO:0007744|PDB:7L6X} RP X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to GNE-371."; RL Submitted (DEC-2020) to the PDB data bank. RN [52] {ECO:0007744|PDB:7LB0} RP X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-295."; RL Submitted (JAN-2021) to the PDB data bank. RN [53] {ECO:0007744|PDB:7LB1} RP X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-585."; RL Submitted (JAN-2021) to the PDB data bank. RN [54] {ECO:0007744|PDB:7LB2} RP X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound RT to ZS1-589."; RL Submitted (JAN-2021) to the PDB data bank. RN [55] {ECO:0007744|PDB:7N42} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1394-1656. RA Karim M.R., Schonbrunn E.; RT "Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound RT to ZS1-681."; RL Submitted (JUN-2021) to the PDB data bank. RN [56] {ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH} RP STRUCTURE BY ELECTRON MICROSCOPY (3.04 ANGSTROMS), FUNCTION, IDENTIFICATION RP IN THE TFIID COMPLEX, AND SUBUNIT. RX PubMed=33795473; DOI=10.1126/science.aba8490; RA Chen X., Qi Y., Wu Z., Wang X., Li J., Zhao D., Hou H., Li Y., Yu Z., RA Liu W., Wang M., Ren Y., Li Z., Yang H., Xu Y.; RT "Structural insights into preinitiation complex assembly on core RT promoters."; RL Science 372:0-0(2021). RN [57] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-290; GLY-318; ASP-474; LYS-672 AND RP ILE-712. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [58] RP INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-596; ARG-807; HIS-976; RP TRP-1246; THR-1337; HIS-1452 AND HIS-1517. RX PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005; RA O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y., Parboosingh J.S., RA Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M., Schuette J.L., RA Hufnagel R.B., Prada C.E., Martinez F., Orellana C., Crain J., RA Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T., Swensen J., RA Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S., Den Hollander N., RA Mittelman D., Highnam G., Robison R., Yang E., Faivre L., Roubertie A., RA Riviere J.B., Monaghan K.G., Wang K., Davis E.E., Katsanis N., RA Kalscheuer V.M., Wang E.H., Metcalfe K., Kleefstra T., Innes A.M., RA Kitsiou-Tzeli S., Rosello M., Keegan C.E., Lyon G.J.; RT "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual RT Disability, and Neurological Manifestations."; RL Am. J. Hum. Genet. 97:922-932(2015). RN [59] RP VARIANTS ASP-493 AND CYS-1190. RX PubMed=25644381; DOI=10.1038/mp.2014.193; RA Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P., RA Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I., RA Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U., RA Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L., RA Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M., RA Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S., RA van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R., RA O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M., RA Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G., RA Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B., RA Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P., RA Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M., RA Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B., RA Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R., RA Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H., RA Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.; RT "X-exome sequencing of 405 unresolved families identifies seven novel RT intellectual disability genes."; RL Mol. Psychiatry 21:133-148(2016). CC -!- FUNCTION: The TFIID basal transcription factor complex plays a major CC role in the initiation of RNA polymerase II (Pol II)-dependent CC transcription (PubMed:33795473). TFIID recognizes and binds promoters CC with or without a TATA box via its subunit TBP, a TATA-box-binding CC protein, and promotes assembly of the pre-initiation complex (PIC) CC (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated CC factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, CC TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF1 is CC the largest component and core scaffold of the TFIID complex, involved CC in nucleating complex assembly (PubMed:25412659, PubMed:27007846, CC PubMed:33795473). TAF1 forms a promoter DNA binding subcomplex of CC TFIID, together with TAF7 and TAF2 (PubMed:33795473). Contains novel CC N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or CC transphosphorylate other transcription factors (PubMed:25412659, CC PubMed:8625415). Phosphorylates TP53 on 'Thr-55' which leads to MDM2- CC mediated degradation of TP53 (PubMed:25412659). Phosphorylates GTF2A1 CC and GTF2F1 on Ser residues (PubMed:25412659). Possesses DNA-binding CC activity (PubMed:25412659). Essential for progression of the G1 phase CC of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, CC PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). CC Exhibits histone acetyltransferase activity towards histones H3 and H4 CC (PubMed:15870300). {ECO:0000269|PubMed:11278496, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300, CC ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:8450888, ECO:0000269|PubMed:8625415, CC ECO:0000269|PubMed:9660973, ECO:0000269|PubMed:9858607}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-lysyl-[protein] + acetyl-CoA = N(6)-acetyl-L-lysyl-[protein] CC + CoA + H(+); Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752, Rhea:RHEA- CC COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969, ChEBI:CHEBI:57287, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48; CC Evidence={ECO:0000269|PubMed:15870300}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Autophosphorylates on Ser residues CC (PubMed:8625415). Inhibited by retinoblastoma tumor suppressor protein, CC RB1 (PubMed:9858607). Binding to TAF7 or CIITA inhibits the histone CC acetyltransferase activity (PubMed:11592977, PubMed:22711989). CC {ECO:0000269|PubMed:11592977, ECO:0000269|PubMed:22711989, CC ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: Component of the TFIID basal transcription factor complex, CC composed of TATA-box-binding protein TBP, and a number of TBP- CC associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, CC TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473, CC PubMed:7680771). Interacts with TAF7; the interaction is direct CC (PubMed:11592977, PubMed:25412659). TAF1, when part of the TFIID CC complex, interacts with C-terminus of TP53 (PubMed:15053879). Part of a CC TFIID-containing RNA polymerase II pre-initiation complex that is CC composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, CC GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, CC TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 CC (PubMed:27007846). Component of some MLL1/MLL complex, at least CC composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and CC RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, CC INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31, CC RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 CC and TEX10 (PubMed:15960975). RB1 interacts with the N-terminal domain CC of TAF1 (PubMed:9858607). Interacts with ASF1A and ASF1B CC (PubMed:10759893, PubMed:12093919, PubMed:12842904). Interacts (via CC bromo domains) with acetylated lysine residues on the N-terminus of CC histone H1.4, H2A, H2B, H3 and H4 (in vitro) (PubMed:22464331). CC {ECO:0000269|PubMed:10759893, ECO:0000269|PubMed:11592977, CC ECO:0000269|PubMed:12093919, ECO:0000269|PubMed:12842904, CC ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15960975, CC ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:25412659, CC ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473, CC ECO:0000269|PubMed:7680771, ECO:0000269|PubMed:9858607}. CC -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen. CC {ECO:0000269|PubMed:8647434}. CC -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1 CC ICP4. {ECO:0000269|PubMed:8649420}. CC -!- INTERACTION: CC P21675; P35269: GTF2F1; NbExp=3; IntAct=EBI-491289, EBI-457886; CC P21675; P20226: TBP; NbExp=11; IntAct=EBI-491289, EBI-355371; CC P21675; P03255; Xeno; NbExp=3; IntAct=EBI-491289, EBI-2603114; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:2038334, CC ECO:0000269|PubMed:25593309, ECO:0000269|PubMed:27007846}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=15; CC Comment=the TAF1/DYT3 multiple transcript system is composed of 38 CC evolutionary conserved exons plus 5 downstream exons referred to as CC exons d1-d5 that are primate-specific. Multiple highly polymorphic CC variants can be generated by splicing exons d3 and d4 to various CC combinations of exons 1-37. {ECO:0000305|PubMed:17952504}; CC Name=2; CC IsoId=P21675-2; Sequence=Displayed; CC Name=1; CC IsoId=P21675-1; Sequence=VSP_061988; CC Name=13; CC IsoId=P21675-13; Sequence=VSP_061987, VSP_061988; CC Name=14; CC IsoId=P21675-14; Sequence=VSP_061987; CC Name=15; CC IsoId=P21675-15; Sequence=VSP_061999, VSP_062000; CC Name=16; CC IsoId=P21675-16; Sequence=VSP_061996, VSP_061998; CC Name=N-TAF1; Synonyms=TA14-391; CC IsoId=P21675-17; Sequence=VSP_061995; CC Name=2a; CC IsoId=P21675-18; Sequence=VSP_061997, VSP_061998; CC Name=2c; CC IsoId=P21675-19; Sequence=VSP_061998; CC Name=2d; CC IsoId=P21675-20; Sequence=VSP_061995, VSP_061998; CC Name=2e; CC IsoId=P21675-21; Sequence=VSP_061993, VSP_061994; CC Name=2g; CC IsoId=P21675-22; Sequence=VSP_061995, VSP_061997, VSP_061998; CC Name=2h; CC IsoId=P21675-23; Sequence=VSP_061990, VSP_061991; CC Name=2i; CC IsoId=P21675-24; Sequence=VSP_061989, VSP_061992; CC Name=4; CC IsoId=P21675-25; Sequence=VSP_061997; CC -!- DOMAIN: The Bromo domain mediates interaction with histones that have CC acetylated lysine residues at specific positions (PubMed:22464331). The CC second domain also recognizes and binds histones that are butyrylated CC and crotonylated (PubMed:26365797). {ECO:0000269|PubMed:22464331, CC ECO:0000269|PubMed:26365797}. CC -!- PTM: Phosphorylated by casein kinase II in vitro. CC {ECO:0000269|PubMed:8625415}. CC -!- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: An X-linked CC dystonia-parkinsonism disorder. Dystonia is defined by the presence of CC sustained involuntary muscle contractions, often leading to abnormal CC postures. DYT3 is characterized by severe progressive torsion dystonia CC followed by parkinsonism. It has a well-defined pathology of extensive CC neuronal loss and mosaic gliosis in the striatum (caudate nucleus and CC putamen) which appears to resemble that in Huntington disease. CC {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Intellectual developmental disorder, X-linked, syndromic 33 CC (MRXS33) [MIM:300966]: A syndrome characterized by intellectual CC deficit, delayed psychomotor development, delayed speech and language, CC and characteristic facial features. {ECO:0000269|PubMed:26637982}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- MISCELLANEOUS: [Isoform 16]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 2a]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2c]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2d]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2e]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2h]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2i]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay (Probable). Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305, ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 2g]: Includes a downstream (d) exon and is CC preferentially expressed in brain (Probable). May play a role in the CC regulation of genes involved in dopamine processing and transport CC (Probable). {ECO:0000305|PubMed:17952504}. CC -!- MISCELLANEOUS: [Isoform 15]: May be produced at very low levels due to CC a premature stop CC codon in the mRNA, leading to nonsense-mediated CC mRNA decay. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform N-TAF1]: Only detected in brain, highest CC expression in the caudate nucleus. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=CAA30073.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal and C-terminal part.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D90359; BAA14374.1; -; mRNA. DR EMBL; AB300418; BAG15901.1; -; mRNA. DR EMBL; AY623109; AAT38105.1; -; Genomic_DNA. DR EMBL; AL590762; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL590763; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; X07024; CAA30073.1; ALT_SEQ; mRNA. DR EMBL; AB209316; BAD92553.1; -; mRNA. DR EMBL; AJ549247; CAD70490.1; -; mRNA. DR EMBL; AJ549248; CAD70491.3; -; mRNA. DR EMBL; AJ549249; CAD70492.2; -; mRNA. DR EMBL; AJ549250; CAD70493.3; -; mRNA. DR EMBL; AJ555148; CAD87527.2; -; mRNA. DR EMBL; AJ555149; CAD87528.2; -; mRNA. DR EMBL; AM711892; CAM98555.1; -; mRNA. DR EMBL; AM711893; CAM98556.1; -; mRNA. DR EMBL; AM711894; CAM98557.1; -; mRNA. DR EMBL; AM711895; CAM98558.1; -; mRNA. DR CCDS; CCDS14412.2; -. [P21675-14] DR CCDS; CCDS35325.2; -. [P21675-13] DR PIR; A40262; A40262. DR RefSeq; NP_620278.2; NM_138923.4. [P21675-13] DR RefSeq; XP_047298351.1; XM_047442395.1. [P21675-14] DR RefSeq; XP_047298355.1; XM_047442399.1. [P21675-13] DR RefSeq; XP_054183607.1; XM_054327632.1. [P21675-14] DR RefSeq; XP_054183611.1; XM_054327636.1. [P21675-13] DR PDB; 1EQF; X-ray; 2.10 A; A=1380-1659. DR PDB; 3AAD; X-ray; 3.30 A; A=1363-1650. DR PDB; 3UV4; X-ray; 1.89 A; A/B=1522-1656. DR PDB; 3UV5; X-ray; 2.03 A; A=1394-1656. DR PDB; 4RGW; X-ray; 2.30 A; A=600-1236. DR PDB; 4YYM; X-ray; 1.50 A; A/B=1518-1659. DR PDB; 4YYN; X-ray; 1.85 A; A/B=1518-1659. DR PDB; 5FUR; EM; 8.50 A; G=1-1893. DR PDB; 5I1Q; X-ray; 1.50 A; A=1518-1659. DR PDB; 5I29; X-ray; 1.21 A; A=1518-1659. DR PDB; 5MG2; X-ray; 1.75 A; A=1522-1656. DR PDB; 6BQD; X-ray; 2.14 A; A/B=1522-1651. DR PDB; 6FIC; X-ray; 2.18 A; T=1380-1659. DR PDB; 6MZD; EM; 9.80 A; A=21-1893. DR PDB; 6MZL; EM; 23.00 A; A=1-1893. DR PDB; 6MZM; EM; 7.50 A; A=609-1104. DR PDB; 6P38; X-ray; 2.80 A; A=1522-1656. DR PDB; 6P39; X-ray; 2.94 A; A=1521-1656. DR PDB; 6P3A; X-ray; 2.99 A; A/B=1522-1656. DR PDB; 7EDX; EM; 4.50 A; A=1-1893. DR PDB; 7EG7; EM; 6.20 A; A=1-1893. DR PDB; 7EG8; EM; 7.40 A; A=1-1893. DR PDB; 7EG9; EM; 3.70 A; A=1-1893. DR PDB; 7EGA; EM; 4.10 A; A=1-1893. DR PDB; 7EGB; EM; 3.30 A; A=1-1893. DR PDB; 7EGC; EM; 3.90 A; A=1-1893. DR PDB; 7EGD; EM; 6.75 A; A=1-1893. DR PDB; 7EGE; EM; 9.00 A; A=1-1893. DR PDB; 7EGH; EM; 3.04 A; A=1-1893. DR PDB; 7EGI; EM; 9.82 A; A=1-1893. DR PDB; 7EGJ; EM; 8.64 A; A=1-1893. DR PDB; 7ENA; EM; 4.07 A; DA=1-1893. DR PDB; 7ENC; EM; 4.13 A; DA=1-1893. DR PDB; 7JJG; X-ray; 1.60 A; A=1522-1656. DR PDB; 7JJH; X-ray; 2.10 A; A=1394-1656. DR PDB; 7JSP; X-ray; 1.70 A; A=1522-1656. DR PDB; 7JTC; X-ray; 2.05 A; A=1522-1656. DR PDB; 7K03; X-ray; 1.60 A; A=1394-1656. DR PDB; 7K0D; X-ray; 2.20 A; A=1394-1656. DR PDB; 7K0U; X-ray; 2.52 A; A/B=1522-1656. DR PDB; 7K1P; X-ray; 2.45 A; A=1522-1656. DR PDB; 7K27; X-ray; 1.50 A; A=1394-1656. DR PDB; 7K3O; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K42; X-ray; 1.70 A; A/B=1522-1656. DR PDB; 7K6F; X-ray; 1.86 A; A=1394-1656. DR PDB; 7L6X; X-ray; 2.75 A; A=1394-1656. DR PDB; 7LB0; X-ray; 2.33 A; A=1394-1656. DR PDB; 7LB1; X-ray; 1.35 A; A=1394-1656. DR PDB; 7LB2; X-ray; 1.70 A; A=1394-1656. DR PDB; 7LB3; X-ray; 1.90 A; A=1522-1656. DR PDB; 7N42; X-ray; 1.90 A; A=1394-1656. DR PDB; 7P4S; X-ray; 2.17 A; A=1522-1656. DR PDB; 7T2I; X-ray; 1.89 A; A=1394-1656. DR PDB; 7T36; X-ray; 1.65 A; A=1394-1656. DR PDB; 8GXQ; EM; 5.04 A; DA=1-1893. DR PDB; 8GXS; EM; 4.16 A; DA=1-1893. DR PDB; 8WAK; EM; 5.47 A; A=1-1872. DR PDB; 8WAL; EM; 8.52 A; A=1-1872. DR PDB; 8WAN; EM; 6.07 A; A=1-1872. DR PDB; 8WAO; EM; 6.40 A; A=1-1872. DR PDB; 8WAP; EM; 5.85 A; A=1-1872. DR PDB; 8WAQ; EM; 6.29 A; A=1-1872. DR PDB; 8WAR; EM; 7.20 A; A=1-1872. DR PDB; 8WAS; EM; 6.13 A; A=1-1872. DR PDBsum; 1EQF; -. DR PDBsum; 3AAD; -. DR PDBsum; 3UV4; -. DR PDBsum; 3UV5; -. DR PDBsum; 4RGW; -. DR PDBsum; 4YYM; -. DR PDBsum; 4YYN; -. DR PDBsum; 5FUR; -. DR PDBsum; 5I1Q; -. DR PDBsum; 5I29; -. DR PDBsum; 5MG2; -. DR PDBsum; 6BQD; -. DR PDBsum; 6FIC; -. DR PDBsum; 6MZD; -. DR PDBsum; 6MZL; -. DR PDBsum; 6MZM; -. DR PDBsum; 6P38; -. DR PDBsum; 6P39; -. DR PDBsum; 6P3A; -. DR PDBsum; 7EDX; -. DR PDBsum; 7EG7; -. DR PDBsum; 7EG8; -. DR PDBsum; 7EG9; -. DR PDBsum; 7EGA; -. DR PDBsum; 7EGB; -. DR PDBsum; 7EGC; -. DR PDBsum; 7EGD; -. DR PDBsum; 7EGE; -. DR PDBsum; 7EGH; -. DR PDBsum; 7EGI; -. DR PDBsum; 7EGJ; -. DR PDBsum; 7ENA; -. DR PDBsum; 7ENC; -. DR PDBsum; 7JJG; -. DR PDBsum; 7JJH; -. DR PDBsum; 7JSP; -. DR PDBsum; 7JTC; -. DR PDBsum; 7K03; -. DR PDBsum; 7K0D; -. DR PDBsum; 7K0U; -. DR PDBsum; 7K1P; -. DR PDBsum; 7K27; -. DR PDBsum; 7K3O; -. DR PDBsum; 7K42; -. DR PDBsum; 7K6F; -. DR PDBsum; 7L6X; -. DR PDBsum; 7LB0; -. DR PDBsum; 7LB1; -. DR PDBsum; 7LB2; -. DR PDBsum; 7LB3; -. DR PDBsum; 7N42; -. DR PDBsum; 7P4S; -. DR PDBsum; 7T2I; -. DR PDBsum; 7T36; -. DR PDBsum; 8GXQ; -. DR PDBsum; 8GXS; -. DR PDBsum; 8WAK; -. DR PDBsum; 8WAL; -. DR PDBsum; 8WAN; -. DR PDBsum; 8WAO; -. DR PDBsum; 8WAP; -. DR PDBsum; 8WAQ; -. DR PDBsum; 8WAR; -. DR PDBsum; 8WAS; -. DR AlphaFoldDB; P21675; -. DR EMDB; EMD-31075; -. DR EMDB; EMD-31107; -. DR EMDB; EMD-31108; -. DR EMDB; EMD-31109; -. DR EMDB; EMD-31110; -. DR EMDB; EMD-31111; -. DR EMDB; EMD-31112; -. DR EMDB; EMD-31113; -. DR EMDB; EMD-31114; -. DR EMDB; EMD-31117; -. DR EMDB; EMD-31118; -. DR EMDB; EMD-31119; -. DR EMDB; EMD-31204; -. DR EMDB; EMD-31207; -. DR EMDB; EMD-34359; -. DR EMDB; EMD-34360; -. DR EMDB; EMD-37395; -. DR EMDB; EMD-37396; -. DR EMDB; EMD-37398; -. DR EMDB; EMD-37399; -. DR EMDB; EMD-37400; -. DR EMDB; EMD-37401; -. DR EMDB; EMD-37402; -. DR EMDB; EMD-37403; -. DR EMDB; EMD-9302; -. DR EMDB; EMD-9305; -. DR EMDB; EMD-9306; -. DR SASBDB; P21675; -. DR SMR; P21675; -. DR BioGRID; 112735; 258. DR ComplexPortal; CPX-915; General transcription factor complex TFIID. DR ComplexPortal; CPX-930; General transcription factor complex TFIID, TAF4B variant. DR CORUM; P21675; -. DR DIP; DIP-147N; -. DR FunCoup; P21675; 3231. DR IntAct; P21675; 83. DR MINT; P21675; -. DR STRING; 9606.ENSP00000406549; -. DR BindingDB; P21675; -. DR ChEMBL; CHEMBL3217390; -. DR GuidetoPHARMACOLOGY; 2231; -. DR GlyCosmos; P21675; 1 site, 1 glycan. DR GlyGen; P21675; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P21675; -. DR PhosphoSitePlus; P21675; -. DR BioMuta; TAF1; -. DR DMDM; 115942; -. DR jPOST; P21675; -. DR MassIVE; P21675; -. DR PaxDb; 9606-ENSP00000406549; -. DR PeptideAtlas; P21675; -. DR ProteomicsDB; 3401; -. DR ProteomicsDB; 53886; -. [P21675-1] DR ProteomicsDB; 53887; -. [P21675-2] DR Pumba; P21675; -. DR ABCD; P21675; 1 sequenced antibody. DR Antibodypedia; 346; 301 antibodies from 39 providers. DR DNASU; 6872; -. DR Ensembl; ENST00000373790.9; ENSP00000362895.5; ENSG00000147133.19. [P21675-13] DR Ensembl; ENST00000423759.6; ENSP00000406549.2; ENSG00000147133.19. [P21675-14] DR Ensembl; ENST00000715246.1; ENSP00000520427.1; ENSG00000147133.19. [P21675-2] DR GeneID; 6872; -. DR KEGG; hsa:6872; -. DR MANE-Select; ENST00000423759.6; ENSP00000406549.2; NM_004606.5; NP_004597.3. [P21675-14] DR UCSC; uc004dzt.6; human. [P21675-2] DR AGR; HGNC:11535; -. DR ClinPGx; PA36310; -. DR CTD; 6872; -. DR DisGeNET; 6872; -. DR GeneCards; TAF1; -. DR GeneReviews; TAF1; -. DR HGNC; HGNC:11535; TAF1. DR HPA; ENSG00000147133; Low tissue specificity. DR MalaCards; TAF1; -. DR MIM; 300966; phenotype. DR MIM; 313650; gene. DR MIM; 314250; phenotype. DR OpenTargets; ENSG00000147133; -. DR Orphanet; 53351; X-linked dystonia-parkinsonism. DR Orphanet; 480907; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome. DR VEuPathDB; HostDB:ENSG00000147133; -. DR eggNOG; KOG0008; Eukaryota. DR GeneTree; ENSGT00940000155242; -. DR HOGENOM; CLU_000572_3_0_1; -. DR InParanoid; P21675; -. DR OMA; PARIWYD; -. DR OrthoDB; 5752at2759; -. DR PAN-GO; P21675; 4 GO annotations based on evolutionary models. DR PhylomeDB; P21675; -. DR BRENDA; 2.3.1.48; 2681. DR PathwayCommons; P21675; -. DR Reactome; R-HSA-167161; HIV Transcription Initiation. DR Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape. DR Reactome; R-HSA-167172; Transcription of the HIV genome. DR Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape. DR Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening. DR Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation. DR Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance. DR SignaLink; P21675; -. DR SIGNOR; P21675; -. DR Agora; ENSG00000147133; -. DR BioGRID-ORCS; 6872; 343 hits in 821 CRISPR screens. DR ChiTaRS; TAF1; human. DR EvolutionaryTrace; P21675; -. DR GeneWiki; TAF1; -. DR GenomeRNAi; 6872; -. DR Pharos; P21675; Tchem. DR PRO; PR:P21675; -. DR Proteomes; UP000005640; Chromosome X. DR RNAct; P21675; protein. DR Bgee; ENSG00000147133; Expressed in sural nerve and 182 other cell types or tissues. DR ExpressionAtlas; P21675; baseline and differential. DR GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL. DR GO; GO:0071339; C:MLL1 complex; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB. DR GO; GO:0005667; C:transcription regulator complex; IPI:ParkinsonsUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB. DR GO; GO:0140046; F:histone H4K16ac reader activity; IDA:BHF-UCL. DR GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0016922; F:nuclear receptor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0002039; F:p53 binding; IPI:BHF-UCL. DR GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0001181; F:RNA polymerase I general transcription initiation factor activity; IDA:ARUK-UCL. DR GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IMP:ParkinsonsUK-UCL. DR GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:BHF-UCL. DR GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:BHF-UCL. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL. DR GO; GO:0017025; F:TBP-class protein binding; IPI:BHF-UCL. DR GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:ParkinsonsUK-UCL. DR GO; GO:0071318; P:cellular response to ATP; IDA:ParkinsonsUK-UCL. DR GO; GO:0034644; P:cellular response to UV; IDA:ParkinsonsUK-UCL. DR GO; GO:0006974; P:DNA damage response; IDA:ParkinsonsUK-UCL. DR GO; GO:0030901; P:midbrain development; IGI:ParkinsonsUK-UCL. DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL. DR GO; GO:1905524; P:negative regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:ParkinsonsUK-UCL. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL. DR GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL. DR GO; GO:0160207; P:positive regulation of androgen receptor signaling pathway; IDA:ParkinsonsUK-UCL. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL. DR GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IDA:ComplexPortal. DR GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB. DR GO; GO:0000209; P:protein polyubiquitination; IDA:ParkinsonsUK-UCL. DR GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL. DR GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; TAS:ParkinsonsUK-UCL. DR GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome. DR GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IPI:ComplexPortal. DR GO; GO:0006366; P:transcription by RNA polymerase II; IGI:BHF-UCL. DR GO; GO:0006361; P:transcription initiation at RNA polymerase I promoter; IGI:ParkinsonsUK-UCL. DR GO; GO:0006367; P:transcription initiation at RNA polymerase II promoter; IDA:BHF-UCL. DR GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL. DR CDD; cd05511; Bromo_TFIID; 2. DR DisProt; DP03451; -. [P21675-1] DR FunFam; 1.10.1100.10:FF:000001; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000019; Transcription initiation factor TFIID subunit; 1. DR FunFam; 1.20.920.10:FF:000020; Transcription initiation factor TFIID subunit; 1. DR Gene3D; 1.20.920.10; Bromodomain-like; 2. DR Gene3D; 1.10.1100.10; TAFII-230 TBP-binding domain; 1. DR IDEAL; IID00545; -. DR InterPro; IPR001487; Bromodomain. DR InterPro; IPR036427; Bromodomain-like_sf. DR InterPro; IPR018359; Bromodomain_CS. DR InterPro; IPR040240; TAF1. DR InterPro; IPR011177; TAF1_animal. DR InterPro; IPR022591; TAF1_HAT_dom. DR InterPro; IPR009067; TAF_II_230-bd. DR InterPro; IPR036741; TAFII-230_TBP-bd_sf. DR InterPro; IPR041670; Znf-CCHC_6. DR PANTHER; PTHR13900; TRANSCRIPTION INITIATION FACTOR TFIID; 1. DR PANTHER; PTHR13900:SF0; TRANSCRIPTION INITIATION FACTOR TFIID SUBUNIT 1; 1. DR Pfam; PF00439; Bromodomain; 2. DR Pfam; PF12157; DUF3591; 1. DR Pfam; PF09247; TBP-binding; 1. DR Pfam; PF15288; zf-CCHC_6; 1. DR PIRSF; PIRSF003047; TAF1_animal; 1. DR PRINTS; PR00503; BROMODOMAIN. DR SMART; SM00297; BROMO; 2. DR SUPFAM; SSF47370; Bromodomain; 2. DR SUPFAM; SSF47055; TAF(II)230 TBP-binding fragment; 1. DR PROSITE; PS00633; BROMODOMAIN_1; 2. DR PROSITE; PS50014; BROMODOMAIN_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Acyltransferase; Alternative initiation; KW Alternative splicing; ATP-binding; Bromodomain; Cell cycle; KW Disease variant; DNA-binding; Dystonia; Host-virus interaction; KW Intellectual disability; Isopeptide bond; Kinase; Nucleotide-binding; KW Nucleus; Parkinsonism; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription; KW Transcription regulation; Transferase; Ubl conjugation. FT CHAIN 1..1893 FT /note="Transcription initiation factor TFIID subunit 1" FT /id="PRO_0000211215" FT DOMAIN 1..435 FT /note="Protein kinase 1" FT DOMAIN 1397..1505 FT /note="Bromo 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DOMAIN 1446..1893 FT /note="Protein kinase 2" FT DOMAIN 1519..1628 FT /note="Bromo 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00035" FT DNA_BIND 1216..1294 FT /note="HMG box; involved in promoter binding" FT /evidence="ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, FT ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, FT ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, FT ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, FT ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH, FT ECO:0007744|PDB:7EGI, ECO:0007744|PDB:7EGJ" FT REGION 155..184 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 197..224 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 534..557 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 538..997 FT /note="Histone acetyltransferase (HAT)" FT REGION 990..1009 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1128..1148 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1158..1177 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1254..1278 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1363..1650 FT /note="Interaction with ASF1A and ASF1B" FT /evidence="ECO:0000269|PubMed:12842904" FT REGION 1651..1676 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1696..1893 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1372..1379 FT /note="Nuclear localization signal" FT /evidence="ECO:0000255" FT COMPBIAS 156..165 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 197..208 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 995..1004 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1139..1148 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1254..1270 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1659..1668 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1709..1723 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1741..1756 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1830..1840 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1846..1857 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1860..1869 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 137 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415" FT MOD_RES 328 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:8625415, FT ECO:0007744|PubMed:24275569" FT MOD_RES 565 FT /note="N6-acetyllysine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1690 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1693 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1799 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1802 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1820 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q80UV9" FT MOD_RES 1847 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT CROSSLNK 570 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 583 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VAR_SEQ 1..20 FT /note="Missing (in isoform 13 and isoform 14)" FT /id="VSP_061987" FT VAR_SEQ 178..198 FT /note="Missing (in isoform 1 and isoform 13)" FT /id="VSP_061988" FT VAR_SEQ 1546..1561 FT /note="SWPFHHPVNKKFVPDY -> VSCLCAKYFLAISSPS (in isoform FT 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061989" FT VAR_SEQ 1546..1549 FT /note="SWPF -> IITK (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061990" FT VAR_SEQ 1550..1893 FT /note="Missing (in isoform 2h)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061991" FT VAR_SEQ 1562..1893 FT /note="Missing (in isoform 2i)" FT /evidence="ECO:0000303|PubMed:17952504" FT /id="VSP_061992" FT VAR_SEQ 1606..1613 FT /note="PESQYTKT -> YMCTTCRT (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061993" FT VAR_SEQ 1614..1893 FT /note="Missing (in isoform 2e)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061994" FT VAR_SEQ 1666 FT /note="Q -> QAK (in isoform N-TAF1, isoform 2d and isoform FT 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17273961, ECO:0000303|PubMed:17952504" FT /id="VSP_061995" FT VAR_SEQ 1706..1708 FT /note="VTQ -> MRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in FT isoform 16)" FT /evidence="ECO:0000303|PubMed:12928496" FT /id="VSP_061996" FT VAR_SEQ 1708 FT /note="Q -> QMRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in isoform FT 4, isoform 2a and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504, ECO:0000303|Ref.7" FT /id="VSP_061997" FT VAR_SEQ 1820..1893 FT /note="SYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRSGPSVLSQVHLS FT EDEEDSEDFHSIAGDSDLDSDE -> RYQ (in isoform 2a, isoform 16, FT isoform 2c, isoform 2d and isoform 2g)" FT /evidence="ECO:0000303|PubMed:12928496, FT ECO:0000303|PubMed:17952504" FT /id="VSP_061998" FT VAR_SEQ 1820 FT /note="S -> R (in isoform 15)" FT /id="VSP_061999" FT VAR_SEQ 1821..1893 FT /note="Missing (in isoform 15)" FT /id="VSP_062000" FT VARIANT 290 FT /note="L -> V (in dbSNP:rs28382158)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4" FT /id="VAR_020678" FT VARIANT 318 FT /note="A -> G (in dbSNP:rs35317750)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041930" FT VARIANT 474 FT /note="G -> D (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041931" FT VARIANT 493 FT /note="N -> D (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs200177996)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077838" FT VARIANT 596 FT /note="P -> S (in MRXS33; dbSNP:rs864321630)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076394" FT VARIANT 672 FT /note="E -> K (in a metastatic melanoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041932" FT VARIANT 712 FT /note="M -> I (in a lung bronchoalveolar carcinoma sample; FT somatic mutation; dbSNP:rs2148297629)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041933" FT VARIANT 807 FT /note="C -> R (in MRXS33; dbSNP:rs864321628)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076395" FT VARIANT 976 FT /note="D -> H (in MRXS33; dbSNP:rs864321631)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076396" FT VARIANT 1190 FT /note="R -> C (found in a patient with X-linked FT intellectual disability; uncertain significance; FT dbSNP:rs1569301036)" FT /evidence="ECO:0000269|PubMed:25644381" FT /id="VAR_077839" FT VARIANT 1246 FT /note="R -> W (in MRXS33; dbSNP:rs864321629)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076397" FT VARIANT 1337 FT /note="I -> T (in MRXS33; dbSNP:rs864321627)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076398" FT VARIANT 1404 FT /note="V -> I (in dbSNP:rs7050748)" FT /id="VAR_048433" FT VARIANT 1452 FT /note="R -> H (in MRXS33; uncertain significance; FT dbSNP:rs2148488251)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076399" FT VARIANT 1517 FT /note="N -> H (in MRXS33; uncertain significance; FT dbSNP:rs1602624914)" FT /evidence="ECO:0000269|PubMed:26637982" FT /id="VAR_076400" FT MUTAGEN 137 FT /note="S->A: No decrease in kinase activity." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 145 FT /note="D->A: Reduces kinase activity; when associated with FT A-147; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 147 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-149; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 149 FT /note="E->A: Reduces kinase activity; when associated with FT A-145; A-147; A-150; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 150 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-152 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 152 FT /note="D->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-154." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 154 FT /note="K->A: Reduces kinase activity; when associated with FT A-145; A-147; A-149; A-150 and A-152." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 326 FT /note="C->A: Reduces kinase activity; when associated with FT A-328; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 328 FT /note="S->A: Reduces kinase activity; when associated with FT A-326; A-329; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 329 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-330 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 330 FT /note="D->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-331." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 331 FT /note="E->A: Reduces kinase activity; when associated with FT A-326; A-328; A-329 and A-330." FT /evidence="ECO:0000269|PubMed:9660973" FT MUTAGEN 742 FT /note="E->Q: 25% decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT MUTAGEN 848..850 FT /note="Missing: Dramatic decrease in histone acetylation." FT /evidence="ECO:0000269|PubMed:15870300" FT STRAND 363..365 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 368..374 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 420..423 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 427..429 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 431..434 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 494..498 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 501..504 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 525..527 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 591..594 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 614..617 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 621..623 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 630..634 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 645..647 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 648..650 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 651..653 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 655..659 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 661..676 FT /evidence="ECO:0007829|PDB:4RGW" FT TURN 677..679 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 689..692 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 696..706 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 718..725 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 729..731 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 739..745 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 750..753 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 760..777 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 782..788 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 799..803 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 818..838 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 841..843 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 845..847 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 848..854 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 860..868 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 871..874 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 877..879 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 882..885 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 894..900 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 903..921 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 946..949 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 952..963 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 968..973 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 979..983 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 985..989 FT /evidence="ECO:0007829|PDB:4RGW" FT HELIX 1014..1018 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1020..1031 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1035..1039 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1043..1055 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1076..1099 FT /evidence="ECO:0007829|PDB:4RGW" FT STRAND 1186..1191 FT /evidence="ECO:0007829|PDB:7EGH" FT TURN 1195..1197 FT /evidence="ECO:0007829|PDB:7EGH" FT STRAND 1201..1206 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1209..1224 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1238..1262 FT /evidence="ECO:0007829|PDB:7EGH" FT HELIX 1402..1418 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1424..1426 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1427..1429 FT /evidence="ECO:0007829|PDB:3AAD" FT TURN 1432..1434 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1438..1441 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1448..1456 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1463..1480 FT /evidence="ECO:0007829|PDB:7LB1" FT STRAND 1483..1485 FT /evidence="ECO:0007829|PDB:3AAD" FT HELIX 1486..1504 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1506..1516 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1518..1521 FT /evidence="ECO:0007829|PDB:7LB1" FT HELIX 1523..1538 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1539..1542 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1547..1549 FT /evidence="ECO:0007829|PDB:5I29" FT TURN 1555..1557 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1558..1560 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1561..1564 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1565..1567 FT /evidence="ECO:0007829|PDB:6P3A" FT HELIX 1571..1579 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1586..1604 FT /evidence="ECO:0007829|PDB:5I29" FT STRAND 1606..1608 FT /evidence="ECO:0007829|PDB:7K6F" FT HELIX 1609..1627 FT /evidence="ECO:0007829|PDB:5I29" FT HELIX 1629..1655 FT /evidence="ECO:0007829|PDB:5I29" FT MOD_RES P21675-16:1718 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-18:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-22:1723 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES P21675-25:1721 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" SQ SEQUENCE 1893 AA; 214714 MW; AE148C222B418BB4 CRC64; MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGVSE NGEGIILPSI IAPSSLASEK VDFSSSSDSE SEMGPQEATQ AESEDGKLTL PLAGIMQHDA TKLLPSVTEL FPEFRPGKVL RFLRLFGPGK NVPSVWRSAR RKRKKKHREL IQEEQIQEVE CSVESEVSQK SLWNYDYAPP PPPEQCLSDD EITMMAPVES KFSQSTGDID KVTDTKPRVA EWRYGPARLW YDMLGVPEDG SGFDYGFKLR KTEHEPVIKS RMIEEFRKLE ENNGTDLLAD ENFLMVTQLH WEDDIIWDGE DVKHKGTKPQ RASLAGWLPS SMTRNAMAYN VQQGFAATLD DDKPWYSIFP IDNEDLVYGR WEDNIIWDAQ AMPRLLEPPV LTLDPNDENL ILEIPDEKEE ATSNSPSKES KKESSLKKSR ILLGKTGVIK EEPQQNMSQP EVKDPWNLSN DEYYYPKQQG LRGTFGGNII QHSIPAVELR QPFFPTHMGP IKLRQFHRPP LKKYSFGALS QPGPHSVQPL LKHIKKKAKM REQERQASGG GEMFFMRTPQ DLTGKDGDLI LAEYSEENGP LMMQVGMATK IKNYYKRKPG KDPGAPDCKY GETVYCHTSP FLGSLHPGQL LQAFENNLFR APIYLHKMPE TDFLIIRTRQ GYYIRELVDI FVVGQQCPLF EVPGPNSKRA NTHIRDFLQV FIYRLFWKSK DRPRRIRMED IKKAFPSHSE SSIRKRLKLC ADFKRTGMDS NWWVLKSDFR LPTEEEIRAM VSPEQCCAYY SMIAAEQRLK DAGYGEKSFF APEEENEEDF QMKIDDEVRT APWNTTRAFI AAMKGKCLLE VTGVADPTGC GEGFSYVKIP NKPTQQKDDK EPQPVKKTVT GTDADLRRLS LKNAKQLLRK FGVPEEEIKK LSRWEVIDVV RTMSTEQARS GEGPMSKFAR GSRFSVAEHQ ERYKEECQRI FDLQNKVLSS TEVLSTDTDS SSAEDSDFEE MGKNIENMLQ NKKTSSQLSR EREEQERKEL QRMLLAAGSA ASGNNHRDDD TASVTSLNSS ATGRCLKIYR TFRDEEGKEY VRCETVRKPA VIDAYVRIRT TKDEEFIRKF ALFDEQHREE MRKERRRIQE QLRRLKRNQE KEKLKGPPEK KPKKMKERPD LKLKCGACGA IGHMRTNKFC PLYYQTNAPP SNPVAMTEEQ EEELEKTVIH NDNEELIKVE GTKIVLGKQL IESADEVRRK SLVLKFPKQQ LPPKKKRRVG TTVHCDYLNR PHKSIHRRRT DPMVTLSSIL ESIINDMRDL PNTYPFHTPV NAKVVKDYYK IITRPMDLQT LRENVRKRLY PSREEFREHL ELIVKNSATY NGPKHSLTQI SQSMLDLCDE KLKEKEDKLA RLEKAINPLL DDDDQVAFSF ILDNIVTQKM MAVPDSWPFH HPVNKKFVPD YYKVIVNPMD LETIRKNISK HKYQSRESFL DDVNLILANS VKYNGPESQY TKTAQEIVNV CYQTLTEYDE HLTQLEKDIC TAKEAALEEA ELESLDPMTP GPYTPQPPDL YDTNTSLSMS RDASVFQDES NMSVLDIPSA TPEKQVTQEG EDGDGDLADE EEGTVQQPQA SVLYEDLLMS EGEDDEEDAG SDEEGDNPFS AIQLSESGSD SDVGSGGIRP KQPRMLQENT RMDMENEESM MSYEGDGGEA SHGLEDSNIS YGSYEEPDPK SNTQDTSFSS IGGYEVSEEE EDEEEEEQRS GPSVLSQVHL SEDEEDSEDF HSIAGDSDLD SDE // ID WNK1_HUMAN Reviewed; 2382 AA. AC Q9H4A3; A1L4B0; C5HTZ5; C5HTZ6; C5HTZ7; H6WZW3; O15052; P54963; Q4VBX9; AC Q6IFS5; Q86WL5; Q8N673; Q96CZ6; Q9P1S9; DT 02-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 18-MAY-2010, sequence version 2. DT 28-JAN-2026, entry version 231. DE RecName: Full=Serine/threonine-protein kinase WNK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913}; DE AltName: Full=Erythrocyte 65 kDa protein; DE Short=p65; DE AltName: Full=Kinase deficient protein; DE AltName: Full=Protein kinase lysine-deficient 1 {ECO:0000312|HGNC:HGNC:14540}; DE AltName: Full=Protein kinase with no lysine 1 {ECO:0000303|PubMed:11571656}; DE Short=hWNK1; GN Name=WNK1 {ECO:0000303|PubMed:11571656, ECO:0000312|HGNC:HGNC:14540}; GN Synonyms=HSN2 {ECO:0000303|PubMed:15060842}, KDP, GN KIAA0344 {ECO:0000312|EMBL:BAA20802.2}, GN PRKWNK1 {ECO:0000312|HGNC:HGNC:14540}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606 {ECO:0000312|EMBL:CAC15059.1}; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, CHROMOSOMAL RP LOCATION, AND VARIANTS PRO-1056; SER-1506 AND ILE-1808. RC TISSUE=Heart {ECO:0000312|EMBL:CAC15059.1}; RX PubMed=11571656; DOI=10.1038/sj.onc.1204726; RA Verissimo F., Jordan P.; RT "WNK kinases, a novel protein kinase subfamily in multi-cellular RT organisms."; RL Oncogene 20:5562-5569(2001). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6), ALTERNATIVE SPLICING, AND TISSUE RP SPECIFICITY. RC TISSUE=Neuron; RX PubMed=22701532; DOI=10.1371/journal.pone.0037751; RA Vidal-Petiot E., Cheval L., Faugeroux J., Malard T., Doucet A., RA Jeunemaitre X., Hadchouel J.; RT "A new methodology for quantification of alternatively spliced exons RT reveals a highly tissue-specific expression pattern of WNK1 isoforms."; RL PLoS ONE 7:E37751-E37751(2012). RN [3] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-1056; SER-1506 AND RP ILE-1808. RG NHLBI resequencing and genotyping service (RS&G); RL Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [5] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-668 (ISOFORMS 1/2), FUNCTION, CATALYTIC RP ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY. RC TISSUE=Mammary carcinoma; RX PubMed=10660600; DOI=10.1074/jbc.275.6.4311; RA Moore T.M., Garg R., Johnson C., Coptcoat M.J., Ridley A.J., Morris J.D.H.; RT "PSK, a novel STE20-like kinase derived from prostatic carcinoma that RT activates the JNK MAPK pathway and regulates actin cytoskeletal RT organisation."; RL J. Biol. Chem. 275:4311-4322(2000). RN [6] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 69-2382 (ISOFORM 2), AND VARIANTS RP PRO-1056 AND SER-1506. RC TISSUE=Brain {ECO:0000312|EMBL:BAA20802.2}; RX PubMed=9205841; DOI=10.1093/dnares/4.2.141; RA Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N., RA Tanaka A., Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. VII. The RT complete sequences of 100 new cDNA clones from brain which can code for RT large proteins in vitro."; RL DNA Res. 4:141-150(1997). RN [7] {ECO:0000305} RP SEQUENCE REVISION TO N-TERMINUS. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [8] RP PROTEIN SEQUENCE OF 163-175, AND GLYCOSYLATION. RX PubMed=2507249; DOI=10.1002/9780470513828.ch7; RA Hart G.W., Haltiwanger R.S., Holt G.D., Kelly W.G.; RT "Nucleoplasmic and cytoplasmic glycoproteins."; RL Ciba Found. Symp. 145:102-118(1989). RN [9] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (N-TERMINUS OF ISOFORM 3), ALTERNATIVE RP PROMOTER USAGE, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY. RC TISSUE=Kidney {ECO:0000269|PubMed:14645531}; RX PubMed=14645531; DOI=10.1128/mcb.23.24.9208-9221.2003; RA Delaloy C., Lu J., Houot A.-M., Disse-Nicodeme S., Gasc J.-M., Corvol P., RA Jeunemaitre X.; RT "Multiple promoters in the WNK1 gene: one controls expression of a kidney- RT specific kinase-defective isoform."; RL Mol. Cell. Biol. 23:9208-9221(2003). RN [10] {ECO:0000305} RP PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1/4/5). RC TISSUE=Placenta {ECO:0000269|PubMed:15489334}; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP IDENTIFICATION (ISOFORMS 4/5), AND INVOLVEMENT IN HSAN2A. RX PubMed=15060842; DOI=10.1086/420795; RA Lafreniere R.G., MacDonald M.L.E., Dube M.-P., MacFarlane J., RA O'Driscoll M., Brais B., Meilleur S., Brinkman R.R., Dadivas O., Pape T., RA Platon C., Radomski C., Risler J., Thompson J., Guerra-Escobio A.-M., RA Davar G., Breakefield X.O., Pimstone S.N., Green R., Pryse-Phillips W., RA Goldberg Y.P., Younghusband H.B., Hayden M.R., Sherrington R., RA Rouleau G.A., Samuels M.E.; RT "Identification of a novel gene (HSN2) causing hereditary sensory and RT autonomic neuropathy type II through the study of Canadian genetic RT isolates."; RL Am. J. Hum. Genet. 74:1064-1073(2004). RN [12] {ECO:0000305} RP INVOLVEMENT IN PHA2C. RX PubMed=11498583; DOI=10.1126/science.1062844; RA Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., RA Nelson-Williams C., Desitter I., Gunel M., Milford D.V., Lipkin G.W., RA Achard J.-M., Feely M.P., Dussol B., Berland Y., Unwin R.J., Mayan H., RA Simon D.B., Farfel Z., Jeunemaitre X., Lifton R.P.; RT "Human hypertension caused by mutations in WNK kinases."; RL Science 293:1107-1112(2001). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-382. RX PubMed=15883153; DOI=10.1074/jbc.m502598200; RA Lenertz L.Y., Lee B.H., Min X., Xu B.E., Wedin K., Earnest S., RA Goldsmith E.J., Cobb M.H.; RT "Properties of WNK1 and implications for other family members."; RL J. Biol. Chem. 280:26653-26658(2005). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY REGULATION, DOMAIN, RP PHOSPHORYLATION AT SER-382, AND MUTAGENESIS OF LYS-233; ASP-368; SER-382; RP PHE-1258; PHE-1860; PHE-1946 AND PHE-1958. RX PubMed=16263722; DOI=10.1074/jbc.m510042200; RA Moriguchi T., Urushiyama S., Hisamoto N., Iemura S., Uchida S., Natsume T., RA Matsumoto K., Shibuya H.; RT "WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters RT via the STE20-related kinases, SPAK and OSR1."; RL J. Biol. Chem. 280:42685-42693(2005). RN [15] RP INVOLVEMENT IN HSAN2A. RX PubMed=15911806; DOI=10.1212/01.wnl.0000161849.29944.43; RA Roddier K., Thomas T., Marleau G., Gagnon A.M., Dicaire M.J., St Denis A., RA Gosselin I., Sarrazin A.M., Larbrisseau A., Lambert M., Vanasse M., RA Gaudet D., Rouleau G.A., Brais B.; RT "Two mutations in the HSN2 gene explain the high prevalence of HSAN2 in RT French Canadians."; RL Neurology 64:1762-1767(2005). RN [16] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2002 AND SER-2032, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [17] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1261, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [18] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT RP SER-382, AND MUTAGENESIS OF SER-382. RX PubMed=16832045; DOI=10.1073/pnas.0604607103; RA Anselmo A.N., Earnest S., Chen W., Juang Y.C., Kim S.C., Zhao Y., RA Cobb M.H.; RT "WNK1 and OSR1 regulate the Na+, K+, 2Cl- cotransporter in HeLa cells."; RL Proc. Natl. Acad. Sci. U.S.A. 103:10883-10888(2006). RN [19] RP FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVITY REGULATION, RP PHOSPHORYLATION AT SER-15; SER-167; SER-382; THR-1848; SER-1261; SER-2012; RP SER-2029; SER-2032 AND SER-2372, AND MUTAGENESIS OF ASP-368 AND SER-382. RX PubMed=17190791; DOI=10.1083/jcb.200605093; RA Zagorska A., Pozo-Guisado E., Boudeau J., Vitari A.C., Rafiqi F.H., RA Thastrup J., Deak M., Campbell D.G., Morrice N.A., Prescott A.R., RA Alessi D.R.; RT "Regulation of activity and localization of the WNK1 protein kinase by RT hyperosmotic stress."; RL J. Cell Biol. 176:89-100(2007). RN [20] RP ALTERNATIVE SPLICING (ISOFORMS 4 AND 5), AND INVOLVEMENT IN HSAN2A. RX PubMed=18521183; DOI=10.1172/jci34088; RA Shekarabi M., Girard N., Riviere J.B., Dion P., Houle M., Toulouse A., RA Lafreniere R.G., Vercauteren F., Hince P., Laganiere J., Rochefort D., RA Faivre L., Samuels M., Rouleau G.A.; RT "Mutations in the nervous system--specific HSN2 exon of WNK1 cause RT hereditary sensory neuropathy type II."; RL J. Clin. Invest. 118:2496-2505(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [22] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-2011; RP SER-2012; SER-2027; SER-2029 AND SER-2032, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [24] RP FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY RP REGULATION. RX PubMed=19739668; DOI=10.1021/bi900666n; RA Yagi Y.I., Abe K., Ikebukuro K., Sode K.; RT "Kinetic mechanism and inhibitor characterization of WNK1 kinase."; RL Biochemistry 48:10255-10266(2009). RN [25] RP FUNCTION. RX PubMed=19665974; DOI=10.1016/j.cell.2009.05.031; RA Rinehart J., Maksimova Y.D., Tanis J.E., Stone K.L., Hodson C.A., Zhang J., RA Risinger M., Pan W., Wu D., Colangelo C.M., Forbush B., Joiner C.H., RA Gulcicek E.E., Gallagher P.G., Lifton R.P.; RT "Sites of regulated phosphorylation that control K-Cl cotransporter RT activity."; RL Cell 138:525-536(2009). RN [26] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1978, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-1261; SER-1978; RP SER-2032 AND SER-2121, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [28] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [29] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=21321328; DOI=10.1242/jcs.077230; RA Richardson C., Sakamoto K., de los Heros P., Deak M., Campbell D.G., RA Prescott A.R., Alessi D.R.; RT "Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and RT -independent pathways."; RL J. Cell Sci. 124:789-800(2011). RN [30] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21220314; DOI=10.1073/pnas.1018567108; RA Tu S.W., Bugde A., Luby-Phelps K., Cobb M.H.; RT "WNK1 is required for mitosis and abscission."; RL Proc. Natl. Acad. Sci. U.S.A. 108:1385-1390(2011). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2027; SER-2029 AND SER-2032, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [32] RP FUNCTION, SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF VAL-318. RX PubMed=22989884; DOI=10.1074/jbc.m112.398750; RA Sengupta S., Tu S.W., Wedin K., Earnest S., Stippec S., Luby-Phelps K., RA Cobb M.H.; RT "Interactions with WNK (with no lysine) family members regulate oxidative RT stress response 1 and ion co-transporter activity."; RL J. Biol. Chem. 287:37868-37879(2012). RN [33] RP UBIQUITINATION BY KLHL2. RX PubMed=23838290; DOI=10.1016/j.bbrc.2013.06.104; RA Takahashi D., Mori T., Wakabayashi M., Mori Y., Susa K., Zeniya M., RA Sohara E., Rai T., Sasaki S., Uchida S.; RT "KLHL2 interacts with and ubiquitinates WNK kinases."; RL Biochem. Biophys. Res. Commun. 437:457-462(2013). RN [34] RP UBIQUITINATION. RX PubMed=23387299; DOI=10.1042/bj20121903; RA Ohta A., Schumacher F.R., Mehellou Y., Johnson C., Knebel A., RA Macartney T.J., Wood N.T., Alessi D.R., Kurz T.; RT "The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome RT interacts with and ubiquitylates WNK isoforms: disease-causing mutations in RT KLHL3 and WNK4 disrupt interaction."; RL Biochem. J. 451:111-122(2013). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-167; SER-174; RP SER-1261; SER-2029; SER-2032; SER-2370 AND SER-2372, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP UBIQUITINATION. RX PubMed=23576762; DOI=10.1073/pnas.1304592110; RA Shibata S., Zhang J., Puthumana J., Stone K.L., Lifton R.P.; RT "Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via RT ubiquitination and degradation of WNK4."; RL Proc. Natl. Acad. Sci. U.S.A. 110:7838-7843(2013). RN [37] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167; SER-174; SER-1978 AND RP SER-2027, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [38] RP FUNCTION. RX PubMed=25362046; DOI=10.1073/pnas.1419057111; RA Dbouk H.A., Weil L.M., Perera G.K., Dellinger M.T., Pearson G., RA Brekken R.A., Cobb M.H.; RT "Actions of the protein kinase WNK1 on endothelial cells are differentially RT mediated by its substrate kinases OSR1 and SPAK."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15999-16004(2014). RN [39] RP FUNCTION. RX PubMed=25477473; DOI=10.1152/ajprenal.00612.2014; RA Roy A., Goodman J.H., Begum G., Donnelly B.F., Pittman G., Weinman E.J., RA Sun D., Subramanya A.R.; RT "Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome RT editing."; RL Am. J. Physiol. 308:F366-F376(2015). RN [40] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH UVRAG. RX PubMed=27911840; DOI=10.1073/pnas.1617649113; RA Gallolu Kankanamalage S., Lee A.Y., Wichaidit C., Lorente-Rodriguez A., RA Shah A.M., Stippec S., Whitehurst A.W., Cobb M.H.; RT "Multistep regulation of autophagy by WNK1."; RL Proc. Natl. Acad. Sci. U.S.A. 113:14342-14347(2016). RN [41] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=29196535; DOI=10.1101/gad.303677.117; RA Volanakis A., Kamieniarz-Gdula K., Schlackow M., Proudfoot N.J.; RT "WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export RT with transcription."; RL Genes Dev. 31:2175-2185(2017). RN [42] RP MUTAGENESIS OF GLY-1255 AND ARG-1257. RX PubMed=29581290; DOI=10.1073/pnas.1802339115; RA Taylor C.A. IV, An S.W., Kankanamalage S.G., Stippec S., Earnest S., RA Trivedi A.T., Yang J.Z., Mirzaei H., Huang C.L., Cobb M.H.; RT "OSR1 regulates a subset of inward rectifier potassium channels via a RT binding motif variant."; RL Proc. Natl. Acad. Sci. U.S.A. 115:3840-3845(2018). RN [43] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT RP SER-378 AND SER-382. RX PubMed=31656913; DOI=10.1021/acsomega.9b02187; RA Jonniya N.A., Sk M.F., Kar P.; RT "Investigating phosphorylation-induced conformational changes in WNK1 RT kinase by molecular dynamics simulations."; RL ACS Omega 4:17404-17416(2019). RN [44] RP FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION AT SER-382. RX PubMed=34289367; DOI=10.1016/j.celrep.2021.109416; RA Schiapparelli P., Pirman N.L., Mohler K., Miranda-Herrera P.A., Zarco N., RA Kilic O., Miller C., Shah S.R., Rogulina S., Hungerford W., Abriola L., RA Hoyer D., Turk B.E., Guerrero-Cazares H., Isaacs F.J., RA Quinones-Hinojosa A., Levchenko A., Rinehart J.; RT "Phosphorylated WNK kinase networks in recoded bacteria recapitulate RT physiological function."; RL Cell Rep. 36:109416-109416(2021). RN [45] RP FUNCTION, INTERACTION WITH EMC2, SUBCELLULAR LOCATION, AND MUTAGENESIS OF RP PHE-2246; ASP-2248; ASP-2249; LEU-2250; HIS-2251; LEU-2253; TRP-2257 AND RP ASP-2260. RX PubMed=33964204; DOI=10.1016/j.molcel.2021.04.013; RA Pleiner T., Hazu M., Tomaleri G.P., Januszyk K., Oania R.S., RA Sweredoski M.J., Moradian A., Guna A., Voorhees R.M.; RT "WNK1 is an assembly factor for the human ER membrane protein complex."; RL Mol. Cell 81:2693-2704(2021). RN [46] RP FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND DOMAIN. RX PubMed=36318922; DOI=10.1016/j.cell.2022.09.042; RA Boyd-Shiwarski C.R., Shiwarski D.J., Griffiths S.E., Beacham R.T., RA Norrell L., Morrison D.E., Wang J., Mann J., Tennant W., Anderson E.N., RA Franks J., Calderon M., Connolly K.A., Cheema M.U., Weaver C.J., RA Nkashama L.J., Weckerly C.C., Querry K.E., Pandey U.B., Donnelly C.J., RA Sun D., Rodan A.R., Subramanya A.R.; RT "WNK kinases sense molecular crowding and rescue cell volume via phase RT separation."; RL Cell 185:4488-4506(2022). RN [47] RP FUNCTION, INTERACTION WITH SGK1, INTERACTION WITH THE MTORC2 COMPLEX, AND RP MUTAGENESIS OF LYS-233. RX PubMed=36373794; DOI=10.1242/jcs.260313; RA Saha B., Leite-Dellova D.C.A., Demko J., Soerensen M.V., Takagi E., RA Gleason C.E., Shabbir W., Pearce D.; RT "WNK1 is a chloride-stimulated scaffold that regulates mTORC2 activity and RT ion transport."; RL J. Cell Sci. 135:0-0(2022). RN [48] {ECO:0007744|PDB:4PWN} RP X-RAY CRYSTALLOGRAPHY (1.84 ANGSTROMS) OF 210-482. RX PubMed=24803536; DOI=10.1126/scisignal.2005050; RA Piala A.T., Moon T.M., Akella R., He H., Cobb M.H., Goldsmith E.J.; RT "Chloride sensing by WNK1 involves inhibition of autophosphorylation."; RL Sci. Signal. 7:RA41-RA41(2014). RN [49] {ECO:0007744|PDB:5TF9} RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP AND RP ALLOSTERIC INHIBITOR. RX PubMed=27712055; DOI=10.1021/acschembio.6b00511; RA Yamada K., Zhang J.H., Xie X., Reinhardt J., Xie A.Q., LaSala D., Kohls D., RA Yowe D., Burdick D., Yoshisue H., Wakai H., Schmidt I., Gunawan J., RA Yasoshima K., Yue Q.K., Kato M., Mogi M., Idamakanti N., Kreder N., RA Drueckes P., Pandey P., Kawanami T., Huang W., Yagi Y.I., Deng Z., RA Park H.M.; RT "Discovery and characterization of allosteric WNK kinase inhibitors."; RL ACS Chem. Biol. 11:3338-3346(2016). RN [50] {ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8} RP X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 206-483 IN COMPLEX WITH ATP RP ANALOG AND ALLOSTERIC INHIBITOR. RX PubMed=28771350; DOI=10.1021/acs.jmedchem.7b00708; RA Yamada K., Levell J., Yoon T., Kohls D., Yowe D., Rigel D.F., Imase H., RA Yuan J., Yasoshima K., DiPetrillo K., Monovich L., Xu L., Zhu M., Kato M., RA Jain M., Idamakanti N., Taslimi P., Kawanami T., Argikar U.A., RA Kunjathoor V., Xie X., Yagi Y.I., Iwaki Y., Robinson Z., Park H.M.; RT "Optimization of allosteric With-No-Lysine (WNK) kinase inhibitors and RT efficacy in rodent hypertension models."; RL J. Med. Chem. 60:7099-7107(2017). RN [51] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-1199 AND GLU-1799. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [52] RP VARIANTS [LARGE SCALE ANALYSIS] THR-141; VAL-149; GLN-419; THR-509; RP GLY-527; ILE-665; ALA-674; ARG-823; VAL-1546; GLU-1799; ILE-1808; LEU-1823; RP HIS-1957; CYS-2190; LEU-2362 AND TRP-2380. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Serine/threonine-protein kinase component of the WNK1- CC SPAK/OSR1 kinase cascade, which acts as a key regulator of blood CC pressure and regulatory volume increase by promoting ion influx CC (PubMed:15883153, PubMed:17190791, PubMed:31656913, PubMed:34289367, CC PubMed:36318922). WNK1 mediates regulatory volume increase in response CC to hyperosmotic stress by acting as a molecular crowding sensor, which CC senses cell shrinkage and mediates formation of a membraneless CC compartment by undergoing liquid-liquid phase separation CC (PubMed:36318922). The membraneless compartment concentrates WNK1 with CC its substrates, OXSR1/OSR1 and STK39/SPAK, promoting WNK1-dependent CC phosphorylation and activation of downstream kinases OXSR1/OSR1 and CC STK39/SPAK (PubMed:15883153, PubMed:16263722, PubMed:17190791, CC PubMed:19739668, PubMed:21321328, PubMed:22989884, PubMed:25477473, CC PubMed:34289367, PubMed:36318922). Following activation, OXSR1/OSR1 and CC STK39/SPAK catalyze phosphorylation of ion cotransporters CC SLC12A1/NKCC2, SLC12A2/NKCC1, SLC12A5/KCC2 and SLC12A6/KCC3, regulating CC their activity (PubMed:16263722, PubMed:21321328). Phosphorylation of CC Na-K-Cl cotransporters SLC12A2/NKCC1 and SLC12A2/NKCC1 promote their CC activation and ion influx; simultaneously, phosphorylation of K-Cl CC cotransporters SLC12A5/KCC2 and SLC12A6/KCC3 inhibit their activity, CC blocking ion efflux (PubMed:19665974, PubMed:21321328). Also acts as a CC regulator of angiogenesis in endothelial cells via activation of CC OXSR1/OSR1 and STK39/SPAK: activation of OXSR1/OSR1 regulates CC chemotaxis and invasion, while STK39/SPAK regulates endothelial cell CC proliferation (PubMed:25362046). Also acts independently of the WNK1- CC SPAK/OSR1 kinase cascade by catalyzing phosphorylation of other CC substrates, such as SYT2, PCF11 and NEDD4L (PubMed:29196535). Mediates CC phosphorylation of SYT2, regulating SYT2 association with phospholipids CC and membrane-binding (By similarity). Regulates mRNA export in the CC nucleus by mediating phosphorylation of PCF11, thereby decreasing the CC association between PCF11 and POLR2A/RNA polymerase II and promoting CC mRNA export to the cytoplasm (PubMed:29196535). Acts as a negative CC regulator of autophagy (PubMed:27911840). Required for the abscission CC step during mitosis, independently of the WNK1-SPAK/OSR1 kinase cascade CC (PubMed:21220314). May also play a role in actin cytoskeletal CC reorganization (PubMed:10660600). Also acts as a scaffold protein CC independently of its protein kinase activity: negatively regulates cell CC membrane localization of various transporters and channels, such as CC SLC4A4, SLC26A6, SLC26A9, TRPV4 and CFTR (By similarity). Involved in CC the regulation of epithelial Na(+) channel (ENaC) by promoting CC activation of SGK1 in a kinase-independent manner: probably acts as a CC scaffold protein that promotes the recruitment of SGK1 to the mTORC2 CC complex in response to chloride, leading to mTORC2-dependent CC phosphorylation and activation of SGK1 (PubMed:36373794). Acts as an CC assembly factor for the ER membrane protein complex independently of CC its protein kinase activity: associates with EMC2 in the cytoplasm via CC its amphipathic alpha-helix, and prevents EMC2 ubiquitination and CC subsequent degradation, thereby promoting EMC2 stabilization CC (PubMed:33964204). {ECO:0000250|UniProtKB:P83741, CC ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:19665974, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:22989884, CC ECO:0000269|PubMed:25362046, ECO:0000269|PubMed:25477473, CC ECO:0000269|PubMed:27911840, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913, ECO:0000269|PubMed:33964204, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922, CC ECO:0000269|PubMed:36373794}. CC -!- FUNCTION: [Isoform 3]: Kinase-defective isoform specifically expressed CC in kidney, which acts as a dominant-negative regulator of the longer CC isoform 1 (PubMed:14645531). Does not directly inhibit WNK4 and has no CC direct effect on sodium and chloride ion transport (By similarity). CC Down-regulates sodium-chloride cotransporter activity indirectly by CC inhibiting isoform 1, it associates with isoform 1 and attenuates its CC kinase activity (By similarity). In kidney, may play an important role CC regulating sodium and potassium balance (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:14645531}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:31656913}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:19739668, CC ECO:0000269|PubMed:21321328, ECO:0000269|PubMed:29196535}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:10660600}; CC -!- ACTIVITY REGULATION: Activated in response to hyperosmotic stress: cell CC shrinkage promotes formation of a membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK CC (PubMed:36318922). Activation requires autophosphorylation of Ser-382 CC and, to a lower extent, Ser-378 (PubMed:15883153, PubMed:16263722, CC PubMed:16832045, PubMed:17190791, PubMed:31656913, PubMed:34289367). CC Autophosphorylation and subsequent activation is inhibited by increases CC in intracellular ionic strength: Cl(-) potently inhibits WNK1 kinase CC activity via direct binding (By similarity). Also inhibited by K(+) CC ions (By similarity). Inhibited by small compounds staurosporine, CC tyrphostin 47, as well as Src tyrosine kinase inhibitors PP1 and PP2 CC (PubMed:19739668). {ECO:0000250|UniProtKB:Q9JIH7, CC ECO:0000269|PubMed:15883153, ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791, CC ECO:0000269|PubMed:19739668, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367, ECO:0000269|PubMed:36318922}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=52.0 uM for ATP {ECO:0000269|PubMed:19739668}; CC KM=68.4 uM for a OXSR1/OSR1 peptide {ECO:0000269|PubMed:19739668}; CC -!- SUBUNIT: Interacts with WNK3 (By similarity). Interacts with WNK4; CC inhibiting the activity of WNK4 (By similarity). Interacts with SGK1; CC promoting its activation (PubMed:36373794). Associates with the mTORC2 CC complex (PubMed:36373794). Interacts with UVRAG (PubMed:27911840). CC Interacts (via amphipathic alpha-helix region) with EMC2; promoting the CC ER membrane protein complex assembly (PubMed:33964204). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36373794}. CC -!- SUBUNIT: [Isoform 3]: Interacts with isoform 1; inhibiting isoform 1 CC activity. {ECO:0000250|UniProtKB:Q9JIH7}. CC -!- INTERACTION: CC Q9H4A3; O95747: OXSR1; NbExp=9; IntAct=EBI-457907, EBI-620853; CC Q9H4A3; P62136: PPP1CA; NbExp=2; IntAct=EBI-457907, EBI-357253; CC Q9H4A3; P31947: SFN; NbExp=4; IntAct=EBI-457907, EBI-476295; CC Q9H4A3; P62258: YWHAE; NbExp=7; IntAct=EBI-457907, EBI-356498; CC Q9H4A3; P61981: YWHAG; NbExp=7; IntAct=EBI-457907, EBI-359832; CC Q9H4A3; P63104: YWHAZ; NbExp=3; IntAct=EBI-457907, EBI-347088; CC Q9H4A3; P29101: Syt2; Xeno; NbExp=2; IntAct=EBI-457907, EBI-458017; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10660600, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:21220314, CC ECO:0000269|PubMed:22989884, ECO:0000269|PubMed:27911840, CC ECO:0000269|PubMed:33964204, ECO:0000269|PubMed:36318922}. Nucleus CC {ECO:0000269|PubMed:29196535}. Cytoplasm, cytoskeleton, spindle CC {ECO:0000269|PubMed:21220314}. Note=Mediates formation and localizes to CC cytoplasmic membraneless compartment in response to hyperosmotic stress CC (PubMed:36318922). Also localizes to the nucleus (PubMed:29196535). CC Localizes to the mitotic spindle during mitosis (PubMed:21220314). CC {ECO:0000269|PubMed:21220314, ECO:0000269|PubMed:29196535, CC ECO:0000269|PubMed:36318922}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=6; CC Comment=WNK1 is a complex 33-exons gene, in total 9 WNK1 exons are CC alternatively spliced, some expressed in a tissue-specific manner. CC Additional isoforms seems to exist.; CC Name=1; Synonyms=L-WNK1 {ECO:0000303|PubMed:22701532}; CC IsoId=Q9H4A3-1; Sequence=Displayed; CC Name=2 {ECO:0000303|PubMed:9205841}; CC IsoId=Q9H4A3-2; Sequence=VSP_040269, VSP_050638; CC Name=3; Synonyms=KS-WNK1, Kidney-Specific; CC IsoId=Q9H4A3-4; Sequence=VSP_050634, VSP_050637; CC Name=4; Synonyms=Brain and spinal cord variant; CC IsoId=Q9H4A3-5; Sequence=VSP_040268; CC Name=5; Synonyms=Dorsal root ganglia and sciatic nerve variant, DRG and CC sciatic nerve variant; CC IsoId=Q9H4A3-6; Sequence=VSP_040267, VSP_040270; CC Name=6; CC IsoId=Q9H4A3-7; Sequence=VSP_040267, VSP_053767; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels observed in CC the testis, heart, kidney and skeletal muscle. CC {ECO:0000269|PubMed:10660600, ECO:0000269|PubMed:11571656, CC ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 1]: Strong expression in dorsal root CC ganglia and spinal cord. {ECO:0000269|PubMed:22701532}. CC -!- TISSUE SPECIFICITY: [Isoform 3]: This isoform is kidney-specific and CC specifically expressed in the distal convoluted tubule (DCT) and CC connecting tubule (CNT) of the nephron. {ECO:0000269|PubMed:14645531}. CC -!- DOMAIN: Disordered regions undergo liquid-liquid phase separation CC (LLPS) for the formation of a cytoplasmic membraneless compartment that CC concentrates WNK1 with its substrates, OXSR1/OSR1 and STK39/SPAK. CC {ECO:0000269|PubMed:36318922}. CC -!- DOMAIN: The RFXV motifs mediate recognition with downstream kinases CC OXSR1/OSR1 and STK39/SPAK. {ECO:0000269|PubMed:16263722, CC ECO:0000269|PubMed:22989884}. CC -!- PTM: Autophosphorylated at Ser-378 and Ser-382, promoting its activity CC (PubMed:15883153, PubMed:16263722, PubMed:16832045, PubMed:17190791, CC PubMed:31656913, PubMed:34289367). Autophosphorylation at Ser-382 is CC inhibited by intracellular calcium (By similarity). Phosphorylation at CC Thr-60 increases ability to activate SGK1 (By similarity). CC {ECO:0000250|UniProtKB:Q9JIH7, ECO:0000269|PubMed:15883153, CC ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, CC ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, CC ECO:0000269|PubMed:34289367}. CC -!- PTM: Ubiquitinated by the BCR(KLHL3) complex, leading to its CC degradation (PubMed:23387299, PubMed:23576762). Also ubiquitinated by CC the BCR(KLHL2) complex (PubMed:23838290). {ECO:0000269|PubMed:23387299, CC ECO:0000269|PubMed:23576762, ECO:0000269|PubMed:23838290}. CC -!- PTM: May be O-glycosylated. {ECO:0000269|PubMed:2507249}. CC -!- DISEASE: Pseudohypoaldosteronism 2C (PHA2C) [MIM:614492]: An autosomal CC dominant disorder characterized by severe hypertension, hyperkalemia, CC hyperchloremia, mild hyperchloremic metabolic acidosis in some cases, CC and correction of physiologic abnormalities by thiazide diuretics. CC {ECO:0000269|PubMed:11498583}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 2A (HSAN2A) CC [MIM:201300]: A form of hereditary sensory and autonomic neuropathy, a CC genetically and clinically heterogeneous group of disorders CC characterized by degeneration of dorsal root and autonomic ganglion CC cells, and by sensory and/or autonomic abnormalities. HSAN2A is an CC autosomal recessive disorder characterized by impairment of pain, CC temperature and touch sensation, onset of symptoms in infancy or early CC childhood, occurrence of distal extremity pathologies (paronychia, CC whitlows, ulcers, and Charcot joints), frequent amputations, sensory CC loss that affects all modalities of sensation (lower and upper limbs CC and perhaps the trunk as well), absence or diminution of tendon CC reflexes (usually in all limbs), minimal autonomic dysfunction, absence CC of sensory nerve action potentials, and virtual absence of myelinated CC fibers with decreased numbers of unmyelinated fibers in sural nerves. CC {ECO:0000269|PubMed:15060842, ECO:0000269|PubMed:15911806, CC ECO:0000269|PubMed:18521183}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: [Isoform 4]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 6]: Contains the nervous system-specific exon CC HSN2. Produced by alternative splicing. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. WNK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Was named WNK/'with no lysine(K)' because key residues for CC catalysis, including the lysine involved in ATP binding, are either not CC conserved or differ compared to the residues described in other kinase CC family proteins. {ECO:0000305|PubMed:27712055}. CC -!- CAUTION: HSN2 was originally thought to be an intronless gene lying CC within a WNK1 gene intron. It has been shown to be a nervous system- CC specific exon of WNK1 included in isoform 4 and isoform 5 CC (PubMed:18521183). {ECO:0000305|PubMed:18521183}. CC -!- CAUTION: It is uncertain whether Met-1 or Met-214 is the initiator in CC isoform 4 and isoform 5. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAF31483.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305}; CC Sequence=AAI30468.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=AAI30470.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305}; CC Sequence=DAA04494.1; Type=Erroneous gene model prediction; Note=Includes 3' and 3' intronic sequences.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AJ296290; CAC15059.1; -; mRNA. DR EMBL; JQ358908; AEY99342.1; -; mRNA. DR EMBL; FJ515833; ACS13726.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13727.1; -; Genomic_DNA. DR EMBL; FJ515833; ACS13728.1; -; Genomic_DNA. DR EMBL; AC004765; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC004803; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AF061944; AAF31483.1; ALT_SEQ; mRNA. DR EMBL; AB002342; BAA20802.2; -; mRNA. DR EMBL; AY231477; AAO46160.1; -; mRNA. DR EMBL; BC013629; AAH13629.2; -; mRNA. DR EMBL; BC130467; AAI30468.1; ALT_SEQ; mRNA. DR EMBL; BC130469; AAI30470.1; ALT_SEQ; mRNA. DR EMBL; BK004108; DAA04494.1; ALT_SEQ; Genomic_DNA. DR CCDS; CCDS73419.1; -. [Q9H4A3-5] DR CCDS; CCDS8506.1; -. [Q9H4A3-1] DR RefSeq; NP_001171914.1; NM_001184985.2. [Q9H4A3-6] DR RefSeq; NP_055638.2; NM_014823.2. DR RefSeq; NP_061852.3; NM_018979.4. [Q9H4A3-1] DR RefSeq; NP_998820.3; NM_213655.5. [Q9H4A3-5] DR RefSeq; XP_016875326.1; XM_017019837.1. DR RefSeq; XP_016875327.1; XM_017019838.2. [Q9H4A3-2] DR PDB; 4PWN; X-ray; 1.84 A; A=210-482. DR PDB; 5TF9; X-ray; 2.50 A; A/B=206-483. DR PDB; 5WDY; X-ray; 2.46 A; A/B=206-483. DR PDB; 5WE8; X-ray; 2.01 A; A/B=206-483. DR PDB; 6FBK; X-ray; 1.74 A; P=1247-1269. DR PDBsum; 4PWN; -. DR PDBsum; 5TF9; -. DR PDBsum; 5WDY; -. DR PDBsum; 5WE8; -. DR PDBsum; 6FBK; -. DR AlphaFoldDB; Q9H4A3; -. DR BMRB; Q9H4A3; -. DR SMR; Q9H4A3; -. DR BioGRID; 122403; 141. DR CORUM; Q9H4A3; -. DR DIP; DIP-32648N; -. DR ELM; Q9H4A3; -. DR FunCoup; Q9H4A3; 2655. DR IntAct; Q9H4A3; 121. DR MINT; Q9H4A3; -. DR STRING; 9606.ENSP00000341292; -. DR BindingDB; Q9H4A3; -. DR ChEMBL; CHEMBL1075173; -. DR GuidetoPHARMACOLOGY; 2280; -. DR MoonDB; Q9H4A3; Predicted. DR TCDB; 8.A.23.1.69; the basigin (basigin) family. DR GlyConnect; 484; 1 O-GlcNAc glycan. DR GlyCosmos; Q9H4A3; 38 sites, 2 glycans. DR GlyGen; Q9H4A3; 67 sites, 2 O-linked glycans (64 sites). DR iPTMnet; Q9H4A3; -. DR MetOSite; Q9H4A3; -. DR PhosphoSitePlus; Q9H4A3; -. DR BioMuta; WNK1; -. DR DMDM; 296453029; -. DR jPOST; Q9H4A3; -. DR MassIVE; Q9H4A3; -. DR PeptideAtlas; Q9H4A3; -. DR ProteomicsDB; 80804; -. [Q9H4A3-1] DR ProteomicsDB; 80805; -. [Q9H4A3-2] DR ProteomicsDB; 80806; -. [Q9H4A3-4] DR ProteomicsDB; 80807; -. [Q9H4A3-5] DR ProteomicsDB; 80808; -. [Q9H4A3-6] DR Pumba; Q9H4A3; -. DR Antibodypedia; 22083; 602 antibodies from 42 providers. DR DNASU; 65125; -. DR Ensembl; ENST00000315939.11; ENSP00000313059.6; ENSG00000060237.20. [Q9H4A3-1] DR Ensembl; ENST00000340908.9; ENSP00000341292.5; ENSG00000060237.20. [Q9H4A3-5] DR Ensembl; ENST00000530271.6; ENSP00000433548.3; ENSG00000060237.20. [Q9H4A3-7] DR Ensembl; ENST00000537687.5; ENSP00000444465.1; ENSG00000060237.20. [Q9H4A3-6] DR Ensembl; ENST00000675631.1; ENSP00000502415.1; ENSG00000060237.20. [Q9H4A3-4] DR GeneID; 65125; -. DR KEGG; hsa:65125; -. DR MANE-Select; ENST00000315939.11; ENSP00000313059.6; NM_018979.4; NP_061852.3. DR UCSC; uc001qio.4; human. [Q9H4A3-1] DR AGR; HGNC:14540; -. DR CIViC; 65125; 1 evidence item across 1 molecular profile. DR ClinPGx; PA33782; -. DR CTD; 65125; -. DR DisGeNET; 65125; -. DR GeneCards; WNK1; -. DR GeneReviews; WNK1; -. DR HGNC; HGNC:14540; WNK1. DR HPA; ENSG00000060237; Low tissue specificity. DR MalaCards; WNK1; -. DR MIM; 201300; phenotype. DR MIM; 605232; gene. DR MIM; 614492; phenotype. DR OpenTargets; ENSG00000060237; -. DR Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2. DR Orphanet; 88940; Pseudohypoaldosteronism type 2C. DR VEuPathDB; HostDB:ENSG00000060237; -. DR eggNOG; KOG0584; Eukaryota. DR GeneTree; ENSGT00940000155474; -. DR InParanoid; Q9H4A3; -. DR OMA; PEPNGMT; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q9H4A3; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q9H4A3; -. DR PathwayCommons; Q9H4A3; -. DR Reactome; R-HSA-2672351; Stimuli-sensing channels. DR SignaLink; Q9H4A3; -. DR SIGNOR; Q9H4A3; -. DR Agora; ENSG00000060237; -. DR BioGRID-ORCS; 65125; 582 hits in 1210 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; WNK1; human. DR EvolutionaryTrace; Q9H4A3; -. DR GeneWiki; WNK1; -. DR GenomeRNAi; 65125; -. DR Pharos; Q9H4A3; Tchem. DR PRO; PR:Q9H4A3; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9H4A3; protein. DR Bgee; ENSG00000060237; Expressed in medial globus pallidus and 204 other cell types or tissues. DR ExpressionAtlas; Q9H4A3; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043232; C:intracellular membraneless organelle; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; ISS:ParkinsonsUK-UCL. DR GO; GO:0072686; C:mitotic spindle; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IDA:UniProtKB. DR GO; GO:0140693; F:molecular condensate scaffold activity; IDA:UniProtKB. DR GO; GO:0019902; F:phosphatase binding; IDA:UniProtKB. DR GO; GO:0030295; F:protein kinase activator activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0004672; F:protein kinase activity; IMP:ParkinsonsUK-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:ParkinsonsUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0006884; P:cell volume homeostasis; IDA:UniProtKB. DR GO; GO:0071474; P:cellular hyperosmotic response; IDA:UniProtKB. DR GO; GO:1990869; P:cellular response to chemokine; IMP:BHF-UCL. DR GO; GO:0038116; P:chemokine (C-C motif) ligand 21 signaling pathway; ISS:BHF-UCL. DR GO; GO:0006974; P:DNA damage response; IBA:GO_Central. DR GO; GO:0007507; P:heart development; IEA:Ensembl. DR GO; GO:0030644; P:intracellular chloride ion homeostasis; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB. DR GO; GO:0097022; P:lymphocyte migration into lymph node; ISS:BHF-UCL. DR GO; GO:0140694; P:membraneless organelle assembly; IDA:UniProtKB. DR GO; GO:0055080; P:monoatomic cation homeostasis; ISS:UniProtKB. DR GO; GO:0006811; P:monoatomic ion transport; ISS:UniProtKB. DR GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB. DR GO; GO:0033633; P:negative regulation of cell-cell adhesion mediated by integrin; IMP:BHF-UCL. DR GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL. DR GO; GO:0090188; P:negative regulation of pancreatic juice secretion; IEA:Ensembl. DR GO; GO:1903077; P:negative regulation of protein localization to plasma membrane; ISS:UniProtKB. DR GO; GO:0031397; P:negative regulation of protein ubiquitination; IDA:UniProtKB. DR GO; GO:0051058; P:negative regulation of small GTPase mediated signal transduction; IMP:BHF-UCL. DR GO; GO:0010766; P:negative regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0048666; P:neuron development; NAS:UniProtKB. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:FlyBase. DR GO; GO:1903490; P:positive regulation of mitotic cytokinesis; IDA:UniProtKB. DR GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl. DR GO; GO:0010820; P:positive regulation of T cell chemotaxis; IMP:BHF-UCL. DR GO; GO:1904595; P:positive regulation of termination of RNA polymerase II transcription; IDA:UniProtKB. DR GO; GO:0055075; P:potassium ion homeostasis; IEA:Ensembl. DR GO; GO:0045050; P:protein insertion into ER membrane by stop-transfer membrane-anchor sequence; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:1904062; P:regulation of monoatomic cation transmembrane transport; IMP:ARUK-UCL. DR GO; GO:0010793; P:regulation of mRNA export from nucleus; IDA:UniProtKB. DR GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0002028; P:regulation of sodium ion transport; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; IDA:ParkinsonsUK-UCL. DR GO; GO:0035725; P:sodium ion transmembrane transport; IEA:Ensembl. DR GO; GO:0050852; P:T cell receptor signaling pathway; ISS:BHF-UCL. DR CDD; cd14030; STKc_WNK1; 1. DR FunFam; 3.10.20.90:FF:000007; Serine/threonine-protein kinase WNK1 isoform 1; 1. DR FunFam; 1.10.510.10:FF:000006; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.10.20.90:FF:000012; Serine/threonine-protein kinase WNK1 isoform 2; 1. DR FunFam; 3.30.200.20:FF:000494; serine/threonine-protein kinase WNK2 isoform X2; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR056865; CCTL2_WNK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR024678; Kinase_OSR1/WNK_CCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR050588; WNK_Ser-Thr_kinase. DR PANTHER; PTHR13902; SERINE/THREONINE-PROTEIN KINASE WNK WITH NO LYSINE -RELATED; 1. DR Pfam; PF24889; CCTL2_WNK; 1. DR Pfam; PF12202; OSR1_C; 1. DR Pfam; PF00069; Pkinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Chloride; Cytoplasm; Cytoskeleton; Direct protein sequencing; KW Glycoprotein; Kinase; Neurodegeneration; Neuropathy; Nucleotide-binding; KW Nucleus; Phosphoprotein; Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..2382 FT /note="Serine/threonine-protein kinase WNK1" FT /id="PRO_0000086819" FT DOMAIN 221..479 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..81 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 95..203 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 488..555 FT /note="Autoinhibitory domain" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT REGION 573..779 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 628..638 FT /note="Interaction with KLHL3" FT /evidence="ECO:0000250|UniProtKB:Q96J92" FT REGION 1018..1041 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1053..1119 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1457..1476 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1733..1790 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1866..1948 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1994..2069 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2101..2196 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2241..2261 FT /note="Amphipathic alpha-helix" FT /evidence="ECO:0000269|PubMed:33964204" FT REGION 2332..2352 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 1257..1260 FT /note="RFXV motif 1" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1859..1862 FT /note="RFXV motif 2" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1945..1948 FT /note="RFXV motif 3" FT /evidence="ECO:0000269|PubMed:16263722" FT MOTIF 1957..1960 FT /note="RFXV motif 4" FT /evidence="ECO:0000269|PubMed:16263722" FT COMPBIAS 50..66 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 95..108 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 125..153 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 573..588 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 598..614 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 615..625 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 637..689 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 709..779 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1041 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1053..1077 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1080..1090 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1098..1119 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1457..1467 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1733..1745 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1869..1884 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1887..1905 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1927..1940 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1994..2003 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2035..2062 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2122..2134 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2135..2145 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2146..2167 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2175..2196 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 368 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:16263722" FT BINDING 231 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 283 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 299 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 301..304 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 351 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000269|PubMed:27712055, FT ECO:0000305|PubMed:28771350, ECO:0007744|PDB:5TF9, FT ECO:0007744|PDB:5WDY, ECO:0007744|PDB:5WE8" FT BINDING 369 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT BINDING 371 FT /ligand="chloride" FT /ligand_id="ChEBI:CHEBI:17996" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 15 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 19 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 60 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q9JIH7" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 174 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 378 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:31656913" FT MOD_RES 382 FT /note="Phosphoserine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:15883153, FT ECO:0000269|PubMed:16263722, ECO:0000269|PubMed:16832045, FT ECO:0000269|PubMed:17190791, ECO:0000269|PubMed:31656913, FT ECO:0000269|PubMed:34289367" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:16964243, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 1848 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:17190791" FT MOD_RES 1978 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 2002 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:17081983" FT MOD_RES 2011 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648" FT MOD_RES 2012 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648" FT MOD_RES 2027 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569" FT MOD_RES 2029 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2032 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 2121 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 2270 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2286 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P83741" FT MOD_RES 2370 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 2372 FT /note="Phosphoserine" FT /evidence="ECO:0000269|PubMed:17190791, FT ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..407 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050634" FT VAR_SEQ 408..437 FT /note="FGMCMLEMATSEYPYSECQNAAQIYRRVTS -> MDIKKKDFCSVFVIINSH FT CCCCPQKDCINE (in isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_050637" FT VAR_SEQ 713 FT /note="V -> VPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQR FT RKSTSFLEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQV FT HPMFEPSQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSS FT PMKQIPEQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTD FT ATRLKFHPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQV FT AVDLNQEELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSS FT QITSSDPSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLT FT ASFSSGGSALHPQ (in isoform 5 and isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_040267" FT VAR_SEQ 714..1037 FT /note="AQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQLPVSQPVPTIQGEPQIPVATQPSVVPVHSGAHF FT LPVGQPLPTPLLPQYPVSQIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTA FT AIPGVSTVVPSQLPTLLQPVTQLPSQVHPQLLQPAVQSMGIPANLGQAAEVPLSSGDVL FT YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFPTVVQPYVES FT NLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLE -> PRRGRSMSVCVPIFLLLPL FT CPASLPVLFHPTASTVCTSFSFPPPDCPEETFAEKLSKALESVLPMHSASQRKHRRSSL FT PSLFVSTPQSMAHPCGGTPTYPESQIFFPTIHERPVSFSPPPTCPPKVAISQRRKSTSF FT LEAQTHHFQPLLRTVGQSLLPPGGSPTNWTPEAVVMLGTTASRVTGESCEIQVHPMFEP FT SQVYSDYRPGLVLPEEAHYFIPQEAVYVAGVHYQARVAEQYEGIPYNSSVLSSPMKQIP FT EQKPVQGGPTSSSVFEFPSGQAFLVGHLQNLRLDSGLGPGSPLSSISAPISTDATRLKF FT HPVFVPHSAPAVLTHNNESRSNCVFEFHVHTPSSSSGEGGGILPQRVYRNRQVAVDLNQ FT EELPPQSVGLHGYLQPVTEEKHNYHAPELTVSVVEPIGQNWPIGSPEYSSDSSQITSSD FT PSDFQSPPPTGGAAAPFGSDVSMPFIHLPQTVLQESPLFFCFPQGTTSQQVLTASFSSG FT GSALHPQAQGQSQGQPSSSSLTGVSSSQPIQHPQQQQGIQQTAPPQQTVQYSLSQTSTS FT SEATTAQPVSQPQAPQVLPQVSAGKQ (in isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_040268" FT VAR_SEQ 740 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_040269" FT VAR_SEQ 792..1037 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9205841" FT /id="VSP_050638" FT VAR_SEQ 792..944 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_040270" FT VAR_SEQ 2215 FT /note="G -> GCAKFNCASEQVTFKPGGRRTRFLRKMVKKVCPCNQLCR (in FT isoform 6)" FT /evidence="ECO:0000303|PubMed:22701532" FT /id="VSP_053767" FT VARIANT 141 FT /note="A -> T (in dbSNP:rs11554421)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041309" FT VARIANT 149 FT /note="A -> V (in dbSNP:rs34880640)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041310" FT VARIANT 419 FT /note="E -> Q (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041311" FT VARIANT 509 FT /note="I -> T (in dbSNP:rs34728563)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041312" FT VARIANT 527 FT /note="D -> G (in dbSNP:rs34408667)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041313" FT VARIANT 665 FT /note="T -> I (in dbSNP:rs2286007)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_019992" FT VARIANT 674 FT /note="T -> A (in dbSNP:rs11833299)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041314" FT VARIANT 823 FT /note="H -> R (in dbSNP:rs56015776)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041315" FT VARIANT 1056 FT /note="T -> P (in dbSNP:rs956868)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059033" FT VARIANT 1199 FT /note="E -> G (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035640" FT VARIANT 1506 FT /note="C -> S (in dbSNP:rs7955371)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:9205841, ECO:0000269|Ref.3" FT /id="VAR_059034" FT VARIANT 1546 FT /note="A -> V (in dbSNP:rs56351358)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041316" FT VARIANT 1799 FT /note="Q -> E (in breast cancer samples; infiltrating FT ductal carcinoma; somatic mutation)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:17344846" FT /id="VAR_035641" FT VARIANT 1808 FT /note="M -> I (in dbSNP:rs12828016)" FT /evidence="ECO:0000269|PubMed:11571656, FT ECO:0000269|PubMed:17344846, ECO:0000269|Ref.3" FT /id="VAR_041317" FT VARIANT 1823 FT /note="P -> L (in dbSNP:rs17755373)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041318" FT VARIANT 1957 FT /note="R -> H (in dbSNP:rs36083875)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041319" FT VARIANT 2190 FT /note="S -> C (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041320" FT VARIANT 2362 FT /note="F -> L (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041321" FT VARIANT 2380 FT /note="R -> W (in dbSNP:rs56262445)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041322" FT MUTAGEN 233 FT /note="K->M: Abolished serine/threonine-protein kinase FT activity. Does not affect ability to activate SGK1." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:36373794" FT MUTAGEN 318 FT /note="V->E: Does not affect ability to phosphorylate FT OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:22989884" FT MUTAGEN 368 FT /note="D->A: Abolished serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:17190791" FT MUTAGEN 382 FT /note="S->A: Decreased autophosphorylation, preventing FT activation of the serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:16263722, FT ECO:0000269|PubMed:16832045, ECO:0000269|PubMed:17190791" FT MUTAGEN 1255 FT /note="G->R,N,D,C,Q,H,I,L,K,M,F,P,S,T,W,Y,V: Does not FT affect binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1257 FT /note="R->A,N,C,E,Q,H,I,L,K,M,F,S,T,W,Y,V: Does not affect FT binding to OXSR1/OSR1." FT /evidence="ECO:0000269|PubMed:29581290" FT MUTAGEN 1258 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1860. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1860, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1860 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1258. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1946 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1946 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1958. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1257, FT A-1860 and A-1958." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 1958 FT /note="F->A: Slightly decreased binding to OXSR1/OSR1 and FT STK39/SPAK; when associated with A-1946. Abolished binding FT to OXSR1/OSR1 and STK39/SPAK; when associated with A-1258, FT A-1860 and A-1946." FT /evidence="ECO:0000269|PubMed:16263722" FT MUTAGEN 2246 FT /note="F->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2248 FT /note="D->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2249 FT /note="D->A,K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2250 FT /note="Missing: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2251 FT /note="H->K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2253 FT /note="L->K: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2257 FT /note="W->K,L,A: Abolished interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT MUTAGEN 2260 FT /note="D->A,K: Does not affect interaction with EMC2." FT /evidence="ECO:0000269|PubMed:33964204" FT CONFLICT 164 FT /note="R -> S (in Ref. 8; AA sequence)" FT /evidence="ECO:0000305" FT CONFLICT 1836 FT /note="Missing (in Ref. 6; BAA20802)" FT /evidence="ECO:0000305" FT STRAND 211..214 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 216..218 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 220..228 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 231..240 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 241..244 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 245..252 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 266..273 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 283..288 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 291..295 FT /evidence="ECO:0007829|PDB:5WDY" FT STRAND 297..302 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 309..316 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 321..340 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 341..343 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 352..354 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 355..358 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 359..362 FT /evidence="ECO:0007829|PDB:5WE8" FT STRAND 364..366 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 369..371 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 377..380 FT /evidence="ECO:0007829|PDB:5WE8" FT HELIX 392..396 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 402..417 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 421..424 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 428..435 FT /evidence="ECO:0007829|PDB:4PWN" FT TURN 436..438 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 442..446 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 450..459 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 464..466 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 470..474 FT /evidence="ECO:0007829|PDB:4PWN" FT HELIX 477..481 FT /evidence="ECO:0007829|PDB:4PWN" FT STRAND 1248..1251 FT /evidence="ECO:0007829|PDB:6FBK" FT STRAND 1257..1261 FT /evidence="ECO:0007829|PDB:6FBK" SQ SEQUENCE 2382 AA; 250794 MW; 426785F98A452A0A CRC64; MSGGAAEKQS STPGSLFLSP PAPAPKNGSS SDSSVGEKLG AAAADAVTGR TEEYRRRRHT MDKDSRGAAA TTTTTEHRFF RRSVICDSNA TALELPGLPL SLPQPSIPAA VPQSAPPEPH REETVTATAT SQVAQQPPAA AAPGEQAVAG PAPSTVPSST SKDRPVSQPS LVGSKEEPPP ARSGSGGGSA KEPQEERSQQ QDDIEELETK AVGMSNDGRF LKFDIEIGRG SFKTVYKGLD TETTVEVAWC ELQDRKLTKS ERQRFKEEAE MLKGLQHPNI VRFYDSWEST VKGKKCIVLV TELMTSGTLK TYLKRFKVMK IKVLRSWCRQ ILKGLQFLHT RTPPIIHRDL KCDNIFITGP TGSVKIGDLG LATLKRASFA KSVIGTPEFM APEMYEEKYD ESVDVYAFGM CMLEMATSEY PYSECQNAAQ IYRRVTSGVK PASFDKVAIP EVKEIIEGCI RQNKDERYSI KDLLNHAFFQ EETGVRVELA EEDDGEKIAI KLWLRIEDIK KLKGKYKDNE AIEFSFDLER DVPEDVAQEM VESGYVCEGD HKTMAKAIKD RVSLIKRKRE QRQLVREEQE KKKQEESSLK QQVEQSSASQ TGIKQLPSAS TGIPTASTTS ASVSTQVEPE EPEADQHQQL QYQQPSISVL SDGTVDSGQG SSVFTESRVS SQQTVSYGSQ HEQAHSTGTV PGHIPSTVQA QSQPHGVYPP SSVAQGQSQG QPSSSSLTGV SSSQPIQHPQ QQQGIQQTAP PQQTVQYSLS QTSTSSEATT AQPVSQPQAP QVLPQVSAGK QLPVSQPVPT IQGEPQIPVA TQPSVVPVHS GAHFLPVGQP LPTPLLPQYP VSQIPISTPH VSTAQTGFSS LPITMAAGIT QPLLTLASSA TTAAIPGVST VVPSQLPTLL QPVTQLPSQV HPQLLQPAVQ SMGIPANLGQ AAEVPLSSGD VLYQGFPPRL PPQYPGDSNI APSSNVASVC IHSTVLSPPM PTEVLATPGY FPTVVQPYVE SNLLVPMGGV GGQVQVSQPG GSLAQAPTTS SQQAVLESTQ GVSQVAPAEP VAVAQTQATQ PTTLASSVDS AHSDVASGMS DGNENVPSSS GRHEGRTTKR HYRKSVRSRS RHEKTSRPKL RILNVSNKGD RVVECQLETH NRKMVTFKFD LDGDNPEEIA TIMVNNDFIL AIERESFVDQ VREIIEKADE MLSEDVSVEP EGDQGLESLQ GKDDYGFSGS QKLEGEFKQP IPASSMPQQI GIPTSSLTQV VHSAGRRFIV SPVPESRLRE SKVFPSEITD TVAASTAQSP GMNLSHSASS LSLQQAFSEL RRAQMTEGPN TAPPNFSHTG PTFPVVPPFL SSIAGVPTTA AATAPVPATS SPPNDISTSV IQSEVTVPTE EGIAGVATST GVVTSGGLPI PPVSESPVLS SVVSSITIPA VVSISTTSPS LQVPTSTSEI VVSSTALYPS VTVSATSASA GGSTATPGPK PPAVVSQQAA GSTTVGATLT SVSTTTSFPS TASQLCIQLS SSTSTPTLAE TVVVSAHSLD KTSHSSTTGL AFSLSAPSSS SSPGAGVSSY ISQPGGLHPL VIPSVIASTP ILPQAAGPTS TPLLPQVPSI PPLVQPVANV PAVQQTLIHS QPQPALLPNQ PHTHCPEVDS DTQPKAPGID DIKTLEEKLR SLFSEHSSSG AQHASVSLET SLVIESTVTP GIPTTAVAPS KLLTSTTSTC LPPTNLPLGT VALPVTPVVT PGQVSTPVST TTSGVKPGTA PSKPPLTKAP VLPVGTELPA GTLPSEQLPP FPGPSLTQSQ QPLEDLDAQL RRTLSPEMIT VTSAVGPVSM AAPTAITEAG TQPQKGVSQV KEGPVLATSS GAGVFKMGRF QVSVAADGAQ KEGKNKSEDA KSVHFESSTS ESSVLSSSSP ESTLVKPEPN GITIPGISSD VPESAHKTTA SEAKSDTGQP TKVGRFQVTT TANKVGRFSV SKTEDKITDT KKEGPVASPP FMDLEQAVLP AVIPKKEKPE LSEPSHLNGP SSDPEAAFLS RDVDDGSGSP HSPHQLSSKS LPSQNLSQSL SNSFNSSYMS SDNESDIEDE DLKLELRRLR DKHLKEIQDL QSRQKHEIES LYTKLGKVPP AVIIPPAAPL SGRRRRPTKS KGSKSSRSSS LGNKSPQLSG NLSGQSAASV LHPQQTLHPP GNIPESGQNQ LLQPLKPSPS SDNLYSAFTS DGAISVPSLS APGQGTSSTN TVGATVNSQA AQAQPPAMTS SRKGTFTDDL HKLVDNWARD AMNLSGRRGS KGHMNYEGPG MARKFSAPGQ LCISMTSNLG GSAPISAASA TSLGHFTKSM CPPQQYGFPA TPFGAQWSGT GGPAPQPLGQ FQPVGTASLQ NFNISNLQKS ISNPPGSNLR TT // ID WRN_HUMAN Reviewed; 1432 AA. AC Q14191; A1KYY9; DT 15-DEC-1998, integrated into UniProtKB/Swiss-Prot. DT 08-FEB-2011, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN {ECO:0000305}; DE AltName: Full=DNA helicase, RecQ-like type 3; DE AltName: Full=RecQ protein-like 2; DE AltName: Full=Werner syndrome protein {ECO:0000303|PubMed:9618508}; DE Includes: DE RecName: Full=3'-5' exonuclease; DE EC=3.1.-.- {ECO:0000269|PubMed:11863428}; DE Includes: DE RecName: Full=ATP-dependent helicase; DE EC=5.6.2.4 {ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:9288107}; DE AltName: Full=DNA 3'-5' helicase WRN {ECO:0000305}; GN Name=WRN; Synonyms=RECQ3, RECQL2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-1074. RX PubMed=8602509; DOI=10.1126/science.272.5259.258; RA Yu C.-E., Oshima J., Fu Y.-H., Wijsman E.M., Hisama F., Alisch R., RA Matthews S., Nakura J., Miki T., Ouais S., Martin G.M., Mulligan J., RA Schellenberg G.D.; RT "Positional cloning of the Werner's syndrome gene."; RL Science 272:258-262(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RX PubMed=16723399; DOI=10.1073/pnas.0600645103; RA Agrelo R., Cheng W.H., Setien F., Ropero S., Espada J., Fraga M.F., RA Herranz M., Paz M.F., Sanchez-Cespedes M., Artiga M.J., Guerrero D., RA Castells A., von Kobbe C., Bohr V.A., Esteller M.; RT "Epigenetic inactivation of the premature aging Werner syndrome gene in RT human cancer."; RL Proc. Natl. Acad. Sci. U.S.A. 103:8822-8827(2006). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-1074. RA Paeper B.W., Gayle M., Brady W., Swartz A., Gillett L.A., Alisch R.S., RA Mulligan J., Galas D., Fu Y.-H.; RT "Genomic structure of the human Werner's gene and cloning of the mouse RT homolog."; RL Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-114; LYS-343; ILE-387; RP SER-533; CYS-612; PHE-708; CYS-834; SER-912; LEU-1079; ALA-1133; ILE-1339 RP AND ARG-1367. RG NIEHS SNPs program; RL Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [6] RP FUNCTION AS A HELICASE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-577. RX PubMed=9288107; DOI=10.1038/ng0997-100; RA Gray M.D., Shen J.C., Kamath-Loeb A.S., Blank A., Sopher B.L., Martin G.M., RA Oshima J., Loeb L.A.; RT "The Werner syndrome protein is a DNA helicase."; RL Nat. Genet. 17:100-103(1997). RN [7] RP FUNCTION AS A HELICASE. RX PubMed=9224595; DOI=10.1093/nar/25.15.2973; RA Suzuki N., Shimamoto A., Imamura O., Kuromitsu J., Kitao S., Goto M., RA Furuichi Y.; RT "DNA helicase activity in Werner's syndrome gene product synthesized in a RT baculovirus system."; RL Nucleic Acids Res. 25:2973-2978(1997). RN [8] RP FUNCTION AS A 3'-5' HELICASE, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=9611231; DOI=10.1093/nar/26.12.2879; RA Shen J.C., Gray M.D., Oshima J., Loeb L.A.; RT "Characterization of Werner syndrome protein DNA helicase activity: RT directionality, substrate dependence and stimulation by replication protein RT A."; RL Nucleic Acids Res. 26:2879-2885(1998). RN [9] RP SUBCELLULAR LOCATION. RX PubMed=9618508; DOI=10.1073/pnas.95.12.6887; RA Marciniak R.A., Lombard D.B., Johnson F.B., Guarente L.; RT "Nucleolar localization of the Werner syndrome protein in human cells."; RL Proc. Natl. Acad. Sci. U.S.A. 95:6887-6892(1998). RN [10] RP REPEATS. RX PubMed=10049920; DOI=10.1093/genetics/151.3.1027; RA Kusano K., Berres M.E., Engels W.R.; RT "Evolution of the RECQ family of helicases: a Drosophila homolog, Dmblm, is RT similar to the human Bloom syndrome gene."; RL Genetics 151:1027-1039(1999). RN [11] RP FUNCTION, AND COFACTOR. RX PubMed=10212265; DOI=10.1074/jbc.274.18.12797; RA Fry M., Loeb L.A.; RT "Human werner syndrome DNA helicase unwinds tetrahelical structures of the RT fragile X syndrome repeat sequence d(CGG)n."; RL J. Biol. Chem. 274:12797-12802(1999). RN [12] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=9989816; DOI=10.1038/sj.onc.1202340; RA Chughtai S.A., Crundwell M.C., Cruickshank N.R., Affie E., Armstrong S., RA Knowles M.A., Takle L.A., Kuo M., Khan N., Phillips S.M., Neoptolemos J.P., RA Morton D.G.; RT "Two novel regions of interstitial deletion on chromosome 8p in colorectal RT cancer."; RL Oncogene 18:657-665(1999). RN [13] RP FUNCTION AS AN EXONUCLEASE, MUTAGENESIS OF GLU-84, DNA-BINDING, INTERACTION RP WITH PCNA, AND SUBUNIT. RX PubMed=11863428; DOI=10.1021/bi0157161; RA Xue Y., Ratcliff G.C., Wang H., Davis-Searles P.R., Gray M.D., Erie D.A., RA Redinbo M.R.; RT "A minimal exonuclease domain of WRN forms a hexamer on DNA and possesses RT both 3'- 5' exonuclease and 5'-protruding strand endonuclease activities."; RL Biochemistry 41:2901-2912(2002). RN [14] RP PHOSPHORYLATION. RX PubMed=11889123; DOI=10.1074/jbc.m111523200; RA Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P., RA Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.; RT "Werner protein is a target of DNA-dependent protein kinase in vivo and in RT vitro, and its catalytic activities are regulated by phosphorylation."; RL J. Biol. Chem. 277:18291-18302(2002). RN [15] RP INTERACTION WITH EXO1. RX PubMed=12704184; DOI=10.1074/jbc.m212798200; RA Sharma S., Sommers J.A., Driscoll H.C., Uzdilla L.A., Wilson T.M., RA Brosh R.M. Jr.; RT "The exonucleolytic and endonucleolytic cleavage activities of human RT exonuclease 1 are stimulated by an interaction with the carboxyl-terminal RT region of the Werner syndrome protein."; RL J. Biol. Chem. 278:23487-23496(2003). RN [16] RP INTERACTION WITH SUPV3L1. RX PubMed=17961633; DOI=10.1016/j.mad.2007.09.001; RA Pereira M., Mason P., Szczesny R.J., Maddukuri L., Dziwura S., RA Jedrzejczak R., Paul E., Wojcik A., Dybczynska L., Tudek B., Bartnik E., RA Klysik J., Bohr V.A., Stepien P.P.; RT "Interaction of human SUV3 RNA/DNA helicase with BLM helicase; loss of the RT SUV3 gene results in mouse embryonic lethality."; RL Mech. Ageing Dev. 128:609-617(2007). RN [17] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=17563354; DOI=10.1073/pnas.0702513104; RA Kamath-Loeb A.S., Lan L., Nakajima S., Yasui A., Loeb L.A.; RT "Werner syndrome protein interacts functionally with translesion DNA RT polymerases."; RL Proc. Natl. Acad. Sci. U.S.A. 104:10394-10399(2007). RN [18] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Embryonic kidney; RX PubMed=17525332; DOI=10.1126/science.1140321; RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E., RA Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., RA Gygi S.P., Elledge S.J.; RT "ATM and ATR substrate analysis reveals extensive protein networks RT responsive to DNA damage."; RL Science 316:1160-1166(2007). RN [19] RP FUNCTION, SUBUNIT, AND DNA-BINDING. RX PubMed=18596042; DOI=10.1074/jbc.m803370200; RA Compton S.A., Tolun G., Kamath-Loeb A.S., Loeb L.A., Griffith J.D.; RT "The Werner syndrome protein binds replication fork and Holliday junction RT DNAs as an oligomer."; RL J. Biol. Chem. 283:24478-24483(2008). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-440 AND SER-467, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [21] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [22] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=19652551; DOI=10.4161/cc.8.17.9410; RA Zecevic A., Menard H., Gurel V., Hagan E., DeCaro R., Zhitkovich A.; RT "WRN helicase promotes repair of DNA double-strand breaks caused by RT aberrant mismatch repair of chromium-DNA adducts."; RL Cell Cycle 8:2769-2778(2009). RN [23] RP FUNCTION. RX PubMed=19283071; DOI=10.1371/journal.pone.0004825; RA Opresko P.L., Sowd G., Wang H.; RT "The Werner syndrome helicase/exonuclease processes mobile D-loops through RT branch migration and degradation."; RL PLoS ONE 4:E4825-E4825(2009). RN [24] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-426; SER-440; SER-453 AND RP SER-467, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [25] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [26] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML. RX PubMed=21639834; DOI=10.1134/s000629791105004x; RA Liu J., Song Y., Qian J., Liu B., Dong Y., Tian B., Sun Z.; RT "Promyelocytic leukemia protein interacts with werner syndrome helicase and RT regulates double-strand break repair in gamma-irradiation-induced DNA RT damage responses."; RL Biochemistry (Mosc.) 76:550-554(2011). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1133, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [28] RP ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [29] RP POSSIBLE INVOLVEMENT IN CRC. RX PubMed=24308539; DOI=10.1186/1755-8794-6-54; RA Lee H., Flaherty P., Ji H.P.; RT "Systematic genomic identification of colorectal cancer genes delineating RT advanced from early clinical stage and metastasis."; RL BMC Med. Genomics 6:54-54(2013). RN [30] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-478; SER-1133 AND SER-1400, RP AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [31] RP FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH XRCC5 AND XRCC6, DOMAIN, RP XLM MOTIF, KBM MOTIFS, AND MUTAGENESIS OF TRP-18 AND GLU-84. RX PubMed=27063109; DOI=10.1038/ncomms11242; RA Grundy G.J., Rulten S.L., Arribas-Bosacoma R., Davidson K., Kozik Z., RA Oliver A.W., Pearl L.H., Caldecott K.W.; RT "The Ku-binding motif is a conserved module for recruitment and stimulation RT of non-homologous end-joining proteins."; RL Nat. Commun. 7:11242-11242(2016). RN [32] RP SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-154; LYS-241 AND LYS-252, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=28112733; DOI=10.1038/nsmb.3366; RA Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., RA Nielsen M.L.; RT "Site-specific mapping of the human SUMO proteome reveals co-modification RT with phosphorylation."; RL Nat. Struct. Mol. Biol. 24:325-336(2017). RN [33] {ECO:0007744|PDB:2AXL} RP STRUCTURE BY NMR OF 949-1092. RX PubMed=16339893; DOI=10.1073/pnas.0509380102; RA Hu J.S., Feng H., Zeng W., Lin G.X., Xi X.G.; RT "Solution structure of a multifunctional DNA- and protein-binding motif of RT human Werner syndrome protein."; RL Proc. Natl. Acad. Sci. U.S.A. 102:18379-18384(2005). RN [34] {ECO:0007744|PDB:2FBT, ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, ECO:0007744|PDB:2FBY, ECO:0007744|PDB:2FC0} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 38-236 IN COMPLEXES WITH RP MAGNESIUM; MANGANESE; EUROPIUM AND GMP, PARTIAL PROTEIN SEQUENCE, RP IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC ACTIVITY, COFACTOR, RP MUTAGENESIS OF GLU-84; TRP-145 AND TYR-212, AND CHARACTERIZATION OF RP VARIANTS ILE-114 AND PRO-172. RX PubMed=16622405; DOI=10.1038/nsmb1088; RA Perry J.J., Yannone S.M., Holden L.G., Hitomi C., Asaithamby A., Han S., RA Cooper P.K., Chen D.J., Tainer J.A.; RT "WRN exonuclease structure and molecular mechanism imply an editing role in RT DNA end processing."; RL Nat. Struct. Mol. Biol. 13:414-422(2006). RN [35] RP REVIEW ON VARIANTS. RX PubMed=10220139; RX DOI=10.1002/(sici)1098-1004(1999)13:4<271::aid-humu2>3.0.co;2-q; RA Moser M.J., Oshima J., Monnat R.J. Jr.; RT "WRN mutations in Werner syndrome."; RL Hum. Mutat. 13:271-279(1999). RN [36] {ECO:0007744|PDB:2DGZ} RP STRUCTURE BY NMR OF 1140-1239. RG RIKEN structural genomics initiative (RSGI); RA Abe C., Muto Y., Inoue M., Kigawa T., Terada T., Shirouzu M., Yokoyama S.; RT "Solution structure of the helicase and RNase D C-terminal domain in Werner RT syndrome ATP-dependent helicase."; RL Submitted (SEP-2006) to the PDB data bank. RN [37] {ECO:0007744|PDB:2E1E, ECO:0007744|PDB:2E1F} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1142-1242, PARTIAL PROTEIN RP SEQUENCE, IDENTIFICATION BY MASS SPECTROMETRY, AND CIRCULAR DICHROISM. RX PubMed=17148451; DOI=10.1074/jbc.m610142200; RA Kitano K., Yoshihara N., Hakoshima T.; RT "Crystal structure of the HRDC domain of human Werner syndrome protein, RT WRN."; RL J. Biol. Chem. 282:2717-2728(2007). RN [38] {ECO:0007744|PDB:3AAF} RP X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 949-1079 IN COMPLEX WITH RP DOUBLE-STRANDED DNA, INTERACTION WITH DNA, AND MUTAGENESIS OF ARG-987; RP SER-989; ARG-993; PHE-1037 AND MET-1038. RX PubMed=20159463; DOI=10.1016/j.str.2009.12.011; RA Kitano K., Kim S.Y., Hakoshima T.; RT "Structural basis for DNA strand separation by the unconventional winged- RT helix domain of RecQ helicase WRN."; RL Structure 18:177-187(2010). RN [39] {ECO:0007744|PDB:6TYV} RP X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) OF 8-23 IN COMPLEX WITH X.LAEVIS RP XRCC5. RX PubMed=31733588; DOI=10.1016/j.dnarep.2019.102739; RA Kim K., Min J., Kirby T.W., Gabel S.A., Pedersen L.C., London R.E.; RT "Ligand binding characteristics of the Ku80 von Willebrand domain."; RL DNA Repair 85:102739-102739(2020). RN [40] {ECO:0007744|PDB:6YHR} RP X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 517-1093 IN COMPLEX WITH ADP AND RP ZINC, FUNCTION, DOMAIN, AND MUTAGENESIS OF GLU-84; LYS-577 AND GLU-669. RX PubMed=33199508; DOI=10.26508/lsa.202000795; RA Newman J.A., Gavard A.E., Lieb S., Ravichandran M.C., Hauer K., Werni P., RA Geist L., Boettcher J., Engen J.R., Rumpel K., Samwer M., Petronczki M., RA Gileadi O.; RT "Structure of the helicase core of Werner helicase, a key target in RT microsatellite instability cancers."; RL Life. Sci Alliance 4:0-0(2021). RN [41] RP VARIANT ARG-1367. RX PubMed=9021029; RX DOI=10.1002/(sici)1096-8628(19970211)68:4<494::aid-ajmg30>3.0.co;2-l; RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RT "Association of a polymorphic variant of the Werner helicase gene with RT myocardial infarction in a Japanese population."; RL Am. J. Med. Genet. 68:494-498(1997). RN [42] RP ERRATUM OF PUBMED:9021029. RA Ye L., Miki T., Nakura J., Oshima J., Kamino K., Rakugi H., Ikegami H., RA Higaki J., Edland S.D., Martin G.M., Ogihara T.; RL Am. J. Med. Genet. 70:103-103(1997). RN [43] RP VARIANTS ILE-387 AND PHE-1074. RX PubMed=9450180; RA Meisslitzer C., Ruppitsch W., Weirich-Schwaiger H., Weirich H.G., RA Jabkowsky J., Klein G., Schweiger M., Hirsch-Kauffmann M.; RT "Werner syndrome: characterization of mutations in the WRN gene in an RT affected family."; RL Eur. J. Hum. Genet. 5:364-370(1997). RN [44] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RECQL5. RX PubMed=23180761; DOI=10.1093/nar/gks1134; RA Popuri V., Huang J., Ramamoorthy M., Tadokoro T., Croteau D.L., Bohr V.A.; RT "RECQL5 plays co-operative and complementary roles with WRN syndrome RT helicase."; RL Nucleic Acids Res. 41:881-899(2013). RN [45] RP VARIANT ILE-387. RX PubMed=10206685; RX DOI=10.1002/(sici)1098-1004(1998)11:5<413::aid-humu16>3.0.co;2-i; RA Vidal V., Bay J.-O., Champomier F., Grancho M., Beauville L., RA Glowaczower C., Lemery D., Ferrara M., Bignon Y.-J.; RT "The 1396del A mutation and a missense mutation or a rare polymorphism of RT the WRN gene detected in a French Werner family with a severe phenotype and RT a case of an unusual vulvar cancer."; RL Hum. Mutat. 11:413-414(1998). RN [46] RP VARIANTS ALA-324 AND ARG-1367. RX PubMed=10069711; RX DOI=10.1002/(sici)1096-8628(19990219)82:5<399::aid-ajmg8>3.3.co;2-i; RA Castro E., Ogburn C.E., Hunt K.E., Tilvis R., Louhija J., Penttinen R., RA Erkkola R., Panduro A., Riestra R., Piussan C., Deeb S.S., Wang L., RA Edland S.D., Martin G.M., Oshima J.; RT "Polymorphisms at the Werner locus: I. Newly identified polymorphisms, RT ethnic variability of 1367Cys/Arg, and its stability in a population of RT Finnish centenarians."; RL Am. J. Med. Genet. 82:399-403(1999). RN [47] RP VARIANTS ARG-32; ILE-114; PRO-172; LYS-240; TRP-383; ILE-387; LEU-724; RP PHE-1074; GLU-1269 AND ARG-1367. RX PubMed=11161804; DOI=10.1006/geno.2000.6405; RA Passarino G., Shen P., Van Kirk J.B., Lin A.A., De Benedictis G., RA Cavalli-Sforza L.L., Oefner P.J., Underhill P.A.; RT "The Werner syndrome gene and global sequence variation."; RL Genomics 71:118-122(2001). RN [48] RP VARIANTS WRN ASN-125 AND GLU-135. RX PubMed=16673358; DOI=10.1002/humu.20337; RA Huang S., Lee L., Hanson N.B., Lenaerts C., Hoehn H., Poot M., Rubin C.D., RA Chen D.-F., Yang C.-C., Juch H., Dorn T., Spiegel R., Oral E.A., Abid M., RA Battisti C., Lucci-Cordisco E., Neri G., Steed E.H., Kidd A., Isley W., RA Showalter D., Vittone J.L., Konstantinow A., Ring J., Meyer P., RA Wenger S.L., Herbay A.V., Wollina U., Schuelke M., Huizenga C.R., RA Leistritz D.F., Martin G.M., Mian I.S., Oshima J.; RT "The spectrum of WRN mutations in Werner syndrome patients."; RL Hum. Mutat. 27:558-567(2006). RN [49] RP VARIANT [LARGE SCALE ANALYSIS] VAL-92. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [50] RP VARIANT [LARGE SCALE ANALYSIS] LEU-1141. RX PubMed=18987736; DOI=10.1038/nature07485; RA Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., RA Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., RA Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., RA Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., RA Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., RA Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., RA Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., RA Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., RA DiPersio J.F., Wilson R.K.; RT "DNA sequencing of a cytogenetically normal acute myeloid leukaemia RT genome."; RL Nature 456:66-72(2008). CC -!- FUNCTION: Multifunctional enzyme that has magnesium and ATP-dependent CC 3'-5' DNA-helicase activity on partially duplex substrates CC (PubMed:9224595, PubMed:9288107, PubMed:9611231). Also has 3'->5' CC exonuclease activity towards double-stranded (ds)DNA with a 5'-overhang CC (PubMed:11863428). Has no nuclease activity towards single-stranded CC (ss)DNA or blunt-ended dsDNA (PubMed:11863428). Helicase activity is CC most efficient with (d)ATP, but (d)CTP will substitute with reduced CC efficiency; strand displacement is enhanced by single-strand binding- CC protein (heterotrimeric replication protein A complex, RPA1, RPA2, CC RPA3) (PubMed:9611231). Binds preferentially to DNA substrates CC containing alternate secondary structures, such as replication forks CC and Holliday junctions. May play an important role in the dissociation CC of joint DNA molecules that can arise as products of homologous CC recombination, at stalled replication forks or during DNA repair. CC Alleviates stalling of DNA polymerases at the site of DNA lesions. CC Plays a role in the formation of DNA replication focal centers; stably CC associates with foci elements generating binding sites for RP-A (By CC similarity). Plays a role in double-strand break repair after gamma- CC irradiation (PubMed:9224595, PubMed:9288107, PubMed:9611231). Unwinds CC some G-quadruplex DNA (d(CGG)n tracts); unwinding seems to occur in CC both 5'-3' and 3'-5' direction and requires a short single-stranded CC tail (PubMed:10212265). d(CGG)n tracts have a propensity to assemble CC into tetraplex structures; other G-rich substrates from a telomeric or CC IgG switch sequence are not unwound (PubMed:10212265). Depletion leads CC to chromosomal breaks and genome instability (PubMed:33199508). CC {ECO:0000250|UniProtKB:O09053, ECO:0000269|PubMed:10212265, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:18596042, ECO:0000269|PubMed:19283071, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109, ECO:0000269|PubMed:33199508, CC ECO:0000269|PubMed:9224595, ECO:0000269|PubMed:9288107, CC ECO:0000269|PubMed:9611231}. CC -!- CATALYTIC ACTIVITY: CC Reaction=Couples ATP hydrolysis with the unwinding of duplex DNA by CC translocating in the 3'-5' direction.; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:9611231, ECO:0000305|PubMed:10212265, CC ECO:0000305|PubMed:9224595, ECO:0000305|PubMed:9288107}; CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=5.6.2.4; CC Evidence={ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:9224595, CC ECO:0000269|PubMed:9288107, ECO:0000269|PubMed:9611231}; CC -!- COFACTOR: CC Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240; CC Evidence={ECO:0000269|PubMed:16622405}; CC Note=Binds 2 magnesium or manganese ions in the exonuclease domain; has CC high exonuclease activity with both ions in vitro (PubMed:16622405). CC Unwinding of G-quadruplex DNA requires Mg(2+) (PubMed:10212265). CC {ECO:0000269|PubMed:10212265, ECO:0000269|PubMed:16622405}; CC -!- COFACTOR: CC Name=Zn(2+); Xref=ChEBI:CHEBI:29105; CC Evidence={ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC Note=Binds a Zn(2+) ion in the helicase domain (PubMed:33199508). CC {ECO:0000269|PubMed:33199508, ECO:0000312|PDB:6YHR}; CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=51 uM for ATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=119 uM for dATP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=2.1 uM for CTP in helicase activity {ECO:0000269|PubMed:9611231}; CC KM=3.9 uM for dCTP in helicase activity {ECO:0000269|PubMed:9611231}; CC -!- SUBUNIT: Monomer, and homooligomer (PubMed:11863428, PubMed:18596042, CC PubMed:20159463). May exist as homodimer, homotrimer, homotetramer CC and/or homohexamer (PubMed:11863428, PubMed:18596042, PubMed:20159463). CC Homotetramer, or homohexamer, when bound to DNA (PubMed:11863428, CC PubMed:18596042, PubMed:20159463). Interacts via its N-terminal domain CC with WRNIP1 (By similarity). Interacts with EXO1, PCNA and SUPV3L1 CC (PubMed:12704184, PubMed:17961633). Interacts with PML (isoform PML-4) CC (PubMed:21639834). Interacts (via KBM motif) with XRCC5 and XRCC6; CC promoting recruitment to DNA damage sites (PubMed:27063109). Interacts CC with RECQL5; this interaction stimulates WRN helicase activity on DNA CC fork duplexes (PubMed:23180761). {ECO:0000250|UniProtKB:O09053, CC ECO:0000269|PubMed:11863428, ECO:0000269|PubMed:12704184, CC ECO:0000269|PubMed:17961633, ECO:0000269|PubMed:18596042, CC ECO:0000269|PubMed:20159463, ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:23180761, ECO:0000269|PubMed:27063109}. CC -!- INTERACTION: CC Q14191; P54132: BLM; NbExp=9; IntAct=EBI-368417, EBI-621372; CC Q14191; P45973: CBX5; NbExp=3; IntAct=EBI-368417, EBI-78219; CC Q14191; P39748: FEN1; NbExp=9; IntAct=EBI-368417, EBI-707816; CC Q14191; P16104: H2AX; NbExp=6; IntAct=EBI-368417, EBI-494830; CC Q14191; P09874: PARP1; NbExp=8; IntAct=EBI-368417, EBI-355676; CC Q14191; P43351: RAD52; NbExp=9; IntAct=EBI-368417, EBI-706448; CC Q14191; P27694: RPA1; NbExp=9; IntAct=EBI-368417, EBI-621389; CC Q14191; Q96EB6: SIRT1; NbExp=9; IntAct=EBI-368417, EBI-1802965; CC Q14191; Q15554: TERF2; NbExp=8; IntAct=EBI-368417, EBI-706637; CC Q14191; P04637: TP53; NbExp=5; IntAct=EBI-368417, EBI-366083; CC Q14191; P12956: XRCC6; NbExp=11; IntAct=EBI-368417, EBI-353208; CC -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:23180761, CC ECO:0000269|PubMed:9618508}. Nucleus {ECO:0000269|PubMed:17563354, CC ECO:0000269|PubMed:19652551, ECO:0000269|PubMed:23180761}. Nucleus, CC nucleoplasm {ECO:0000269|PubMed:21639834}. Chromosome CC {ECO:0000269|PubMed:27063109}. Note=Gamma-irradiation leads to its CC translocation from nucleoli to nucleoplasm and PML regulates the CC irradiation-induced WRN relocation (PubMed:21639834). Localizes to DNA CC damage sites (PubMed:27063109). {ECO:0000269|PubMed:21639834, CC ECO:0000269|PubMed:27063109}. CC -!- DOMAIN: The KBM 2 (Ku-binding motif 2) and XLM (XLF-like motif) mediate CC cooperative interaction with XRCC5/Ku80 and XRCC6/Ku70 and recruitment CC to DNA damage sites (PubMed:27063109). The isolated helicase core CC (residues 517-1093) interacts weakly with the HDRC domain in vitro CC (PubMed:33199508). {ECO:0000269|PubMed:27063109, CC ECO:0000269|PubMed:33199508}. CC -!- PTM: Phosphorylated by PRKDC. {ECO:0000269|PubMed:11889123}. CC -!- DISEASE: Werner syndrome (WRN) [MIM:277700]: A rare autosomal recessive CC progeroid syndrome characterized by the premature onset of multiple CC age-related disorders, including atherosclerosis, cancer, non-insulin- CC dependent diabetes mellitus, ocular cataracts and osteoporosis. The CC major cause of death, at a median age of 47, is myocardial infarction. CC {ECO:0000269|PubMed:16673358}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. {ECO:0000305|PubMed:24308539, CC ECO:0000305|PubMed:9989816}. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the helicase family. RecQ subfamily. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=WRN; Note=WRN mutation db (Warner disease); CC URL="http://www.pathology.washington.edu/werner/ws_wrn.html"; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/284/WRN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L76937; AAC41981.1; -; Genomic_DNA. DR EMBL; AY818673; AAX21098.1; -; mRNA. DR EMBL; AF091214; AAC63361.1; -; mRNA. DR EMBL; AF181897; AAF06162.1; -; Genomic_DNA. DR EMBL; AF181896; AAF06162.1; JOINED; Genomic_DNA. DR EMBL; AY442327; AAR05448.1; -; Genomic_DNA. DR EMBL; AC084736; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR CCDS; CCDS6082.1; -. DR RefSeq; NP_000544.2; NM_000553.6. DR PDB; 2AXL; NMR; -; A=949-1092. DR PDB; 2DGZ; NMR; -; A=1140-1239. DR PDB; 2E1E; X-ray; 2.30 A; A=1142-1242. DR PDB; 2E1F; X-ray; 2.00 A; A=1142-1242. DR PDB; 2FBT; X-ray; 2.05 A; A=38-236. DR PDB; 2FBV; X-ray; 2.40 A; A=38-236. DR PDB; 2FBX; X-ray; 2.20 A; A=38-236. DR PDB; 2FBY; X-ray; 2.00 A; A=38-236. DR PDB; 2FC0; X-ray; 2.00 A; A=38-236. DR PDB; 3AAF; X-ray; 1.90 A; A/B=949-1079. DR PDB; 6TYV; X-ray; 1.93 A; B=8-23. DR PDB; 6YHR; X-ray; 2.20 A; A=517-1093. DR PDB; 7GQS; X-ray; 1.57 A; A=517-945. DR PDB; 7GQT; X-ray; 2.21 A; A=517-945. DR PDB; 7GQU; X-ray; 1.54 A; A=517-945. DR PDB; 7XUT; X-ray; 1.60 A; A/B=435-451. DR PDB; 8PFL; X-ray; 1.80 A; A=517-945. DR PDB; 8PFO; X-ray; 1.90 A; A=517-945. DR PDB; 8PFP; X-ray; 1.60 A; A=517-945. DR PDB; 8YLE; X-ray; 1.86 A; A=517-945. DR PDB; 9OG3; X-ray; 2.06 A; A=526-946. DR PDB; 9OG8; X-ray; 1.66 A; A=526-946. DR PDB; 9OW9; X-ray; 2.34 A; A=500-942. DR PDB; 9OWA; X-ray; 1.98 A; A=500-942. DR PDB; 9OWB; X-ray; 1.56 A; A/B/C/D=500-942. DR PDB; 9OWC; X-ray; 1.67 A; A=500-942. DR PDB; 9OWD; X-ray; 1.96 A; A=500-942. DR PDBsum; 2AXL; -. DR PDBsum; 2DGZ; -. DR PDBsum; 2E1E; -. DR PDBsum; 2E1F; -. DR PDBsum; 2FBT; -. DR PDBsum; 2FBV; -. DR PDBsum; 2FBX; -. DR PDBsum; 2FBY; -. DR PDBsum; 2FC0; -. DR PDBsum; 3AAF; -. DR PDBsum; 6TYV; -. DR PDBsum; 6YHR; -. DR PDBsum; 7GQS; -. DR PDBsum; 7GQT; -. DR PDBsum; 7GQU; -. DR PDBsum; 7XUT; -. DR PDBsum; 8PFL; -. DR PDBsum; 8PFO; -. DR PDBsum; 8PFP; -. DR PDBsum; 8YLE; -. DR PDBsum; 9OG3; -. DR PDBsum; 9OG8; -. DR PDBsum; 9OW9; -. DR PDBsum; 9OWA; -. DR PDBsum; 9OWB; -. DR PDBsum; 9OWC; -. DR PDBsum; 9OWD; -. DR AlphaFoldDB; Q14191; -. DR BMRB; Q14191; -. DR SMR; Q14191; -. DR BioGRID; 113323; 124. DR CORUM; Q14191; -. DR DIP; DIP-31380N; -. DR ELM; Q14191; -. DR FunCoup; Q14191; 2264. DR IntAct; Q14191; 67. DR MINT; Q14191; -. DR STRING; 9606.ENSP00000298139; -. DR BindingDB; Q14191; -. DR ChEMBL; CHEMBL2146312; -. DR GuidetoPHARMACOLOGY; 3259; -. DR GlyGen; Q14191; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q14191; -. DR PhosphoSitePlus; Q14191; -. DR SwissPalm; Q14191; -. DR BioMuta; WRN; -. DR DMDM; 322510082; -. DR jPOST; Q14191; -. DR MassIVE; Q14191; -. DR PaxDb; 9606-ENSP00000298139; -. DR PeptideAtlas; Q14191; -. DR ProteomicsDB; 59913; -. DR Pumba; Q14191; -. DR ABCD; Q14191; 1 sequenced antibody. DR Antibodypedia; 10619; 313 antibodies from 41 providers. DR DNASU; 7486; -. DR Ensembl; ENST00000298139.7; ENSP00000298139.5; ENSG00000165392.12. DR GeneID; 7486; -. DR KEGG; hsa:7486; -. DR MANE-Select; ENST00000298139.7; ENSP00000298139.5; NM_000553.6; NP_000544.2. DR UCSC; uc003xio.5; human. DR AGR; HGNC:12791; -. DR ClinPGx; PA367; -. DR CTD; 7486; -. DR DisGeNET; 7486; -. DR GeneCards; WRN; -. DR GeneReviews; WRN; -. DR HGNC; HGNC:12791; WRN. DR HPA; ENSG00000165392; Low tissue specificity. DR MalaCards; WRN; -. DR MIM; 114500; phenotype. DR MIM; 277700; phenotype. DR MIM; 604611; gene. DR OpenTargets; ENSG00000165392; -. DR Orphanet; 902; Werner syndrome. DR VEuPathDB; HostDB:ENSG00000165392; -. DR eggNOG; KOG0351; Eukaryota. DR eggNOG; KOG4373; Eukaryota. DR GeneTree; ENSGT00940000159168; -. DR HOGENOM; CLU_001103_11_1_1; -. DR InParanoid; Q14191; -. DR OMA; TYLIHMV; -. DR OrthoDB; 10261556at2759; -. DR PAN-GO; Q14191; 11 GO annotations based on evolutionary models. DR PhylomeDB; Q14191; -. DR BRENDA; 3.6.4.12; 2681. DR PathwayCommons; Q14191; -. DR Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere. DR Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand. DR Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins. DR Reactome; R-HSA-5685938; HDR through Single Strand Annealing (SSA). DR Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR). DR Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA). DR Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates. DR Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange. DR Reactome; R-HSA-5693607; Processing of DNA double-strand break ends. DR Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange. DR Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation. DR Reactome; R-HSA-69473; G2/M DNA damage checkpoint. DR Reactome; R-HSA-9701192; Defective homologous recombination repair (HRR) due to BRCA1 loss of function. DR Reactome; R-HSA-9704331; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function. DR Reactome; R-HSA-9704646; Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function. DR Reactome; R-HSA-9709570; Impaired BRCA2 binding to RAD51. DR Reactome; R-HSA-9709603; Impaired BRCA2 binding to PALB2. DR SignaLink; Q14191; -. DR SIGNOR; Q14191; -. DR Agora; ENSG00000165392; -. DR BioGRID-ORCS; 7486; 55 hits in 1158 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; 91857CE7; Nucleolus. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; WRN; human. DR EvolutionaryTrace; Q14191; -. DR GeneWiki; Werner_syndrome_ATP-dependent_helicase; -. DR GenomeRNAi; 7486; -. DR Pharos; Q14191; Tbio. DR PRO; PR:Q14191; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q14191; protein. DR Bgee; ENSG00000165392; Expressed in calcaneal tendon and 165 other cell types or tissues. DR ExpressionAtlas; Q14191; baseline and differential. DR GO; GO:0005813; C:centrosome; IDA:UniProtKB. DR GO; GO:0005694; C:chromosome; IBA:GO_Central. DR GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL. DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005730; C:nucleolus; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005657; C:replication fork; ISS:BHF-UCL. DR GO; GO:0043138; F:3'-5' DNA helicase activity; IDA:UniProtKB. DR GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB. DR GO; GO:0070337; F:3'-flap-structured DNA binding; IDA:BHF-UCL. DR GO; GO:1905773; F:8-hydroxy-2'-deoxyguanosine DNA binding; IDA:BHF-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB. DR GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB. DR GO; GO:0003677; F:DNA binding; IDA:UniProtKB. DR GO; GO:0003678; F:DNA helicase activity; IDA:UniProtKB. DR GO; GO:0004527; F:exonuclease activity; IDA:MGI. DR GO; GO:0061749; F:forked DNA-dependent helicase activity; IDA:BHF-UCL. DR GO; GO:0000400; F:four-way junction DNA binding; IDA:BHF-UCL. DR GO; GO:0009378; F:four-way junction helicase activity; IDA:UniProtKB. DR GO; GO:0051880; F:G-quadruplex DNA binding; IDA:UniProtKB. DR GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB. DR GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB. DR GO; GO:0032405; F:MutLalpha complex binding; IDA:UniProtKB. DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB. DR GO; GO:0061821; F:telomeric D-loop binding; IDA:BHF-UCL. DR GO; GO:0061849; F:telomeric G-quadruplex DNA binding; IDA:BHF-UCL. DR GO; GO:0000403; F:Y-form DNA binding; IDA:UniProtKB. DR GO; GO:0006284; P:base-excision repair; IDA:UniProtKB. DR GO; GO:0071480; P:cellular response to gamma radiation; IDA:UniProtKB. DR GO; GO:0009267; P:cellular response to starvation; IDA:MGI. DR GO; GO:0090398; P:cellular senescence; IMP:GO_Central. DR GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl. DR GO; GO:0006974; P:DNA damage response; IDA:UniProtKB. DR GO; GO:0032392; P:DNA geometric change; IDA:BHF-UCL. DR GO; GO:0006259; P:DNA metabolic process; IDA:UniProtKB. DR GO; GO:0006260; P:DNA replication; IMP:UniProtKB. DR GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB. DR GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB. DR GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central. DR GO; GO:0006298; P:mismatch repair; IDA:BHF-UCL. DR GO; GO:0051345; P:positive regulation of hydrolase activity; IDA:UniProtKB. DR GO; GO:0098530; P:positive regulation of strand invasion; IDA:BHF-UCL. DR GO; GO:1902570; P:protein localization to nucleolus; IDA:MGI. DR GO; GO:0040009; P:regulation of growth rate; IEA:Ensembl. DR GO; GO:0031297; P:replication fork processing; IDA:UniProtKB. DR GO; GO:0090399; P:replicative senescence; IEA:Ensembl. DR GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB. DR GO; GO:0010225; P:response to UV-C; IDA:UniProtKB. DR GO; GO:0090656; P:t-circle formation; TAS:BHF-UCL. DR GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL. DR GO; GO:0032201; P:telomere maintenance via semi-conservative replication; TAS:Reactome. DR GO; GO:0061820; P:telomeric D-loop disassembly; IDA:BHF-UCL. DR CDD; cd18017; DEXHc_RecQ3; 1. DR CDD; cd06129; RNaseD_like; 1. DR CDD; cd18794; SF2_C_RecQ; 1. DR DisProt; DP00443; -. DR FunFam; 1.10.10.10:FF:000369; Werner syndrome ATP-dependent helicase; 1. DR FunFam; 1.10.150.80:FF:000005; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.30.420.10:FF:000053; Werner syndrome ATP-dependent helicase homolog; 1. DR FunFam; 3.40.50.300:FF:000941; Werner syndrome RecQ like helicase; 1. DR FunFam; 3.40.50.300:FF:001023; Werner syndrome RecQ like helicase; 1. DR Gene3D; 1.10.150.80; HRDC domain; 1. DR Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2. DR Gene3D; 3.30.420.10; Ribonuclease H-like superfamily/Ribonuclease H; 1. DR Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1. DR IDEAL; IID00246; -. DR InterPro; IPR002562; 3'-5'_exonuclease_dom. DR InterPro; IPR011545; DEAD/DEAH_box_helicase_dom. DR InterPro; IPR004589; DNA_helicase_ATP-dep_RecQ. DR InterPro; IPR014001; Helicase_ATP-bd. DR InterPro; IPR001650; Helicase_C-like. DR InterPro; IPR029491; Helicase_HTH. DR InterPro; IPR010997; HRDC-like_sf. DR InterPro; IPR002121; HRDC_dom. DR InterPro; IPR044876; HRDC_dom_sf. DR InterPro; IPR027417; P-loop_NTPase. DR InterPro; IPR032284; RecQ_Zn-bd. DR InterPro; IPR012337; RNaseH-like_sf. DR InterPro; IPR036397; RNaseH_sf. DR InterPro; IPR018982; RQC_domain. DR InterPro; IPR036388; WH-like_DNA-bd_sf. DR InterPro; IPR036390; WH_DNA-bd_sf. DR NCBIfam; TIGR00614; recQ_fam; 1. DR PANTHER; PTHR13710:SF120; BIFUNCTIONAL 3'-5' EXONUCLEASE_ATP-DEPENDENT HELICASE WRN; 1. DR PANTHER; PTHR13710; DNA HELICASE RECQ FAMILY MEMBER; 1. DR Pfam; PF00270; DEAD; 1. DR Pfam; PF01612; DNA_pol_A_exo1; 1. DR Pfam; PF00271; Helicase_C; 1. DR Pfam; PF00570; HRDC; 1. DR Pfam; PF14493; HTH_40; 1. DR Pfam; PF16124; RecQ_Zn_bind; 1. DR Pfam; PF09382; RQC; 1. DR SMART; SM00474; 35EXOc; 1. DR SMART; SM00487; DEXDc; 1. DR SMART; SM00490; HELICc; 1. DR SMART; SM00341; HRDC; 1. DR SMART; SM00956; RQC; 1. DR SUPFAM; SSF47819; HRDC-like; 1. DR SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1. DR SUPFAM; SSF53098; Ribonuclease H-like; 1. DR SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1. DR PROSITE; PS51192; HELICASE_ATP_BIND_1; 1. DR PROSITE; PS51194; HELICASE_CTER; 1. DR PROSITE; PS50967; HRDC; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; ATP-binding; Chromosome; KW Direct protein sequencing; Disease variant; DNA damage; DNA repair; KW DNA-binding; Exonuclease; Helicase; Hydrolase; Isomerase; Isopeptide bond; KW Magnesium; Metal-binding; Multifunctional enzyme; Nuclease; KW Nucleotide-binding; Nucleus; Phosphoprotein; Proteomics identification; KW Reference proteome; Repeat; Ubl conjugation; Zinc. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..1432 FT /note="Bifunctional 3'-5' exonuclease/ATP-dependent FT helicase WRN" FT /id="PRO_0000205045" FT DOMAIN 60..228 FT /note="3'-5' exonuclease" FT /evidence="ECO:0000255, ECO:0000269|PubMed:11863428" FT REPEAT 424..450 FT /note="1" FT /evidence="ECO:0000269|PubMed:10049920" FT REPEAT 451..477 FT /note="2" FT /evidence="ECO:0000269|PubMed:10049920" FT DOMAIN 558..724 FT /note="Helicase ATP-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT DOMAIN 749..899 FT /note="Helicase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00542" FT DOMAIN 1150..1229 FT /note="HRDC" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00328" FT REGION 2..277 FT /note="Interaction with WRNIP1" FT /evidence="ECO:0000250|UniProtKB:O09053" FT REGION 424..477 FT /note="2 X 27 AA tandem repeats of H-L-S-P-N-D-N-E-N-D-T-S- FT Y-V-I-E-S-D-E-D-L-E-M-E-M-L-K" FT REGION 498..529 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 987..993 FT /note="Interaction with DNA" FT /evidence="ECO:0000269|PubMed:20159463" FT MOTIF 11..23 FT /note="KBM 1" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 668..671 FT /note="DEAH box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00541" FT MOTIF 1403..1412 FT /note="KBM 2" FT /evidence="ECO:0000305|PubMed:27063109" FT MOTIF 1419..1432 FT /note="XLM" FT /evidence="ECO:0000305|PubMed:27063109" FT COMPBIAS 507..525 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 82 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 84 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 216 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /ligand_note="catalytic" FT /evidence="ECO:0000269|PubMed:16622405, FT ECO:0007744|PDB:2FBV, ECO:0007744|PDB:2FBX, FT ECO:0007744|PDB:2FC0" FT BINDING 546 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 548 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 550 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508" FT BINDING 553 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 574 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000312|PDB:6YHR" FT BINDING 908 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 935 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 936 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT BINDING 939 FT /ligand="Zn(2+)" FT /ligand_id="ChEBI:CHEBI:29105" FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000312|PDB:6YHR" FT SITE 145 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT SITE 1037 FT /note="Interaction with DNA" FT /evidence="ECO:0000305|PubMed:20159463" FT MOD_RES 2 FT /note="N-acetylserine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 426 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 440 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 467 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 478 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1133 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 1400 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 154 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 241 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT CROSSLNK 252 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in SUMO2)" FT /evidence="ECO:0007744|PubMed:28112733" FT VARIANT 32 FT /note="K -> R (in dbSNP:rs34477820)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017453" FT VARIANT 92 FT /note="G -> V (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036318" FT VARIANT 114 FT /note="V -> I (no effect on exonuclease activity; FT dbSNP:rs2230009)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405, ECO:0000269|Ref.4" FT /id="VAR_017454" FT VARIANT 125 FT /note="K -> N (in WRN; dbSNP:rs387906337)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026588" FT VARIANT 135 FT /note="K -> E (in WRN; dbSNP:rs267607008)" FT /evidence="ECO:0000269|PubMed:16673358" FT /id="VAR_026589" FT VARIANT 172 FT /note="T -> P (no effect on exonuclease activity; FT dbSNP:rs367991517)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16622405" FT /id="VAR_017455" FT VARIANT 240 FT /note="N -> K (in dbSNP:rs148229804)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017456" FT VARIANT 324 FT /note="T -> A (in dbSNP:rs1800390)" FT /evidence="ECO:0000269|PubMed:10069711" FT /id="VAR_006904" FT VARIANT 329 FT /note="Q -> R (in dbSNP:rs4987237)" FT /id="VAR_020450" FT VARIANT 343 FT /note="E -> K (in dbSNP:rs11574222)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018941" FT VARIANT 383 FT /note="L -> F (in dbSNP:rs4987238)" FT /id="VAR_020451" FT VARIANT 383 FT /note="L -> W" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017457" FT VARIANT 387 FT /note="M -> I (in dbSNP:rs1800391)" FT /evidence="ECO:0000269|PubMed:10206685, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9450180, FT ECO:0000269|Ref.4" FT /id="VAR_006905" FT VARIANT 533 FT /note="N -> S (in dbSNP:rs11574240)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018942" FT VARIANT 612 FT /note="S -> C (in dbSNP:rs11574250)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018943" FT VARIANT 708 FT /note="S -> F (in dbSNP:rs11574289)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018944" FT VARIANT 711 FT /note="R -> W (in dbSNP:rs34560788)" FT /id="VAR_057124" FT VARIANT 724 FT /note="Q -> L" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017458" FT VARIANT 834 FT /note="R -> C (in dbSNP:rs3087425)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014913" FT VARIANT 912 FT /note="I -> S (in dbSNP:rs11574323)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018945" FT VARIANT 1074 FT /note="L -> F (in dbSNP:rs1801195)" FT /evidence="ECO:0000269|PubMed:11161804, FT ECO:0000269|PubMed:16723399, ECO:0000269|PubMed:8602509, FT ECO:0000269|PubMed:9450180, ECO:0000269|Ref.3" FT /id="VAR_007903" FT VARIANT 1079 FT /note="S -> L (in dbSNP:rs3087414)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_014914" FT VARIANT 1133 FT /note="S -> A (in dbSNP:rs11574358)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018946" FT VARIANT 1141 FT /note="S -> L (in dbSNP:rs139323683)" FT /evidence="ECO:0000269|PubMed:18987736" FT /id="VAR_054162" FT VARIANT 1269 FT /note="K -> E (in dbSNP:rs746648510)" FT /evidence="ECO:0000269|PubMed:11161804" FT /id="VAR_017459" FT VARIANT 1339 FT /note="V -> I (in dbSNP:rs11574395)" FT /evidence="ECO:0000269|Ref.4" FT /id="VAR_018947" FT VARIANT 1367 FT /note="C -> R (associated with a higher risk of myocardial FT infarction; dbSNP:rs1346044)" FT /evidence="ECO:0000269|PubMed:10069711, FT ECO:0000269|PubMed:11161804, ECO:0000269|PubMed:9021029, FT ECO:0000269|Ref.4" FT /id="VAR_006906" FT MUTAGEN 18 FT /note="W->G: Abolished interaction with XRCC5 and XRCC6." FT /evidence="ECO:0000269|PubMed:27063109" FT MUTAGEN 84 FT /note="E->A: Abolishes exonuclease activity. Restores FT chromosome stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:11863428, FT ECO:0000269|PubMed:16622405, ECO:0000269|PubMed:27063109, FT ECO:0000269|PubMed:33199508" FT MUTAGEN 88 FT /note="L->A: No effect on exonuclease activity." FT MUTAGEN 145 FT /note="W->A: Reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 212 FT /note="Y->F: Strongly reduces exonuclease activity." FT /evidence="ECO:0000269|PubMed:16622405" FT MUTAGEN 577 FT /note="K->M: Loss of helicase activity, loss of DNA- FT dependent ATPase activity. Does not restore chromosome FT stability in depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508, FT ECO:0000269|PubMed:9288107" FT MUTAGEN 669 FT /note="E->A: Does not restore chromosome stability in FT depletion experiments." FT /evidence="ECO:0000269|PubMed:33199508" FT MUTAGEN 987 FT /note="R->A: Reduces affinity for DNA about 8-fold. Loss of FT DNA binding; when associated with A-993." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 989 FT /note="S->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->A: Reduces affinity for DNA about 20-fold. Loss FT of DNA binding; when associated with A-987." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 993 FT /note="R->E: Loss of DNA binding." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1037 FT /note="F->A: Reduces affinity for DNA about 8-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT MUTAGEN 1038 FT /note="M->A: Reduces affinity for DNA about 4-fold." FT /evidence="ECO:0000269|PubMed:20159463" FT HELIX 17..19 FT /evidence="ECO:0007829|PDB:6TYV" FT HELIX 39..41 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 51..56 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 59..72 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 78..84 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 99..105 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 108..112 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 114..116 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 117..119 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 122..128 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 133..139 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 140..151 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 157..160 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 161..169 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 177..185 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 193..196 FT /evidence="ECO:0007829|PDB:2FBY" FT STRAND 202..204 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 207..228 FT /evidence="ECO:0007829|PDB:2FBY" FT HELIX 435..447 FT /evidence="ECO:0007829|PDB:7XUT" FT HELIX 524..527 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 534..544 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 551..563 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 567..570 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 575..577 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 579..588 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 590..595 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 599..611 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 616..618 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 625..632 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 637..641 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 643..648 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 650..659 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 662..667 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 670..673 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 677..679 FT /evidence="ECO:0007829|PDB:8PFL" FT HELIX 682..688 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 689..693 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 699..704 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 708..718 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 724..727 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 735..741 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 746..750 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 751..753 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 761..765 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 767..770 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 774..786 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 791..795 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 800..811 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 816..821 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 826..828 FT /evidence="ECO:0007829|PDB:7GQS" FT STRAND 835..840 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 845..853 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 862..868 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 873..875 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7GQS" FT HELIX 886..904 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 909..915 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 917..919 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 924..929 FT /evidence="ECO:0007829|PDB:7GQU" FT TURN 933..935 FT /evidence="ECO:0007829|PDB:7GQU" FT HELIX 937..944 FT /evidence="ECO:0007829|PDB:7GQU" FT STRAND 956..958 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 960..972 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 973..975 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 980..986 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 996..1000 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1002..1009 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1012..1024 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1027..1032 FT /evidence="ECO:0007829|PDB:3AAF" FT TURN 1036..1038 FT /evidence="ECO:0007829|PDB:2AXL" FT STRAND 1039..1043 FT /evidence="ECO:0007829|PDB:3AAF" FT HELIX 1045..1054 FT /evidence="ECO:0007829|PDB:3AAF" FT STRAND 1062..1064 FT /evidence="ECO:0007829|PDB:6YHR" FT TURN 1067..1069 FT /evidence="ECO:0007829|PDB:6YHR" FT HELIX 1147..1171 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1175..1178 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1181..1190 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1195..1198 FT /evidence="ECO:0007829|PDB:2E1F" FT STRAND 1201..1203 FT /evidence="ECO:0007829|PDB:2DGZ" FT HELIX 1206..1211 FT /evidence="ECO:0007829|PDB:2E1F" FT HELIX 1213..1225 FT /evidence="ECO:0007829|PDB:2E1F" SQ SEQUENCE 1432 AA; 162461 MW; 63F10D19E90AA461 CRC64; MSEKKLETTA QQRKCPEWMN VQNKRCAVEE RKACVRKSVF EDDLPFLEFT GSIVYSYDAS DCSFLSEDIS MSLSDGDVVG FDMEWPPLYN RGKLGKVALI QLCVSESKCY LFHVSSMSVF PQGLKMLLEN KAVKKAGVGI EGDQWKLLRD FDIKLKNFVE LTDVANKKLK CTETWSLNSL VKHLLGKQLL KDKSIRCSNW SKFPLTEDQK LYAATDAYAG FIIYRNLEIL DDTVQRFAIN KEEEILLSDM NKQLTSISEE VMDLAKHLPH AFSKLENPRR VSILLKDISE NLYSLRRMII GSTNIETELR PSNNLNLLSF EDSTTGGVQQ KQIREHEVLI HVEDETWDPT LDHLAKHDGE DVLGNKVERK EDGFEDGVED NKLKENMERA CLMSLDITEH ELQILEQQSQ EEYLSDIAYK STEHLSPNDN ENDTSYVIES DEDLEMEMLK HLSPNDNEND TSYVIESDED LEMEMLKSLE NLNSGTVEPT HSKCLKMERN LGLPTKEEEE DDENEANEGE EDDDKDFLWP APNEEQVTCL KMYFGHSSFK PVQWKVIHSV LEERRDNVAV MATGYGKSLC FQYPPVYVGK IGLVISPLIS LMEDQVLQLK MSNIPACFLG SAQSENVLTD IKLGKYRIVY VTPEYCSGNM GLLQQLEADI GITLIAVDEA HCISEWGHDF RDSFRKLGSL KTALPMVPIV ALTATASSSI REDIVRCLNL RNPQITCTGF DRPNLYLEVR RKTGNILQDL QPFLVKTSSH WEFEGPTIIY CPSRKMTQQV TGELRKLNLS CGTYHAGMSF STRKDIHHRF VRDEIQCVIA TIAFGMGINK ADIRQVIHYG APKDMESYYQ EIGRAGRDGL QSSCHVLWAP ADINLNRHLL TEIRNEKFRL YKLKMMAKME KYLHSSRCRR QIILSHFEDK QVQKASLGIM GTEKCCDNCR SRLDHCYSMD DSEDTSWDFG PQAFKLLSAV DILGEKFGIG LPILFLRGSN SQRLADQYRR HSLFGTGKDQ TESWWKAFSR QLITEGFLVE VSRYNKFMKI CALTKKGRNW LHKANTESQS LILQANEELC PKKLLLPSSK TVSSGTKEHC YNQVPVELST EKKSNLEKLY SYKPCDKISS GSNISKKSIM VQSPEKAYSS SQPVISAQEQ ETQIVLYGKL VEARQKHANK MDVPPAILAT NKILVDMAKM RPTTVENVKR IDGVSEGKAA MLAPLLEVIK HFCQTNSVQT DLFSSTKPQE EQKTSLVAKN KICTLSQSMA ITYSLFQEKK MPLKSIAESR ILPLMTIGMH LSQAVKAGCP LDLERAGLTP EVQKIIADVI RNPPVNSDMS KISLIRMLVP ENIDTYLIHM AIEILKHGPD SGLQPSCDVN KRRCFPGSEE ICSSSKRSKE EVGINTETSS AERKRRLPVW FAKGSDTSKK LMDKTKRGGL FS //